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1007-9 Elevation and Prognostic Value of Cardiac Troponin I 
in Patients with Stable Angina Scheduled for Routine 
Angioplasty During Long-Time Follow Up
Kjell Vikenes, Tor Mellberg, Mikael Farstad, Jan Erik Nordrehaug, Haukeland University 
Hospital, Bergen, Norway, Rogaland Central Hospital, Stavanger, Norway
Background: The prognostic value of elevated cardiac troponins after routine angioplasty 
(PCI) is not clear. Many previous studies have included unstable patients in which a rise of 
the cardiac troponins would be expected and most studies have included few patients. In this 
study, we have determined the prognostic value of troponin elevation after elective PCI.
Methods: 204 consecutive patients were included in the analysis of which 42 patients 
had elevated cTnI. The cTnI positive and cTnI negative groups were comparable 
regarding diabetes (9%), hypercholesterolemia (80%), smoking, hypertension, lesion 
morphology, treatment with IIb/IIIa (12.5%) and use of stents (75%). Mean diameter was 
2.9 mm, 1.4 stents were implanted per procedure, and mean length was 16.4 mm. Blood 
samples were drawn just before and 3 times after procedure up to 24 hours. Patients with 
elevated troponin values at baseline or suffering an acute coronary syndrome < 3 weeks 
before the time of inclusion, were excluded. The 99 percentile was used as cut-off for the 
cardiospeciﬁ c troponins and twice upper limit (> 10 µg/L) for CK-MB.
Results: 21% of patients had peak values of cTnI above the reference level, 11% of 
cTnT and 10% of CK-MB. Most values of cTnI were between 0.05 µg/L and 1.0 µg/L. Two 
of three biomarkers were elevated in 10% of the patients. Mortality and reinterventions 
(around 20%) were similar in the cTnI positive and cTnI negative groups during 4-5 
years of follow up. However, readmission for acute coronary syndromes were much more 
frequent in the cTnI positive group (29% vs 19%, P<0.05).
Conclusions: Around 1 in 5 patients with stable angina had elevated cTnI after routine 
PCI. However, only about 20% of these patients have marked elevation of cTnI as well 
as concomitant elevation of CK-MB, suggesting necrosis. Thus, cardiac TnI seems most 
sensitive to minor injury and this may be explained by the small molecular size and 
subsequent release from the cytosolic fraction during ischemia, supporting the concept 
of reversible injury. Elevated troponins after elective PCI suggested an increased risk of 
readmission for nontransmural acute coronary syndromes.
1007-10 Advantageous Effects of Sirolimus-Eluting Stents on 
Neutrophilic Count and early Endothelial Activation 
after Percutaneous Coronary Intervention
Mary E. Marketou, George E. Kochiadakis, Dragana Nikitovic, Dimitris A. Arfanakis, 
Emmanuel I. Skalidis, Nick E. Igoumenidis, Michael I. Hamilos, Panos E. Vardas, 
Heraklion University Hospital, Heraklion, Greece
Background: We evaluated the possible beneﬁ ts of using sirolimus-eluting stents 
(SES) on neutrophilic count (NC) and soluble intercellular vascular adhesion molecule-1 
(sICAM-1) levels compared to uncoated stents (US) in patients with stable angina, after 
percutaneous coronary intervention (PCI).
Methods: We included 48 patients (30 male, 59±19 years) with stable angina > 6 months 
and single vessel CAD, who underwent elective PCI. SES were implanted in 22 patients 
and UC in the remainder. Blood samples were taken before PCI, 24 and 48 hours later to 
evaluate NC and the levels of sICAM-1 (measured by an Eliza method).
Results: All procedures were successful. There were no signiﬁ cant baseline differences
in NC and s-ICAM-1 between the two groups (p=NS, for both). At 24 hours after PCI, NC 
in US group showed an increase that was not noted in the SES group. In addition, the SES 
group showed a signiﬁ cant reduction in the sICAM levels compared to baseline values 
that was also maintained at 48 hours. See Table 1.
Conclusions: Patients with stable angina treated with SES showed a signiﬁ cant 
postprocedural attenuation in the early endothelial and neutrophilic activation compared 
to those with conventional stents. These results suggest a possible favorable mechanism 
in the prevention of restenosis after SES implantation.
Table 1
SES US
Before 24 hours 48 hours Before 24 hours 48 hours
NC (103/µL) 2.9±1.6 3.1±1.5 3.0±1.2 2.8±1.9 4.2±2.0* 3.9±2.3*
sICAM (ng/ml) 269±117 201±96* 210±122* 255±95 295±130 285±127
*: p< 0.05 compared to 
baseline values
1007-11 Cytokine Activation Before Percutaneous Coronary 
Intervention Reﬂ ects Clinical and Laboratory Variables 
Associated With Increased Risk
Prospero B. Gogo, Jr., David J. Schneider, Edward F. Terrien, Matthew W. Watkins, Burton 
E. Sobel, Harold L. Dauerman, University of Vermont College of Medicine, Burlington, VT
Background: Elevated C reactive protein (CRP) before percutaneous coronary 
intervention (PCI) is associated with increased risk of adverse early and late outcomes.
We hypothesized that pre-PCI elevations of cytokines would be indicative of clinical, 
angiographic and laboratory variables known to increase risk.
Methods: 100 patients undergoing PCI were enrolled in a registry through April 2004. The 
concentrations of CRP and interleukin-6 (IL-6) were determined by ELISA from pre-PCI 
blood samples. Quantitative coronary angiography was performed in all patients. Patients 
with CRP ≥ 3.0 ng/ml or IL-6 ≥ 5.0 pg/ml before PCI were considered to have a high risk 
inﬂ ammatory state.
Results: There were signiﬁ cantly more patients with marker positive acute coronary 
syndromes in the groups with pre-PCI elevated IL-6 (Table). Other baseline clinical 
and treatment characteristics were similar. Patients with heightened inﬂ ammation were 
characterized by increased white blood cell and platelet counts. Among patients in the 
lowest tertile of WBC, mean CRP was 2.81±3.13 compared with 11.86±16.36 for the 
highest tertile (p <0.01). Angiographic variables previously associated with high risk 
(Table) were not associated with pre-PCI cytokine activation.
Conclusions: Many variables have been associated with increased risk of adverse 
events after PCI. Our ﬁ ndings suggest that cytokine activation in patients undergoing PCI 
reﬂ ects risk mediated by clinical and laboratory, but not angiographic, variables.
Table-Pre-PCI 
Cytokine 
levels
CRP <3.0 pg/ml 
(n=48)
CRP≥3.0 pg/ml
(n=51) p Value*
IL-6 <5.0 ng/ml
(n=22)
IL-6 ≥5.0 ng/ml
(n=77) p Value*
White cell 
count/mm3 7.01±1.75 8.60±2.51 <0.01 7.23±1.90 8.02±2.398 0.18
Platelet count 
x 109/L 218± 56 245±56 0.02 203±57 240±55 <0.01
Troponin-I 
positive ACS 9 (19%) 16 (31%) 0.15 1 (5%) 24 (31%) 0.01
ACC/AHA B2/C 
lesions 31 (69%) 25 (50%) 0.17 13 (62%) 43 (59%) 0.98
RVD (mm) 2.77±0.54 2.80±0.67 0.81 2.78±0.55 2.79±0.63 0.95
Lesion length 
(mm) 18.57±15.09 15.85±12.83 0.34 15.71±10.52 17.54±14.86 0.59
* * Values are for comparison between patients deﬁ ned as high versus low risk for adverse events based 
upon inﬂ ammatory marker parameters using Student’s t or Chi-square tests
Values expressed as mean ± SD; RVD = Reference Vessel Diameter
; ACS = acute coronary syndrome
1007-12 C-Reactive Protein Levels are Independently Associated 
With Peri-Procedural Myonecrosis and Two-Years Risk 
of Death After PCI
Luigi M. Biasucci, Claudio Cavallini, Stefano Savonitto, Fillippo Crea, Gustavo Arraiz, 
Giovanna Liuzzo, Luigi Oltrona, Stefano De Servi, Gian Battista Danzi, Walter Pitcheider, 
Bernard Reimers, Diego Ardissino, Gruppo Italiano Trombosi, Aterosclerosi e Biologia 
Vascolare, Rome, Italy
Bakground: C-Reactive protein (CRP) levels have been associated with the risk of death 
after PCI in patients with unstable angina, but less consistent data are available for stable 
patients undergoing PCI. Furthermore the relationship between CRP and peri-procedural 
elevation of markers of myocardial damage has been poorly investigated, leaving 
unanswered the question of whether inﬂ ammation is associated with an increased risk 
of post-PCI myonecrosis. 
Methods: to this aim we studied in a large multi-centre prospective cohort study involving 
16 italian centers (CK-MB and PCI study) 2625 consecutive patients, 1456 with UA and 
1169 with SA undergoing PCI. Blood samples were collected at baseline and 12 and 
24 hours after the procedure; hs-CRP, cTnI and mass CK-MB were measured in a core 
biochemistry laboratory and all of the patients were followed for two years. 
Results: baseline CRP levels (quartiles) were signiﬁ cantly and independently associated 
with the risk of one year death in the whole population (p per trend <0.0001) and in the two 
subgroup SA (p per trend <0.0003) and UA (p per trend <0.0003). Basal levels of CRP were 
signiﬁ cantly associated with post-procedural CK-MB elevation (p per trend <0.001). Baseline 
CRP values and post-procedural CK-MB elevation were both independently associated with 
2 year risk of death (OR respectively 2.4 for CRP and 1.044 for post-procedural CK-MB 
peak ratio, evaluated as continuous variable), whereas post-procedural cTnI was not. 
Discussion: our study conﬁ rms that CRP levels at baseline are a strong and independent 
marker of risk of death at two years in both stable and unstable coronary artery disease 
patients undergoing PCI and of peri-procedural occurrence of myonecrosis as detected 
by CK-MB elevation. Taken together these data suggest that vascular inﬂ ammation in the 
major determinant of short and long term risk after PCI.
1007-13 Small Troponin Elevations Following Uncomplicated 
Percutaneous Coronary Interventions are Not 
Associated with Increased Mortality
Henry S. Loeb, Jayson C. Liu, Edward Hines Jr. Veteran’s Administration Hospital, Hines, 
IL, Loyola University Stritch School of Medicine, Maywood, IL
Background: Elevation of CKMB to 5 times the upper normal is associated with decreased 
survival following percutaneous coronary intervention (PCI). Increases of troponin i 
(TROP) commonly occur after PCI and often exceed 5 times the upper normal value for 
TROP which is 0.1 ng/mL. Whether or not such increases have the same signiﬁ cance as 
has CKMB is uncertain.
Methods: From 1/1/98 to 6/30/04 1137 patients had an initial PCI at our hospital. We 
measured TROP several hours after PCI and the next morning. Patients who had an acute 
myocardial infarction within 48 hrs prior to the PCI or had a pre PCI TROP =>0.1ng/mL 
were excluded from analysis as were patients having a recognized complication related 
to the PCI. Followup was done using our hospital’s CPRS or searching the Social Security 
Death Index for patients lost to the VA system.
Results: Six hundred and thirty four patients met the above criteria of whom 82 were 
known to have expired an average of 603 days after PCI. The remaining 552 patients were 
alive an average of 791 days after PCI. The following variables were examined.
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SURVIVORS NON SURVIVORS P
N 552 82
AGE (+-SD) 65.1+-10.4 68.7+-9.5 <0.005
TROP ng/mL 0.79+-1.90 1.06+-2.28 NS
USE OF STENT 94% 91% NS
PCI OF VEIN GRAFT 10.5% 13.4% NS
Using the Cox Proportional Hazards Model only the patients’s age was an indepndant 
predictor of survival.
Conclusions: Unlike CKMB a small rise in TROP can be expected in the majority of 
patients undergoing uncomplicated PCI but does not predict survival. Increases of TROP 
to 5 times the upper normal should not be considered a procedural complication. The 
absolute value of TROP which might predict an adverse outcome following PCI has yet 
to be determined.
1007-14 Effects of Baseline Troponin Levels on the Timing, 
Magnitude and Prognostic Signiﬁ cance of Troponin 
Levels Post-PCI
Wayne L. Miller, Kirk N. Garratt, Guy S. Reeder, Mary F. Burritt, Ryan J. Lennon, Allan S. 
Jaffe, Mayo Clinic, Rochester, MN
Background: The prognostic signiﬁ cance of biomarker elevations after PCI is well 
established. However, often baseline values are not included in the analysis. Accordingly, 
we assessed the timing and magnitude of post PCI troponin T (cTnT) levels and their 
relationship to outcomes.
Methods/Results: Blood was drawn to measure cTnT at baseline, 8 hrs and 16 hrs post-
PCI in 2352 patients during the period of January 2000 to September 2002. A cTnT 
elevation was deﬁ ned as ≥0.03 ng/ml. No baseline elevations were detected in 1619 
patients undergoing mostly (97%) non-emergent procedures (cTnT=0.01±0.002 ng/ml; 
mean±SD). Of these, 1396 had complete data. No post-PCI elevations occurred in 756 
(55%). Of those with elevations, only 10% had peak values at 8 hrs (0.55±1.96 ng/ml); the 
remainder at 16 hrs post-PCI (0.17±0.36 ng/ml). In contrast, 733 patients had elevations 
at baseline (0.58±1.03 ng/ml). Of the 603 patients with complete data, 119 (20%) had no 
further elevations above baseline while 231 (38%) demonstrated increased peak levels at 
8 hrs (1.66±2.24 ng/ml) and 253 (42%) at 16 hrs (0.87±1.34 ng/ml) post-PCI.
Neither the timing nor the magnitude of the elevations post-PCI were predictors of 6 
month death/MI but late peaking values did predict in-hospital death/MI (11% with and 
8% without baseline cTnT elevation vs. 3% with no peak above baseline or 3% with early 
peak). Elevated baseline levels predicted a higher cumulative 6 month death/MI rate of 
72/603 (12%) vs. 86/1396 (6%) for those without elevated baseline (p<0.05). Those with 
elevated baseline cTnT but no increases post-PCI did well (4% event rate), comparable to 
those without baseline elevations (3%).
Conclusions: Early post-PCI peak cTnT elevations (8 hrs) are less common (15%) than 
late peaks (42%) but tend to be of greater magnitude. When baseline cTnT is elevated 
(≥0.03 ng/ml) early peaks are more frequent. Six month death/MI outcome is related to 
pre-PCI elevated baseline values more than the timing or magnitude of cTnT elevations 
post-PCI. However, late peaking (16 hrs) cTnT is associated with high in-hospital event 
rate. These data emphasize the need to include all troponin data points in the analysis of 
post-PCI elevations.
1007-15   Prediction of Complications, Including Biomarker 
Elevation, Following Nonemergent Percutaneous 
Coronary Interventions
Mandeep Singh, Charanjit Rihal, Ryan Lennon, Kirk Garratt, Verghese Mathew, David 
Holmes, Mayo Clinic, Rochester, MN
Background Previous models for prediction of complications following percutaneous 
coronary interventions (PCI) have included in-hospital mortality, and major in-hospital 
complications. In general these models have excluded elevated creatine kinase as a 
complication.
Objectives We sought to determine whether a risk model could predict complications, 
including biomarker elevation in patients undergoing non-emergent PCI.
Methods We determined outcome on non-emergent PCI performed on patients at 
Mayo Clinic from August 2000 through October 2003. The primary end point was in-
hospital complications of death, MI [Q-wave MI, or post-PCI CK-MB elevation (≥ 3 ULN)], 
emergency CABG, or stroke. Logistic regression was used to ﬁ t the ﬁ nal model. The 
Hosmer-Lemeshow (H-L) test was used to test the adequacy of the model ﬁ t, and c-index 
to assess the discriminatory ability of the model.
Results Out of 2894 non-emergent PCI, the primary end point was noted in 232 (8%). 
The ﬁ nal prediction model included presence of vein graft intervention (odds ratio 2.55, 
95% conﬁ dence interval 1.67, 3.90), presence of thrombus 2.24 (95% CI 1.6, 3.13), 
stenosis of minor 2.03 (95% CI 1.49, 2.76), or major 1.78 (95% CI 1.26, 2.54) side branch 
during the procedure. The model had modest ability to discriminate between event and 
non-event patients (c=0.638). In the 500 bootstrap samples for internal validation, the 
mean c-index was 0.633 ± 0.017, indicating only fair discriminatory ability. The average 
number of observed events was 232 ± 14.7 compared to 232.1 ± 2.4 expected events, for 
an average of difference of -0.04 ± 14.5.
ConclusionsThe four risk variables associated with increased risk for complications in 
patients undergoing elective PCI include vein graft intervention, presence of angiographic 
thrombus, and stenosis of a major or minor side branch, however, the predictive accuracy 
of the model derived from the commonly identiﬁ ed clinical and angiographic variables is 
only modest.
1007-16 Plasma Levels Of nε-(carboxymethyl) Lysine Increase 
After Angioplasty And Stent Positioning In Coronary 
Artery Desease Patients
Giuseppina Basta, Guido Lazzerini, Sergio Berti, Maria Serena Parri, Silverio Sbrana, 
Serena Del Turco, Andrea Biagini, Raffaele De Caterina, Annamaria Mazzone, Institute 
of Clinical Phisiology, Pisa, Italy
Background and Objective. N�-(Carboxymethyl) lysine (CML), an advanced glycation 
end product formed on proteins by combined nonenzymatic reactions of glycation 
and oxidation is a signal transducing ligand of receptors for advanced glycation end 
products (RAGE). It may be considered an oxidative stress marker and a risk factor for 
atherosclerosis and diabetes, and is produced in inﬂ ammatory processes. Since several 
studies in animal models of accelerated neointimal expansion after carotid artery injury, 
suggest that RAGE/ligand interaction plays a key role in neointimal formation irrespective 
of the diabetic status, we explored CML plasma levels in coronary artery disease patients 
in basal conditions and after coronary stent implantation.
Methods. CML plasma levels were analysed by a speciﬁ cally developed EIA in 22 patients 
with acute coronary syndromes (ACS) (11 Unstable Angina (UA); 11 acute Myocardial 
Infarction (MI)) and 17 with stable coronary artery diseases (Effort Angina (EA)). Time 
course of CML plasma levels was evaluated before and 1, 7, 14, 21, 30, 90, 180 days 
after coronary angioplasty and stent positioning. C-reactive protein levels were measured 
by a high-sensitivity EIA.
Results. Basal values of C Reactive Protein (CRP) were higher in UA than in EA patients: 
1.6±0.6 vs 0.33±0.1 (p<0.05). Baseline plasma CML concentrations were not different 
in UA, MI and EA patients: 31.1±9 µg/mL (mean±SEM), 21.5±6 µg/mL, 24.4±4.7 µg/
mL respectively. Plasma levels of CML were signiﬁ cantly increased (from 24.9±3.29 to 
39.8±3.86 µg/mL; P<0.01) in all patients at 7 days after coronary angioplasty with stent 
and remained elevated until to 30 days. Within 180 days, while in EA patients CML levels 
were normalized, in UA patients they were further increased (76.3±11.7 , P<0.05 ).
Conclusions. Our data highlight, for ﬁ rst time in vivo, that angioplasty and stent positioning 
increase circulating CML levels, likely through the activation of a systemic oxidative 
process. The amount of oxidative response to coronary wall injury may be conditioned by 
a major degree of acute inﬂ ammation of unstable coronary patients, and may contribute 
to the accelerated neointimal formation after arterial injury.
1007-17 The Importance of Fibrinolysis in Restenosis After 
Percutaneous Coronary Intervention, a Protective Effect 
of the Functional 4G/4G Genotype of the Plasminogen 
Activator Inhibitor-1 Gene
Pascalle S. Monraats, Willem R.P. Agema, Aeilko H. Zwinderman, Moniek P.M. de Maat, 
Robbert J. de Winter, Rene A. Tio, Pieter A.F.M. Doevendans, Johannes Waltenberger, 
Rune R. Frants, Arnoud van der Laarse, Ernst E. van der Wall, J.Wouter Jukema, Leiden 
University Medical Center, Leiden, The Netherlands
Background: Fibrinolysis, and especially plasminogen activator inhibitor-1 (PAI-1), an 
essential factor in ﬁ brinolysis, is thought to play a major role in the wound healing response 
of the restenotic process. Evidence exists that genetic variation is of importance in the 
development of restenosis. The 4G motif of the 4G/5G deletion/insertion polymorphism 
has been found to lead to higher transcriptional activity than presence of the 5G motif. We 
examined the association of the functionally relevant 4G/5G polymorphism of the PAI-1 
gene with the risk of restenosis after percutaneous coronary intervention (PCI) in a large 
unselected patient population.
Methods: The GENetic DEterminants of Restenosis (GENDER) project is a multicenter 
follow-up study, including patients after successful PCI. Genotyping in these patients was 
determined by validated multilocus genotyping assay (Roche Molecular Systems).
Results: A total of 3,146 patients (age 62.1±10.7 years) were followed for 10±2 months. 
Of these patients, 2,250 (71.5%) were male and 459 (14.6%) had diabetes. Stenting was 
performed in 2,340 (74.4%) patients. Post 30-day target vessel revascularisation (TVR) 
by either CABG or PCI was necessary in 304 patients (9.7%). Genotyping was possible 
for 3,035 patients (97.8%). The genotype distributions were; 27.6% 5G/5G, 51.7% 4G/5G 
and 20.8% 4G/4G. The 4G/4G genotype showed a lower risk of restenosis (p=0.005, RR 
0.8, 95%CI 0.67-0.93).
Conclusions: In our large prospective unselected patient population, we found a signiﬁ cant 
association between the 4G/5G PAI-1 polymorphism and TVR. The 4G/4G genotype lowered 
the risk of TVR, this genotype has been found to lead to higher transcriptional activity. Besides 
the key role PAI-1 plays in ﬁ brin homeostasis by controlling plasmin formation, PAI-1 may also 
modulate vascular pathology via alternative pathways, such as inhibiting activated protein C 
and altering interactions between vascular smooth muscle cells and the extracellular matrix 
and in that way could be involved in the restenotic process. Genotyping could lead to a better 
risk stratiﬁ cation and to a more tailored therapy for patients to prevent restenosis after PCI.
1007-18 Accuracy of Data is Dependent on Whether it is 
Subjective or Objective: Results from the ACC-NCDR™ 
Pilot Data Audit Program
Frances F. Fiocchi, Jerry D. Kennett, Tony Hermann, Stephen Dobson, William S. 
Weintraub, Richard E. Shaw, Kristi R. Mitchell, Kathleen Hewitt, Ralph G. Brindis, 
American College of Cardiology, Bethesda, MD
Background: Data quality issues in cooperative databases are concerning, but can be 
mitigated by an audit program. In 2003, the ACC-NCDR™, in collaboration with the ACC 
Missouri chapter and the state’s quality improvement organization (MissouriPRO), piloted a 
national, on-site data audit program to ensure data submitted to the registry were accurate.
Methods: MissouriPRO conducted onsite chart reviews and data abstraction in 7 Missouri 
cath labs. A 10% random sample of patient records was included from each site for a total 
of 282. For each record, 41 data elements were audited for accuracy. The data originally 
submitted to the registry was then compared to the audit.
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Results: The average accuracy across all 7 sites was 87.28%; individual sites ranged 
from 84.15% to 89.51%. Average accuracy for each data element was also calculated; 
90% of audited data elements were at least 80% accurate. The variables were divided 
into 17 objective variables(e.g., gender), 16 subjective variables (e.g., anginal type), and 
8 variables that were between objective and subjective. Discharge alive was correct in 
98.58%. Results varied by type of element (p=0.0019): 
Mean % Accurate SD Minimum Maximum
Objective: 94.3% 6.7 71.89 99.29
Subjective 80.7% 13.9 51.96 94.66
Obj/Sub 87.6% 6.4 78.29 96.44
Conclusions: Results of the audit appear to be satisfactory with 87.28% accuracy. 
Perhaps more reassuring is the 94.3% correspondence for more objective variables 
between the original submission and the independent audit. These results may be difﬁ cult 
to improve upon since no audit can be 100% accurate. Based on these results, the pilot 
audit program will be expanded.
1007-19 The Impact of Clinical Trials of Antithrombotic Therapy 
in Patients Undergoing Contemporary Percutaneous 
Coronary Intervention
Thomas Tsai, Dean E. Smith, Eva Kline-Rogers, Chris D’Haem, Miland Karve, Kirit 
Patel, Mauro Moscucci, University of Michigan Medical Center, Ann Arbor, MI
The objective of our study was to evaluate the impact of clinical trials on the use of 
antithrombotics (A) in contemporary PCI.
Methods: Data on 56,735 PCI were collected in a regional consortium between 1/2000 
and 12/2003. Major clinical trials published after 1/2000 on the use of IIb-IIIa’s and 
bivalirudin in PCI were collected. We examined the use of abciximab, other IIb-IIIa’s 
(tiroﬁ ban and eptiﬁ batide), and bivalirudin in 1) All PCI (All-PCI) and 2) Acute myocardial 
infarction (AMI) treated with PCI (AMI-PCI). Inﬂ uence was determined by a congruent 
positive or negative effect within 6 months of publication.
Results: In AMI-PCI, abciximab use decreased from 37.9% in Q1-2000 to 9.6% in Q1-
2003 while the use of other IIb-IIIa’s increased from 36.6% to 75.1% over the same 
period, despite the limited evidence of the beneﬁ t of other IIb-IIIa’s in AMI-PCI and 
the increasing evidence for abciximab. Major trials during this period included ISAR-2, 
STOP-AMI, ADMIRAL and CADILLAC and did not show a congruent relationship. In All-
PCI (FIGURE), IIb-IIIa’s use peaked at 81.2 % in Q3-2001. That peak may reﬂ ect the 
publication of ESPIRIT in 12/2000. Since that peak, overall use has decreased to 68.5% 
in Q4-2003 with the emergence of bivalirudin (9% of A used in that quarter). This trend 
was likely inﬂ uenced by the publication of REPLACE 2 in 2/2003.
Conclusions: While, clinical trials have a variable impact on the use of A in contemporary 
PCI, economic factors and treatment costs seem to inﬂ uence at least in part their use.
1007-20 A Simpliﬁ ed Approach to Non-Aorto Ostial Lesions: 
Stent Pull-Back Technique
Annapoorna S. Kini, Samin K. Sharma, Mount Sinai Medical Center/ Cardiovascular 
Institute, New York, NY
Background: PCI of non-aorto ostial lesions is challenging due to the need for accurate 
placement of the stent for complete coverage of the side-branch (SB) ostium without 
encroachment into the parent vessel. It has higher restenosis rate due to incomplete SB 
ostial coverage and higher need for PCI of uninvolved parent vessel due to lumen pinch 
by the SB stent encroachment.
Methods and Results: Stent pull-back (SPB) technique involves accurate deployment 
of SB ostial stent, which is initially advanced into the SB. A balloon (1:1 balloon-to-
artery ratio) inﬂ ated in the parent vessel at low atm; subsequently, the SB stent is pulled 
back until it makes a dent after contacting the inﬂ ated balloon in the parent vessel and 
then deployed. We analyzed our ﬁ rst 55 consecutive PCI patients who underwent SPB 
technique and compared with 45 pts who underwent conventional ostial stenting (COS) 
technique (stent the SB with or without pre-dilatation) for the treatment of non-aorto ostial 
lesions using DES.
Conclusion: SPB technique seems to be a safe and effective approach for treatment of 
non-aorto ostial lesions using DES with lower need for parent vessel intervention and a 
trend toward lower TVR. 
SPB (n = 55) COS (n = 45) P
Procedural success (%) 99.7 99.8 NS
Clinical success (%) 98.6 97.3 NS
Need for >1 stent in SB (%) 0 4 NS
30-day MACE (%) 4.2 4.9 NS
Stent thrombosis (%) 0 0 NS
PCI of MV for Plaque shift (%) 1.8 22.2 0.002
TLR at 9 months (%) 5.5 8.8 0.322
TVR (%) 5.5 15.5 0.074
1007-21 Integrating Biomarkers With Invasive and Noninvasive 
Coronary Plaque Imaging: The IBIS Study (Integrated 
Biomarker and Imaging Study)
Carlos Van Mieghem, Eugene McFadden, Pim De Feyter, Patrick Serruys, Johannes 
Schaar, Nico Bruining, Clemens Disco, Sebastian de Winter, Nico Mollet, Filippo 
Cademartiri, Gaston Rodriguez Granillo, Frits Mastik, Anton van der Steen, Willem van 
der Giessen, Georgios Sianos, Bianca Backx, Marie-angele Morel, Gerrit-Anne van 
Es, Jonathon Sawyer, June Kaplow, Andrew Zalewski, Thoraxcenter, Erasmus Medical 
Center, Rotterdam, The Netherlands
Background: Ischemic events develop unpredictably in patients with coronary 
atherosclerosis. Novel imaging techniques could reﬁ ne risk stratiﬁ cation, provide insights 
into plaque biology, and potentially direct local preventive strategies.
Methods: Non-invasive multislice computed tomography (MSCT) and novel invasive 
IVUS-based imaging (palpography and tissue characterization) were used to characterize 
non-intervened vessel segments with <50% angiographic stenosis in 84 patients (93 
vessels) referred for PCI. Imaging parameters were correlated with circulating biomarkers 
and clinical presentation.
Results: The study group included patients presenting with STEMI (n=18), recent history 
of unstable angina (n=27), and stable angina (n=39). Although mean angiographic 
diameter stenosis was only 26±11 %, large plaques occupying more than 50 percent 
cross-sectional area were seen in 67/89 (75 percent) vessels on IVUS. The sensitivity, 
speciﬁ city, positive and negative predictive values of non-invasive MSCT to detect such 
non-ﬂ ow limiting plaques were 86, 69, 90 and 61 %, respectively. On palpography, that 
identiﬁ es structurally vulnerable plaques, high strain patterns (grade 3/4), were observed 
in 58/74 (78 %) vessels and were quite frequent (4.2±4.2 per segment studied). IVUS-
based tissue characterization showed that most plaque was hypoechogenic (89.7±5.6 %). 
When novel imaging parameters were characterized according to clinical presentation, 
the density of grade 3/4 strain in non-culprit vessels was highest in STEMI (P=0.017 
vs. stable angina), as was the percentage of hypoechogenic plaque (P=0.009 vs. stable 
angina). Systemic inﬂ ammatory status showed signiﬁ cant correlations with plaque 
hypoechogenicity (CRP: r=0.32, P=0.005; and IL-6: r=0.27, P=0.015).
Conclusions: Most coronary vessels with mild angiographic disease have large 
atherosclerotic plaques that can be identiﬁ ed on non-invasive imaging. Novel invasive 
IVUS-based plaque imaging identiﬁ es abnormal ﬁ ndings, suggestive of “high risk” plaque, 
that are both widespread and highly prevalent, thereby challenging the concept that local 
preventive strategies could reduce ischemic events.
1007-22 Local Catheter Delivery of Novel Antisense in De-Novo 
and Restenotic Coronary Arteries: Early and 6 Month 
Follow-up from AVAIL Study
Nicholas N. Kipshidze, Paul Overlie, Tom Dunlap, Bradley Titus, Don Lee, Michael Lauer, 
Lenox Hill Hopstal, New York, NY
Background: A novel antisense phosphorodiamidate Morpholino oligomer, AVI-4126, 
shown to be effective in reducing neointimal formation in different animal models. The 
purpose of the AVAIL study was to investigate both safety and efﬁ cacy of AVI-4126 
delivered locally via Inﬁ ltrator catheter after PCI in humans.
Methods: The AVAIL trial is prospective, evaluator blinded, randomized study including 
clinical follow-up at 30 days and 6 months after intervention and 6 month angiographic 
and IVUS follow-up. Inﬁ ltrator catheter was advanced to target lesion and either drug was 
delivered (group A and B) or catheter was inﬂ ated (group C) after stent implantation in 
de novo lesions or PTCA in restenotic lesions. Primary endpoints include MACE, TVR, 
angiographic restenosis and IVUS at 6 months.
Results: Forty six patients either with de novo lesions or restenosis were randomized into 
three groups: A (low dose)-3mg (15pts); B (high dose) - 10mg (15 pts) and C-control (16 
pts). Baseline angiographic characteristics did not differ between the groups (reference 
vessel diameter: 2.5-4 mm, lesion length< 16mm). Procedural success was 84, 2 %( 
unable to advance Inﬁ ltrator catheter to target lesion in 7 pts (1 pt group B and 6 pts 
from group C). There was no in-hospital or 30 days MACE recorded in any group. Clinical 
follow-up was available in 36 pts. At six months 3 pts (33.3%) from control group (n=9) and 
6(46.1%) pts from low dose A group (n=13) required TVR. In contrast in high dose group 
B (n=14) only one patient (7.1%) needed TVR. Angiographic follow-up in 33 pts ( 12 pts-
group A, 12 pts-group B and 9 patients -group C) demonstrated Late loss of 1.45+-0.19, 
0.74+-0.16 and 1.26+-0.19 respectively (p=0.025). Binary restenosis was 33.3% in group 
C (control), 33.3% in group A (low dose) and 8.3% in group B (high dose).
Conclusion: Local catheter delivery of antisense is safe and feasible. These ﬁ ndings 
from the small cohort of patients require conﬁ rmation in a larger trial utilizing DES 
technologies.
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1008  Percutaneous Intervention: Acute 
Myocardial Infarctions, Vein Grafts, 
and Total Occlusions
Sunday, March 06, 2005, 9:00 a.m.-12:30 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 11:00 a.m.-Noon
1008-1 Multivariate Predictors of Mortality With Contemporary 
Percutaneous Coronary Intervention for Acute 
Myocardial Infarction: A Report From the 1999-2000 
New York State Angioplasty Database
Sridhar Sampath Kumar, E. Scott Monrad, Abdissa Negassa, Sangeeta Garg, Aaron 
Levalley, V.S Srinivas, Monteﬁ ore Medical Center, Bronx, NY
Background: Newer risk prediction models for Primary Percutaneous Coronary 
Intervention (PPCI) are needed due to limitations in existing models which lack current 
therapies such as stent implantation.
Methods: Patients undergoing PPCI (n=3006) within six hours of chest pain onset 
were identiﬁ ed from the 1999-2000 New York State PCI database. Baseline clinical and 
angiographic features were analyzed for univariate predictors of death. Using stepwise 
logistic regression analysis, two multivariable models of death were created, one including 
cardiogenic shock and one without.
Results: Overall mortality following PPCI was 4.7 %; however, among 114 pts with 
cardiogenic shock, it was 36 % .Univariate predictors of death (OR; 95% CI, respectively) 
were older age (1.06; 1.05- 1.08), female sex (1.7; 1.2-2.4), Congestive Heart Failure 
(CHF: 9.8; 6.8-14.1), COPD (2.42;1.4-4.1), femoropopliteal disease (3.4;1.8-6.5), aortoiliac 
disease (2.4; 1.2-5.0), malignant ventricular arrhythmia (5.5, 3.5-8.3), prior stroke (2.8, 
1.6-4.9), shock (15.8, 10.2-24.4) and hemodynamic instability (2.4; 1.4-3.9).Presence of 
left main disease was also a predictor of death. Higher Ejection fraction(EF; 0.93; 0.9-0.9), 
BMI ( 0.95,0.91-0.98) and stent use (0.42, 0.2-0.6) predicted lower risk of death.
In a multivariable model, signiﬁ cant independent predictors of death were older age (1.05; 
1.03-1.07), CHF (4.3; 2.7-7.1) and shock (9.4; 5.2-17.0). Stent use (0.29, 0.16-0.50) and 
increasing EF (0.96, 0.94-0.98) predicted improved outcome(c-statistic for model: 0.88).
With shock excluded, older age (1.05; 1.03-1.07), CHF (5.2, 3.3-8.3) and malignant 
ventricular arrhythmia (2.8, 1.5 - 5.1) independently predicted death, while stent use (0.3, 
0.2 - 0.5) and increasing EF (0.95, 0.94 - 0.97) were protective (c-statistic: 0.87).
Conclusions: Regardless of cardiogenic shock, risk prediction following PPCI can 
be achieved using a combination of three clinical and two procedural characteristics.If 
validated, this simple risk prediction model could be used to develop risk scores to identify 
high risk patients and in comparing institutional PPCI outcomes.
1008-2 Impact Of Routine Stenting In Acute Myocardial 
Infarction On Myocardial Perfusion And The Extent Of 
Myocardial Necrosis: Results From A Randomized Trial 
In Unselected Patients
Giuseppe De Luca, Harry Suryapranata, Arnoud WJ van ‘t Hof, Jan Paul Ottervanger, 
AT Marcel Gosselink, Jan-Henk E. Dambrink, Jan CA Hoorntje, Menko-Jan de Boer, De 
Weezenlanden Hospital, Zwolle, The Netherlands
Background. Primary stenting for ST-segment elevation myocardial infarction (STEMI) 
has been shown to improve the outcome mainly due to beneﬁ ts in terms of restenosis. 
However, still controversial are the beneﬁ ts in terms of reperfusion. In the Zwolle-6 
randomized trial, a consecutive cohort of patients with STEMI were randomized to balloon 
angioplasty or stenting, without exclusion criteria. In this substudy, we evaluated the 
impact of stenting on myocardial perfusion and the extent of myocardial necrosis.
Methods. From April 1997 to October 2001, a total of 1683 consecutive patients with 
STEMI were randomized to stenting or balloon angioplasty. No exclusion criteria was 
applied. The endpoint of the sub-study, was to evaluate the impact of stenting on myocardial 
perfusion, evaluated by myocardial blush grade and ST-segment resolution, and the extent 
of myocardial necrosis, evaluated by enzymatic infarct size and predischarge ejection 
fraction. All data were prospectively collected.
Results. A total of 785 patients (92.5%) in the stent group and 763 patients (91.5%) in 
balloon group underwent primary angioplasty. The two groups showed similar baseline 
characteristics. At intention-to-treat analysis no difference was observed between stent 
and balloon in terms of myocardial blush 2-3 (80.5% vs 79.8%, p = NS), complete ST-
segment resolution (60.4% vs 60.8%, p = NS), distal embolization (14.3% vs 15.6%, 
p = NS), enzymatic infarct size (1746+1525 U/L vs 1821+1549 U/L) and predischarge 
ejection fraction (43+11% vs 44+11, p = NS). These data were conﬁ rmed at actual 
treatment analysis and in the analysis restricted to patients with anterior infarction. No 
difference was observed in 1-year mortality (6.0% vs 5.9%, p = NS).
Conclusion. As compared to balloon angioplasty, routine stenting does not seem to 
improve myocardial perfusion and myocardial salvage in a large cohort of unselected 
patients with STEMI.
1008-3 Predictors And Clinical Implications Of Early 
Reinfarction After Primary Angioplasty For ST-Segment 
Elevation Myocardial Infarction
Giuseppe De Luca, Harry Suryapranata, Arnoud WJ van’t Hof, Jan Paul Ottervanger, 
Jan CA Hoorntje, AT Marcel Gosselink, Jan-Henk E. Dambrink, Nicolette Ernst, Menko-
Jan de Boer, De Weezenlanden Hospital, Zwolle, The Netherlands
Background. Recurrent infarction after ﬁ brinolytic therapy has been shown to be 
associated with increased mortality, particularly in high-risk patients. The aim of this study 
was to analyze predictors and outcome of early reinfarction in a consecutive series of 
unselected patients undergoing primary angioplasty.
Methods. Our population is represented by a total of 1548 patients with STEMI treated by 
primary angioplasty between 1997 to 2001. All clinical, angiographic and follow-up data 
were prospectively collected.
Results. Early reinfarction was observed in 70 patients (4.5%). At multivariate analysis, 
advanced Killip class (p=0.003), poor preprocedural TIMI ﬂ ow (=0.023), coronary stenting 
(p=0.031) and lesion location in left anterior descending coronary artery (LAD) (p=0.044) 
were independent predictors of 30-day reinfarction. At 1-year follow-up early reinfarction 
was associated with a signiﬁ cantly higher mortality (22.9% vs 5.1%, p < 0.001) (Figure 
1). At multivariate analysis, early reinfarction was an independent predictor of 1-year 
mortality (RR [95%CI] = 4.85 [2.82-8.31]), p = 0.006).
Conclusions. This study showed that advanced Killip class at presentation, coronary 
stenting, location of the culprit lesion in the LAD and poor preprocedural TIMI ﬂ ow are 
independently associated with 30-day reinfarction. Early reinfarction is an independent 
predictor of 1-year mortality. 
1008-4 Sirolimus-Eluting Stents are Safe and Effective for 
Acute and Long-Term Management of ST-Segment 
Elevation Myocardial Infarction in the “Real World”
Marc Newell, Christopher Sigakis, David M. Larson, M. Nicholas Burke, Ivan J. Chavez, 
Daniel L. Lips, Christopher R. Henry, Timothy D. Henry, Minneapolis Heart Institute 
Foundation, Minneapolis, MN, Ridgeview Medical Center, Waconia, MN
Background: Sirolimus-eluting stents (SES) are superior to bare metal stents (BMS) 
for percutaneous coronary intervention (PCI). PCI is superior to thrombolytics for ST-
segment elevation myocardial infarction (STEMI). The data regarding SES in STEMI is 
limited, including no data from randomized clinical trials. There is also no data regarding 
how physicians make decisions to use drug-eluting stents in STEMI.
Methods: We measured the clinical characteristics, acute, and long-term outcomes in 
312 consecutive STEMI patients presenting to Abbott Northwestern Hospital from 4/1/03 
to 6/30/04 who received either an SES (159) or BMS (153). A total of 223 (BMS) and 194 
(SES) stents were successfully deployed per investigator discretion. Follow-up through 30 
days is complete and near complete through 6 months.
Results: Patients with SES had a 0.6% in hospital and 30 day mortality, compared to a 
5.2% (in hospital and 30 day, p=0.016) mortality rate in the BMS patients. The 6 month 
mortality rates were 2.1% (SES) and 10.2% (BMS) (p=0.002). Cause of death: SES, n=3; 
1 in hospital (anoxic brain injury (ABI) after out of hospital cardiac arrest), 2 heart failure 
deaths at 6 months); BMS, n=15; 8 in hospital (4 ABI, 3 cardiogenic shock, 1 non-cardiac), 
7 after discharge (2 non-cardiac, 5 sudden death). At 6 months, patients receiving BMS 
were more likely to have repeat, unplanned revascularization (1.4% v 7.8%, p=0.005) 
and reinfarction (0.6% v 4.1%, p=0.05) than patients receiving SES. At 6 months, the 
overall cardiac endpoint of death, reinfarction, and revascularization was 3.4% SES v 
16.3% BMS (p<0.0001). No subacute thrombosis occurred in the SES group at 6 months. 
Patients receiving BMS were older and more likely to have comorbid conditions such as 
cardiogenic shock or ABI.
Conclusions: SES are safe and effective in STEMI at 6 months with no acute or subacute 
thrombosis. While mortality, reinfarction, and unplanned revascularization were higher in 
patients receiving BMS, this clearly was effected by physician decision making based on 
initial presentation, and therefore needs to be tested in a randomized clinical trial.
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1008-34 Comparison Between Stent and Balloon in Elderly 
Patients With ST-Segment Elevation Myocardial 
Infarction Undergoing Primary Angioplasty: A Substudy 
of the Zwolle-6 Randomized Trial
Giuseppe De Luca, Harry Suryapranata, Menko-Jan de Boer, Jan Paul Ottervanger, Jan 
CA Hoorntje, AT Marcel Gosselink, Jan-Henk E. Dambrink, Arnoud WJ van’t Hof, De 
Weezenlanden Hospital, Zwolle, The Netherlands
Background. In order to overcome the limitations of previous randomized trials conducted 
in ST-segment elevation myocardial infarction (STEMI), related to the enrollment of highly 
selected patients, after the initial angiogram, in the Zwolle 6 randomized trial 1683 
patients were randomized before angiography to stent (S) or balloon (B), without any 
exclusion criteria. In this study we present data form the subanalysis in elderly patients 
(> 75 years).
Methods. Among a total of 1683 consecutive patients with STEMI enrolled in the study, 
160 patients older than 75 years underwent primary angioplasty (87 randomized to S and 
73 to B). All angiographic, clinical and 1-year follow-up data were prospectively collected.
Results. The two groups of patients showed similar clinical and angiographic 
characteristics. The cross-over rates from B to S and S to B were 28.6% and 27.6%, 
respectively. No difference was observed in 1-year mortality (17.1% vs 11.9%, p = NS) 
and MACE (28.9% vs 26.9%, p = NS) according to intention-to-treat analysis.
Conclusions. Our study is the ﬁ rst randomized trial comparing stenting and balloon 
angioplasty in a large cohort of unselected, consecutive patients. This subanalysis showed 
that routine stenting does not improve clinical outcome in elderly patients undergoing 
primary angioplasty for STEMI.
1008-35 Treatment of Saphenous Vein Grafts Lesions With Drug-
Eluting Stents: Immediate and Mid-Term Outcome
Lei Ge, Ioannis Iakovou, Giuseppe M. Sangiorgi, Alaide Chieffo, Gloria Melzi, Matteo 
Montorfano, Iassen Michev, Flavio Airoldi, Mauro Carlino, Nicola Corvaja, Antonio 
Colombo, EMO Centro Cuore Columbus, Milan, Italy
Background: Although drug-eluting stent (DES) implantation in native coronary arteries 
showed promising results, the safety and effectiveness of DES implantation for the 
treatment saphenous vein graft (SVG) lesions remains uncertain. In addition the dramatic 
treatment effect of DES on native coronary artery lesions may preclude performing a 
randomized trial versus bare metal stents (BMS) in this lesion subset.
Methods: We identiﬁ ed 76 consecutive patients who underwent percutaneous 
revascularization in SVG lesions treated with DES from April 2002 to June 2004. A control 
group was composed of 89 consecutive patients with SVG lesions treated with BMS in 
the same length period immediately before the introduction of DES (26 months). The 
incidence of major adverse cardiac events (MACE) including death, myocardial infarction, 
target lesion revascularization, and target vessel revascularization was evaluated in-
hospital and at 6 months.
Results: Among patients treated with DES, 44 patients received sirolimus-eluting stents 
and 32 patients received paclitaxel-eluting stents. No signiﬁ cant differences between the 
2 groups in angiographic success rate and in-hospital outcome. Clinical follow-up at 6 
months was complete for all patients and angiographic follow-up was complete 63.6% 
in the DES group and 65.2% in the BMS group. Cumulative MACE during 6-month 
was 12.7% in the DES group and 28.1% in the BMS group (P=0.04). Patients treated 
with DES had a signiﬁ cant lower incidence of in-segment restenosis (10.9% vs. 27.7%,
P=0.03), target lesions revascularization (3.2% vs. 17.5%, P=0.005) and target vessel 
revascularization (6.5% vs. 20.8%, P=0.01). By multivariate logistic regression analysis, 
diabetes (OR: 3.67; 95% CI: 1.24 to 10.84; P=0.02), usage of BMS (OR: 3.57; 95% CI: 
1.19 to 10.8; P =0.02), age of SVG (OR: 1.20; 95% CI: 1.07 to 1.34; P=0.002), maximal 
inﬂ ation pressure (OR: 1.15; 95% CI: 1.0 to 1.32; P=0.049), and baseline reference vessel 
diameter (OR: 0.52; 95% CI: 0.28 to 0.95; P=0.03) were identiﬁ ed as predictors of MACE 
during 6-month follow-up.
Conclusions: Compared to BMS implantation, DES implantation in SVG lesions appears 
safe with favorable and improved mid-term outcomes.
1008-36 In-hospital Outcomes and Trends in Usage of Drug-
Eluting Stents in Aortocoronary Bypass Grafts:A 
Report From the American College of Cardiology - 
National Cardiovascular Data Registry(ACC-NCDR)
Angampally G. Rajeev, Satish Surabhi, Vishal Gupta, Sanjeev Wasson, Timothy 
Catchings, Richard Webel, Kul B. Aggarwal, Richard E. Shaw, University of Missouri - 
Columbia, Columbia, MO, American College of Cardiology, Bethesda, MD
Background:Although Drug Eluting Stents (DES) are considered the standard of care in 
native vessel Percutaneous Coronary Intervention (PCI) their role in bypass graft PCI is 
less known. We sought to determine the prevalence of usage of DES and the in-hospital 
outcomes as compared to Baremetal stents (BMS).
Methods:Between January 2003 and April 2004 data on 17,287 PCI procedures involving 
bypass grafts were submitted from 313 institutions to the ACC-NCDR. To analyze the 
use of DES in grafts, the most recent 4 quarters representing the DES era (Q2-2003, 
Q3-2003, Q4-2003, Q1-2004) were analyzed. In 14,010 (81.0%) a stent was used. The 
groups were designated as follows B for BMS, D for DES and C for both.
Results:The following table displays the stent use by the type of stent for each quarter 
and the trends in mortality. 
Trends of DES in Graft Lesions
Q2-2003 Q3-2003 Q4-2003 Q1-2004 Overall Observed Mortality%
Expected 
Mortality%
Adjusted 
Mortality%
B
(%)
2816
(84.8%)
2317
(69.3%)
2297
(62..4%)
2002
(54.5%)
9432
(67.3%) 1.4% 1.5% 1.0%
D (%) 390(11.7%)
782
(23.4%)
1106
(30.1%)
1435
(39.1%)
3713
(26.5%) 0.6% 1.0% 0.6%
C(%) 114(3.5%)
243
(7.3%)
274
(7.5%)
234
(6.4%)
865
(6.2%) 0.9% 1.1% 0.8%
Although DES patients had a lower adjusted mortality, patient receiving BMS were more 
likely to present with STEMI (6.3% vs 4.6% vs 3.0% : B vs C vs D), those receiving 
both BMS and DES had more lesions attempted (2.36 vs 1.42 vs1.39; C vs D vs B) and 
more high-risk complex leisions treated (52% vs 45% vs 42%;C vs D vs B). All these 
comparisons were at P<.0001 level.
Conclusions :DES are being used with increasing frequency for treatment of graft 
disease with favorable in-hospital results. However,BMS are still predominantly used in 
treatment of patients presenting with STEMI or high risk lesions. Long-term outcome data 
are needed to validate DES usage in graft disease.
1008-37 One-Year Clinical Follow Up of Sirolimus-Eluting Stents 
in the Treatment of Saphenous Vein Graft Disease
Atul Sharma, Robert M. Minutello, Felix Yang, Edward Wingﬁ eld, Sherrita Bhagan, 
Eric T. Chou, Steve S. Kim, James A. Kong, Srihari S. Naidu, Manish Parikh, Geoffrey 
Bergman, Mun K. Hong, S. Chiu Wong, New York Presbyterian Hospital - Weill Cornell 
Medical College, New York, NY
Background: Percutaneous revascularization of saphenous vein graft (SVG) lesions with 
bare metal stents (BMS) is associated with frequent in-stent restenosis and suboptimal 
long-term clinical outcomes. Sirolimus-eluting stents (SES) have been shown to 
signiﬁ cantly reduce restenosis rates in various native lesion subsets. However, the impact 
of SES in the treatment of SVG lesions is unclear.
Methods: We compared our ﬁ rst 47 patients who underwent SES implantation in SVGs with 
52 consecutive patients who received BMS in the 9 months prior to SES availability. Major 
adverse cardiac events (MACE: death, myocardial infarction, target vessel revascularization, 
and clinical restenosis, i.e. anginal symptoms or an abnormal stress test and at least 50% 
angiographic in-stent diameter stenosis) were compared in both groups.
Results (See table): Baseline variables between both groups were similar. Patients 
undergoing SES implantation more frequently received embolic distal protection. Mean 
stent diameter was smaller in the SES treatment group, with a trend towards increased total 
stent length in the SES cohort. At a mean follow-up of 12.3 months, the SES group had a 
56% reduction in MACE, primarily driven by an 84% reduction in clinical restenosis.
Conclusion: Despite placement of longer stents in patients with smaller SVGs, the use of 
SES in treatment of SVG lesions appears to be safe, and is associated with less clinical 
restenosis and more favorable one-year clinical outcomes compared to conventional BMS.
SES (N=47) BMS (N=52) P Value
Clinical Characteristics
Age (years) 72.3 ± 10.7 69.7 ± 10.9 NS
Male sex (%) 72.3 76.9 NS
Hypertension (%) 85.1 86.5 NS
Diabetes (%) 40.4 46.2 NS
Hyperlipidemia (%) 85.1 75 NS
Prior MI (%) 42.6 30.8 NS
Peripheral Arterial Disease (%) 23.4 13.5 NS
Congestive Heart Failure (%) 21.3 13.5 NS
Acute Coronary Syndrome (%) 66 71.2 NS
Ejection Fraction (%) 45.8 ± 11.1 47 ± 10.4 NS
Mean Graft Age (years) 10.7 ± 6.4 8.3 ± 5.7 0.07
Procedural Data
Use of Bivalirudin (%) 36.7 24.6 NS
Glycoprotein 2b3a Inhibitor Use (%) 61.0 68.8 NS
Distal Protection Device Usage (%) 69.4 46.2 0.02
Mechanical Thrombectomy (%) 22.4 13.1 NS
Number of Stents per Patient 1.27 ± 0.6 1.16 ± 0.4 NS
Mean Stent Diameter (mm) 3.15 ± 0.4 3.43 ± 0.5 0.002
Total Stent Length per Patient (mm) 27.2 ± 18.1 22.0 ± 10.4 0.07
Events
Mean Follow Up (Months) 12.3 ± 5.3 13.6 ± 4.7 NS
Total MACE (%) 15.0 34.2 0.03
Death (%) 2.1 1.9 NS
Non-Fatal MI (%) 4.3 1.9 NS
Clinical Restenosis (%) 4.3 26.9 0.002
TLR (%) 4.3 13.5 NS
TVR (%) 6.4 17.3 NS
Subacute Thrombosis (%) 0 0 NS
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1008-38 Real World Use of Sirolimus-Eluting Stents in 
Saphenous Vein Graft Disease: Data From the e-
CYPHER Registry
J Eduardo Sousa, Alexandre Abizaid, Antony H. Gershlick, Giulio Guagliumi, Philippe 
Guyon, Chaim Lotan, Ashok Seth, Philip Urban, William Wijns, Jose R. Costa, Galo 
Maldonado, Amanda Sousa, for the e-CYPHER Investigators, Institute Dante Pazzanese 
of Cardiology, Sao Paulo, Brazil
Background: The efﬁ cacy of Sirolimus-Eluting stents (SES) in the treatment of native 
vessel disease has been proven in several randomized trials. However, there is no data to 
support the use of SES for the treatment of saphenous graft disease (SVG) stenosis.
Methods and Results: The e-CYPHER registry enrolled 14,316 patients to assess the 
performance of SES in a “real-world” scenario. 14,068 pts had native coronary lesions 
(Native) and 248 had SVG lesions. SVG pts presented with worst risk proﬁ le: older pts 
(68+9.6 vs. 61+11years old; p=0.0001), more male pts (82.7% vs. 77.6%; p=0.060), more 
diabetic pts. (34.3% vs. 28.5%; p=0.046), more hypertention (69.4% vs. 62.1%; p=0.020), 
more hyperlipidemia (80.2% vs. 62.8%; p=0.0001), and more restenostic lesions (27.8% 
vs. 12.1%; p=0.0001). Regarding procedural characteristics: direct stenting was more 
often applied in the SVG group (43.9% vs. 33.2%; p=0.0001), and the number of stents 
per lesion was similar in both groups (1.39+0.7 vs. 1.34+0.6; p=0.273). Reference vessel 
diameter was larger for the SVG group (3.0+0.37 vs. 2.86+0.35; p=0.0001), and lesion 
length was similar (17.1+10 vs. 17.2+8.8; p=0.782).
Conclusions: In the e-cypher registry, SES treatment of SVG lesions was associated 
with a low rate of 6-month TLR (2.5%). The higher MACE rates (6.5%) compared to 
the native group is explained by the higher TVR (non-TLR) rates. This still represents a 
striking improvement when compared with historical bare metal stent data.
Table (6-month clinical follow-up)
SVG Native P value
n 248 14,068
Death 4 (2.0%) 159 (1.48%) 0.538
Q-wave MI 2 (1.0%) 35 (0.33%) 0.101
Non-Q-wave MI 2 (1.0%) 60 (0.56%) 0.404
TLR 5 (2.51%) 132 (1.23%) 0.105
TVR 5 (2.51%) 87 (0.81%) 0.009
Subacute/late thrombosis 1 (0.5%)/1 (0.5%) 67 (0.6%)/ 16 (0.15%) 0.745
Total MACE 13 (6.53%) 361 (3.35%) 0.014
1008-39 Efﬁ cacy of Sirolimus-Eluting Stents in Comparison to 
Bare Metal Stents for Saphenous Vein Graft Intervention
William W. Chu, Seung-Woon Rha, Rebecca Torguson, Daniel A. Canos, Augusto 
Pichard, William Suddath, Lowell Satler, Kenneth Kent, Ron Waksman, Washington 
Hospital Center, Washington, DC
Background: Saphenous vein graft (SVG) intervention is asscociated with increased 
rates of periprocedural complications and late clinical outcomes. We sought to examine 
the efﬁ cacy and safety of sirolimus-eluting stents (SES; CypherTM) compared with bare 
metal stents (BMS) in SVG intervention .
Methods: A total of 56 patients (pts) with 70 SVG lesions who underwent standard PCI 
with SES were compared with 511 pts with 721 SVG lesions with BMS. All pts received 
distal protection devices (DPD) during SVG intervention. The periprocedural, in-hospital, 
30-day, and 6-month clinical outcomes in both groups were compared.
Results: Baseline clinical and procedural characteristics were balanced between both 
groups, however the SES group had more ostial lesions (22.7% vs. 12.7%, p = 0.024) and 
restenotic lesions (18.6% vs. 10.3%, p = 0.035). The pts in the SES group had lower in-
hospital major CK-MB elevations. At 30 days, non-Q-wave MIs were signiﬁ cantly lower in 
the SES group. This beneﬁ t continued to be lower up to 6 months, although death, Q-wave 
MI, TLR, TVR, and MACE were similar between both groups (Table).
Conclusions: The use of SES in patients undergoing SVG intervention is clinically safe 
and feasible with lower periprocedural ischemic complications compared with BMS but 
does not carry beneﬁ t over BMS for this indication.
Table. Clinical Outcomes
Variables (%) SES (n=56) BMS (n=511) p Value
In-hospital outcomes
CK-MB >2X normal 9.1 26.3 0.005
CK-MB >3X normal 7.3 19.6 0.025
CK-MB >4X normal 5.5 16.6 0.030
At 30 days SES (n=49) BMS (n=314)
Death 2.0 3.1 0.684
Q-wave MI 0.0 0.0 -
Non-Q-wave MI 8.2 26.1 0.006
TVR-MACE 2.0 3.4 0.607
At 6 months SES (n=42) BMS (n=290)
Death 4.8 5.7 0.801
Q-wave MI 0.0 0.8 0.568
Non-Q-wave MI 9.5 28.3 0.010
TVR-MACE 4.8 8.7 0.385
1008-40 CYPHER Sirolimus-Eluting Bx Velocity Stent Is a Safe 
and Effective Treatment For Arterial and Saphenous 
Vein Bypass Grafts
Emerson C. Perin, Marco A. Costa, Sidney Cohen, Peter B. Berger, Texas Heart 
Institute, Houston, TX
Background: The efﬁ cacy of the sirolimus-eluting stent (SES) in native coronary arteries 
is proven; however, its beneﬁ ts in coronary bypass grafts (CBG) is less certain.
Methods: We sought to evaluate the efﬁ cacy of SES in 126 patients with arterial and 
venous bypass grafts based on data extracted from E-CYPHER. In the registry, 2071 pts 
were enrolled at 38 centers, and 3103 lesions (1.5/pt) treated. 2993 CYPHER and 304 
non-CYPHER stents (1.6 stents/pt) were deployed. Adverse events were adjudicated by 
an independent clinical events committee. Enrollment was completed 12/31/03.
Results: 126 of 2067 pts 126 had an SES placed in a bypass graft. Cumulative 6 month 
event rates, demographics, lesion characteristics and procedural data are presented in the 
table below. Comprehensive 12-month data will be available at the time of presentation.
Variable % (N) 95% Conﬁ dence Interval
Diabetes 49.2% (62/126) [40.2%, 58.3%]
Insulin dependent 15.1% (19/126) [9.3%, 22.5%]
Target vessel type
Arterial 28.1% (65/231) [22.4%, 34.4%]
SVG 71.9% (166/231) [65.6%, 77.6%]
Reference Vessel Diameter (mm)
Mean±SD (n) 3.13 ±0.56 (154) [3.04, 3.22]
Lesion length (mm)
Mean±SD (n) 16.25 ±9.55 (170) [14.81, 17.70]
De novo Lesion 80.5% (186/231) [74.8%, 85.4%]
Restenotic following failed hx of PCI 19.5% (45/231) [14.6%, 25.2%]
Procedure Success 88.4% (122/138) [81.9%, 93.2%]
TIMI 3 ﬂ ow
Pre-procedure TIMI 3 81.1% (154/190) [74.7%, 86.4%]
Post-procedure TIMI 3 98.6% (207/210) [95.9%, 99.7%]
MACE (Death, Q or Non-Q Wave MI, 
Em CABG, TLR) 6.3% (8/126) [2.8%, 12.1%]
Death 1.6% (2/126) [02%, 5.6%]
Myocardial Infarction (Q Wave or 
Non-Q Wave) 0.8%(1/126) [0.0%, 4.3%]
Q Wave MI 0 [-, -]
Non-Q Wave MI 0.8%(1/126) [0.0%, 4.3%]
Target Lesion Revascularization (TLR) 4.0%(5/126) [1.3%, 9.0%]
Target Vessel Failure 7.9%(10/126) [3.9%, 14.1%]
Stent Thrombosis 0 [-, -]
Conclusions: Percutaneous treatment of CBG with SES appears to be both safe and 
efﬁ cacious with a high angiographic success and low cumulative MACE rate 6 months 
after the procedure.
1008-41 An Evaluation of Drug Eluting Stents in Saphenous Vein 
Grafts
Gregory J. Mishkel, Nilesh J. Goswami, John B. Gill, Frank V. Aguirre, Robert W. Ligon, 
Anna L. Moore, Prairie Heart Institute, Springﬁ eld, IL, Memorial Medical Center, 
Springﬁ eld, IL
Background: Drug eluting stents (DES) in saphenous vein grafts (SVG) have been 
excluded from randomized controlled trials. We evaluated the clinical outcomes of stenting 
in SVG in the era of DES.
Methods: Utilization, angiographic, and outcome data from between May 1, 2003 and 
June 30, 2004 was obtained from our facility’s American College of Cardiology National 
Cardiovascular Data Registry database and adjunct DES data registry. We excluded 
patients with both bare metal stents (BMS) and DES, or with an additional vessel dilated. 
One-year mortality, myocardial infarction (MI) and target lesion revascularization will be 
available at presentation.
Results: During the study period there were 3909 percutaneous coronary interventions 
performed in 3354 patients. Of these, there were 203 patients (85 BMS, 118 DES), 
217 procedures (88 BMS, 129 DES), and 346 lesions (118 BMS, 228 DES) involving 
implantation of a stent in a SVG. The distribution of SVG lesion locations was 7% in the 
aortic anastomosis, 74% in the body of the graft, and 19% in the distal anastomosis. 
There was no difference in patient demographics, graft age, use of embolic protection, 
glycoprotein IIbIIIa inhibitor usage, or incidence of acute MI. Post TIMI III ﬂ ow was similar 
between the two groups (99.8 % BMS, 99.6 % DES). There was no difference in in-
hospital coronary artery bypass (0% BMS, 0.8% DES) or death (1.1% BMS, 0% DES). 
Target lesion revascularization at six months was 6% BMS versus 8% DES (p=NS).
Conclusions: DES placement in SVG appears to be safe clinical practice, but as of yet 
there is no indication that there is a lower restenosis rate in the long term.
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1008-42 A Prospective, Randomized U.S. Trial of the PTFE 
Covered JOSTENT for the Treatment of Diseased 
Saphenous Vein Grafts: The BARRICADE Trial
Gregg W. Stone, Sheldon Goldberg, Roxana Mehran, Charles O’Shaughnessy, Mark 
Midei, Robert Siegel, Barry George, Lowell Satler, Albert Raizner, Manuela Negoita, 
Martin Fahy, Heidar Arjomand-Fard, Alexandra J. Lansky, Columbia University Medical 
Center, New York, NY, Cardiovascular Research Foundation, New York, NY
Background. Bare metal stent (BMS) implantation in diseased saphenous vein grafts 
(SVG) results in a high rate of peri-procedural complications and restenosis. Whether 
PTFE covered stent grafts can further improve outcomes is uncertain.
Methods. BARRICADE is a multicenter, prospective, randomized trial in which 500 pts with 
SVG lesions ≤25 mm in length with RVD ≥3.0 - ≤5.0 mm are randomized to the PTFE 
covered JOSTENT stent graft or BMS. Unlike in prior stent graft trials, the protocol mandated 
stent graft implantation at high (≥18 atm.) pressure, and clopidogrel continuation for at least 
8 months. The primary endpoint was angiographic restenosis at 8 months.
Results. After 241 pts were randomized, a futility analysis was performed on the ﬁ rst 
125 pts who had reached 8-month follow-up. On the basis of these data, the trial was 
terminated. Baseline features were well matched between the 2 groups. Mean pt age 
was 68 yrs, 39% had diabetes and 40% prior MI. Multiple lesions were treated in 22.3% 
of pts. Distal protection or thrombectomy devices were used in ~38% of pts in each arm. 
Results appear in the table.
Conclusions. Despite high pressure implantation techniques and prolonged 
thienopyridine use, the PTFE covered JOSTENT stent graft did not reduce angiographic 
restenosis nor enhance event free-survival, and was associated with an increased rate of 
late SVG closure compared to BMS. Alternative approaches are required to improve graft 
patency and clinical outcomes after percutaneous intervention of diseased SVGs.
JOSTENT BMS P value
N pts, vessels, lesions 57, 60, 74 68, 71, 81 -
30 day MACE 8.8% 10.3% 0.77
8 month binary restenosis 44.4% 38.5% 0.55
8 month total occlusion 26.7% 9.6% 0.028
9 month death 3.5% 1.5% 0.49
9 month MI 12.5% 15.0% 0.69
9 month TLR 16.6% 20.5% 0.53
9 month TVR 18.5% 23.3% 0.47
9 month MACE 31.9% 32.2% 0.94
1008-43 Recanalization of Chronic Total Coronary Occlusion 
With Sirolimus-Eluting Stent: Eight-Months 
Angiographic Follow-Up. Single Center Experience.
Angelo Cioppa, Luigi Salemme, Vittorio Ambrosini, Salvatore Battaglia, Maria Letizia 
Lo Muzio, Gregory Popusoi, Giovanni Sorropago, Tullio Tesorio, Paolo Rubino, 
“Montevergine” Clinic, Mercogliano, Italy
Background: coronary chronic total occlusion (CTO) represents a challenging artery 
lesion for the interventional cardiologists due an high restenosis and reocclusion rate.
Aim: to asses the immediate and mid-term outcome of Sirolimus -eluting stent Cypher®
(Cordis) (SES) on treatment of CTOs.
Methods: from August, 2002 to January, 2003 75 consecutive patients (54 males, 
21 females) aged 57±16 years, with documented myocardial ischemia and/or viability 
in occluded artery -related myocardial segmentes, underwent SES implantation after 
successful CTO (> 30 days) recanalisation. Vessel diameter was in the 2,5-30 mm and 
lesion length in 8-33 mm range. After procedure all patients have been clinically followed-
up at 30, 90 and 180 days. Repeat catheterization was performed at 8 months.
Results: A Cipher stent was successfully implanted in all lesions. No complications occurred 
during procedure. In 5 patients(6,8%) an additional SES has been implanted due to a ﬂ ow-
limiting dissection at the distal edge. No MACEs occurred during Hospital stay. Six-months 
clinical follow-up, obtained in all patients showed: one non-cardiac death, no myocardial 
infarction(MI), no need for repeat target vessel revascularization(TLR). Six patients had 
residual angina in absence of demonstrated target vessel related myocardial ischemia. 
Twenty-three patients(31%) had PCI forother vessel, without target vessel restenosis. Eight-
months angiographic follow-up, obtained in 67 patients (89%) showed 4 (5,9%) focal in-stent 
restenosis (ISR). No diffuse or proliferative ISR pattern or reocclusion were seen.
Conclusion: the use of SES for CTO is feasible, safe and is associated with a low 
incidence of clinical events during clinical follow-up.Excellent results at angiographic 
follow-up may allow to consider SES for extensive use in CTOs’ treatment.
1008-44 Successful Prevention of Lesion Recurrence in Chronic 
Total Coronary Occlusions Treated With a Paclitaxel-
Eluting Polymer-Based Stent: Long-Term Results From 
the Paclitaxel in Chronic Total Occlusion (PACTO) Study
Gerald S. Werner, Friedrich-Schiller-University, Jena, Germany
Background. The recurrence rate after percutaneous coronary intervention (PCI) for 
chronic total coronary occlusions (CTO) is in the range of 30-50% even with routine 
stenting. The reduction of restenosis by drug-eluting stents would provide a new 
therapeutic approach to improve the late outcome in CTOs.
Methods. In 48 consecutive patients a CTO (duration >2 weeks) was successfully recanalized 
with implantation of paclitaxel-eluting stents (Taxus, Boston Scientiﬁ c Corp.). Each of these 
patients was matched to a patient treated with bare metal stents (BMS) in the preceding time 
period based on lesion characteristics and clinical parameters. Angiographic results after 6 
months and major clinical adverse events (MACE: death, MI, CKMB increase above the upper 
limit of normal, repeat revascularization) after 12 and 18 months were compared.
Results. Clinical and demographic data were similar in both groups with a high rate of 
diabetes in 32% and 34%. Duration of CTOs was >3 months in 50% of patients. The 
number of stents was 1.7±0.9 in both groups, with a mean diameter of the implanted 
stent of 3.0±0.3 mm. The mean stented segment length was similar in the BMS group 
with 36±17 mm and the Taxus group with 40±20 mm. Periprocedural MACE consisted 
only of an asymptomatic increase of CKMB in 4.5% with BMS and 5% with Taxus. At 
6 months repeat angiography the target vessel failure was signiﬁ cantly lower with PES 
than with BMS (8% vs. 51%; p<0.001). Notably, the rate of late reocclusion was lower 
with Taxus in 2% vs. 23% (p<0.001). The late loss was signiﬁ cantly reduced by Taxus 
with 0.19±0.62mm vs. 1.21±0.70mm (p<0.001). All nonocclusive restenotic lesions in the 
Taxus group were focal and underwent repeat PCI. No patient in the Taxus group, but 13% 
in the BMS group with lesion recurrence required bypass surgery. The overall MACE rate 
at 12 months was 13% with Taxus and 48% with BMS (p<0.001). The clinical success 
persisted in all 28 patients who completed 18 months follow-up
Conclusions. The use of Taxus in CTOs is safe with no increased risk of periprocedural 
MACE. It reduced target vessel failure and MACE in these high-risk lesions by more than 
80%. CTOs should be preferred lesions for the use of drug-eluting stents.
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1009-23 Mandatory Diagnostic Angiography for Carotid Artery 
Stenosis Prior to Carotid Artery Intervention
Amgad N. Makaryus, Lawrence M. Phillips, Paul Wright, Jason Freeman, Stephen Green, 
Lawrence Ong, Donna Marchant, North Shore University Hospital, Manhasset, NY
Introduction: Revascularization is an important strategy for reducing stroke risk in 
patients with severe carotid atherosclerosis. Both carotid endarterectomy (CEA) and 
carotid artery stenting (CAS) have been proven to have beneﬁ cial outcomes. Magnetic 
resonance angiography (MRA) and/or carotid ultrasound have been used as the only 
diagnostic modalities prior to revascularization. Guidelines for endovascular treatment 
have included stenoses of greater than 70%. Patients undergoing CEA frequently have 
no further assessments of carotid anatomy prior to surgery. For patients undergoing 
CAS, diagnostic angiography is performed at the time of stenting. Evaluation with carotid 
ultrasound and MRA can often overestimate the degree of stenosis. We sought to 
determine if noninvasive imaging was sufﬁ cient for determining whether a patient should 
be referred for carotid intervention.
Methods: We performed a retrospective review of 101 patients referred to our institution 
for CAS between July 2001 and August 2004. All patients had previously been evaluated 
with carotid ultrasound and 94% had undergone MRA as well. We sought to determine 
if the noninvasive diagnostic imaging for carotid stenosis was sufﬁ cient to determine the 
necessity for endovascular intervention.
Results: Of the 101 patients referred for carotid intervention, 36 (36%) were shown 
to have < 70% stenoses and did not require intervention. Of those who had signiﬁ cant 
disease, 49 (75%) underwent successful CAS, 15 (23%) underwent CEA, and one patient 
was treated medically for a total occlusion. Three of the 36 patients not requiring carotid 
intervention were found to have subclavian stenosis. Two (4%) of the patients undergoing 
CAS, and 4 (27%) of the patients undergoing CEA had minor complications. No patients 
suffered a major stroke, MI, or death at follow-up.
Conclusion: This retrospective review demonstrates that 36% of patients referred 
for endovascular intervention based on noninvasive imaging did not meet criteria 
by angiography. This emphasizes the need for carotid angiography prior to carotid 
intervention.
1009-24 Short-term Outcomes of Carotid Stenting under 
Protection in High and Low Risk Patient
Michel Henry, Isabelle Henry, Antonios Polydorou, Ad Polydorou, Edmond Le Borgne, 
Michèle Hugel, Cabinet de Cardiologie, Nancy, France
Background: Recent studies have shown that Carotid Angioplasty and Stenting (C.A.S.) 
has superior short term outcomes than Carotid Endarterectomy (C.E.A.) in high surgical 
risk patients (H.R.). It is not clear however, whether low surgical risk patients (L.R.) are 
also at lower risk. We compared short term outcomes of C.A.S. in H.R. and L.R. patients.
Methods: We analyzed all C.A.S. performed under protection devices. HR factors included 
age=80 yrs, post surgical restenosis, prior neck surgery or radiation, contralateral 
occlusion, low or high anatomic lesion, unstable or severe coronary or hearty diseases, 
severe commorbidities. Patients were followed for 30 days.
Results: C.A.S. were performed in 514 arteries under protection devices using occlusion 
balloon (n=330), ﬁ lters (n=178), reversal ﬂ ow technique (n=6). 334 (65%) were found to 
be at HR and 180 (35%) at LR. HR and LR patients had similar success rate of protection 
device deployment (99% both), and stent placement (100% both).
There was no statistical difference between occlusion balloon and ﬁ lter for 30 day death 
and stroke rate (0.3% vs 0.6, p=n.s) and embolic events (1.4% vs 1.1%, p=n.s.). the 30 
day outcomes are shown in the table: 
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514 PROCEDURES
30 DAY COMPLICATION
HIGH RISK
n = 334
LOW RISK
n = 180 P VALUE
T.I.A. 4 (1.2%) 2 (1.1%) N.S.
MINOR STROKE 1 (0.3%) 0 N.S.
MAJOR STROKE 1 (0.3%) 0 N.S.
RETINAL EMBOLUS 0 2 (1.1%) N.S.
HYPERPERFUSION SYNDROME 2 (0.6%) 1 (0.6%) N.S.
DEATH
FATAL STROKE
NON STROKE DEATH
2 (0.6%)
2 (0.6%)
1 (0.6%)
1 (0.6%)
N.S.
N.S.
N.S.
DEATH AND STROKE 4 (1.2%) 1 (0.6%) N.S.
EMBOLIC EVENTS 6 (1.8%) 3 (1.7%) N.S.
Conclusions: C.A.S under protection is safe with favourable low event rate in HR and 
LR patients. LR patients have a trend toward lower death and stroke rate after C.A.S. 
compared to C.E.A., but it is not statistically signiﬁ cant. C.A.S should be enlarged to L.R. 
patients.
1009-25 Long-Term Results of Carotid Stent Implantation Up to 
11 Years in Patients With Carotid Stenosis
Jennifer Sugita, Eric Schluessmann, Kasja Rabe, Heike Goedel, Albrecht Roemer, 
Klaus Lang, Ilona Hofmann, Thomas Middeldorf, Peter Schneider, Catherine Thomalske, 
Ulrich Oetjen, Horst Sievert, CardioVascular Center Frankfurt, Sankt Katharinen, 
Frankfurt, Germany, Sankt Katharinen Hospital, Frankfurt, Germany
Background: Stent implantation has become an alternative treatment to surgery in 
patients with stenoses of the carotid artery and is recommended in surgically high-risk 
patients. Yet compared to the traditional surgical standard of care, only limited information 
is available regarding the long-term outcomes of carotid stenting.
Methods: Since 1993 470 high-grade lesions of the internal carotid artery in 429 
consecutive patients have been treated by stent implantation. In 392 lesions the procedure 
was performed with use of embolic protection devices. 473 stents were implanted. Follow-
up investigations included a neurological examination after 1 month and thereafter 
whenever an event occurred. A carotid duplex scan was performed after 1 and 6 months. 
Thereafter, a questionnaire was sent every year.
Patients: The age ranged from 40 - 90 years (70 ± 9 years). 206 lesions (44%) were 
symptomatic. 30% of the patients were ineligible for carotid endarterectomy (CEA) 
according to the North American Symptomatic Carotid Endarterectomy Trial (NASCET). 
68% were male. 192 patients (41%) had a contralateral stenosis of > 50% and 42 (9%) 
a contralateral occlusion. 61% of the patients suffered from coronary heart disease, 72% 
from hypertension, 32% from diabetes, 54% from hyperlipidemia and 45% were previous 
or current smokers. Mean percentage of lesion was 76 ± 11%, mean length of lesion was 
8.8 ± 5.3mm.
Results: The procedure was technically successful in 467/470 interventions. 19 patients 
had one of the following acute or subacute (<30 days) complications: Cerebrovascular 
death in 4, non-fatal major stroke in 7, minor stroke in 9, asymptomatic occlusion in 1, 
non-cerebrovascular death in 3 patient. During follow-up (1027 patient years) 4 cerebral 
deaths, 4 major, 4 minor ipsilateral strokes and 18 asymptomatic re-stenoses occurred. 
51 patients died from non-cerebral causes.
Conclusion: Carotid stenting is a successful technique for preventing stroke in patients 
with a carotid stenosis. Complications occur mostly within 30 days. Neurological events, 
cerebrovascular mortality and re-stenosis throughout long-term follow-up are rare.
1009-26 Low Body Mass Index (bmi) Is A Strong Predictor Of 
Long-term Mortality In Patients Undergoing Carotid 
Artery Stenting.
Hitinder S. Gurm, David S. Lee, Robert B. Fathi, Deepak Vivek, Michael H. Yen, Alex 
Abou-Chebl, Samir Kapadia, Christopher Bajzer, Jay S. Yadav, Cleveland Clinic 
Foundation, Cleveland, OH
Background: Low body mass index (BMI) has been demonstrated to be a strong 
predictor of adverse outcome in patients undergoing coronary revascularization. Its 
signiﬁ cance in predicting outcome of patients undergoing carotid artery stenting (CAS) 
has never been ascertained.
Methods: We evaluated the long-term outcome of 717 patients that underwent CAS at 
our institution according to BMI. Patients were divided into tertiles of BMI for descriptive 
analysis. The primary outcome was long-term mortality.
Results: The patients with low BMI were older (mean age 71 years vs 70 years vs 67 
years) and had lower EF (mean LVEF 40 vs 43 vs 44 %). There was no difference in gender, 
baseline creatinine, CRP, systolic or diastolic blood pressure, history of congestive heart 
failure (CHF), peripheral vascular disease (PVD),chronic obstructive pulmonary disease 
(COPD) or smoking. Diabetes was markedly more common among patients with higher 
BMI (29% vs 36% vs 52%). The mean follow up was 2.1 yrs. There were 51 deaths in 
tertile 1, 39 in tertile 2 and 30 in tertile 3 (P = 0.02). An elevated BMI remained signiﬁ cant 
protector against mortality after adjusting for age, baseline renal function, anemia, history 
of diabetes and COPD (HR 0.93, 95% CI,0.90-.98, P=0.004)
Conclusion: Low BMI is a major predictor of mortality among patients undergoing CAS. 
Further research is warranted to elucidate the mechanism of this association. Further, 
our ﬁ ndings suggest a need to incorporate BMI into risk adjustment models in this 
population. 
1009-29 BEACH Trial: 30 Day Outcomes of Carotid Wallstent and 
FilterWire EX/EZ Distal Protection System Placement 
for Treatment of High Surgical Risk Patients
Christopher J. White, for the Beach Investigators, Ochsner Clinic Foundation, New 
Orleans, LA
Background: Carotid artery stent placement with distal emboli protection is being 
investigated as an alternative to carotid endarterectomy (CEA) for stroke prevention. 
The BEACH trial is a multicenter, prospective registry to evaluate outcomes of patients 
(pts) with carotid artery stenosis at high risk for CEA using the Carotid Wallstent and the 
FilterWire EX/EZ distal protection system.
Methods: We enrolled 747 pts at high surgical risk for CEA due to prespeciﬁ ed anatomical 
criteria or medical comorbidities who had a stenosis severity of ≥ 50% in symptomatic 
(Sx) and ≥ 80% in asymptomatic (Asx) pts. Three groups entered the trial. The “roll-in” (R) 
group (n = 189) included up to 5 pts per site for initiation and familiarization; the “pivotal” 
(P) group (n = 480) is the primary group; and the “bilateral” (B) group (n = 78) included 
those with treatment of both carotids. We are reporting the 30-day results.
Results: Overall, one of the anatomical criteria was the most common indication for 
enrollment (62%), but the most common qualiﬁ er was age > 75 years (39%) followed by 
prior CEA (32%), contralateral occlusion (27%), and multivessel coronary artery disease 
(20%). The percentage of Asx pts was not different among the 3 groups (R=75%, P=76%, 
and B=64%; p = 0.06). The 30-day composite endpoint (all death = 1.5%, all stroke = 
4.8%, and all MI’s = 0.8%) for this high surgical risk group receiving carotid stents with 
distal emboli protection was 5.7% which was not different among the 3 groups studied 
(R=6.9%, P=5.8%, B=2.6%, p=.39). Pts enrolled due to medical comorbidities had a 
higher periprocedural event rate than did those with anatomical criteria (9.1% vs 3.7%, 
p=.008).
Conclusion: The similarity in periprocedural event rates for R and P groups suggest a 
ﬂ at/short learning curve for this carotid stent system. The similarity in event rates for the B 
group suggests that staged sequential treatment of bilateral stenoses may be performed 
at the same risk as for unilateral lesions. The 30-day safety of this stent and distal emboli 
protection system is very encouraging and favorably compares with other high surgical 
risk carotid stent trials.
1009-30 Marked Underutilization of Effective Therapies in 
Patients With Documented Cerebrovascular Disease
Jitesh V. Vasadia, Dat Do, Steven Bailey, Robert Chilton, Michael Wholey, Mark Wholey, 
Walter Tan, Stanislaw Skaluba, Umesh Arora, University of Texas Health Science Center 
San Antonio, San Antonio, TX
Background: CHAMP, a structured risk factor reduction program, has demonstrated 
reduced cardiovascular event rates in patients treated after myocardial infarction. 
Currently, there are no proposed structured treatment programs for patients with known 
cerebrovascular disease. We evaluated the need for such a program in patients with 
documented cerebrovascular disease undergoing carotid stenting.
Method: This is a retrospective review of 495 patients (291 men; mean age 71.2 years) 
who underwent carotid stent placement from 3/95 to 11/01. Clinical data was analyzed. 
The use of cardiovascular medications was compared with a post-MI population published 
in a CHAMP study.
Results: In the 495 patients, the use of aspirin, statins, ACE-inhibitors and beta-blockers 
was signiﬁ cantly lower in this population compared with the CHAMP population. Of 375 
hypertensive patients in this study, 123 received single therapy, 111 were on 2 meds, 
56 were on three meds, but importantly, 85 patients were not on any treatment. Among 
186 patients with HTN and history of CVA-TIA, 40 (22%) were not on any anti-HTN 
medication. 
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Carotid stent compared with CHAMP intervention population
Carotid stent population
N = 495
CHAMP
1 Year
N = 302
P value
Medication N (%) N (%)
Aspirin 350 (71%) 284 (94%) <0.001
Clopidogrel or Ticlopidine 356 (72%) ---
Statins 95 (19%) 275 (91%) <0.001
Beta-blockers 126 (25%) 172 (57%) <0.001
Calcium channel blockers 144 (29%) 18 (6%) <0.001
ACE-inhibitors 166 (34%) 145 (48%) <0.001
Diuretics 165 (33%) ---
Conclusion: Therapies proven to prevent CVA include statins, ASA, Clopidogrel, ACE-
inhibitors and blood pressure control. Notably, the use of statins, ACE-inhibitors and blood 
pressure medication was disappointingly low in patients with cerebrovascular disease. 
Structured treatment programs should be developed, to reinforce the use of these proven 
therapies in patients with cerebrovascular disease.
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1010-27 Predicting the Site of Plaque Rupture in Native 
Coronary Arteries: A Three-Vessel Intravascular 
Ultrasound Analysis
Myeong-Ki Hong, Cheol Whan Lee, Young-Hak Kim, Bong-Ki Lee, Deok-Woo Park, 
Bong-Ryong Choi, Kwan-Ho Koh, Kyoung-Ha Park, Ki-Hoon Han, Duk-Hyun Kang, 
Jae-Kwan Song, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park, Asan Medical 
Center, Seoul, South Korea
We evaluated the axial location of plaque ruptures in native coronary arteries. Three-
vessel intravascular ultrasound (IVUS) examination was performed in 392 patients; 
231 had acute coronary syndrome (ACS) and 161 had stable angina pectoris (SAP). 
IVUS detected plaque ruptures in 206 patients; 158 ACS patients and 48 SAP patients. 
Using motorized IVUS transducer pullback in all three coronary arteries, the distance 
between each coronary plaque rupture segment and the respective coronary ostium was 
measured. There were a total of 273 plaque ruptures in these 206 patients; 143 in the 
left anterior descending artery (LAD), 40 in the left circumﬂ ex artery (LCX), and 90 in the 
right coronary artery (RCA). There were 67 plaque ruptures in SAP patients and 206 in 
ACS patients. LAD plaque ruptures were predominantly located between 10 and 40mm 
from the LAD ostium (83%, 119/143). LCX plaque ruptures were evenly distributed in the 
entire LCX tree. Most RCA plaque ruptures were located in the segments between 10 
and 40 mm (48%, 43/90) and in segments >70mm from the RCA ostium (32%, 29/90). 
Conclusions: Three-vessel IVUS imaging showed that plaque ruptures occurred mainly 
in the proximal segments of the LAD (83% of LAD plaque rupture were 10-40mm from 
the LAD ostium) and the proximal and distal segments of the RCA (48% of RCA plaque 
ruptures were 10-40mm from RCA ostium and 32% of RCA plaque rupture were >70mm 
from RCA ostium). 
1010-28 Angioscopic Classiﬁ cation of Culprit Lesion Is 
Associated With Infarct Size in Acute Myocardial 
Infarction
Yasunori Ueda, Atsushi Hirayama, Kazuhisa Kodama, Osaka Police Hospital, Osaka, 
Japan
Background: Thrombus and protruded lipid core at the culprit lesion of acute myocardial 
infarction (MI) has been demonstrated by angioscopy to fragment and wash into the 
distal arteries, and has been demonstrated by distal protection device to cause distal 
embolization. We tested the hypothesis that angioscopic classiﬁ cation of culprit lesion 
would be associated with infarct size.
Methods and Results: Patients with ﬁ rst anterior acute MI were prospectively enrolled. 
Type of culprit lesion was determined by angioscopy as ruptured (group R, n=18) or 
erosive (group E, n=13). Ruptured type had protruded lipid core with massive thombus at 
the culprit lesion; however, erosive type had smooth plaque surface with mural thrombus. 
Reperfusion therapy was successfully performed by balloon angioplasty in all patients. 
Background data including coronary occlusion time or collateral ﬂ ow grade did not differ 
between the groups. Peak value of serum creatine kinase (3835 vs. 1724 U/L, p<0.0001), 
defect size of thalium-201 SPECT (1311 vs. 634, p=0.02), resolution of ST-segment 
elevation (39.8 vs. 67.6%, p=0.02), and left ventricular ejection fraction (44.2% vs. 53.5%, 
p=0.03) revealed larger infarct size in group R.
Conclusions: Angioscopically determined type of culprit lesion was signiﬁ cantly 
associated with infarct size in the patients with acute MI. Patients who had protruded lipid 
core with massive thrombus at culprit lesion were revealed to have larger infarct size than 
those who had smooth plaque surface with mural thrombus, although the cause-effect 
relationship had not been demonstrated.
1010-31 Myocardial Infarction Caused by Erosion is Limited to 
the Smaller Coronary Artery as Compared With That by 
Rupture
Takahiro Hayashi, Takashi Kiyoshima, Masayoshi Matsuura, Masafumi Ueno, Naoya 
Kobayashi, Takuo Ishise, Yukiko Miyamura, Hajime Nakamura, Nobutaka Masunaga, 
Hiroshi Yabushita, Atsuhiro Kurooka, Mitsugu Taniguchi, Akio Kimura, Kinji Ishikawa, 
Kinki University School of Medicine, Osakasayama, Japan
Backgrounds: There may be some clinical differences between myocardial infarction 
(MI) caused by ruptured plaque (R) and that by eroded plaque (E) in their culprit lesions. 
We hypothesized that the intraluminal morphological features in the culprit lesion may 
depend on the vessel size of the infarct-related lesion.
Methods: We studied 136 consecutive patients (109 men, mean age, 62.9+/-10.2 years) 
within 24 hours after acute MI onset in whom both coronary angioscopy and intravascular 
ultrasound (IVUS) were performed immediately before percutaneous coronary 
interventions. Culprit lesions of infarct-related artery were classiﬁ ed into R or E observed 
with the use of both angioscopy and IVUS. R was deﬁ ned as the culprit lesion showing 
dissection or ulceration and the communication between lipid core and vessel lumen, 
and E was deﬁ ned as the culprit lesion showing only redness without any evidence of 
dissection nor ulceration. The vessel area of the culprit lesion and the reference portion 
were measured by IVUS. We compared the vessel size and the remodeling type at culprit 
lesion between group R and E.
Results: Fifty-ﬁ ve patients were classiﬁ ed as R and 32 were E by both angioscopy and 
IVUS, but 49 could not be classiﬁ ed. The vessel area of the culprit lesion was smaller in 
group E than in group R (14.5+/-4.7mm2 vs. 17.9+/-5.9mm2, p=0.0062). As compared 
with group R, group E had higher incidence of negative remodeling (31.3% vs. 10.9%, 
p=0.0182) and lower incidence of positive remodeling (25.0% vs. 45.5%, p=0.0580). The 
locations of the culprit lesion were similar between the 2 groups.
Conclusions: Patients with E have acute MI in the smaller coronary artery or in negative 
remodeling lesions compared with those with R. E with negative remodeling, which has 
less potent thrombogenicity as compared with R with positive remodeling, develops acute 
MI in the smaller coronary artery, not the larger one.
1010-32 Ruptured Plaque and Incomplete Resolution of ST-
Segment Elevation in Patients With Acute ST-Segment 
Myocardial Infarction
Hideo Takebayashi, Yoshio Kobayashi, Kenichi Fujii, Satoru Sumitsuji, Hiroyuki Okura, 
Mitsuyasu Terashima, Kenei Shimada, Motomaru Masutani, Mitsumasa Ohyanagi, Toru 
Kataoka, Kojiro Awano, Haruyuki Taguchi, Yuji Yasuga, Gary S. Mintz, Cardiovascular 
Research Foundation, New York, NY, Fukuyama Cardiovascular Hospital, Hiroshima, 
Japan
Background: Incomplete resolution of ST-segment elevation is associated with a poor 
prognosis after successful primary angioplasty (PCI) for acute myocardial infarction (AMI). 
We sought to investigate whether pre-intervention intravascular ultrasound (IVUS) lesion 
morphology predicts incomplete ST resolution (STR) after PCI in AMI patients.
Methods: IVUS data were obtained from Japan-ACS study, a prospective, multicenter trial 
of three vessel IVUS. Forty-eight patients with acute ST-segment elevation MI underwent 
successful primary PCI and had available serial 12-lead ECG (pre- and post-PCI). The 
sum of ST-segment elevations (∑STE) was measured in leads I, aVL, and V1-V6 for left 
anterior descending coronary artery occlusion and in leads II, III, aVF, V5, and V6 for right 
coronary and left circumﬂ ex artery occlusions. STR index was calculated as (∑STE before 
PCI minus ∑STE after PCI) divided by ∑STE before PCI. Incomplete ST resolution was 
deﬁ ned as STR index <0.5.
Results: Half of the patients presented with lesion-associated ruptured plaque. See Table. 
Lesions with ruptured plaque had more thrombus and more incomplete ST resolution. 
Independent predictors of incomplete ST resolution in these AMI patients were lesion 
EEM area (p=0.03), remodeling index (p=0.04), and plaque rupture (p=0.03).
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Conclusion: IVUS assessment of lesion morphology may predict incomplete ST 
resolution after primary infarct intervention and, therefore, potentially stratify clinical 
outcomes in these patients.
Ruptured plaque (n=24) Non-ruptured plaque (n=24) P
Morphology
(soft/ﬁ brous/mixed) 13/4/7 13/3/8 0.90
Thrombus (%) 96 65 0.01
Calcium (%) 48 52 0.38
Calcium arc (º) 24±50 49±73 0.18
Mean reference
EEM area, mm2 15.8±3.2 14.8±4.9 0.41
Lumen area, mm2 8.7±2.5 8.2±2.7 0.48
Plaque area, mm2 7.0±2.1 6.6±2.6 0.50
Lesion site
EEM area, mm2 17.5±3.3 15.6±3.9 0.07
Lumen area, mm2 2.5±0.6 2.5±0.9 0.99
Plaque area, mm2 15.1±3.4 13.2±3.7 0.07
Plaque burden (%) 85±5 84±6 0.30
Plaque eccentricity 0.41±0.22 0.36±0.23 0.41
Remodeling index 1.14±0.26 1.07±0.17 0.29
STR index 0.23±0.18 0.55±0.23 <0.01
Incomplete ST 
resolution (%) 88 33 <0.01
1010-33 Multiple Plaque Rupture and C-reactive Protein in Acute 
Myocardial Infarction
Atsushi Tanaka, Masashi Namba, Tsunemori Sakamoto, Yukio Nishida, Baba Memorial 
Hospital, Sakai, Japan
Background: Several studies have demonstrated that ruptured plaque or vulnerable 
plaques exist not only at the culprit lesion but also in the whole coronary artery in some 
acute coronary syndrome patients. Recent studies have reported that a ruptured plaque 
at the culprit lesion is associated with elevated C-reactive protein (CRP) that indicates 
poor prognosis in patients with acute coronary syndrome. This study sought to investigate 
the relationship between multiple plaque ruptures, CRP, and clinical prognosis in acute 
myocardial infarction (AMI).
Methods: We performed intravascular ultrasound (IVUS) in 45 infarct-related arteries 
and another 84 major coronary arteries in 45 ﬁ rst AMI patients.
Results: Plaque rupture was observed in 21 (47%) patients at the culprit site. IVUS 
revealed 17 additional plaque ruptures at remote sites in 11(24%) patients. Patients with 
multiple risk factors were more frequently found in our multiple plaque rupture patients 
compared with single plaque rupture or non-rupture patients (82% vs. 40% vs. 29%, 
p=0.01). High-sensitive CRP levels had a positive correlation with the number of plaque 
ruptures (p<0.01). All culprit lesions were successfully treated by percutaneous coronary 
intervention. Patients with multiple plaque rupture showed signiﬁ cantly poor prognosis 
compared with others (p=0.01).
Conclusions: Multiple plaque rupture is associated with systemic inﬂ ammation and 
patients with multiple plaque rupture show poor prognosis. Our results suggest that 
treatment for AMI should focus not only on stabilization of the culprit site but also a 
systemic approach to systemic stabilization of the arteries.
POSTER SESSION
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Presentation Hour: 3:30 p.m.-3:30 p.m.
1037-9 Percutaneous Coronary Intervention without Anti-
thrombin Therapy: The REMOVE Trial.
Neil Sawhney, Matthew J. Price, Steve S. Lee, Garrett Wong, Richard A. Schatz, Paul S. 
Teirstein, Scripps Clinic, La Jolla, CA
Background: Since the inception of percutaneous coronary intervention (PCI ), anti-
thrombin (i.e. heparin) therapy has been used to prevent thrombus formation and ischemic 
complications. The addition of anti-platelet therapy has reduced ischemic events, but can 
result in increased bleeding. We hypothesized that maximal antiplatelet therapy with aspirin, 
thienopyridines, and a GP IIb-IIIa inhibitor without the addition of heparin would result in 
fewer bleeding complications without an increase in thrombotic and/or ischemic events.
Methods: We randomized 150 patients to either a platelet GP IIb-IIIa inhibitor (epitiﬁ bide) 
plus heparin or a GP IIb-IIIa inhibitor without heparin (i.e. no anti-thrombin). All patients 
were preloaded with aspirin (325mg) and clopidogrel (300mg). All complex lesion 
subsets including left main, ostial, bifurcation, and vein graft lesions were included 
with the exception of chronic total occlusions. Procedural and in-hospital events were 
prospectively evaluated.
Results: To date, 97 patients have been equally randomized between treatment groups. 
In the GP IIb-IIIa alone arm, no patient required bailout anti-thrombin use. There was no 
mortality, in-hospital target vessel revascularization, or stent thrombosis in either group. 
There were 6 procedural myocardial infarctions (deﬁ ned as CK-MB>3x normal) in each 
group (12% vs 12.5%, p=ns). In the GP IIb-IIIa plus heparin arm, there was one major bleed 
(deﬁ ned as either an intracranial hemorrhage or a fall in hemoglobin of >5 g/dl) and 2 minor 
bleeds (deﬁ ned as hemorrhage associated with a fall in hemoglobin of 3-5 g/dl). In the 
GP IIb-IIIa alone arm, there was also one major bleed and no minor bleeds. Any bleeding 
complication (which included major bleeding, minor bleeding, and nuisance bleeding) was 
numerically higher in the GP IIa-IIIa plus heparin arm (46% vs 35%, p=ns).
Conclusion: Our interim analysis suggests PCI using anti-platelet therapy without an 
antithrombin agent can be performed safely and may decrease peri-procedure bleeding 
complications. Results from the entire 150 randomized patients will be presented.
1037-10 Effect of Blood Transfusion on In-Hospital Mortality in 
Anemic Patients with Myocardial Infarction Undergoing 
Percutaneous Coronary Interventions
Sandeep M. Jani, Dean E. Smith, Eva Kline-Rogers, Sanjaya Khanal, Michael A. Lauer, 
Michael O’Donnell, David Share, Mauro Moscucci, University of Michigan Medical 
Center, Ann Arbor, MI
Background: Prior studies have shown a poor prognostic implication of anemia in patients 
with myocardial infarction and in patients undergoing PCI. The impact of blood transfusion 
in these patient populations remains controversial. The objective of our study was to 
examine the effect of transfusion on in-hospital mortality in anemic patients undergoing 
PCI for myocardial infarction (MI).
Methods: Data from 67,501 PCI performed between June 1, 1997 and January 31, 2004 
were prospectively collected in a multi-centered registry (the Blue Cross Blue Shield of 
Michigan Cardiovascular Consortium - BMC2). Of these, 4,623 patients classiﬁ ed as 
anemic according to the World Health Organization criteria underwent PCI within 7 days 
of presentation with acute MI. Transfusion was deﬁ ned as post-procedure transfusion of 
red blood cells, platelets, FFP, or whole blood. A propensity score for being transfused 
was estimated for each patient, and a prediction model for death in the hospital was 
developed. Demographic, baseline comorbidities, and the propensity score were included 
in the regression process for development of the ﬁ nal model.
Results: The average age was 67.8 and 57.7% were male. 22.3% of patients received a 
transfusion during hospitalization. Transfused patients were more likely to be older, female, 
had lower pre-procedure hemoglobin levels and had more comorbidities compared to non-
transfused patients. The in-hospital mortality rate in the transfused group was over 4 times 
higher than in the non-transfused group (14.52% vs. 3.01%, p<0.0001). After adjustment 
for comorbidities, propensity for transfusion and other confounders, blood transfusion was 
associated with twice as high risk of death in the hospital (adjusted OR=2.02, 95% CI 
1.47-2.79, p<0.0001).
Conclusion: In anemic patients undergoing PCI within 7 days of an MI, transfusion 
was associated with an increased crude and adjusted rate of in-hospital mortality. A 
randomized controlled trial is needed to determine the safety of transfusion and the ideal 
hemoglobin level at which to transfuse.
1037-11 Anemia Is An Independent Predictor Of Mortality In 
Patients With Acute Myocardial Infarction Undergoing 
Contemporary Percutaneous Coronary Intervention For 
Acute Myocardial Infarction
Ahmed S. Ahmed, Abdul Rashid, Faisal Nabi, Mohammed Murtaza, Mohammad Zafar, 
Rasha Mohamed, Almutaz Kartoumah, Tarek Kteleh, Mohammad Jarbou, Qaiser Bashir, 
Walid Hassan, Kul Aggarwal, The University of Missouri-Columbia, Columbia, MO
Background: The poor long term cardiovascular outcome associated with anemia is well 
established. Whether anemia in patients with ST elevation as well as Non-ST elevation 
acute myocardial infarction (STEMI and NSTEMI) undergoing percutaneous coronary 
intervention (PCI) in the current era entails a worse prognosis is unknown.
Methods: Prospectively collected data on consecutive patients undergoing PCI for AMI 
was obtained from the American College of Cardiology-National Cardiovascular Data 
Registry. Patients were divided into 5 strata based on baseline hemoglobin. Three years 
follow up data for major adverse cardiac events was analyzed.
Results: There were 496 patients including 260/496 (52.42%) patients with STEMI and 
236/496 (47.58%) patients with NSTEMI. The admission hemoglobin ranged from 4.8 to 
18.4 mg/dL. Baseline characteristics including age, gender and cardiac risk factors were 
not signiﬁ cantly different among groups. Anemia deﬁ ned as baseline hemoglobin <11.6 
mg/dL was associated with higher mortality (p <0.0001).
Conclusion: Anemia in patients with acute myocardial infarction undergoing PCI in the 
current era predicts a higher mortality risk.
Baseline hemoglobin in patients with acute myocardial infarction undergoing PCI could 
select patients for more aggressive post PCI therapeutic strategies. 
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1037-12 Anemia Increases Mortality but Does Not Increase 
Ischemic Complications During Percutaneous Coronary 
Intervention
Michele D. Voeltz, Michael J. Attubato, Frederick Feit, A. Michael Lincoff, Steven V. 
Manoukian, Emory University School of Medicine, Atlanta, GA
Background: Recent data suggest that preprocedural anemia increases mortality 
associated with percutaneous coronary intervention (PCI). However, it is unclear whether 
the higher mortality seen in patients with anemia is driven by a rise in the number of 
ischemic complications or due to other causes. We hypothesized that increased mortality 
in anemic patients undergoing PCI, if conﬁ rmed, would not be associated with a greater 
number of ischemic endpoints.
Methods: We reviewed the Randomized Evaluation in PCI Linking Angiomax to 
Reduced Clinical Events (REPLACE)-2 Trial, which compared bivalirudin plus provisional 
glycoprotein IIb/IIIa inhibitors to planned glycoprotein IIb/IIIa inhibitors plus heparin, 
in patients undergoing urgent or elective PCI. The methods and results of REPLACE-
2 have been previously described. Preprocedural anemia was deﬁ ned using baseline 
hemoglobin levels and the World Health Organization deﬁ nition (hemoglobin <12.0 in 
women and <13.0 in men).
Results: 1,362 (23%) of the 6,010 patients enrolled in REPLACE-2 were classiﬁ ed 
as anemic. When anemic patients were compared to their nonanemic counterparts, 
mortality was higher during hospitalization (0.6% vs. 0.1%, p=0.0011), at 30 days (0.9% 
vs. 0.2%, p<0.0001), six months (2.6% vs. 0.7%, p<0.0001), and one year (4.3% vs. 1.5%, 
p<0.0001). Despite this dramatic increase in mortality, there were no differences between 
anemic and nonanemic patients at 30 days with regard to the ischemic endpoints of 
myocardial infarction (6.9% vs. 6.5%, p=ns) and urgent revascularization (1.2% vs. 1.3%, 
p=ns). Similarly, there was no difference in major adverse cardiac events (MACE), a 
combined endpoint of death, myocardial infarction, and urgent revascularization at 30 
days, between anemic and non-anemic patients (7.6% vs. 7.3%, p=ns).
Conclusion: In contrast to recently published data, we conclude that although 
preprocedural anemia increases the risk of mortality in patients undergoing percutaneous 
coronary intervention, it is not the result of an increase in either individual or combined 
ischemic endpoints.
1037-13 Anemia Is Associated With Increased Major Bleeding 
Complications and Early Mortality in Patients 
Undergoing Percutaneous Coronary Intervention: 
Implications for Choices in Antithrombotic Therapy
Michele D. Voeltz, Michael J. Attubato, Frederick Feit, A. Michael Lincoff, Steven V. 
Manoukian, Emory University School of Medicine, Atlanta, GA
Background: The relationship between anemia, bleeding complications, and mortality 
associated with percutaneous coronary intervention (PCI) is unclear. We hypothesized 
that anemia increases the risk of bleeding complications and early mortality in patients 
undergoing PCI, and that the antithrombotic regimen used in anemic patients inﬂ uences 
the magnitude of these risks.
Methods: We reviewed the Randomized Evaluation in PCI Linking Angiomax to 
Reduced Clinical Events (REPLACE)-2 Trial, which compared bivalirudin with provisional 
glycoprotein IIb/IIIa inhibitors (BIV) to planned glycoprotein IIb/IIIa inhibitors plus heparin 
(GPI+H), in patients undergoing urgent or elective PCI. The methods and results of 
REPLACE-2 have been previously described. Anemia was deﬁ ned using the World Health 
Organization deﬁ nition (hemoglobin <12.0g/dL in women and <13.0g/dL in men).
Results: Of the 6,010 patients in REPLACE-2, 1,362 (23%) were anemic based upon 
preprocedural hemoglobin values. Major bleeding was more common in anemic vs. 
nonanemic patients (4.9% vs. 2.8%, p=0.0001). Among anemic patients, treatment with 
BIV (n=674) resulted in a 44% lower relative risk of major bleeding vs. GPI+H (n=688; 
3.5% vs. 6.2%, p=0.0221). Similarly, the relative risk of minor bleeding was 52% lower 
in anemic patients treated with BIV vs. GPI+H (13.4% vs. 28.1%, p<0.0001). Mortality 
was higher in anemic vs. nonanemic patients, both in-hospital (0.6% vs. 0.1%, p=0.0011) 
and at 30 days (0.9% vs. 0.2%, p<0.0001). Among GPI+H patients, anemia increased 
in-hospital (0.9% vs. 0.1%, p=0.0073) and 30 day (1.2% vs. 0.2%, p=0.0018) mortality vs. 
nonanemic patients. In contrast, among BIV patients, anemia did not increase in-hospital 
(0.3% vs. 0.1%, p=ns) or 30-day mortality (0.6% vs. 0.1%, p=ns).
Conclusion: We conclude that preprocedural anemia increases major bleeding and early 
mortality in patients undergoing PCI. The use of bivalirudin with provisional glycoprotein 
IIb/IIIa inhibitors reduces the risk of major and minor bleeding when compared to 
glycoprotein IIb/IIIa inhibitors plus heparin. Bivalirudin offers a superior safety proﬁ le in 
anemic patients undergoing percutaneous coronary intervention.
1037-14 Acetylcysteine Does Prevent Contrast-Induced 
Nephropathy After Coronary Angiography in Patients 
Submitted to Low-Osmolar Contrast Media but not in 
Patients Submitted to Iso-Osmolar Contrast Media and 
in Higher Risk Patients - a Meta-Analysis
Christopher J. Wolf, Ramin Ebrahimi, UCLA, Los Angeles, CA, VA Greater Los Angeles 
Healthcare System, Los Angeles, CA
Objective: Contrast nephropathy related to coronary intervention has been shown to be a strong 
predictor of increased all cause mortality and morbidity. Clinical trials evaluating the efﬁ cacy of N-
Acetylcysteine in preventing contrast-induced nephropathy have yielded conﬂ icting results.
Methods: The databases MEDLINE, EMBASE and CENTRAL (January 1966 to August 
2004) were searched in all languages, as well as conference proceedings from several 
professional societies from the years 1999 to 2004. Risk ratios and the corresponding 
tests for homogeneity were combined using the Mantel-Haenzel method.
Results: Out of 18 trials including 1973 patients that addressed the efﬁ cacy of N-
Acetylcysteine in prevention of contrast-induced nephropathy in patients undergoing 
coronary angiography, 10 trials with a total of 1141 patients met our inclusion criteria for 
quality and homogeneity. Administration of N-Acetylcysteine with periprocedural hydration 
with 1/2 normal saline signiﬁ cantly reduced the incidence of contrast-induced nephropathy 
in patients undergoing procedures using low-osmolar contrast media by 60% (RR 0.408, 
95% CI 0.251-0.663, p < 0.0001). In patients undergoing procedures with administration 
of N-Acetylcysteine and the same periprocedural hydration using iso-osmolar contrast 
media there was no reduction in the incidence of contrast-induced nephropathy (RR 
1.129, 95% CI 0.643-1.983, p = 0.6755).
Conclusion: N-Acetylcysteine with periprocedural hydration with 1/2 normal saline 
prevents contrast-induced nephropathy in patients undergoing coronary interventions using 
low-osmolar, nonionic contrast media but not in patients undergoing procedures using iso-
osmolar contrast media. Studies with a higher proportion of elderly individuals or diabetic 
patients, or studies that used a relatively high osmolality agent were associated with a 
change in the estimated risk difference in a direction favoring N-Acetylcysteine. Thus it is 
conceivable that the effectiveness of N-Acetylcysteine may be greatest among a population 
of individuals with a high baseline risk of developing radiocontrast-induced nephropathy.
1037-15 Metabolic Syndrome Increases the Risk of Contrast 
Induced Nephropathy in Patients Undergoing PCI
Leonardo C. Clavijo, Pramod Kuchulakanti, Stephan Zbinden, William Chu, Daniel A. 
Canos, Rebecca Torguson, Lowell F. Satler, William O. Suddath, Augusto D. Pichard, 
Kenneth M. Kent, Ron Waksman, Washington Hospital Center, Washington, DC
Background: Diabetes mellitus (DM) increases the risk of contrast-induced nephropathy 
(CIN) after PCI. Metabolic syndrome (MS) is a pre-diabetic state associated with CAD. 
The occurrence of CIN after PCI in non-diabetic patients with MS is unknown.
Methods: We investigated the occurrence of CIN in 1,900 patients after PCI (deﬁ ned as 
an elevation of serum creatinine ≥ 0.5 mg/dL). MS was deﬁ ned as patients having at least 
3 of 5 criteria: BP ≥ 130/85 mm Hg, fasting glucose ≥110 and ≤ 125mg/dL, triglycerides 
≥150 mg/dL, HDL < 40 mg/dL and obesity (BMI ≥ 30). Patients were divided into the four 
groups: 1. Insulin requiring DM (IRDM, n= 218); 2. Oral medication or diet controlled DM 
(NIDDM, n= 471); 3. MS (n= 210); 4. Controls (n= 1008).
Results: Baseline characteristics were similar except for a higher prevalence of chronic 
renal insufﬁ ciency in diabetics (p<0.05). Volume of contrast used during PCI was equivalent 
in all groups (p= 0.97). The incidence of CIN was 6.88%&, 3.82%*&, 3.33%*& and 1.09%* in 
IRDM, NIDDM, MS and controls respectively ( *p<0.05 vs IRDM, and &p<0.05 vs control).
Conclusions: MS and DM (IRDM and NIDDM), both increase the risk of CIN in patients 
undergoing PCI compared to controls. Among patients with abnormal glucose metabolism 
IRDM confers the greatest risk of developing CIN. The risk of CIN in patients with MS is 
equivalent to NIDDM. Precaution for prevention of CIN should be taken when perorming 
PCI on patietns with MS.
1037-16 Renal Insufﬁ ciency in Patients Undergoing 
Percutaneous Coronary Intervention: Results of the 
SHAKESPEARE Registry
Luis Gruberg, Rafael Beyar, Jean-Pierre Bassand, Ricardo Seabra-Gomes, Paolo Fioretti, 
Martin G. Gottwik, Keith Dawkins, Andrej Cieslinski, David Hasdai, Anselm K. Gitt, on 
Behalf of the SHAKESPEARE Study Group, Rambam Medical Center, Haifa, Israel
Background: Cardiovascular disease is the leading cause of death in patients with renal 
insufﬁ ciency (RI). Even mild or moderate RI is associated with increased morbidity and 
mortality in these patients during percutaneous coronary intervention (PCI). We evaluated 
the impact of RI in a large, contemporary registry of consecutive patients undergoing 
elective, urgent or emergent PCI. 
Methods: Since 2/2002, a total of 13,100 consecutive patients have been enrolled in 7 
countries (France, Germany, Israel, Italy, Poland, Portugal, UK) of the European Society of 
Cardiology to document clinical practice of coronary interventions and outcomes as part 
of the SHAKESPEARE Registry. We assessed the outcomes of RI patients (creatinine 
>2.0 mg/dL) in this registry and compared them to patients without RI. 
Results: RI at baseline was present in 371 patients (3%). Patients with RI were older 
and had more co-morbid diseases. Short-term and 12-month outcomes are shown in the 
Table. By multivariate analysis, RI was an independent predictor of in-hospital mortality 
(OR:2.69, CI=1.70-4.27), as were age (OR:1.06, CI=1.04-1.07), heart failure (OR:5.73, 
CI=3.86-8.52) and diabetes (OR:1.37, CI=1.00-1.71).
No RI
n=12,729
RI
n=371 p
Age (years) 64 (54-72) 70 (62-76) <0.05
Hypertension (%) 63 75 <0.05
Diabetes mellitus (%) 23 41 <0.05
Unstable angina (%) 28 41 <0.05
Ejection fraction <30% (%) 4.1 12.4 <0.05
GP IIb/IIIa use (%) 46 40 NS
Death (in-hospital) (%) 1.6 6.2 <0.05
Death (30-days) (%) 0.6 3.2 <0.05
Death (12-months) (%) 2.4 9.5 <0.05
MACE (%) 4.3 13.0 <0.05
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Conclusions: Baseline RI in patients undergoing PCI was associated with an increased 
risk in short-term and late mortality after PCI. After correction for differences in baseline 
characteristics and treatment, RI was a strong, independent determinant of outcome with 
a nearly three--fold increase in mortality.
1037-17 Iodixanol is Less Nephrotoxic than Ioxaglate in Patients 
With Renal Insufﬁ ciency After Coronary Angiography
Sang-Ho Jo, Tae-Jin Youn, Jin-Sik Park, Bon-Kwon Koo, Hyun-Jae Kang, Yong-Jin Kim, 
Hyo-Soo Kim, Dae-Won Sohn, Byung-Hee Oh, Myoung-Mook Lee, Young-Bae Park, Yun-
Shik Choi, Cardiovascular Center, Seoul National University Hospital, Seoul, South Korea
Background: Contrast-induced nephropathy(CIN) is a common complication after 
coronary angiography and can affect the prognosis especially in high risk patients. It is 
uncertain whether iodixanol is less nephrotoxic than ioxaglate in high-risk patients.
Methods: We conducted randomized, prospective, single center study comparing the 
nephrotoxic effects of an iso-osmolar, dimeric, non ionic, contrast medium (iodixaol), with 
those of a low-osmolar, ionic, dimeric contrast medium (ioxaglate). This study involved 
282 patients with calculated creatinine clearance (by Cockroft-Gault formula) ≤60mL/min 
who underwent coronary angiography. Half-saline was given intravenously at a rate of 1ml 
per kilogram per hour at least for 8hours before and 8hours after administration of contrast 
agent. The primary end point was a development of CIN. CIN was deﬁ ned is an increase 
of 25% or more in serum creatinine within 2 days after coronary angiography.
Results: There were no differences in age, sex, incidence of diabetes mellitus, baseline 
serum creatinine, creatinine clearance or contrast volume. CIN occurred in 10 of 164 
patients (6.1%) in iodixanol group and 18 of 117 patients (15.4%) in ioxaglate group 
(P=0.013, odd ratio 2.99, 95% conﬁ dence interval, 1.262 to 7.127). This difference was 
more distinct in patients with diabetes mellitus. The occurrence of CIN within the diabetic 
patients were 5.8% (4/69) in iodixanol group and 21.7% (10/46) in ioxaglate group 
(p=0.018). And in patients with baseline serum creatinine ≥1.4, the CIN after coronary 
angiography occurred signiﬁ cantly higher in ioxaglate group than in iodixanol group, 25% 
(12/48) and 8.2% (5/61) respectively (p=0.019). In ioxaglate group, 4.3% of patients had 
an increase of 1.0mg per deciliter or more, but in the iodixanol group, only in 2.4% patients 
had. By multivariate analysis, the use of iodixanol was the only risk factor for developing 
CIN (odds ratio 3.1, 95% conﬁ dence interval, 1.27 to 7.53).
Conclusion: The incidence of CIN was lower in patients with iodixanol than those with ioxaglate 
after coronary angiography. This difference was more prominent in higher risk groups.
1037-18 Long-term Outcome after Coronary Angioplasty in 
Renal Transplant and Hemodialysis Patients.
Maria Borentain, Claude Le Feuvre, Farzin Beygui, Gérard Helft, Jean Paul Batisse, 
Jean Philippe Metzger, AP-HP, Paris, France
Objectives: In order to determine how renal transplantation modiﬁ es in hospital and 
long-term outcome after coronary angioplasty we compared dialysis and renal transplant 
patients with control patients without renal failure.
Background: Little is known about the impact of renal transplantation on the long term 
mortality compared with dialysis treatment.
Methods: 75 consecutive dialysis patients (group D) and 37 renal transplant patients 
(group T) undergoing coronary angioplasty, were compared with two controls groups 
(groups control D and control T respectively) matched 1:1 with group D and T for clinical 
and angiographic characteristics. The mean follow up was 50 months.
Results: The rate of angiographic success was high and comparable in the 4 groups 
(p=0.7). Renal transplant patients were younger than dialysis non-transplant patients 
(p=0.004). The rates of non-fatal myocardial infarction and coronary revascularisation 
were comparable between the 4 groups. The risk of 4-year cardiac death was higher 
in dialysis patients (29 % in group D vs 16 % in group T, 11 % in group control D, and 
0 % in group control T, p = 0.0003). After adjusting for age, diabetes and multivessel 
disease, long-term mortality risk was similar in dialysis and renal transplant patients. On 
multivariate analysis, renal function (p=0.002), age (p=0.005) and tobacco consumption 
(p=0.005) were independently associated with 4-year cardiac death.
Conclusion: In patients with end stage renal disease who undergo coronary angioplasty, 
renal transplantation was not independently associated with a lower long-term mortality 
compared with dialysis treatment. Both dialysis and renal transplant patients show lower 
survival rates compared with matched control patients.
1037-19 The Impact of Acute Renal Failure on Outcomes and 
Resource Utilization Among Medicare Beneﬁ ciaries 
Undergoing Percutaneous Coronary Intervention
Aaron Kugelmass, Phillip Brown, Edmund Becker, Steven Culler, April W. Simon, Henry 
Ford Healthcare System, Detroit, MI, Emory University, Atlanta, GA
Background: This abstract reports the trend in the complication rates and hospital 
resources consumed by Medicare beneﬁ ciaries who experienced acute renal failure 
during a hospitalization associated with a PCI intervention.
Method: This retrospective analysis uses the Medicare Provider Analysis and Review 
(MedPAR) ﬁ les from 10-1-00 through 9-30-03 to identify 1,294,937 hospitalizations 
associated with PCI interventions. Acute renal failure was identiﬁ ed if the patient 
underwent hemodialysis without having had dialysis prior to the admission (HEMO). All 
procedures and complications were identiﬁ ed using ICD-9-CM codes. Hospital costs were 
estimated using the hospital’s Medicare cost-to-charge ratio.
Results: The Table indicates that the rate of HEMO has increased from 0.82% to 0.89%. 
While selected complication rates have declined over the study period for both groups 
of patients, HEMO patients were signiﬁ cantly more likely to die and have vascular 
complications but less likely to experience emergency CABG than all other Medicare 
patients. HEMO patients had higher hospitalization costs (approximately $5,000) and 
longer length of stays (approximately 3.0 days) depending on the ﬁ scal year.
Conclusions: Increased attention should be focused on the prevention of HEMO given 
that nearly 1.0% of all Medicare beneﬁ ciaries undergoing a PCI procedure experience 
this complication and the complication is associated with other adverse events.
2000 2001 2002 2003
NEWHEMO 0.84% 0.82% 0.84% 0.89%
Mortality: NEWHEMO 6.0% 4.8% 4.6% 4.6%
Mortality: All Other 2.0% 1.9% 1.9% 1.8%
Vascular Complication: NEWHEMO 11.6% 10.0% 10.6% 9.4%
Vascular Complication: All Other 6.0% 5.5% 5.4% 5.2%
CABG: NEWHEMO 0.6% 0.6% 0.6% 0.3%
CABG: All Other 1.3% 1.2% 1.2% 1.1%
1037-20 Clinical Evaluation of the Concomitant Use of 
Bivalirudin and Drug-Eluting Stents: Results the 
Prospective, Multicenter ADEST Study
George D. Dangas, Roxana Mehran, Zoran Lasic, David Cox, Magdi G. H. Ghali, Timothy 
D. Henry, Paul S. Teirstein, Joseph F. Stella, Kevin F. Browne, Jr., Stephen Alan Lewis, 
William Knopf, Edward Kreps, Martin B. Leon, Michael Collins, Jeffrey W. Moses, Gregg 
W. Stone, Columbia University Medical Center, New York, NY
Background: Sirolimus-eluting stents (SES) provide improved beneﬁ t over bare 
metal stents (BMS) for preventing restenosis after percutaneous coronary intervention 
(PCI). Safety issues are particularly important due to initial concerns about increased 
subacute thrombosis with drug-eluting stents. Bivalirudin reduces the risk of hemorrhage 
associated with non-urgent PCI compared with heparin plus glycoprotein IIb/IIIa inhibitor, 
while having non-inferior efﬁ cacy to this combination. The safety and efﬁ cacy of SES with 
bivalirudin have not been studied in prospective studies.
Methods and Results: This prospective, multi-center study evaluated 1182 patients 
referred for PCI with SES and treated with bivalirudin 0.75 mg/kg bolus plus 1.75 mg/kg/
hr infusion during PCI; exclusion was only acute MI. In-hospital and 30-day ischemic and 
bleeding event rates were particularly low, the cumulative 30-day rates being: mortality 
0.3%, myocardial infarction (MI, deﬁ ned as CK-MB>3x normal) 4.4%, target vessel 
revascularization (TVR) 1.7%, stent thrombosis 0.6%, and major bleeding 0.8%.
Conclusions: In this multicenter study, the SES plus bivalirudin combination in “real world” 
patients with coronary artery disease undergoing PCI resulted in low rates of MACE, stent 
thrombosis and bleeding events, with no unexpected safety or efﬁ cacy issues.
1037-21 Predictors and Clinical Impact of the Procedural ACT 
Level in Patients Receiving Bivalirudin during PCI: A 
REPLACE II Sub Study.
Gregg W. Stone, A. Michael Lincoff, Giora Weisz, Ramin Ebrahimi, Gadi Keren, Jeffrey 
Carr, Fred Feit, Roxana Mehran, Jeffrey W. Moses, Martin B. Leon, Allan Schwartz, 
Columbia University Medical Center, New York, NY, Cardiovascular Research 
Foundation, New York, NY
Background: Bivalirudin is being increasingly utilized as the antithrombotic agent of 
choice in elective PCI. As a direct thrombin inhibitor, bivalirudin signiﬁ cantly increases the 
procedural activated clotting time (ACT) level. Whether the ACT level impacts the safety 
and efﬁ cacy proﬁ le of bivalirudin is unknown.
Methods: In the REPLACE II trial, 6,010 patients undergoing elective or urgent PCI were 
randomly assigned to bivalirudin and provisional GP IIb/IIIa inhibition (n=2999) or heparin 
plus planned GP IIb/IIIa inhibition (n=3011). Bivalirudin was dosed as a bolus of 0.75 
mg/kg followed by a 1.75 mg/kg/h infusion during the procedure. The primary endpoint 
was the net clinical beneﬁ t composite of death, MI, urgent revascularization or major 
bleeding at 30 days.
Results: The mean ACT 5 minutes after drug infusion was 358 ± 74 seconds. Outcomes 
as a function of ACT level in tertiles appear in the table. By multivariate analysis, the 
5 minute ACT was unrelated to major (p=0.92) or minor (p=0.17) bleeding, or 30 day 
ischemic MACE (p=0.33). 
Description Tertile 1 (ACT <335)
Tertile 2 
(ACT 335-381)
Tertile 3
 (ACT >381)
Overall 
p-value
5 min ACT (mean) 287 ± 53 357 ± 12 429 ± 59 <0.0001
Major bleeding (protocol defn) 2.5% 2.0% 2.2% 0.71
Minor bleeding (protocol defn) 12.4% 14.2% 14.1% 0.46
TIMI Major/Minor Bleeding 1.8% 2.2% 1.8% 0.74
30 Day Death/MI/Urg Revasc 8.9% 8.1% 6.5% 0.17
30 Day Death/MI/Urg revasc/Major bleed 10.4% 9.4% 8.1% 0.23
Conclusion: In patients receiving bivalirudin during elective or urgent PCI, ACT levels 
measured 5 minutes after drug administration vary widely, but are not associated with 
major or minor hemorrhagic complications or peri-procedural ischemic complications
1037-22 Anti-chlamydia Azithromycin Antibiotic Therapy Does 
Not Reduce The Risk Of Coronary Renarrowing After 
Stenting: Final Results Of A Randomized, Double-blind, 
Controlled Trial.
Dimas Tadahiro Ikeoka, Pedro Alves Lemos, Expedito Ribeiro da Silva, Marco Antonio 
Perin, Tania Strabelli, Carolina Zilli Vieira, Bruno Caramelli, Heart Institute University of 
Sao Paulo Medical School, Sao Paulo, Brazil
Background: Chlamydophila pneumoniae infection has been proposed as a contributor 
for restenosis after percutaneous coronary intervention. We hypothesized that pre-
procedure and follow-up antibiotic treatment with azithromycin would reduce the incidence 
of angiographic restenosis after coronary stenting.
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Methods: A total of 90 patients treated with at least one single-lesion stenting were 
randomized to azythromycin (500 mg weekly) or placebo in a double-blinded fashion. 
The assigned treatment was administered from two weeks before the intervention (three 
days ﬁ rst shot in the ﬁ rst week) up to twelve weeks thereafter (and three days second 
shot at last week). The primary endpoint was the 6-month angiographic minimal luminal 
diameter.
Results: Two patients were lost in the follow-up period and deregistered from study. 
Coronary angiography at follow up was performed between four and six months in 69/88 
(78%) patients. A total of 96 stented lesions, 51 lesions in azithromycin group (34 patients) 
and 45 lesions in placebo group (31 patients), were ﬁ nally analyzed. We did not observe 
signiﬁ cant differences regarding baseline and immediate results after angioplasty in 
both groups. Minimal luminal diameter at follow up angiogram was 1.66 + 0.82 mm in 
azithromycin group and 1.71 + 0.61 mm in placebo group (p=0.704). Other measured 
angiographic parameters, incidence of risk factors, biochemical proﬁ le and major adverse 
cardiac events were also similar in both groups.
Conclusion: Azithromycin do not modify angiographic outcomes six months after 
coronary stenting.
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1038-1 High Dose Dexamethasone Eluting BiodivYsio 
Drug Delivery Phosphorylcholine Coated Stent Can 
Signiﬁ cantly Reduce In-Stent Restenosis and Prevent 
Major Adverse Cardiac Events
Seung Hwan Han, Tae Hoon Ahn, Woong Chol Kang, Kyung Leem Choi, Kyu Jin Oh, 
Eak Kyun Shin, Heart Center, Gil Hospital, Gachon Medical School, Incheon, South Korea
Background: Phosphorylcholine (PC) is a biocompatible polymer coating with 
antithrombotic properties. PC coated stent had a similar clinical event rates and restenosis 
rate compared with bare metal stent. Dexamethasone (DEX) has anti-inﬂ ammatory and 
immunosuppressive effects, in part through the inhibition of cytokine release. 
Methods: This study was a prospective study including 92 patients (98stents) randomized 
by period to either DEX eluting Bio DD PC coated stent (67patients, 71 stents) (DEX-
group) or Bio DD PC coated stent without DEX (25 patients, 27stents) (non-DEX group). 
The inclusion criteria for stent implantation were de novo lesion, diameter in 2.75-4.0 
mm. The exclusion criteria were primary angioplasty in AMI patients, CTO lesion, left 
main lesion, bifurcation intervention, vein graft lesion, severe calciﬁ ed lesion, thrombus 
containing lesion, restenosis lesion. Bio DD PC coated stent was immersed in a 20mg/ml 
DEX solution, yielding a total DEX dose of 50µg per mm stent before implantation. The 
primary end-point of the study was 12-months MACE rate. The secondary end-point was 
6-months angiographic restenosis rate. Results: Demographics are as follows : Mean age 
was 60.6 years ; 38% are diabetic patients, respectively. The 12-months MACE rate and 
angiographic ﬁ ndings are shown table. Conclusions: DEX eluting Bio DD PC coated 
stent can signiﬁ cantly reduce in-stent restenosis and prevent MACE compared with Bio 
DD PC Coated Stent without DEX.
DEX group Non-DEX group p
RD (mm) 3.19 ± 0.33 3.21 ± 0.32 NS
post MLD (mm) 3.02 ± 0.31 3.00 ± 0.27 NS
F/U MLD (mm) 2.16 ± 0.73 1.64 ± 0.75 0.007
Loss Index 0.38 ± 0.33 0.65 ± 0.31 0.001
Restenosis Rate (%) 12.3 (7/57) 42.9 (9/21) 0.009
MACE Rate (%) 9.9 (7/71) 29.6 (8/27) 0.026
1038-2 Safety of and Adherence to Aspirin, Clopidogrel, and 
Cilostazol After Coronary Stent Implantation in the 
Cilostazol for RESTenosis (CREST) Trial
Jovonne K. Foster, Paul Kolm, Grant T. Anderson, Karen M. Parker, John S. Douglas, Jr., 
William S. Weintraub, Emory University, Atlanta, GA
Background: The Cilostazol for RESTenosis (CREST) Trial, a randomized clinical trial 
testing the efﬁ cacy of cilostazol to prevent restenosis after PCI, resulted in a 35% relative risk 
reduction in restenosis from 34% to 22% with cilostazol (p=0.002). This is the largest dataset 
testing the safety of triple anti-platelet therapy. The purpose of this study was to determine the 
safety of and adherence to aspirin plus clopidogrel plus cilostazol in the CREST trial. 
Methods: A total of 705 patients in the CREST trial were randomized to cilostazol (354) or 
placebo (351) following successful stent implantation. Clopidogrel 75 mg daily for 30 days 
and aspirin daily for 6 months were administered to all patients. 
Results: Twenty-nine patients experienced bleeding complications (17 major and 12 minor) 
in the CREST trial. There was no signiﬁ cant difference in the rate of bleeding for patients 
who received aspirin plus clopidogrel plus cilostazol versus those who received aspirin plus 
clopidogrel (4.1% vs. 4.4%, p=0.82). Similarly, there was no signiﬁ cant difference in type of 
bleeding (major or minor) experienced by treatment (p=0.77). At one month, 89% of patients 
were taking study drug as directed (86% in the cilostazol group and 93% in the placebo 
group, p=0.01). At three months, 90% of patients were taking study drug as directed (88% 
in the cilostazol group and 91% in the placebo group, p=0.42). At six months, 72% of 
patients were taking study drug as directed (71% in the cilostazol group and 72% in the 
placebo group, p=0.86). The most common reasons for discontinuing treatment were chest 
pain, headache, and bleeding. Cilostazol patients experienced headaches more often, 
whereas placebo patients experienced chest pain more often. There was no signiﬁ cant 
difference in target segment restenosis by treatment for patients who experienced bleeding 
complications (p=0.63). 
Conclusions: There was no evidence of increased risk of bleeding in patients treated 
with aspirin plus clopidogrel plus cilostazol. Adherence to treatment was high, with little 
difference between treatment arms.
1038-3 Effect of Cilostazol on Neointimal Hyperplasia After 
Coronary Artery Stenting : Volumetric IVUS study
Pil-Ki Min, Jae-Hun Jung, Sungha Park, Jong-Youn Kim, Eui-Young Choi, Young-Guk Ko, 
Won-Heum Shim, Yonsei Cardiovascular Center, Yonsei University College of Medicine, 
Seoul, South Korea
Background: In-stent restenosis following coronary artery stenting, mainly attributable 
to neointimal hyperplasia and thrombus formation, remains a major limitation of the 
procedure. Recently, cilostazol was reported to have antiproliferative properties and 
reduce restenosis after coronary angioplasty and stenting.
Methods: This study was designed to investigate the efﬁ cacy of triple combination of 
aspirin, ticlopidine, and cilostazol for the prevention of in-stent restenosis in comparison 
with aspirin plus ticlopidine. Fifty-three consecutive patients (36 men, age 63 years), 
scheduled for elective coronary stenting, were randomly assigned to receive a drug 
regimen with aspirin and ticlopidine plus 100 mg bid cilostazol ( A+T+C group, n=28 ) 
or aspirin plus ticlopidine ( A+T group, n=25 ). Initial and follow-up quantitative coronary 
angiography(QCA) and volumetric intravascular ultrasound(IVUS) were performed after 
PCI and at 6 months. Only one type of stent ( Express stent, Boston Scientiﬁ c) was used 
for this study. The primary endpoint was MLD at 6 months and intimal hyperplasia index 
(intimal hyperplasia volume / stent length ).
Results: Fifty-eight coronary lesions in ﬁ fty-three patients were analyzed by QCA ( 31 in 
A+T+C group, 27 in A+T group ), and 35 lesions were analyzed by volumetric IVUS ( 20 in 
A+T+C group, 15 in A+T group ). There were no signiﬁ cant differences in mean reference 
diameter, initial MLD, stent diameter, stent length and post-stent MLD at initial angiography 
between the two groups. At 6 months follow-up, in-stent MLD(mm) was 2.38 in A+T+C 
group versus 1.90 in A+T group (p=0.033). The loss index was lower in A+T+C group than 
in A+T group (0.37 vs. 0.55, p=0.039). The volumetric IVUS at 6 months demonstrated 
that intimal hyperplasia index (mm3/mm) was 1.02 in A+T+C group and 1.97 in A+T group 
(p=0.003). The binary restenosis rate was not statistically different between the two groups 
but slightly lower in the A+T+C group than the A+T group (13% vs. 26%, p=0.177).
Conclusions: This study showed that the triple antiplatelet therapy including cilostazol 
signiﬁ cantly reduced in-stent neointimal hyperplasia after coronary stent implantation.
1038-4 Inhibitory Effect Of Low Dose Pioglitazone On The 
Development Of In-stent Restenosis In Patients With 
Type 2 Diabetes Mellitus.
Jin Yokoyama, Kunihiko Kameda, Masahiro Yamada, Yujin Tamura, Takumi Higuma, 
Shingo Sasaki, Naoyuki Suto, Toshirou Matsunaga, Hiroyuki Hanada, Tomohiro Osanai, 
Ken Okumura, Hirosaki University School of Medicine, Hirosaki, Japan
Background: The incidence of in-stent restenosis (ISR) has been dramatically reduced 
by the use of drug-eluting stent (DES). Insulin sensitizers such as thiazolidinedione have 
an antiatherosclerosic effect, and are suggested to reduce neointimal tissue proliferation 
after coronary stenting in patients with type 2 diabetes mellitus (DM).
Methods: We investigated the inhibitory effect of low dose pioglitazone on the 
development of ISR in 40 patients (50 lesions) with type 2 DM who underwent successful 
coronary angioplasty with the use of bare metal stent. In 16 patients (24 lesions), low 
dose pioglitazone (15mg per day) was orally administered for 6 months after stenting 
while previous anti-diabetic therapy being maintained (pioglitazone group). The incidence 
of ISR in these patients was compared with that in the other 24 patients (26 lesions) 
(control group) who were treated with conventional anti-diabetic therapy not including 
pioglitazone.
Results: No adverse events including acute coronary occlusion, emergency bypass 
surgery, and subacute thrombosis occurred in any patients. There was no signiﬁ cant 
difference in the baseline clinical proﬁ les including the prevalences of hyperlipidemia and 
hypertension and the severity of DM before the procedure between the two groups. There 
was no signiﬁ cant difference in the type of the lesion, reference vessel diameter and 
length of the lesion. At 6 months after the procedure, the angiographic ISR (deﬁ ned as 
a diameter stenosis >50%) was signiﬁ cantly lower in pioglitazone group compared with 
that in control group (8.3% vs 42.3%, p=0.009). Actually, it was observed only in 2 of the 
24 lesions in pioglitazone group. The rate of ISR in the patients treated with low dose 
pioglitazone was compatible with that observed after application of DES. 
Conclusion: Pioglitazone therefore seems to have a potential to reduce ISR in patients 
with type 2 DM and treated with bare metal stent.
1038-34 High Platelet Reactivity is a Risk Factor for Post-
Discharge Ischemic Complications Following Elective 
Coronary Stenting.
Kevin P. Bliden, Udaya Tantry, Kazi Zaman, Ashwani Bassi, K. Hayes, J. Yoho, Paul A. 
Gurbel, Sinai Center for Thrombosis Research, Baltimore, MD
Background: Insufﬁ cient platelet inhibition may be a risk factor for the development of 
ischemic complications and thrombosis post-elective stenting.
Methods: In a prospective study, we serially measured platelet reactivity by platelet 
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aggregation (LTA) and thromboelastography (TEG) in 120 patients undergoing elective 
coronary stenting. We analyzed the relation of platelet reactivity at discharge to the 
development of stent thrombosis and ischemic events post-discharge up to 6 months. 
Platelet reactivity was divided into 4 groups ( mean ± 2 SD) and the event rate (ER) was 
calculated per group
Results: Median age was 64 years; There was one case of stent thrombosis and 19 
other ischemic events ( MI, stroke, recurrent angina with revascularization (RV) and 
recurrent angina with hospitalization/no (no RV). Patients with ischemic events had 
greater platelet aggregation ( 68±8% vs. 55±12, p <.001 ) and greater TEG indices [(TEG 
clot strenght(MA) 75.2± 6mm vs. 66.1± 7mm, p<.001) and (Reaction time(R) 4.1± 1min 
vs.5.7± 2 min, p <.05)]. (Figure,* p < 0.05).
Conclusion: High discharge platelet reactivity measured by multiple methods is a 
predicator of ischemic events and SAT. Studies to routinely measure platelet reactivity at 
discharge, and thus adjust therapy in order to improve patient outcomes, are ongoing. 
1038-35 Intravascular Ultrasound Assessment of Stent 
Thrombosis After Successful Implantation of Sirolimus-
Eluting Stents
Kenichi Fujii, Stéphane G. Carlier, Gary S. Mintz, Yi-ming Yang, Issam Moussa, Ricardo 
A. Costa, Jose de Ribamar Costa, Jr., Masashi Kimura, Koichi Sano, George Dangas, 
Roxana Mehran, Alexandra J. Lansky, Gregg W. Stone, Jeffrey W. Moses, Martin B. 
Leon, Columbia University Medical Center and Cardiovascular Research Foundation, 
New York, NY
Background: Sirolimus-eluting stents (SES) dramatically reduce the risk of angiographic 
restenosis. Stent thrombosis (ST) is an infrequent, but life-threatening complication of 
percutaneous coronary intervention. One year ago, the US FDA issued a warning of ST 
with SES. We undertook this intravascular ultrasound (IVUS) study to assess the factors 
leading to ST after SES implantation.
Methods and Results: Between April 2003 and February 2004, 2,575 patients were 
treated with 4,722 SES. There were 21 patients (0.8%) with documented ST. Of those 
21 patients, 15 patients had IVUS imaging and were compared with 45 matched controls 
who had no evidence of ST. Stent expansion - deﬁ ned as minimal stent CSA/reference 
lumen CSA - was reduced in ST patients compared to matched controls (Table). A 
signiﬁ cant residual reference segment stenosis - deﬁ ned as IVUS minimum lumen 
cross-sectional area <4 mm2 and plaque burden >70% - was present in 10 ST patients 
(67%) versus 4 control patients (9%, p<0.001). Other potential causes (dissection and 
malapposition) were similar between the two groups. Multivariate analysis identiﬁ ed stent 
underexpansion (p=0.03) and a signiﬁ cant residual reference segment stenosis (p=0.02) 
as the independent predictors of ST.
Conclusions: The incidence of ST with SES was less than 1% in real world coronary 
interventions. IVUS analysis shows that stent underexpansion and signiﬁ cant residual 
reference segment stenosis were associated with ST after successful SES implantation.
Intravascular Ultrasound Findings
Stent thrombosis(n=15) Matched control(n=45) p
Reference vessel area (mm2) 12.4 ± 4.1 12.4 ± 3.4 1.0
Reference lumen area (mm2) 6.8 ± 2.2 7.4 ± 2.0 0.3
Minimum stent area (mm2) 4.3 ± 1.6 6.2 ± 1.9 <0.001
Maximum stent area (mm2) 8.6 ± 2.2 7.6 ± 2.0 0.1
Stent expansion 0.65 ± 0.18 0.85 ± 0.14 <0.001
Residual signiﬁ cant stenosis (%) 67 9 <0.001
Edge dissection (%) 0 7 0.3
Malapposition (%) 13 16 0.8
Plaque protrusion (%) 0 2 0.6
1038-36 TAXUS II: Prolonged Clinical Follow-Up After 
Thienopyridine Withdrawal
Sigmund Silber, Antonio Colombo, Adrian Banning, Karl E. Hauptmann, Janusz 
Drzewiecki, Eberhard Grube, Joerg Koglin, Mary E. Russell, Internistische Klinik Dr. 
Muller, Munchen, Germany
Background: TAXUS II mandated the use of clopidogrel for 6 months and aspirin (ASA) 
for 12 months post-procedure. Stents with polymer-based elution of paclitaxel provide an 
effective way to prevent restenosis as shown by low rates of target lesion revascularization 
(TLR) with no identiﬁ ed safety concerns up to 1 year. It is unclear whether these beneﬁ ts 
are due to a sustained inhibition of restenosis or just a timely delay. Protocol mandated 
double antiplatelet therapy could suppress major adverse cardiac events (MACE) for up to 
1 year in the absence of complete vascular healing; however, this beneﬁ t would disappear 
after therapy withdrawal. TAXUS II 2-year clinical follow-up addresses these issues.
Methods: TAXUS II is a randomized, double-blind clinical trial conducted at 38 sites 
comparing the safety and efﬁ cacy of the TAXUS slow-release (SR, n = 131) and TAXUS 
moderate-release (MR, n = 135) stents to bare control stents (BMS, n = 270) in patients 
with focal, de novo lesions. Clinical follow-up, including use of antiplatelet and cardiac 
medications, is being conducted annually for 5 years.
Results: Six months post-procedure, there were signiﬁ cant reductions in MACE for 
TAXUS compared to BMS, mainly due to a decrease of TLR. These beneﬁ ts, along with an 
absence of late stent thrombosis, were preserved at 1 year when 10.2% of patients were 
on double antiplatelet therapy and 94.4% were on ASA only. The 2-year clinical follow-up 
rate was 97.2% with 92.7% patients still on ASA and 7.7% on ASA and clopidogrel. Within 
the TAXUS groups, there was only 1 new TLR, associated with a late stent thrombosis, 
while 8 new TLRs were reported for BMS. As seen at 6 months and 1 year, TAXUS groups 
had signiﬁ cantly lower MACE rates (14.2% for both SR and MR vs. 24.6% BMS, P=0.0178) 
and TLR rates (5.5% SR and 3.9% MR vs. 15.5% BMS, P=0.0002) than BMS.
Conclusions: The reduction of restenosis in TAXUS, as evidenced by lower TLR rates, 
is maintained over time, conﬁ rming that paclitaxel-eluting stents inhibit rather than delay 
restenosis. Withdrawal of double antiplatelet therapy did not result in increased incidence 
of MACE or stent thrombosis, demonstrating stability of the TAXUS safety proﬁ le, and 
indicating complete healing.
1038-37 The Clopidogrel REsistance and Stent Thrombosis 
(CREST ) Study
Paul A. Gurbel, Kevin P. Bliden, Waiel Samara, Jason A. Yoho, Kevin M. Hayes, Udaya 
Tantry, Sinai Center for Thrombosis Research, Baltimore, MD
Background: High post-treatment platelet reactivty has been reported and may result 
in stent thrombosis.
Methods: We identiﬁ ed 20 patients with subacute stent thrombosis (SAT) treated at 2 
tertiary care centers over a 1.5 year period. As measures of platelet reactivity, aggregation 
(5 and 20 M ADP; and 0.5 and 1 mM arachidonic acid ); stimulated p-selectin and activated 
GP IIb/IIIa expression; and vasodilator-stimulated phosphoprotein phosphorylation 
(VASP) were determined and compared to an age-matched group of patients without stent 
thrombosis (n = 50). All patients had been treated with clopidogrel ( 300mg load/75 mg 
maintenance) and daily 325 mg ASA. High reactivity was deﬁ ned as the 75th percentile for 
20 M ADP aggregation in the group without SAT. Results: Demographics were the same. 
Three patients with SAT died. Patients with SAT had markedly greater platelet reactivity 
than those without SAT by all measures ( p < 0.05 ) (Table). 76 % of patients with SAT 
had high reactivity. 
Conclusions: High platelet reactivity despite clopidogrel and aspirin is associated 
with the development of stent thrombosis. Measures to identify and to improve platelet 
inhibition in these patients are warranted.
Table 1
(-)SAT (n=50) (+) SAT (n=18) P- value
5 uM ADP (%) 26 ±2 49± 4 <0.001
20 uM ADP (%) 46 ± 2 65± 3 <0.001
Arachidonic Acid 0 non-responders 1 non-responder
VASP (index) 46 ± 9 69± 5 0.030
GP IIb/IIIa (MFI) 42 ± 4 138 ±19 <0.001
1038-38 Increased Risk of Sub-acute Thrombosis After 
Overlapping With Drug Eluting Stents: an Analysis 
From the Real-world Eluting Stent Comparative Italian 
Retrospective Evaluation (RECIPE) Study
Francesco Meucci, Elena Falchetti, Guido Vittori, Massimo Margheri, Flavio Airoldi, 
Giuseppe Biondi Zoccai, Antonio Colombo, Azienda Ospedaliero-Universitaria Careggi, 
Florence, Italy, San Raffaele Hospital, Milan, Italy
Background: Overlapping stent technique with drug eluting stents (DES) has been 
encouraged instead of leaving small gaps between two implanted DES in order to avoid 
neointimal proliferation within these gaps. It remains unknown if doubling the stent struts 
and the local drug dose would result in higher incidence of acute or sub-acute stent 
thrombosis.
Methods: Consecutive patients undergoing DES implantation at 4 high-volume and high-
expertise Italian centers were enrolled in the Real-world Eluting-stent Comparative Italian 
retrosPective Evaluation Study . The aim of this study was to assess the clinical outcome 
(in-hospital and 1 month follow up) in patients treated with DES overlapping. Documented 
stent thrombosis was explicitly adjudicated.
Results: A total of 2495 patients (4578 lesions) were included in the study, 49% treated 
with Sirolimus (SES), 43% with Paclitaxel (PES) Eluting Stent and 8% with both. Of the 
2306 patients treated with SES or PES, 2129 (92.4%) have been treated without (A) 
and 177 (7.6%) with (B) stent overlapping; baseline characteristics were not signiﬁ cantly 
different in the populations considered. The incidence of acute (in-hospital) or sub-acute 
(1 month follow up) stent thrombosis has been 3% (5 patients) in group B vs 0.7% (16 
patients) in group A (p=0.02). In hospital mortality was 1.7% (B) vs 0.5% (A) (p=0.07). The 
incidence of other adverse events was low and not signiﬁ cantly different in the two groups. 
Speciﬁ cally the 1-month incidence of Major Adverse Cardiac and Cerebrovascular events 
(death, Q wave myocardial infarction - QWMI -, stroke, CABG, TVR, TLR) was 3% (B) 
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vs 2% (A) (p=NS). Comparing patients treated with SES vs PES no difference has been 
observed in acute or sub-acute stent thrombosis (1 vs 3 %, p=NS) and QWMI (0 versus 
1 % p= NS).
Conclusion: In case of stent overlapping with DES, the higher local drug dose and the 
double metal burden may increase the thrombogenicity in the artery. Our retrospective 
analysis in a real world population treated with DES overlapping demonstrate a higher 
incidence of acute or sub-acute stent thrombosis; a difference between SES and PES 
in the risk of thrombosis and QWMI with stent overlapping may only be investigated by 
a larger study.
1038-39 Incidence and Predictors of Thrombosis After 
Implantation of Drug-Eluting Stents in Unselected 
Patients
IOANNIS IAKOVOU, Thomas Schmidt, Lei Ge, Giuseppe Sangiorgi, Flavio Airoldi, 
Goran Stankovic, Antonio Chieffo, Matteo Montorfano, Nicola Corvaja, Mauro Carlino, 
Urlich Gerckens, Eberhard Grube, Antonio Colombo, EMO Centro Cuore Columbus, 
Milan, Italy, EMO Centro Cuore Columbus, Milan, Italy
Background. There are limited data about stent thrombosis after drug-eluting stent 
(DES) implantation in unselected patients with a variety of coronary lesions. The aim 
of this study was to evaluate the frequency, the predictors, and the clinical outcome of 
stent thrombosis after sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) 
implantation in routine clinical practice.
Methods. A total of 2229 consecutive patients who underwent successful SES (1062 
patients, 1996 lesions, 2272 stents) or PES (1167 patients, 1801 lesions, 2223 stents) 
implantation in 3 Institutions were included in this study.
Results. There were no signiﬁ cant differences between the 2 groups in procedural 
complications and in-hospital outcome. At a mean follow-up of 9.3 ± 5.6 months, the 
cumulative incidence of stent thrombosis was 1.2% (0.9% with SES and 1.5% with 
PES, P=0.2). Independent predictors of stent thrombosis were: renal failure (OR=11.48; 
95%CI, 4.27 to 30.83, p<0.0001), bifurcational lesions (OR=7.19; 95%CI, 2.36 to 21.82, 
p<0.0001), diabetes (OR=3.36; 95%CI, 1.53 to 7.37, p=0.002), and ejection fraction 
(OR=0.91; 95%CI, 0.88 to 0.95, p<0.0001 for each 10% decrease). Among patients who 
stopped antiplatelet treatment prematurely stent thrombosis occurred in 29% of them. 
Death occurred in 12 (44%) and non-fatal myocardial infarction in 13 (48%) patients.
Conclusions. The incidence of stent thrombosis at a mean follow-up of 9.3 months after 
successful DES implantation in unselected lesions was 1.2% with no difference between 
PES and SES. Renal failure, bifurcational lesions, diabetes, and low ejection fraction 
were predictors of thrombosis. Alternative therapeutic approaches to stenting should be 
considered when multiple predisposing factors are present or when there is the risk of 
premature discontinuation of double antiplatelet therapy.
1038-40 Sirolimus-Eluting Stents May Decrease Stent 
Thrombosis: A Meta-Analysis of Randomized Clinical 
Trials and the Cleveland Clinic Experience
Anthony A. Bavry, Dharam J. Kumbhani, Thomas J. Helton, Stephen Ellis, Cleveland 
Clinic Foundation, Cleveland, OH, Brigham and Women’s Hospital, Harvard Medical 
School, Boston, MA
Objectives: The incidence of coronary thrombosis with sirolimus-eluting stents 
was compared to that of bare-metal stents, using the Cleveland Clinic Database and 
performing a meta-analysis of the published literature.
Background: There is concern that drug-eluting stents may be associated with increased 
risk of coronary thrombosis.
Methods: All occurrences of coronary thrombosis (within six months of the index stent 
and in the same coronary distribution) were queried from the Cleveland Clinic Database 
from May 01, 2003 to November 30, 2003. Two controls were randomly assigned to each 
case. Multivariate logistic regression analysis controlled for confounding variables.
Results: During seven months of follow-up there were 14 cases of stent-associated 
thrombosis. During this period there were 1,607 stent-based coronary revascularizations 
performed in 1,278 patients. Cases tended to have a lower ejection fraction (42% 
versus 50%, p=0.058) and a higher proportion of diabetics (64% versus 36%, p=0.08), 
compared to controls. Most procedures were performed for unstable angina/non-ST-
elevation myocardial infarction (86% for cases versus 68% for controls, p=0.28). Aspirin, 
clopidogrel, and glycoprotein IIb/IIIa inhibitors were used at operator discretion in both 
groups. Technical aspects of the procedures were similar between groups. Overall, 
there was no difference in coronary thrombosis with the use of sirolimus-eluting stents 
compared to bare-metal stents (crude odds ratio [OR]=0.56, 95% conﬁ dence interval [CI] 
0.15-2.06, p=0.38). Adjusting for diabetes, ejection fraction and lesion length (OR=0.81, 
95% CI 0.17-3.77, p=0.78). A meta-analysis of six published studies (SIRIUS, E-SIRIUS, 
C-SIRIUS, RESEARCH, SES-SMART and RAVEL) revealed (RR=0.41, 95% CI 0.22-
1.12, p=0.09). The overall summary that combines the Cleveland Clinic experience with 
the meta-analysis was (OR=0.52, 95% CI 0.32-0.83, p=0.006).
Conclusions: Current evidence suggests that the incidence of coronary thrombosis 
is not increased or may even be decreased with sirolimus-eluting stents along with 
concomitant anti-platelet therapy compared to bare-metal stents.
1038-41 Standard Compared With Selective Coronary Stent-
Implantation Improves Cardiac Outcome And Cost-
Effectiveness
Hendrik M. Nathoe, Peter R. Stella, Peter P.T. de Jaegere, University Medical Center, 
Utrecht, The Netherlands
Background: Stent-implantation compared with balloon angioplasty reduces the number 
of re-interventions signiﬁ cantly. In daily practice however, not every patient receives stents 
(selective stenting). It is unknown whether clinical outcome and costs of standard and 
selective stenting are comparable.
Methods: Data of the patients who were eligible for the Octopus study were used to 
answer these clinical questions. In the Octopus study, patients were randomized to either 
standard stenting or off-pump bypass surgery. Eligible patients who refused assignment 
for the study received selective stenting. Patients who received standard stenting were 
compared with those with selective stenting. All patients were followed similarly according 
to the study-protocol during one year. The primary clinical endpoint was deﬁ ned by 
survival free from cardiovascular events: stroke, myocardial infarction, or re-interventions. 
Direct medical costs were also assessed.
Results: 514 of 1772 patients screened (29 %) were eligible for the Octopus study. 
234 eligible patients refused participation in the study (163 due to referral physicians 
preferences and 71 patients preferences). 138 of the 280 participants in the Octostent 
study were randomized to stenting. Finally, 138 patients who were randomized to 
standard stenting were compared with 234 non-randomized patients who received 
selective stenting.
The baseline characteristics of the patients were not different. Patients were predominantly 
male with a mean age of 60 years, 70 % with 1-vessel and 30% with 2-vessel disease. 
Most patients had a preserved left ventricle function. Stents were implanted in 100% 
and 57% of the patients in the standard-group and the stent-group, respectively. Event-
free survival in the standard and selective -group was 87.0% and 77.4 %, respectively, 
difference 9,6% (95% CI: 1.8% to 17%). The number of re-interventions was 10.1% versus 
20.9%, respectively, difference -10.8% (95% CI: -12.8% to -1.9%). Direct medical costs at 
one year were US$ 9123 in the selective and US$ 7043 in the standard-group (p<0.01).
Conclusions: standard compared with selective stent-implantation improved clinical 
outcome and cost-effectiveness.
1038-42 Thirty-Month Outcome After Fractional Flow Reserve-
Guided Versus Conventional Multivessel Percutaneous 
Coronary Intervention
Nattawut Wongpraparut, Vankata Yalamanchili, Venkat Pasnoori, Aaron Satran, Ronlad 
Masden, Massoud A. Leesar, University of Louisville, Louisville, KY
BACKGROUND: Conventional mutlivessl percutaneous coronary intervention (CM-
PCI) is currently being performed based on a visual estimation of a stenosis. Deferral 
of a percutaneous coronary intervention (PCI) based on a fractional ﬂ ow reserve (FFR 
>0.75) is associated with low event rates. However, the value of FFR-guided multivessel 
PCI (FFRM-PCI) in patients with multivessel disease (MVD) is unknown. We sought to 
investigate the value of FFRM-PCI vs. CM-PCI in patients with MVD.
METHODS: In the FFRM-PCI group, FFR of all vessels was performed and PCI of 
stenoses with an FFR <0.75 was proceeded. In the CM-PCI group, patients underwent 
multivessel PCI by a visual estimation of stenoses. Procedural characteristics, event 
rates, and cost were compared between the two groups.
RESULTS: In the FFRM-PCI group, after FFR analysis in 60 patients (134 vessels), in 
74 vessels (55%) FFR was 0.86 ± 0.06 and PCI was deferred. However, in 48 patients 
(53 vessels) PCI was performed and FFR increased from 0.67 ± 0.07 at baseline to 0.96 
± 0.03 after PCI, P<0.001; 43 patients (84%) underwent single vessel PCI, ﬁ ve patients 
(10%) underwent 2-vessel PCI, and three patients (6%) underwent bypass surgery. 
Among the CM-PCI group, 80 patients (184 vessels) underwent PCI; 58 patients (72%) 
underwent 2-vessel PCI, 20 patients (25%) underwent 3-vessel PCI, and two patients 
(3%) underwent 4-vessel PCI. The average number of vessels per patient underwent 
PCI was signiﬁ cantly greater in the CM-PCI group than in the FFRM-PCI group (2.27 ± 
0.50 versus 1.12 ± 0.30, respectively; P <0.001). The procedure time, radiation exposure 
time, and amount of contrast media used were not statistically different between the two 
groups. The 30-month Kaplan-Meier event-free survival estimate was signiﬁ cantly greater 
in the FFRM-PCI group than in the CM-PCI group (89% versus 59 %, p<0.01). The cost 
of procedure was signiﬁ cantly higher in the CM-PCI group than in the FFRM-PCI group 
($3167 ± 1194 vs. $2572 ± 934, respectively; P <0.01).
CONCLUSIONS:The present study demonstrates that in patients with MVD, compared 
with CM-PCI, FFRM-PCI signiﬁ cantly reduces the number of vessels undergoing PCI, 
event rates, and the cost of procedure.
1038-43 Postocclusive Hyperemia Provides a Better Estimate 
of Coronary Reserve Than Intracoronay Adenosine in 
Patients With Coronary Artery Stenosis
Éric Durand, Wissem Sdiri, Saliha Rahal, Antoine Lafont, Alain Nitenberg, Service 
de Cardiologie 1, Hôpital Européen Georges Pompidou, Paris, France, Service 
d’Explorations Fonctionnelles, Hôpital Jean Verdier, Bondy, France
Background: Coronary stenosis assessment depends on the induction of maximal 
hyperemia. Current clinical standard for induction of maximal coronary hyperemia is the 
administration of intracoronary adenosine (ADE). However, animal studies have shown 
that maximal hyperemia was not achieved by ADE and that postocclusion hyperemia 
(POH) yielded a better hyperemic response. The aim of this study was to compare the 
ability of ADE and POH to cause maximal hyperemia in human beings.
Methods: In 8 patients with stable coronary artery disease and with coronary artery stenosis 
> 80%, basal and peak coronary blood ﬂ ow velocity (intracoronary Doppler ﬂ ow probe) 
were measured before and after percutaneous coronary angioplasty (PTCA) both after an 
intracoronary bolus of 30 µg ADE, and after 30 sec occlusion of coronary artery by a balloon 
angioplasty catheter. Coronary reserve was estimated through ﬂ ow reserve (CFR = peak-to-
resting coronary ﬂ ow velocity), and resistance reserve (CRR = [resting aortic pressure/resting 
coronary ﬂ ow velocity]/[aortic pressure at peak velocity/peak coronary ﬂ ow velocity]).
Results: Before PTCA, ADE and POH result in comparable CFR (1.83±0.73 vs 
1.94±0.72 respectively, p=0.2353) but CRR was higher with POH (1,74±0.57 vs 2.18±0.93 
respectively, p=0.0305). After PTCA, CFR and CRR were signiﬁ cantly lower after ADE 
than after POH (CFR = 2.48±0.65 vs 3.29±0.76 respectively, p=0.0007, CRR = 2.54±0.54 
vs 3.79±0.84, p=0.0027). Before PTCA, CRR was underestimated by 17±14%, and after 
PTCA, CFR was underestimated by 25±11% and CRR by 32±14%. Lastly, the higher was 
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the coronary reserve, the more was the difference between ADE and POH values.
Conclusion: ADE does not achieve maximal hyperemia which might result in an 
underestimation of physiological signiﬁ cance of a coronary artery stenosis and represents 
a potential source of error in coronary reserve measurements. A better estimation of 
physiological signiﬁ cance of coronary artery stenosis and of coronary reserve is provided 
by POH, which induces a better hyperemic response, and CRR calculation.
1038-44 Non-ﬂ uoroscopic Intra-Coronary Navigation and Stent 
Deployment Using a 3-Dimensional Computerized 
Positioning System
Moshe Y. Flugelman, Avinoam Shiran, Rona Shofti, Martin B. Leon, Basil S. Lewis, Lady 
Davis Carmel Medical Center, Haifa, Israel, Columbia Presbyterian Medical Center, New 
York, NY
Background: Conventional imaging and navigation during intravascular intervention 
depends on use of contrast medium and ﬂ uoroscopic positioning of intracoronary 
devices. We report stent placement using a new non-ﬂ uoroscopic, intra-coronary medical 
positioning system (MPSTM, MediGuide Ltd, Israel).
Methods: The MPSTM system consists of a catheter-based miniaturized sensor with 
surrounding magnetic ﬁ eld that provides automatic online quantitative computerized 3D 
reconstruction of the target vessel. The system delineates coronary anatomy by tracking 
in 3D space the route taken by the miniaturized sensor in the catheter tip. Integration with 
intravascular ultrasound (IVUS) creates a guided IVUS (GIVUSTM) 3D image of the vessel 
and its wall. A similar MPSTM sensor on the stent delivery system reports stent position in 
real time and 3D to facilitate precise deployment of intracoronary stents/devices.
The MPSTM system was used to deploy 12 stents in 7 adult pigs. Reconstructed 2D and 
3D roadmap images were used to place stents at pre-speciﬁ ed locations in coronary 
arteries (4 LAD, 4 RCA, 4 Cx) close to bifurcations. The target for stent deployment was 
marked electronically on the road map using proximal and distal position markers. As stent 
advanced into vessel, electronic stent markers showed its position superimposed on road 
map image. Without ﬂ uoroscopy and using only static roadmap for guidance, stents were 
deployed when stent markers coincided with the pre-speciﬁ ed markers on the roadmap. 
Stent position in the artery was validated at post-mortem by pathologic examination.
Results: MPS tracked the ﬂ uoroscopic image with mean accuracy of 0.45±0.39mm 
(distance from stent marker to electronic MPS marker on cine-loop angiography during 
diastole). Stent positioning in the artery was highly accurate. At post mortem (N=10) 9 
stents were <1mm from selected bifurcation site, 1 was 2 mm into the bifurcation jailing 
the side branch.
Conclusions: The MPSTM non-ﬂ uoroscopic system allowed highly accurate computer-
assisted stent positioning and deployment. The MPSTM system is a promising new 
method to improve ease and accuracy of stent/device placement during intravascular 
interventions.
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Presentation Hour: 3:30 p.m.-4:30 p.m.
1039-23 Impact of Vascular Closure Devices on Hemorrhagic 
Complications After Angioplasty with Bivalirudin 
Compared to Heparin plus IIb/IIIa Inhibitors: Analysis 
from REPLACE-2
Tayo A. Addo, A. Micheal Lincoff, Roxana Mehran, George Dangas, Neal S. Kleiman, 
Daniel S. Jackman, Fred Feit, Gregg W. Stone, Cardiovascular Research Foundation, 
New York, NY, Cleveland Clinic Foundation, Cleveland, OH
Background. Whether vascular closure devices (VCD) compared to manual compression 
(MC) affect the rate of hemorrhagic complications (HC) after percutaneous coronary 
intervention (PCI) remains controversial, especially when GPIIb/IIIa inhibitors are used. 
Moreover, scant data exists examining the outcomes of VCD after PCI utilizing the direct 
thrombin inhibitor bivalirudin.
Methods. HC in pts randomized to unfractionated heparin + IIb/IIIa inhibitors (H+IIb/
IIIa) vs. bivalirudin + bail-out IIb/IIIa inhibitors (Biv) were examined in the large-scale, 
multicenter REPLACE-2 trial, stratiﬁ ed by VCD or MC.
Results. VCD (Angioseal™ (n=733), Perclose™ (511), Duet™ (31), and Vasoseal™ (26)) 
were used in 1,341 pts (22.6%) of 5,936 pts. There were no signiﬁ cant differences in 
baseline characteristics, procedural data or ischemic events between the pooled VCD 
and MC groups. Median ACT at procedure end was 309 vs. 312, respectively (p=NS). 
The pooled rates of major hemorrhage were similar (3.3% vs. 3.2% respectively, p=0.93), 
though minor bleeding complications were less frequent with VCD (16.9% vs. 20.3%, 
p=0.004). HC stratiﬁ ed by anticoagulant strategy are shown in the Table.
Conclusions. Use of VCD after contemporary PCI does not increase hemorrhagic complications, 
and may decrease minor bleeding. Bivalirudin compared to heparin + GP IIb/IIIa inhibitors 
decreases hemorrhagic complications whether arterial stasis is obtained by VCD or MC. 
Vascular Closure Devices Manual Compression
Biv
N=667
H + IIb/IIIa
N=674 P
Biv
N=2,295
H + IIb/IIIa
N=2,300 P P1 P2
Protocol Major 
Bleeding 1.6% 4.9% 0.001 2.6% 3.9% 0.01 0.22 0.31
Protocol Minor 
Bleeding 10.6% 23.0% <0.001 14.3% 26.4% <0.001 0.02 0.09
TIMI Major 
Bleeding 0.6% 1.2% 0.39 0.7% 0.8% 0.73 1.0 0.45
TIMI Minor 
Bleeding 1.0% 3.6% 0.004 1.4% 2.9% <0.001 0.62 0.46
P1=Bivalirudin VCD vs. MC; P2=heparin+IIb/IIIa VCD vs. MC
1039-24 Triple Combination Therapy With Aspirin, Clopidogrel, 
and Coumadin Following Coronary Stenting is 
Associated With a Signiﬁ cantly Higher Risk of Bleeding
Khurram S. Zakaria, Eric T. Chou, S Chiu Wong, Geoffrey Bergman, Manish Parikh, 
Robert Minutello, Mun K. Hong, New York Presbyterian Hospital-Weill Medical College of 
Cornell University, New York, NY
Background: Dual-antiplatelet therapy of aspirin and clopidogrel is the standard of care 
following coronary stenting, but is associated with a bleeding risk (approximately 3% 
major bleeding risk in PCI-CURE trial). Patients who are on chronic coumadin therapy 
and receive coronary stent need to be treated with aspirin, clopidogrel, and coumadin. 
Methods: We compared consecutive patients (n=107) on chronic coumadin therapy, who 
underwent coronary stenting and discharged on aspirin, clopidogrel, and coumadin to a 
contemporary cohort of randomly selected patients (n=107) who were treated with dual-
antiplatelet therapy alone post stenting. We evaluated their bleeding history before and at 
six months after stenting. Major bleeding was deﬁ ned as bleeding that was signiﬁ cantly 
disabling, intraocular, or requiring ≥ 2 units of blood transfusion. Minor bleeding was 
deﬁ ned as other bleeding that led to interruption of the medication. 
Results: Patients on triple therapy were younger (69 ± 11 vs. 72 ± 6; p<0.001), and 
more likely to have hypertension (82% vs. 68%, p=0.03), but there was no difference 
in prior history of major or minor bleeding between the two groups. Following stenting, 
patients on triple therapy had more major bleeding (6.6% vs. 0.0%, p = 0.004), and more 
minor bleeding (14.9% vs. 3.8%; p= 0.01). Mean INR levels were no different between 
patients with or without major bleeding (2.3±1.1 vs. 2.6±1.4; p=ns), or between patients 
with or without minor bleeding (2.9±1.5 vs. 2.6± 1.4; p=ns). Among patients on triple 
therapy, clopidogrel was discontinued prematurely in 8%, while coumadin was stopped 
in 6% of patients. In this cohort, there was one fatal death from intracranial bleeding 
which occurred in a patient with a prior history of major bleeding. Importantly, there was 
no difference in the frequency of bleeding with respect to 81 or 325 mg aspirin dosing. 
Conclusion: In patients on chronic coumadin therapy, the addition of dual-antiplatelet 
therapy is associated with a signiﬁ cantly higher risk of major bleeding as compared to 
dual-antiplatelet therapy alone. Novel regimens are needed to reduce bleeding risk, 
especially in those with a prior history of major bleeding on coumadin therapy alone.
1039-25 Bivalirudin Versus Heparin in Percutaneous Coronary 
Interventions: A Meta-Analysis
Ramin Ebrahimi, A. Michael Lincoff, Atman P. Shah, John A. Bittl, Derek Chew, Kathy 
Wolski, UCLA School of Medicine - Greater Los Angeles VA, Los Angeles, CA, 
Cleveland Clinic Foundation, Cleveland, OH
Background: Bivalirudin, a short acting direct thrombin inhibitor, is being increasingly 
utilized in percutaneous coronary interventions (PCI). We performed a meta-analysis of 
four prospective randomized clinical trials comparing the safety and efﬁ cacy of bivalirudin 
to heparin or heparin plus glycoprotein IIB/IIA inhibitors (GPI) in PCI.
Methods: The BAT (n=4312), CACHET (n=268), REPLACE-1 (n=1056), and REPLACE-
2 (n=6002) trials compared bivalirudin to heparin in PCI and were included in this meta-
analysis. The incidence of major bleeding events (MBE), revascularization (RV), myocardial 
infarction (MI), and death at 48 hours was compared between the two groups.
Results: The trials consisted of 11,638 patients (bivalirudin 5861, heparin 5777). There 
was no signiﬁ cant difference between the two groups with regards to baseline clinical 
characteristics. At 48 hours, the incidence of MBE, RV, and death was signiﬁ cantly less 
in the bivalirudin group and there was a decreased incidence of combined endpoints 
(Figure 1). Analysis of subgroups of patients who received bivalirudin alone (n=2318) 
versus heparin alone (n=2298) and those who received bivalirudin plus provisional GPI 
(n=3138) versus heparin plus GPI revealed a signiﬁ cant reduction in MBE (3.6% vs. 
2.0%,p=0.001).
Conclusions: This meta-analysis supports the superiority of bivalirudin versus heparin 
in reducing major adverse clinical endpoints as well as a composite of these endpoints 
without sacriﬁ cing efﬁ cacy at 48 hours in PCI. 
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1039-26   Safety of Switching Glycoprotein IIb/IIIa Inhibitors for 
Percutaneous Coronary Intervention
Mark A. Grabarczyk, Sid Staton, Robert J. Applegate, Matthew Sacrinty, Talal T. Baki, 
Sanjay K. Gandhi, William C. Little, Michael A. Kutcher, David C. Sane, Wake Forest 
University School of Medicine, Winston-Salem, NC
Background. Eptiﬁ batide (E) has become standard of care for high risk patients with acute 
coronary syndrome (ACS), and is frequently continued during and after percutaneous 
coronary intervention (E + E). Alternatively, abciximab (A) has been shown to be effective 
for PCI and is often chosen for high risk PCI. Whether A can be used safely or effectively 
after pretreatment with E (E + A) is unclear.
Methods. We evaluated procedural and in hospital outcomes after PCI in patients with 
ACS: E + A (n=331); E + E (n=607). Platelet function by ﬂ ow cytometry was assessed in 50 
patients; platelet inhibition 1 hour after E + A was 90±1% vs. 91±1% after A alone, p=NS.
Results. Clinical characteristics of the two groups were comparable. PCI success rates 
were 96.9% E + E vs. 97.9% E + A, p=NS.
Hemoglobin (Hgb) Platelet (plt) ↓Hgb>3gm plt<50K
Pre PCI Post PCI Pre PCI Post PCI Post PCI Post PCI
E + E 13.2 ± 1.6 12.2 ± 1.7 225 ± 69 206 ± 69 0.2% 0.0%
E + A 13.0 ± 1.7 12.0 ± 1.7 216 ± 67 195 ± 68 0.3% 0.9%*
* = p<0.05 vs. E + E
Vascular complications occurred in 2.3% E + E vs. 3.9% E + A, p=NS. Any major adverse 
cardiac event (death, MI, or urgent revascularization) occurred in 4.5% E + E vs. 1.5% 
E + A, p<0.05.
Conclusion. Platelet inhibition is similar after abciximab in the presence of pretreatment 
with eptiﬁ batide compared to platelet inhibition with abciximab alone. Abciximab use after 
eptiﬁ batide for PCI is as safe as eptiﬁ batide alone after PCI, and is at least as effective. These 
data suggest that pretreatment with eptiﬁ batide does not preclude PCI with abciximab.
1039-29 Percutaneous Coronary Intervention Outcomes and the 
Impact of Pharmacologic Selection: Glycoprotein IIbIIIa 
Inhibitors versus Bivalirudin
Heath R. Jennings, Kevin L. Poe, Jeffery M. Carrico, Eric C. Miller, Richard A. Blake, 
John C. Sartini, Saint Joseph HealthCare, Lexington, KY
Background: This three-year cohort study evaluated percutaneous coronary intervention 
(PCI) drug therapies established by EPISTENT, ESPRIT, and REPLACE-2 and compared 
associated hemorrhagic and ischemic complications (per ACC Clinical Standards). 
Methods: Treatment occurred per cardiologist discretion and drug combinations included: 
heparin + a glycoprotein IIbIIIa inhibitor (H+G), bivalirudin ± a glycoprotein IIbIIIa inhibitor 
(B±G), and bivalirudin monotherapy (BM). Primary endpoints included a quadruple 
composite of death, MI, urgent revascularization, and TIMI major bleeding and a triple 
composite of death, MI, and urgent revascularization. Secondary endpoints included TIMI 
major and minor bleeding. Statistical analysis included X2, Bonferroni, T-test, and ANOVA. 
Results: 6097 patients were evaluated and 3635 were included: 1881 treated with H+G 
(68% eptiﬁ batide and 32% abciximab) and 1754 with B±G (47% BM). Relative reductions 
in the quadruple and triple endpoints were noted with H+G versus B±G (24% and 36% 
respectively; p < 0.05) and versus BM (27% and 42% respectively; p < 0.05). Within the 
H+G group, relative reductions in quadruple and triple endpoints of 26% and 20% were 
noted with eptiﬁ batide versus abciximab. Secondary endpoint analysis revealed decreased 
bleeding with B±G and BM versus H+G (p > 0.05) and with eptiﬁ batide versus abciximab 
(p < 0.01). Relative risk of combined events was 0.76 with H+G (95% conﬁ dence interval 
[CI] 0.58-0.97, p < 0.05), 1.31 with B±G (CI 1.03-1.72, p < 0.05), and 1.39 with BM (CI 
1.03-1.91, p < 0.05). Relative risk of ischemic events was 0.64 with H+G (CI 0.47-0.84, p 
< 0.01), 1.56 with B±G (CI 1.20-2.13, p < 0.01), and 1.72 with BM (CI 1.23-2.5, p < 0.01). 
Conclusion: Hemorrhagic complications were decreased with the use of B±G and BM 
versus H+G; however, the use of H+G offered superior ischemic outcomes versus B±G 
or BM. Additionally, eptiﬁ batide plus heparin appeared to possess favorable ischemic and 
hemorrhagic outcomes versus abciximab plus heparin. From these results, clinicians may 
question the use of B±G or BM during PCI and consider eptiﬁ batide plus heparin a cost 
effective option to maximize patient outcomes.
1039-30 Risk of Vascular Bleeding in Renal Failure Patients 
Receiving Adjunctive Clopidogrel for Percutaneous 
Coronary Intervention: A Report from the American 
College of Cardiology - National Cardiovascular Data 
Registry (ACC-NCDR)
Henry W. Huang, Richard E. Shaw, California Paciﬁ c Medical Center, San Francisco, CA, 
American College of Cardiology, Bethesda, MD
Background: Renal failure is present in many patients undergoing percutaneous coronary 
intervention (PCI). Multiple anti-platelet/anti-coagulant drugs are routinely administered 
for PCI, including clopidogrel. However, renal failure leads to platelet dysfunction and 
increased bleeding. Data is lacking on the effects of clopidogrel in renal failure patients. 
The purpose of this study was to examine rates of vascular bleeding in renal failure 
patients receiving adjunctive clopidogrel for PCI.
Methods: Between 1/1/01 and 12/31/03, 448,043 consecutive PCI procedures from 
313 institutions were submitted to the American College of Cardiology - National 
Cardiovascular Data Registry (ACC-NCDR). Of these, 11,510 presented with a history 
of renal dysfunction, deﬁ ned as a documented history of renal failure that was treated 
with medication, low protein diet, or dialysis by a physician. The combination of aspirin, 
heparin and glycoprotein IIb/IIIa inhibitor therapy was used in 6,698 procedures. The 
group was further divided into those receiving clopidogrel (5,634) and those who did not 
(1,064). Vascular bleeding events were compared between these 2 groups, with outcomes 
stratiﬁ ed by gender and age.
Results: A total of 170 patients (2.5%) experienced a vascular bleeding complication 
post-PCI. No signiﬁ cant increase in vascular bleeding complications was seen with or 
without the addition of clopidogrel (2.6% vs. 2.0%, p-value=0.20). Although females 
had an increased risk of bleeding with the addition of clopidogrel, this difference was 
not statistically signiﬁ cant (3.8 vs. 2.4%, p-value=0.16); age>70 years with and without 
clopidogrel showed no difference (3.5% vs. 3.1%, p-value=0.73).
Conclusion: The addition of clopidogrel to standard anticoagulant therapy for PCI does not 
confer a signiﬁ cantly higher risk of vascular bleeding complications in renal failure patients.
POSTER SESSION
1040  Studies of Coronary Flow Velocity 
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Sunday, March 06, 2005, 1:30 p.m.-5:00 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 3:30 p.m.-4:30 p.m.
1040-27 Prediction of Residual Myocardial Viability in Patients 
Achieving TIMI Grade 3 Flow: Analysis Using a Doppler 
Guidewire
Koichi Tamita, Atsushi Yamamuro, Shunichirou Kaji, Minako Katayama, Shin Kinoshita, 
Shigefumi Morioka, Takashi Akasaka, Kobe General Hospital, Kobe, Japan, Kawasaki 
Medical School, Kurashiki, Japan
Background: Reperfusion therapy for acute myocardial infarction (AMI) aims to achieve 
patency of the epicardial infarct-related coronary artery and TIMI 3 ﬂ ow. However, it 
has been reported that even if TIMI 3 ﬂ ow is achieved in epicardial coronary arteries, 
microvascular injury results in insufﬁ cient reperfusion of the infracted myocardium, leading 
to severe myocardial damage. Recent studies have shown that microvascular injury can 
be assessed from coronary ﬂ ow velocity (CFV) patterns. The purpose of this prospective 
study was to examine whether the CFV pattern may predict myocardial viability at the late 
stage in patients who have achieved TIMI grade 3 ﬂ ow after reperfusion.
Methods: The study population consisted of 88 consecutive patients with a ﬁ rst anterior 
AMI successfully treated with percutaneous coronary intervention (PCI) (angiographically 
<50% residual stenosis with TIMI grade 3). We examined the CFV pattern immediately after 
coronary intervention using a Doppler guidewire. Patients were divided into two groups based 
on myocardial viability assessed by thallium-201 SPECT 6 months after the infarction; 66 
patients with viable myocardium and 22 patients with nonviable myocardium. Redistribution 
patterns or residual maximal myocardial activity >50% are indices of tissue viability.
Results: Coronary ﬂ ow velocity variables showed signiﬁ cantly higher systolic peak velocity 
(26±17 vs -33±11 cm/s; p<0.001) and longer diastolic deceleration time (DDT) (746±181 
vs 324±1617 ms; p<0.001) in viable myocardial group than in nonviable myocardial 
group. The optimal cutoff values to predict viable myocardium was 0 cm/s for systolic 
peak velocity and 600ms for DDT (sensitivity=0.88, speciﬁ city=0.95 and sensitivity=0.94, 
speciﬁ city=0.91, respectively).
Conclusion: Even patients achieving TIMI grade 3 ﬂ ow after PCI showed less myocardial 
viability in the infracted regions if their CFV patterns indicated low systolic peak velocity 
and short DDT. Thus, the evaluation of CFV patterns immediately after PCI is clinically 
useful to predict residual myocardial viability in patients with anterior AMI.
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1040-28 Intracoronary Ultrasound Assessment of 
Angiographically Borderline Left Main Coronary 
Artery Stenosis - Comparison With Pressure-Derived 
Fractional Flow Reserve.
Jacek Legutko, Dariusz Dudek, Lukasz Rzeszutko, Marcin Wizimirski, Jacek S. Dubiel, 
Institute of Cardiology, Krakow, Poland
Background: Intracoronary ultrasound (ICUS) and pressure-derived fractional ﬂ ow 
reserve (FFR) is used to deﬁ ne clinical signiﬁ cance of borderline left main coronary 
artery stenosis (BLM). However there are no strict ICUS criteria for the detection of BLM 
stenosis causing myocardial ischemia. The aim of the study was to establish ICUS cut-off 
values for the detection of clinically signiﬁ cant left main stenosis.
Methods: In 44 pts with isolated BLM, without prior myocardial infarction or left ventricular 
hypertrophy, FFR was calculated during continuous intravenous infusion of adenosine 
(140 µg/kg/min for 6 min.). Than, in all lesions ICUS was performed using automated pull-
back (0.5 mm/sec) to calculate left main minimal lumen cross-sectional area (LAmin, mm
2), 
minimal luminal diameter (MLD, mm) and percent area stenosis.
Results: There was no complications occurring during invasive assessment of BLM. 
Angiographic percent diameter stenosis (assessed by QCA) was similar in pts with FFR 
>0.75 and ≤0.75 (p=NS). There was a strong positive correlation between FFR and 
LAmin (r=0,84, p<0,0001), and FFR and MLD (r=0,84, p<0001). ROC analysis revealed 
LAmin=8,0 (AUC=0,987, p<0,0001) and MLD=2,8 (AUC=0,976, p<0,0001) as the best cut 
off-values to distinguish between FFR>0,75 and FFR≤0,75. 
Conclusions: Left main minimal lumen cross sectional area <8mm2 and minimal lumen 
diameter <2,8mm are the best ICUS criteria for critical stenosis.
1040-31 The Diagnostic Value of the Flow Velocity Pressure 
Gradient Slope for Assessment of Functional Coronary 
Lesion Severity.
Martijn Meuwissen, Bart-Jan Verhoeff, Steven J. Chamuleau, Robbert J. de Winter, Karel 
Th. Koch, Jan G. P. Tijssen, Jan J. Piek, Academic Medical Center, Asmterdam, The 
Netherlands
Background: The slope of the ﬂ ow pressure gradient (V-DPs) has been proposed as a 
lesion-speciﬁ c parameter of functional coronary stenosis severity. The aim of this study 
was to compare V-DPs, hyperemic stenosis resistance index (h-SRv) fractional ﬂ ow 
reserve (FFR), coronary ﬂ ow velocity reserve (CFR), relative CFR (rCFR) and myocardial 
perfusion scintigraphy (MPS).
Methods: MPS was performed in 199 patients with angina to identify reversible perfusion 
defects (RPDs). Coronary pressure and ﬂ ow velocity was measured during baseline and 
maximum hyperemia distal to 243 single coronary lesions with a mean diameter stenosis 
of 55% (range: 35-84%). V-DPs was calculated as the slope between baseline and 
maximum hyperemic ﬂ ow velocity to pressure gradient. Receiver-operating-characteristic 
curves (ROC) of V-DPs were calculated to evaluate the predictive value for the presence 
of RPDs on MPS using the area under curve (AUC). Accuracy (highest sum of sensitivity 
and speciﬁ city) was calculated for the best cut-off values (BCV) for V-DPs, h-SRv, FFR, 
CFR and rCFR .
Results: AUC for V-DPs for RPDs was 0.862 ± 0.032 (Figure). BCV for RPDs was 
determined at 0.90. Sensitivity, speciﬁ city and accuracy for this BCV were 81%, 88% and 
86%, respectively. AUC for h-SRv, FFR, CFR and rCFR for reversible ischemia were 0.85, 
0.77, 0.74 and 0.79, respectively.
Conclusion: Indices using both intracoronary pressure and ﬂ ow demonstrate a higher 
diagnostic accuracy for RPDs compared to indices using pressure or ﬂ ow alone.
1040-32 Coronary Flow Reserve Versus Coronary Flow Velocity 
Pattern for Predicting Wall Motion Recovery After 
Primary Coronary Stenting for Acute Myocardial 
Infarction
Takefumi Takahashi, Yoshikazu Hiasa, Shinichiro Miyazaki, Takeshi Tomokane, Riyo Ogura, 
Hitoshi Miyajima, Yoshikazu Ohara, Kenichiro Yuba, Naoki Suzuki, Shinobu Hosokawa, 
Koichi Kishi, Ryuji Ohtani, Tokushima Red Cross Hospital, Komatsushima, Japan
Background: Both coronary ﬂ ow reserve (CFR) and coronary ﬂ ow velocity pattern 
(CFVP) measured immediately after reperfusion are thought to be useful for predicting 
functional recovery after acute myocardial infarction (AMI). We compared the utility of 
CFR and CFVP in the early prediction of wall motion recovery in AMI. Methods: By using 
a Doppler guidewire, we evaluated CFR and CFVP immediately after primary coronary 
stenting in 65 consecutive patients with a ﬁ rst anterior AMI. According to the previous 
reports, CFVP of severe microvascular injury was deﬁ ned as the presence of systolic ﬂ ow 
reversal and diastolic deceleration time <600 ms. A two-dimensional echocardiography 
was performed before revascularization and at 3 weeks, to assess the change in the wall 
motion score (ΔWMS; normal=0 to dyskinesia=4). For each patient, wall motion recovery 
was deﬁ ned as an improvement of wall thickening in more than 2 contiguous segments 
at 3 weeks. Results: On the basis of ROC curve analysis, an optimal cutoff value of 
1.4 for CFR was chosen to predict wall motion recovery. Conclusion: CFR measured 
immediately after primary coronary stenting has a diagnostic value similar to CFVP in 
detecting wall motion recovery after reperfused AMI. 
Sensitivity Speciﬁ city PPV NPV Accuracy
CFR 83% 84% 89% 75% 83%
CFVP 80% 80% 86% 71% 80%
PPV: positive predictive value, NPV: negative predictive value
1040-33 Relationship Between Abnormal Glucose Metabolism 
and Microvascular Injury in Patients With Acute 
Myocardial Infarction
Koichi Tamita, Atsushi Yamamuro, Shunichirou Kaji, Minako Katayama, Shin Kinoshita, 
Shigefumi Morioka, Takashi Akasaka, Kobe General Hospital, Kobe, Japan, Kawasaki 
Medical School, Kurashiki, Japan
Background: Previous studies have reported that acute hyperglycemia at hospital 
admission is associated with adverse outcomes after acute myocardial infarction (AMI) in 
patients without diagnosed diabetes. However, its underlying mechanism remains unclear. 
Recent studies have shown that severe microvascular injury can be assessed from coronary 
ﬂ ow velocity (CFV) patterns with a rapid diastolic deceleration time (DDT). The purpose of 
this prospective study was to examine the relationship between newly diagnosed abnormal 
glucose metabolism (AGM) and microvascular injury in patients with AMI.
Methods: The study population consisted of 95 consecutive patients with no diagnosis 
of diabetes and a ﬁ rst anterior AMI successfully treated with percutaneous coronary 
intervention (PCI) (angiographically <50% residual stenosis). We examined the CFV 
pattern immediately after coronary intervention using a Doppler guidewire. We did 
standardized oral glucose tests with 75g of glucose at discharge. Patients were divided 
into two groups based on the results of oral glucose tests; 44 patients with normal glucose 
tolerance (group1) and 51 patients with newly diagnosed AGM (=IGT+DM) (group 2).
Results: Fasting blood glucose and HbA1c showed signiﬁ cantly higher (100±19 vs 90±15 
ms, p=0.01 and 5.6±0.8 vs 5.2±0.4 ms, p=0.01, respectively) in group 2 than in group 1. 
Coronary ﬂ ow velocity variables showed signiﬁ cantly shorter DDT (542±257 vs 691±202 
ms; p=0.01) in group 2 compared with group 1. By regression analysis, the values of blood 
glucose taken 60 min and 120 min after ingestion of 75g glucose signiﬁ cantly correlated 
with DDT (r=0.33, p<0.01 and r=0.32, p=0.01, respectively).
Conclusion: AGM is related to severe microvascular injury after reperfusion in patients with AMI.
POSTER SESSION
1064  Evaluation of Myocardial Perfusion 
After Primary Percutaneous Coronary 
Intervention or Acute Coronary 
Syndrome
Monday, March 07, 2005, 9:00 a.m.-12:30 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 10:00 a.m.-11:00 a.m.
1064-27 Contrast Echocardiography and Magnetic Resonance 
Imaging to Predict Recovery of Left Ventricular Ejection 
Fraction after Coronary Intervention
Elena Biagini, Robert J. van Geuns, Timo Baks, Vittoria Rizzello, Tjebbe W. Galema, Pim 
J. de Feyter, Folkert J. Ten Cate, Thoraxcenter, Rotterdam, The Netherlands, S. Orsola 
Hospital, Bologna, Italy
Background. The aim of this study was to compare myocardial contrast echocardiography 
(MCE) with magnetic resonance imaging (MRI) and other methods that assess 
microvascular reperfusion to predict recovery of global left ventricular (LV) ejection 
fraction (EF) after primary percutaneous coronary intervention (PCI).
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Methods. Twenty-six consecutive patients with acute myocardial infarction (AMI) were 
studied after PCI by MCE and MRI using ﬁ rst-pass imaging (hypo-enhancement) for 
evaluation of myocardial perfusion. Delayed-enhancement MRI (hyper-enhancement) 
was included as another methodology to differentiate viable from infarcted tissue. 
Percentage of ST segment resolution, MB-CK, corrected TIMI frame count (cTFC) and 
myocardial blush grade (MBG) were recorded. A 16-segment model of the left ventricle 
was used to analyze all MCE and MRI images. LV volumes and EF were measured by 2D-
echocardiography with left ventricular opaciﬁ cation using the standard biplane Simpson 
method. In each patient, a MCE/MRI score index was derived by dividing the number of 
viable segments by the number of dysfunctional segments. A follow-up study with MCE 
was obtained at 60 days in all patients. Uni- and multivariable logistic regression analyses 
were performed to characterize predictors of recovery of EF.
Results. LV-EF at baseline and at follow-up was respectively 41±8 and 47±11 (p=0.02). 
At univariate analysis model MB-CK peak (p=0.0001), EF at the ﬁ rst evaluation 
(p=0.02), MCE and MRI score index (all p=0.0001) were univariable predictors of LV-EF 
improvement. A linear regression analysis showed a signiﬁ cant correlation between MCE 
(r=0.59), MRI hypo- (r=0.64) and hyper-enhancement (r=0.72) score index with recovery 
of LV-EF. A multivariate analysis model including clinical and angiographic variables and 
MCE score index showed the last one as the only independent predictor of recovery of EF 
(p=0.001). Adding MRI score index at this model, MRI hyper-enhancement resulted the 
only independent predictor of LV improvement (p=0.001).
Conclusions. Recovery of LV-EF after AMI can be assessed both by MCE and MRI. Delayed 
hyper-enhancement is superior to the other methods for assessment of reperfusion.
1064-28 Myocardial Blush Predicts Left Ventricular Remodeling 
After Primary Angioplasty
Marco De Carlo, Gabriele Borelli, Salvatore Evola, Nicola Ciabatti, Giulia Branchitta, 
Bernardo Cortese, Anna Sonia Petronio, Mario Mariani, University of Pisa, Pisa, Italy
Background: Primary angioplasty fails to achieve adequate myocardial reperfusion in 
25-30% of patients, despite Thrombolysis In Myocardial Infarction (TIMI) grade 3 ﬂ ow. 
These patients show poorer functional recovery and a higher incidence of left ventricular 
(LV) remodeling. Our aim was to identify the predictors of 6-month LV remodeling among 
baseline clinical and angiographic parameters.
Methods: in 207 consecutive patients undergoing primary angioplasty, myocardial 
reperfusion was evaluated by means of Myocardial Blush Grade (MBG), corrected TIMI 
frame count (cTFC), and ST segment elevation resolution. The use of abciximab and distal 
protection devices was also analyzed. All patients underwent echocardiographic follow-
up at 6 months to evaluate the contractile recovery and the presence of LV remodeling 
(increase in end-diastolic volume ≥20%).
Results: Mean symptom onset-to-balloon time was 218±96 min. A ﬁ nal TIMI 3 ﬂ ow was 
obtained in 193 patients (94%), but a MBG 3 was observed only in 85 patients (41%). 
Mean ﬁ nal cTFC was 28±10 f/s. A ﬁ lter-based distal protection device was used in 38 
patients (18%), of whom 25 (66%) also received abciximab. Abciximab alone was used 
in 116 patients (56%). Six patients died before discharge, and 7 more during follow-up. 
LV remodeling occurred in 45 patients (22%), and was associated with: shock (P<0.001), 
baseline LV ejection fraction<40% (P<0.001), anterior wall infarction (P=0.04), ﬁ nal TIMI 
<3 ﬂ ow (P<0.001), cTFC>40 f/s (P=0.002), MBG 0-1 (P<0.001), and peak creatine kinase 
(P<0.001). Use of abciximab and/or distal protection devices was not associated with 
a lower rate of LV remodeling. At multivariate analysis, only MBG 0-1 (P<0.001; OR 
6.4) and LV ejection fraction<40% (P=0.02; OR 3.1) were independent predictors of LV 
remodeling.
Conclusion: The assessment of MBG is an inexpensive method to evaluate the 
effectiveness of myocardial reperfusion during primary angioplasty and predicts the 
development of LV remodeling at 6 months. MBG should routinely be used for the 
prognostic stratiﬁ cation of patients undergoing primary angioplasty.
1064-31 Impact of Diabetes Mellitus on Myocardial Perfusion 
Following Primary Angioplasty in Patients with Acute 
Myocardial Infarction
Abhiram Prasad, Gregg Stone, Tom Stuckey, Constantino Constantini, Peter Zimetbaum, 
Michael McLaughlin, Roxana Mehran, Eulogio Garcia, James Tcheng, David Cox, Cindy 
Grines, Alexandra Lansky, Bernard Gersh, Mayo Clinic, Rochester, MN, Columbia 
University and Cardiovascular Research Foundation, New York, NY
Objectives We investigated the impact of diabetes mellitus on myocardial perfusion 
following primary percutaneous coronary intervention (PCI) utilizing myocardial blush 
grade (MBG) and ST-segment elevation resolution (STR).
Background. Diabetes is an independent predictor of outcomes following primary PCI 
for acute myocardial infarction (AMI). Whether the poor prognosis is due to lower rates of 
myocardial reperfusion is unknown.
Methods. Reperfusion success in those with and without diabetes mellitus was 
determined by measuring MBG (n=1301) and STR analysis (n=700) in two substudies of 
the CADILLAC trial among patients undergoing primary PCI for AMI.
Results. There were no differences between those with or without diabetes with regards 
to postprocedural TIMI grade 3 ﬂ ow (>95%), distribution of infarct-related artery, and the 
frequency of stent deployment or abciximab administration. Patients with diabetes mellitus 
were more likely to have absent myocardial perfusion (MBG 0/1, 56.0% versus 47.1%, 
p=0.01) and absent STR (20.3% versus 8.1%, p=0.002). Diabetes mellitus (hazards ratio 
and 95% conﬁ dence intervals) (1.63[1.17, 2.28], p=0.004) was an independent predictor 
of absent myocardial perfusion (MBG 0/1) and absent STR (2.94[1.64, 5.37], p=0.005) 
by multivariate modeling.
Conclusions. Despite similar high rates of TIMI-3 ﬂ ow after primary PCI in patients with 
and without diabetes, patients with diabetes are more likely to have abnormal myocardial 
perfusion as assessed by both incomplete STR and reduced MBG. Diminished 
microvascular perfusion in diabetics after primary PCI may contribute to adverse 
outcomes.
1064-32 Nicorandil (K+ Channel Opener) Can Prevent Acute 
Complication Including Slow and No Flow During 
Rotational Atherectomy - Prospective Randomized 
Comparison Between Verapamil and Nicorandil
Tai Kojima, Hitoshi Matsuo, Takatomo Watanabe, Shun-ichiro Warita, Takeru Shiraki, 
Takeshi Hirose, Makoto Iwama, Kouji Ono, Masahiko Kouda, Haruki Takahashi, 
Tomonori Segawa, Yukihiko Matsuno, Sachiro Watanabe, Gifu Prefectural Gifu Hospital, 
Gifu city, Japan
Objectives : Potential risk of microcirculation abnormality during rotational athrectomy 
(RA) produced by embolization of abraded non-compliant plaque, platelet aggregation, 
and vasospasm is an important issue. The aim of this prospective randomized trial was to 
conﬁ rm the favorable effect of nicorandil during RA in comparison with verapamil.
Methods : We randomly assigned 200 patients with 219 lesions who were treated by RA 
perfused by either to nicorandil cocktail (100 patients with 109 lesions), which consisted of 
24mg of nicorandil, 5mg of nitroglycerin, and 10,000 unit of heparin in 1000ml saline, or to 
verapamil cocktail(100 patients with 110 lesions) which used 10mg of verapamil instead 
of nicorandil . The drug cocktail was infused through 4F Teﬂ on sheath of rotablator system 
during the RA procedure. And acute peri-procedural results and long term prognoses 
were compared.
Results : Baseline demographics and coronary angiographic characteristics were similar 
in both groups. RA was performed successfully, and no death and no emergency CABG 
occured. One patients with Q wave MI occurred in each group. The incidence of slow ﬂ ow, 
persistent ST elevation, and the occurrence of non-Q wave MI were signiﬁ cantly lower in 
nicorandil group (slow ﬂ ow: nicorandil 5/109lesions verapamil 13/110 lesions p<0.005, ST 
elevation: nicorandil 3/100 patients verapamil 10/100 patients p<0.05, non-Q MI nicorandil 
2/100 verapamil 9/100 patients p<0.05). 6 month angiographic follow-up revealed no 
difference as for restenosis rate (Nicorandil 28%, verapamil 34%, ns) and target lesion 
revascularization rate (24% vs 28% ns).
Conclusion: It is conﬁ rmed by this prospective randomized trial that intra-coronary 
continuous infusion of nicorandil during rotational athrectomy prevents acute 
periprocedural complications.
1064-33 Impact Of Intracoronary Sodium Nitroprusside On 
Epicardial Timi Flow, Myocardial Blush And Timi Frame 
Count After Primary Angioplasty In Acute Myocardial 
Infarction
Guillermo Marchetti, Alejandro J. Salvatierra Ruiz, Juan Arellano, Juan Fernández, 
Pablo Kantor, Ricardo Iglesias, Carlos Haiek, Gustavo Tamashiro, Raul Ferreyra, 
Antonio Pocoví, Alejandro Palacios, Sanatorio Mitre, Buenos Aires, Argentina
Background: epicardial Timi ﬂ ow, myocardial blush and Timi frame count assess the 
culprit vessel status after primary angioplasty in acute myocardial infarction. Sodium 
nitroprusside is a potent vasodilator with possible effects on these three parameters. 
Methods: we performed a prospective analysis of 45 patients with less than 12 hours of 
acute myocardial infarction and sistolic blood pressure more than 100 mmHg, all of them 
treated with primary angioplasty. We deﬁ ned Timi grades according to Timi investigators 
and both myocardial blush and Timi frame count according to Gibson’s criteria. After 
the last dilation, all patients received three doses (600 microgrames) of intracoronary 
nitroglycerin and then, three doses (600 microgrames) of sodium nitroprusside. We 
analized the incidence of Timi 3 (Mc. Nemar’s test), myocardial blush 3 (Mc. Nemar’s test) 
and Timi frame count (Wilcoxon’s test) with nitroglycerin and then we analized these three 
parameters with the addition of sodium nitroprusside.
Results:
Nitroglycerin Sodium Nitroprusside p
Timi 3 % 84.44 93.33 0.221
Myocardial Blush 3 % 28.88 48.88 0.008
Timi Frame Count 40.5 ± 29 24.3 ± 12 <0.001
Conclusions: sodium nitroprusside improved myocardial blush 3 and Timi frame count, 
with a tendency to improve Timi 3 ﬂ ow. These patients could have some beneﬁ t with this 
additional therapeutic intervention.
1064-34 Quantitative Perfusion Analysis of Catheter-Based 
Ventricle-Coronary Vein Bypass in Myocardial Infarction 
Porcine Models by Magnetic Resonance Imaging
Motoya Hayase, Ryuichi Yoneyama, Yoshiaki Kawase, Kozo Hoshino, Jennifer McGregor, 
Briain D. Mac Neill, Harry C. Lowe, Roger J. Hajjar, Massachusetts General Hospital, 
Boston, MA, Harvard Medical School, Boston, MA
Background: Percutaneous coronary venous arterialization has been proposed as a 
potential treatment strategy for otherwise untreatable coronary artery disease (CAD). 
Objectives: The goal of this study was to investigate the perfusion efﬁ cacy of a catheter-
based ventricle-to-coronary vein bypass (VPASS™) from the left ventricle (LV) to the 
anterior interventricular vein (AIV) to achieve retrograde myocardial perfusion by a conduit 
(VSTENT™) in myocardial infarction porcine models.
Methods: The VPASS procedure was completed on three animals that had a mid-LAD 
occlusion. At Day 30 post-VPASS procedure, coronary angiography (CAG) and magnetic 
resonance imaging (MRI) were performed to assess the myocardial viability. First-pass 
perfusion imaging was performed after intravenous contrast injection using ECG-gated 
echo-planer imaging sequence for 30s. Images were aquired distal to the VSTENT to 
avoid the artifact caused by the VSTENT. The LV short-axis was divided into 6 segments 
using the interactive program CINE (GE Medical Systems). The segments were divided 
into two groups: Perfused segments (PS) (n=9), anterior wall perfused by VPASS; and 
Inferior wall (IW) (n=9), normal perfusion by the native coronary artery. To evaluate the 
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quantitative perfusion analysis, average percent signal intensity change (APSIC) was 
calculated and compared in two groups. Percent signal intensity change was deﬁ ned as: 
PSIC=(signal intensity at time t - signal intensity at time 0)/ signal intensity at time 0 x100 
in each pixel. 
Results: The VSTENT implant deployment was performed without complication. At day 
30, contrast MRI showed myocardial perfusion and viability even with LAD occlusions 
in all animals. There was no difference in APSIC between PS and IW (125±26% vs. 
137±38%, p= 0.46). 
Conclusions: Similar patterns of perfusion were seen in ischemic myocardium supplied 
by the VPASS as compared to native coronary artery perfusion. Coronary retrograde 
perfusion using the VPASS procedure is feasible and may represent a potential treatment 
technique for refractory CAD patients.
1064-35 Coronary Collateral Status Impacts Outcome After 
Percutaneous Coronary Intervention: An Analysis From 
the NHLBI Dynamic Registry
J. Dawn Abbott, Edward J. Choi, Faith Selzer, V. S. Srinivas, David O. Williams, Brown 
University Rhode Island Hospital, Providence, RI, University of Pittsburgh, Pittsburgh, PA
Background: The impact of the coronary collateral circulation on outcome following 
percutaneous coronary intervention (PCI) is unknown.
Methods: Baseline characteristics and cumulative 1-year event rates were compared 
among consecutive patients undergoing PCI by collateral status; no angiographic 
evidence of collateral circulation (NCC, n=5529), treated lesion supplied collaterals (SCC, 
n=239) or received collaterals (RCC, n=893) using three recruitment waves (1997-98, 
1999, and 2001-02) of the NHLBI Dynamic Registry.
Results: Patients in the SCC group were older with more prior CABG, myocardial infarction 
(MI), comorbid illness, and CHF than the NCC and RCC groups and were less often 
revascularized for acute MI (p<0.01 for all). Angiographic PCI success was comparable 
for SCC and NCC but higher than RCC (94.1% vs. 94.4% vs. 83.9%, p<0.001). Overall 
stent use was 77.1%, highest in the SCC group (82.4%, p<0.001). At 1-year signiﬁ cant 
differences in outcomes were observed according to collateral status (Table 1). Patients 
with PCI for SCC lesions had the highest adjusted death/MI rate (RR 1.74, CI 1.12-2.71), 
whereas PCI for RCC had the lowest (RR 0.73, CI 0.55-0.98).
Conclusion: The presence of angiographic collateral circulation independently inﬂ uenced 
late clinical outcomes and should be considered when selecting a revascularization 
strategy. Patients whose attempted lesions RCC experienced a protective effect whereas 
those whose lesion SCC were more likely to suffer death/MI.
Table 1: Adjusted Risk Ratios and 95% Conﬁ dence 
Intervals for Selected Cumulative One-Year Outcomes
SCC vs. NCC RCC vs. NCC
Adverse Event RR 95% CI p-value RR 95% CI p-value
Death 1.74 1.12-2.71 0.013 0.88 0.59-1.13 0.54
Death/MI 1.76 1.26-2.45 <0.001 0.73 0.55-0.98 0.03
1064-36 Transradial Versus Transfemoral Access for Coronary 
Angiography in Elderly Patients: Comparison of 
Procedural Data and Complication Rates
Stephan Achenbach, Dieter Ropers, Nesrin Turan, Lisa Kallert, Robert Kraehner, Tobias 
Wolf, Matthias Regenfus, Werner G. Daniel, Josef Ludwig, University of Erlangen, 
Erlangen, Germany
Transradial (TR) access for coronary angiography and intervention may be technically 
more challenging than the transfemoral (TF) approach due to vascular anatomy in elderly 
patients (pts). We therefore performed a prospective randomized comparison of TF versus 
TR coronary angiography and intervention in pts of 75 years or more.
400 pts (187 male, 213 female, 79±3 years) scheduled for coronary angiography were 
included. 93 pts could not be randomized due to pathologic Allen´s test (n = 37), other 
clinical reasons prohibiting femoral or radial access (20), renal failure (18), planned right 
heart catheterization (5), cardiogenic shock (4), thrombocytopenia (1), or hospital stay < 
24 hours (8). The remaining pts were randomized to TR (152) or TF access (155). 28 pts 
had bypass grafts. 6F sheaths were used in all pts, ad hoc PCI was performed in 79. Next 
to procedural data, pts were reassessed after 24 hours (including duplex ultrasound of 
access site) and 72 hours.
TR angiography was successful in 139 pts (cross-over to TF due to failure to insert 
sheath in 5 pts and failure to advance catheters in 8). In pts randomized to TF access, 
cross-over to TR or the contralateral femoral artery was necessary in one pt each (cross-
over rate 9% vs. 1%, p=0.01). For TR versus TF, mean duration to ﬁ rst cine acquisition 
was 7.7±6.1min (TR) vs. 4.8±3.7min (TF, p<0.001), mean overall duration of diagnostic 
angiography 22.3±10.0min vs. 19.6±9.0min (p=0.004). Interestingly, overall durations 
were not signiﬁ cantly different between TR (17.1±10.5 min) and TF (17.3±7.6 min) in high-
volume operators (> 1000 TR angiographies). Fluoroscopy time, radiation dose, contrast 
agent, number of catheters used were not signiﬁ cantly different. Major local complications 
occured in 4 pts after TF access (bleeding with need for transfusion in 3, surgery in 1 pt), 
minor complications (bleeding or aneurysms treated by ultrasound guided compression) 
in 8 pts randomized to TF and 2 pts to TR (in both pts after cross-over to TF access).
TR coronary angiography is feasible with high success rate in elderly patients. Local 
complication rates are signiﬁ cantly lower as compared to the TF approach.
1064-37 Feasibility and Safety of Routine Transradial 
Interventions in Women: Analysis of a Database 
Consisting of 2628 Coronary Procedures
Christian Pristipino, Francesco Pelliccia, Antonino Granatelli, Vincenzo Pasceri, Bruno 
Pironi, Giulio Speciale, Adriana Roncella, Giuseppe Richichi, S. Filippo Neri Hospital, 
Rome, Italy
Background.Transradial interventions carry several advantages as compared to femoral 
approach (FA) but a default transradial approach (TRA) in all may be questionable as a 
higher incidence of complications was reported in women.
Methods. To assess whether clinical selection of apparently more suitable cases for TRA 
in women may lead to better outcomes we analysed a database containing data regarding 
2395 patients collected from May 2003 to May 2004 by 8 experienced radial interventionalists 
(>100 cases each): four adopting TRA as a routine default procedure in all patients with 
a negative Allen test (routine operators: RO) and 4 adopting a clinical selection strategy 
resulting in <60% of personal cases performed with TRA (selective operators: SO).
Results. Overall 2628 procedures were performed in acute and stable patients, 1321 of 
which (50%) were performed with TRA. Women were only 16%(61/373)of the population 
undergoing TRA by SO as compared to 39% (502/1287) in the population undergoing 
FA (p<0.0001). On the contrary TRA performed by RO showed a higher proportion of 
women as compared with FA (162/341 vs. 502/1287; 47% vs. 39%, p<0.01). In TRA, radial 
spasm requiring a change in arterial approach occurred in a low proportion of patients 
(54/1321, 4%) among which the majority were women (36/54) but with a trend towards 
a lower incidence for RO (9/326, 2.7%), despite the selection performed by SO. Overall 
minor bleedings were signiﬁ cantly lower in women undergoing TRA as compared to those 
undergoing FA (7/221 vs. 79/502, 3% vs. 16%, p<0.0001) without differences among RO 
and SO. Major bleedings needing transfusion or causing death occurred only in patients 
undergoing FA (9/1307 vs. 0/1321, 0.7% vs. 0% p=0.007) among which the majority were 
women. Moreover women undergoing TRA in both RO and SO subgroups showed similar 
age, risk factors, body mass index, contrast volume administered during procedure, 
ﬂ uoroscopy time and X-rays exposition as compared to women with FA.
Conclusions. Extensive routine TRA in women: (1) is safer than femoral approach; (2) 
shows a risk proﬁ le comparable to a selective strategy. Extensive routine TRA may be 
recommended in women.
1064-38 Risk of Local Adverse Events Following Cardiac 
Catheterization by Hemostasis Device and Gender
Dale R. Tavris, Syamal Dey, William S. Weintraub, Richard E. Shaw, Beverly Albrecht 
Gallauresi, Ralph G. Brindis, Kristi Mitchell, on behalf of the ACC-NCDR, American 
College of Cardiology, Bethesda, MD, Food and Drug Administration, Rockville, MD
Background: Reports to the FDA of local complications resulting in serious injuries and 
deaths associated with the use of hemostasis devices following cardiac catheterization 
provided the impetus for this study of risk factors from a national cardiac database.
Methods: Data were obtained from the American College of Cardiology-National 
Cardiovascular Data RegistryTM, updated to include supplemental information speciﬁ cally 
for this research. It included information from 59 institutions and 13,878 cardiac 
catheterizations (diagnostic and therapeutic) performed during October-December of 
2003. Multiple logistic regression, using ten different outcomes, was used to assess 
the risk associated with type of device and gender, while controlling for demographic, 
physiologic, procedure-related variables, and several indices of co-morbidity.
Results: Serious adverse events were reported in 3.54 % of patients, the most common 
being hematoma (2.00 %). In the multivariate analysis, factors that were positively associated 
with ‘any vascular complication’ included female gender (OR=1.69, p<.0001), sheath size 
(OR=1.24, p=.005), activated clotting time (ACT) (OR=1.02, p<.0001), renal failure (OR=1.85, 
p=.006), and emergency indication for the procedure (OR=1.59, p=.001). Compared with 
manual compression controls, there was one hemostasis device that demonstrated an 
association with ‘any vascular complication’ (OR=2.42[1.41-4.16], p=.001).
Conclusions: Women have almost twice the risk of men for most local complications 
following cardiac catheterization. Other risk factors included sheath size, ACT, renal 
failure, emergency indication for the procedure, and one type of hemostasis device. 
Possible reasons for these associations (including unmeasured confounding variables) 
will be discussed.
1064-39 The Safety and Effectiveness of the Matrix VSG to 
Achieve Rapid Hemostasis and Ambulation After 
Coronary Procedures: A Multi-Center Study
Eberhard Grube, Horst Sievert, Karl Hauptmann, Siegburg Heart Center, Siegburg, 
Germany, Cardiovascular Center Frankfurt Sankt Katharinen, Frankfurt, Germany
Background: As previously reported, the feasibility of the Matrix VSG™ System 
(AccessClosure, Inc.) to rapidly achieve femoral artery access site closure with a low rate 
of complications has been tested in a single center trial at the Heart Center Siegburg, 
Germany. The Matrix VSG™ incorporates a bioresorbable, synthetic, non-thrombogenic, 
dilution-sensitive (i.e. does not solidify in ﬂ owing blood), Polyethylene glycol (PEG) based 
hydrogel, which is delivered in the form of two liquids, extravascularly through a standard 
introducer sheath following endovascular procedures. The two liquid components mix in-
situ and quickly seal the arteriotomy and tissue tract resulting in rapid and safe hemostasis. 
The PEG hydrogel is resorbable and completely resorbs within 30 days. The purpose of 
the current study is to extend evaluation of safety and effectiveness of the Matrix VSG™ 
System into a multi-center setting.
Methods: Primary endpoints for this prospective, multi-center, nonrandomized trial were 
times to hemostasis and ambulation and the rate of device-related complications through 
30 day follow up. The results of the multi-center investigation were combined with the 
previously reported single-center results.
Results: Single and Multi-Center Results
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Time to 
Hemostasis
Time to 
Ambulation
Major
Events
Minor
Events
Procedure/Device 
Success
All Patients n=922.94 min
n=73
2.01 hrs
0/112
0%
7/112
6.25%
90/97
92.8%Diagnostic
n=44
2.53 min
n=37
2.01 hrs
Interventional n=483.31 min
n=36
2.04 hrs
Conclusion: Combined single and multi-center results validate that access site closure 
achieved with the Matrix VSG™ resulted in rapid and safe hemostasis and ambulation.
1064-40 Closure Devices Decrease Vascular Complications in 
Patients Receiving Clopidogrel
Ahmed S. Ahmed Ahmed, Abdul Rashid, Faisal Nabi, Mohammed Murtaza, Richard 
Webel, Rasha Mohamed, Timothy Catchings, Walid Hassan, Greg C. Flaker, University 
of Missouri, Columbia, MO
Background: The contemporary widespread use of potent antithrombotics comes at the 
expense of increased bleeding, often at the site of vascular access. We hypothesized that 
closure devices reduce vascular complications in patients receiving the oral antiplatelet 
agent Clopidogrel
Methods: Prospectively collected data on consecutive patients undergoing cardiac 
catheterization and PCI in a single center was obtained from the American College of 
Cardiology-National Cardiovascular Data Registry. Hemostasis was obtained by either 
manual compression or closure device.
The vascular complications evaluated included hematoma >10 cm, retroperitoneal 
bleeding, loss of pulse AV ﬁ stula or dissection.
Results: 734 patients received periprocedural Clopidogrel; 175 patients had manual 
compression and 559 patients received either a collagen plug (n=360 Angioseal, Daig) or 
suture device (n=199 Perclose, Abbott Vascular). The two groups were similar in terms of age, 
gender, sheath size, BMI, heparin, thrombolytic and glycoprotein IIbIIIa inhibitor therapy. 
Manual Compression Closure device(Angioseal & Perclose) P-Value
Vascular Complications 9/175 (5.14%) 9/559 (1.61%) 0.0201
Conclusion: Closure devices decreased vascular complications in patients undergoing 
cardiac catheterization and PCI receiving the oral antithrombotic Clopidogrel.
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1065-12 Five Years After Intracoronary Radiation for the 
Prevention of In-Stent Restenosis: Not as Hot we 
Thought
Luis Gruberg, Mahmoud Suleiman, Shirush Petchersky, Eugenia Nikolsky, Ehud Grenadier, 
Monther Boulus, Walter Markewicz, Rafael Beyar, Rambam Medical Center, Haifa, Israel
Background: Intracoronary radiation therapy (IRT), utilizing both �- and �-emitting sources, 
has demonstrated a reduction in restenosis rates and revascularization procedures in 
patients with in-stent restenosis. We analyzed the clinical and angiographic characteristics 
and outcomes of patients who underwent IRT. Methods: We retrospectively analyzed data 
of all patients who underwent IRT (n=133) at our institution between 3/1999 and 1/2004. 
Patients who had either target lesion revascularization (TLR) or need for CABG during 
the follow-up period were considered as failed IRT (n=47; 35.3%). We compared them 
to patients who had successful IRT (n=86, 64.7%). Results: Clinical and angiographic 
characteristics are shown in the Table. Furthermore, 56 patients (42.1%) underwent 
either TLR, TVR or CABG and 67 patients (50.4%) either died or underwent coronary 
revascularization. By multivariate analysis, baseline TIMI 0/1 ﬂ ow was an independent 
predictor of restenosis (OR:3.6, CI=1.1-11.6, p=0.02). The number of prior restenosis 
showed a strong trend (OR:1.7, CI=0.96-3.0, p=0.06). 
Failed IRT
(n=47) Successful IRT (n=86) p
Age (years) 60±10 61±11 0.5
Diabetes (%) 45 40 0.7
Hyperlipidemia (%) 79 81 0.7
# prior restenosis 1.4±0.7 1.7±1.0 0.02
Baseline TIMI 0-1 (%) 19 7 0.03
New stent (%) 30 18 0.1
MLD Baseline (mm) 0.91±0.54 (mm) 0.68±0.45 (mm) 0.59
MLD Final (mm) 2.09±0.71 (mm) 2.10±0.66 (mm) 0.95
Lesion length (mm) 21.1±12 (mm) 20.2±8.8 (mm) 0.7
Conclusions: One-third of all patients who underwent IRT required reintervention due 
to failed IRT. A totally occluded artery at the time of the procedure was an independent 
predictor of IRT failure (p=0.02). Baseline and ﬁ nal vessel diameters did not seem to play 
a role in the process. Half of all patients had a major event (death or revascularization) 
during the follow-up period.
1065-15 Early Inﬂ ammatory Response by Dendritic Cells, 
Lymphocytes and Macrophages is Associated with 
AT1 Receptor Upregulation in Post Stent Neointima 
Formation.
Izabela Tuleta, Matthias Peuster, Dirk Skowasch, Katarina Mikuskova, Berndt Lüderitz, 
Gerhard Bauriedel, Department of Cardiology,University of Bonn, Bonn, Germany, Heart 
Center Nordrhein-Westfalen, Bad Oeynhausen, Germany
Background: We recently reported the presence of dendritic cells in porcine in-stent 
neointima formation. In the present study, we sought to assess a possible relationship 
between the number of inﬂ ammatory cells: dendritic cells, lymphocytes, macrophages 
and the level of AT1 receptor (AT1R) expression in neointima post stenting.
Methods: Juvenile female domestic pigs underwent stent implantation to abdominal 
aortic segments and animals were sacriﬁ ced at 7,14,30 or 90 days (n=3 per time). Cross 
sections of the injured vessels were subjected to immunohistochemistry using S100, 
CD3, CD14 and AT1R antibodies to detect dendritic cells, T-lymphocytes, macrophages 
and AT1R+ cells, respectively. Labeling was quantiﬁ ed as % positive cells per total cell 
count/mm2.
Results: Seven days post stenting, neointima consisted of up to 3 cell layers with maximal 
expression levels of S100, CD3, CD14 and AT1R (13.0±2.7%; 5.3±0.8%; 37.3±3.3%; 
42.8±3.4%, resp.). At day 14, signalling had decreased for S100 (11.9±2.2%), CD3 (4.2±0.2%), 
CD14 (33.9±3.0%) and AT1R (39.2±1.0%), however was without statistical signiﬁ cance. With 
ongoing neointima formation, at day 30, immunolabeling of inﬂ ammatory cell markers and AT1 
receptor further reduced (7.3±0.9%; 3.4±0.8%; 21.6±3.8%; 24.8±2.7%, p<0.05, resp.), mostly 
located at the luminal border and adjacent to stent struts. At day 90, only few cells staining 
for all markers were observed (3.4±0.4%; 0.5±0.2%; 14.2±1.5%; 8.2±0.3%, p<0.05, resp.). 
Throughout the time course of neointima formation, a strong positive relationship was seen 
between the expression of S100 and that of CD3 (r=0.89, p=0.01) and between the expression 
of S100 and that of AT1R (r=0.95, p=0.01).
Conclusions: Our data demonstrate that neointima post stenting is characterised by an 
early inﬂ ammatory response and coordinated expression of inﬂ ammatory markers with 
parallel AT1 receptor upregulation. Positive correlation between S100 and AT1R expression 
suggests the dendritic cell type that promotes AT1 upregulation in neointimal formation.
1065-16 A New Anti-Restenotic Mechanism of Sirolimus Eluting 
Stents: Higher Levels of CD31 Positive Cells and VEGF 
when Compared to Bare Metal Stent in a Pig Restenosis 
Model
Emerson C. Perin, Joao A. Assad, Guilherme V. Silva, Rosalina Maddona, Andre L. 
Sousa, Andrew Civitello, Romeu Majano, James Feldman, Rodrigo VC Branco, Willian 
K. Vaughn, Robert Falotico, Leonardo Carvalho, Edie M. Oliveira, Franca S. Angeli, Yong 
Geng, Texas Heart Institute, Houston, TX
Background:Sirolimus-Eluting Stent (SES) drastically reduces late loss (LL) when 
compared to bare-metal stent (BMS). Rapamycin arrests cell division inhibiting neo-intimal 
proliferation. Additional effects of SES on vascular endothelial growth factor (VEGF) and 
endothelial cell (EC) concentration are unknown.
Methods: In 16 pigs using a coronary restenosis model (balloon/artery ratio=1.2/1) SES 
and BMS were deployed into the LAD and LCx. The RCA remained as a control. Animals 
were sacriﬁ ced at 2 (n=8) and 4 wks(n=8). Protein expression of VEGF and CD-31(EC’s) 
of each artery was quantiﬁ ed by Western-Blot. QCA and ANOVA were performed.
Results:SES signiﬁ cantly reduced LL(mm) when compared BMS ( 2 wks: < 0.1 and 0.6; 
4 wks:0.1 and 1.1 respectively). VEGF and CD31 levels in each group are displayed in 
ﬁ gures 1 and 2.
Conclusion: In the SES group there was a higher expression of CD-31 and VEGF than 
the bare metal and control groups. This initial data may suggest a new mechanism of 
action of SES by improving endothelization through increased VEGF expression and 
increased EC concentration. 
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1065-17 Sirolimus Eluting Stent (SES) Inhibits Growth Factor 
Expression and Cell Proliferation Without Worsening 
Endothelial Function in a Pig Coronary Restenosis 
Model
Emerson C. Perin, Guilherme V. Silva, Joao A. Assad, Rosalinda Maddona, Andre 
L. Sousa, Romeu Majano, Andrew Civitello, James Feldman, Judy Ober, William K. 
Vaughn, Rodrigo VC Branco, Edie M. Oliveira, Leonardo Carvalho, Franca S. Angeli, 
Yong Geng, James T. Willerson, Robert Falotico, Texas Heart Institute, Houston, TX
Background:Sirolimus-Eluting Stent (SES) has been shown to reduce drastically the 
rates of restenosis when compared to bare-metal stent (BMS). Additional effects of SES 
on growth factors and endothelial function are unknown.
Methods: In 16 pigs utilizing a coronary restenosis model (balloon/artery ratio=1.2/1) 
SES and BMS were deployed into LAD and LCx. RCA was used as a control. Animals 
were sacriﬁ ced at 2 (n=8) and 4 wks (n=8). Protein expression of platelet derived growth 
factor (PDGF),basic Fibroblast Growth Factor (b-FGF), Cyclin A and endothelial derived 
nitric oxide (E-NOS) within each artery was quantiﬁ ed by Western-Blot. ANOVA and QCA 
were performed.
Results:SES signiﬁ cantly reduced LL(mm) when compared BMS ( 2 wks: < 0.1 and 0.6; 
4 wks:0.1 and 1.1 respectively). Results are displayed in ﬁ g 1 and 2.
Conclusion:In addition to inhibiting cell proliferation, SES decreases neo-initimal 
growth through marked inhibition of growth factor expression.This was achieved without 
worsening endothelial function (similar E-NOS expression). 
1065-18 The Effect of Stem Cell Mobilization by Granulocytes-
Colony Stimulating Factor on Neointimal Hyperplasia 
After Vascular Stenting: Drug-Eluting Stent...Is the 
Solution in Stem Cell Clinical Trial?
Hyun-Jai Cho, Tae-Youn Kim, Shu-Ying Zhang, Sung-Hwan Kim, Ji-Hyun Kim, Hyun-Ju 
Cho, Sang-Hoon Na, Hyun-Jae Kang, Bon-Kwon Koo, Byung-Hee Oh, Young-Bae Park, 
Yun-Shik Choi, Hyo-Soo Kim, Seoul National University College of Medicine, Seoul, 
South Korea, Seoul National University Hospital, Seoul, South Korea
Background- We, recently, reported that G-CSF mobilization with intracoronay infusion 
improved cardiac function, however, also raised a question on aggravation of restenosis.
Methods- One iliac artery of hypercholesterolemic rabbits were subjected to BMS 
(EXPRESS2™) and contralateral iliac artery to DES (TAXUS™). Rabbits received rhG-
CSF or placebo daily for 6 days, after stent deployment.
Results- G-CSF signiﬁ cantly increased endothelial progenitor cells, and remarkably 
increased the double positive (CD31/�SMA or VE-CAD/�SMA) fraction which implied 
vascular progenitor cells. In serial cultures, endothelial lineage cells were predominant 
with VEGF stimulation and smooth muscles overgrew with PDGF, and also a few cells 
were double positive.
We evaluated endothelial recovery by scanning EM at 28 days, and morphometirc 
analysis was performed at 60 days. In the control group, DES reduced restenosis but 
delayed reendothelialization, and G-CSF mobilization worsened BMS restenosis. G-
CSF mobilization with DES accelerated the reendothelialization and reduced restenosis. 
[Morphometric analysis: See ﬁ gure]
Conclusion- Here, we demonstrated that G-CSF mobilized putative vascular progenitor 
cells in peripheral blood, which aggravated in-stent restenosis of BMS, and DES 
effectively inhibited accumulation of smooth muscle lineage cells, but not endothelial 
lineage cells. Therefore, drug eluting stent with stem cell mobilization may be the best 
option for regeneration trial in heart.
1065-19 Effects Of Drug-eluting Stents On Plasma High 
Sensitivity C-reactive Protein Levels After Coronary 
Stenting : Comparison With Bare Metal Stents
Jong-Youn Kim, Young Guk Ko, Yangsoo Jang, Won-Heum Shim, Seung-Yun Cho, Yonsei 
Cardiovascular Center and Cardiovascular Research Institute, Seoul, South Korea
Background: After coronary artery stenting, inﬂ ammatory mechanisms play a crucial 
role the pathogenesis of neointimal proliferation and in-stent restenosis. Drug eluting 
stents (DES) with anti-inﬂ ammatory and anti-proliferative properties had been shown 
to reduce neointimal hyperplasia effectively in animal and clinical studies. However, few 
data regarding anti-inﬂ ammatory effects of DES in clinical studies are currently available. 
Therefore, we investigated plasma levels of high sensitivity C-reactive protein (hsCRP) 
after DES insertion and compared with those after bare metal stent (BMS) implantation
Methods: In a prospective single center study, we performed percutaneous coronary 
intervention (PCI) with single stent in 67 patients with clinically stable angina. There were 
21 patients in the BMS group and 46 patients in DES (Cypher® n=29, Taxus® n=17). 
Plasma levels of hsCRP were determined before intervention and 48 hours, 72 hours and 
2 weeks after coronary stenting.
Results: There were 54 men (80.6%) and the age of patients ranged from 37 to 75 years 
(mean, 59 ± 9 years). There was no difference in age, frequency of DM, lipid proﬁ le, stent 
length, frequency of statin medication and initial hsCRP level. However, DM was more 
frequently in DES group (34.8 % vs. 9.5 %, p = 0.04) and the stent diameter was larger 
in BMS group (3.4 ± 0.5 mm vs. 3.0 ±0.4 mm, p < 0.01). The plasma levels of hsCRP at 
48 hours (13.4 ± 14.7 vs. 5.9 ± 4.9 mg/L, p < 0.01) and 72 hours (16.7 ± 19.8 vs. 5.4 ± 
3.9 mg/L, p < 0.01) after coronary stenting were signiﬁ cantly higher in BMS group than 
DES group. Between sirolimus-eluting stent and paclitaxel-eluting stent, there was no 
signiﬁ cant difference in hsCRP levels at 48 (6.4 ± 5.2 vs. 4.5 ± 3.1 mg/L) and 72 hours 
(6.9 ± 5.8 vs. 5.0 ± 4.3 mg/L). The hsCRP levels decreased to 2.0 mg/L ± 2.5 mg/L in 
BMS group and 1.2 ± 1.9 mg/L in DES group at 2 weeks after coronary intervention, which 
showed no statistical difference (p =0.07).
Conclusion: DES showed signiﬁ cantly reduced plasma hsCRP levels at 48 and 72 hours 
after coronary stenting compared to BMS. This may reﬂ ect potent effects of DES on 
inﬂ ammatory reactions induced by coronary stenting.
1065-20 Hyperinsulinemia During An Oral Glucose Torelance 
Test Is An Important Determinant Of Stent Restenosis 
In Non Diabetic Patients
Rintaro Nakajima, Masato Nakamura, Masaya Yamamoto, Masamichi Wada, Takahiro 
Tsuji, Taro Tsunoda, Toho University Ohashi Hospital, Tokyo, Japan
Background and Objects: Stent restenosis still remains a signiﬁ cant clinical problem. 
Though insulin is known to promote the proliferation of arterial smooth muscle cell, an 
association between hyperinsulinemia and restenosis after stenting is unclear. The aim of 
this study was to determine whether hyperinsulinemia during a-75g oral glucose tolerance 
test (OGTT) is a predictor of the development of restenosis after stent implantation in 
nondiabetic patients. 
Methods: A total of 201 de-novo, native coronary lesions in 166 non diabetic patients who 
underwent successful stenting was enrolled in this study. An OGTT was performed in all 
patients. Plasma glucose (PG: mg/dl) and immunoreactive insulin (IRI; µU/ml) were measured 
at baseline and 30min, 60min, and 120min after the glucose load. QCA was performed before 
and after PCI and follow up at 6 month. Patients were divided into two groups according to the 
value of sigma IRI. Correlation between IRI value and QCA data were investigated. 
Results: Results were presented as in the table. Lesion characteristics pre PCI and 
procedural characteristics of PCI were similar in both groups. By multiple logistic 
regression analysis, higher sum of insulin was found to be an independent predictor of 
stent restenosis (OR = 4.41; 95% CI = 2.13-9.15; P <0.001). 
Conclusions: Hyperinsulinemia during an OGTT is signiﬁ cantly associated with stent 
restenosis in non-diabetic patients, and performing this simple test before PCI may be 
useful for the prediction of stent restenosis.
OGTT and angiographic results
sum of IRI < 240 (n=148) sum of IRI > 240 (n=53) p value
fasting PG 91 +/- 9 93 +/- 10 0.11
fasting IRI 5.3 +/- 2.6 8.7 +/- 4.6 <0.001
120 min PG 132 +/- 32 138 +/- 31 0.21
120 min IRI 48.3 +/- 24.6 119.9 +/- 80.9 <0.001
RD pre PCI 2.99 +/- 0.65 2.93 +/- 0.45 0.52
lesion length pre PCI 14.0 +/- 6.8 12.1 +/- 5.6 0.08
acute gain 2.34 +/- 0.55 2.24 +/- 0.49 0.21
late loss 1.17 +/- 0.68 1.48 +/- 0.67 0.005
restenosis n=35 (24%) n=29 (54%) <0.001
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1065-21 Pioglitazone Reduces Neointimal Hyperplasia After 
Coronary Stent Implantation in Non-diabetic Patients
Takuji Katayama, Jichi Omiya Medical Center, Saitama, Japan
Background: Recent works have reported that peroxisome proliferator-activated 
receptor-gamma (PPAR-gamma) agonists reduce neointimal hyperplasia after coronary 
stent implantation in type 2 diabetes. However, the effect of PPAR-gamma agonists on 
that in non-diabetic patients remains to be determined.
Objectives: The aim of this study was to investigate whether pioglitazone reduces 
neointimal proliferation after coronary stent implantation in non-diabetic patients using 
intravascular ultrasound (IVUS).
Methods: 22 non-diabetic patients with stable angina who underwent coronary stent 
implantation were randomized to 6 months treatment with or without pioglitazone 30 mg/day 
after coronary stent implantation (pioglitazone group; 11 patients with 13 lesions, control 
group; 11 patients with 11 lesions). All patients underwent oral glucose tolerance test and 
proved to be normal or impaired glucose tolerance. At 6 months follow-up, quantitative 
angiographic analysis was performed, and intimal area and intimal index (intimal area/stent 
area) were measured using continuous intravascular ultrasound pullbacks.
Results: Intimal area and intimal index in pioglitazone group were signiﬁ cantly larger 
than those in control group (0.91mm2 vs 1.81mm2; p<0.05, 0.103 vs 0.204; p<0.05, 
respectively). Diameter stenosis in pioglitazone group was smaller than that in control 
group (19.8% vs 35.7%: P<0.05). 3 patients in control group underwent target lesion 
revascularization, while no patient in pioglitazone group required it.
Conclusions: These data demonstrate that pioglitazone reduces neointimal hyperplasia 
after coronary stent implantation in non-diabetic patients. Because PPAR-gamma agonists 
have been shown to inhibit vascular smooth muscle proliferation, our data provide a novel 
therapeutic approach for in-stent restenosis by PPAR-gamma agonists regardless of 
comorbidity of diabetes.
1065-22 Nitric Oxide Preservation Through a Polymer Coated 
Stent to Decrease Neointimal Hyperplasia: Final 
Clinical, Angiographic and Stent Volumetric Results 
from the NOBLESSE Trial.
Costantino R. Costantini, Hugo Londero, Ivan DeScheedrer, Rubens Z. Darwich, 
Marcelo F. Santos, Sergio G. Tarbine, Costantino O. Costantini, Fundação Francisco 
Costantini, Curitiba, Brazil
Objectives: To assess the safety and efﬁ cacy of the Genic coronary stent coated 
with biodegradable polymer that preserves nitric oxide (NO) to avoid excessive intimal 
hyperplasia after percutaneous treatment of denovo coronary artery lesions.
Methods: The NO through Biodegradable Layer Elective Study for Safety and Efﬁ cacy 
reduction of in-stent restenosis (NOBLESSE) is a multicenter, prospective non randomized 
study. In total 45 patients of any age or sex with indication for percutaneous coronary 
intervention of a type A or B1 de novo native coronary lesion were enrolled by 2 centers. 
Patients were clinically assessed at 30 days, 4 and 12 month after stent implantation. The 
primary endpoint was late loss of the treated coronary segment as assessed per QCA 
at 4 month. Patients were re schedule to a new angiographic and IVUS analysis at 12 
month follow up.
Results: Mean age was 61.3, male 64.4% and diabetes 15%. Lesion location was LAD 
in 42% and 41% of the lesions were type B1. Baseline RVD was 3.0±0.2 mm, pre MLD 
1.07 ± 0.34 mm and the %DS 64. MLD after stent implantation was 2.76 ± 0.24 mm and 
acute gain 1.69 ± 0.43 mm. There were no adverse events at 30 days. At 4 month the TLR 
rate was 6% (3 pts). At 12 months there was 1 non-cardiac death resulting in a MACE 
free rate of 94%. Angiographic FU was obtained in 98% of pts at 4 months and 76% at 
12 months. There were no signiﬁ cant angiographic differences (p=NS) between 4 and 
12 months QCA (MLD=2.09 ± 0.53 vs 2.25±0.38 mm, %DS= 30% vs 25%, Late Loss= 
0.69 ± 0.52 vs 0.53 ± 0.08 mm, Binary Restenosis= 9.5% vs. 9.5%). Intimal hyperplasia 
volume at the stented segment at 12 months was 25.9±13.2 mm3 and the stent volume 
obstruction % 21.8±11.8.
Conclusions: The absence of major adverse cardiac events either at 30 days or 12 
months suggests that the Genic stent coated with a NO preserver polymer is safe. A late 
loss of 0.69 mm and a binary restenosis rate of 9.5% suggest neointimal hyperplasia 
inhibition by the polymer. The IVUS volumetric analysis supports this afﬁ rmation. The NO 
preserver polymer might be an ideal carrier for drug elution from a stent system.
1065-23 Primarily Extravascular Cells In In-stent Restenosis And 
In In-stent Restenosis After Intracoronary Bachytherapy
Gerhard Bauriedel, Dirk Skowasch, Alexander Jabs, Sabine Dinkelbach, Thomas M. 
Schiele, Berndt Lüderitz, University of Bonn, Bonn, Germany, University of Munich, 
Munich, Germany
Background: Intralesional data of atherosclerotic target lesions following stent implantation, 
in particular after intracoronary brachytherapy are infrequent. There is ongoing controversy 
on cell type and origin of neointimal cells. Therefore, the objective of the present study was 
to assess the presence of primarily extra-vascular cells in intimal hyperplasia.
Methods: Atherectomy specimens from 21 patients with coronary ISR (n=14; time post 
stenting 5±3 months), of these 4 after intracoronary brachytherapy, and with peripheral 
ISR (n=7; 7±3 months) versus those from 10 patients with primary lesions were 
immunohistochemically examined for the presence of endothelial progenitor cells (EPCs: 
CD34, CD133), dendritic cells (DCs: S100), neural-crest derived cells (NCCs: GFAP, NSE, 
NGFR) and α-smooth muscle (SM) actin followed by computer-assisted morphometry. .
Results: ISR probes demonstrated pronounced hypercellularity (930±320 cells/mm2) 
compared to primary lesions (347±120 cells/mm2, P<0.001). α-SM actin positive cells 
occupied 67% of intimal cells in ISR. As a key ﬁ nding, expression of EPCs (CD34: 7.2% 
positive/total cells vs. 0.6%; CD133: 6.8 vs. 1.0%), DCs (S100: 10.2 vs. 1.4%) and NCCs 
(GFAP: 8.0 vs. 3.1%; NSE: 4.3 vs. 1.3%; NGFR: 4.2 vs. 1.1%) was signiﬁ cantly increased 
in ISR compared to primary lesions (each P<0.001). Of note, there were no signiﬁ cant 
differences between coronary or peripheral vascular bed and/or ISR lesions without or 
after brachytherapy. Importantly, double immunostaining did not demonstrate α-SM actin 
positive cells exhibiting markers of EPCs, DCs or NCCs. Consistently, there were a few 
cells found in ISR atherectomy probes that demonstrated coexpression of EPC, DC or 
NCC markers. Our data show residual 5-15% yet unidentiﬁ ed neointimal cells, that were 
not stained by any speciﬁ c cell type marker used. 
Conclusions: Bone-marrow and neural-crest derived cells, the most dendritic cells, are 
consistently found in ISR, whereas α-SM actin positive cells constitute the largest intimal 
cell pool. These data clearly indicate the recruitment of primarily extra-vascular cells in 
human ISR as well as in ISR after intracoroary brachytherapy.
1065-24 Geographical Miss During Implantation of Sirolimus-
Eluting Stents: Insights on Deployment Techniques 
from The S.T.L.L.R. Trial
Marco A. Costa, Dominick J. Angiolilllo, William Kuehl, Michael Fenster, Mark 
Tannenbaum, Alan L. Niederman, Carlos E. Morales, David S. Cochran, Michelle 
Ho, Paula Hu, Martin M. Zenni, Paul S. Gilmore, Theodore A. Bass, on behalf of the 
S.T.L.L.R. study investigators, University of Florida, Shands Jacksonville, Jacksonville, 
FL, Cardiovascular Imaging Core Laboratories, Jacksonville, FL
Geographical miss (GM = injured or diseased coronary segment not covered by the 
treatment zone) has been associated with clinical failure. Sirolimus-eluting stent (SES) has 
been shown to prevent restenosis. However, events are still observed in 5-10% of patients 
treated with SES. The STLLR is the ﬁ rst multicenter study to assess SES deployment 
techniques. The aims are to deﬁ ne factors associated with suboptimal deployment, and 
establish the association between GM and clinical outcomes in real world practice.
Methods: The trial will include 1500 patients treated with at least 1 SES in 50 US hospitals. 
GM is deﬁ ned as longitudinal (injured or diseased segment not covered by SES) or axial 
(measured balloon/artery size ratio is <0.9[undersize] or >1.3[oversize]. The occurrence, 
magnitude and location of GM are determined by an independent core lab.
Results: To date, 750 patients have been enrolled. Lengths (in mm) of implanted SES 
were: 8(6%), 13(28%), 18(31%), 23(17%), 28(6%) and 33(7%).All clinical characteristics 
were similar between GM and no-GM groups. Mean age was 64.4 vs 62.5 years, incidence 
of diabetes 28.9% vs 29%, prior MI 41.6% vs 37%, males 67.6% vs 62.8% respectively.
Incidence and Patterns of Geographical Miss
Study Variable Estimate
No Geographical Miss 41.0%
No Longitudinal Geographical Miss 54.2%
No Axial Geographical Miss 68.2%
Longitudinal Geographical Miss - Proximal 29.0%
Longitudinal Geographical Miss - Distal 29.8%
Longitudinal Geographical Miss - Both 12.9%
Undersize Axial Geographical Miss 11.7%
Oversize Axial Geographical Miss 20.1%
Conclusion: Preliminary results demonstrate that GM is a frequent phenomenon in real 
world SES procedures, and may not be predicted based on clinical risk-factors. Updated 
data, including 6-month outcomes of the enrolled population will be presented at the 
meeting. The data will provide mechanistic insights on SES failures.
1065-25 Efﬁ cacy of Reduced Sirolimus Doses on Neointimal 
Hyperplasia: Serial IVUS Analyses From the REDOX 
Trial
Atsushi Hirohata, Alexandre Abizaid, Mamoo Nakamura, Paul G. Yock, Luis Fernando 
Tanajura, Luis Alberto Mattos, Aurea Chaves, Marinela Centemero, Fausto Feres, 
Joseph A. Giorgianni, Amanda Sousa, Yasuhiro Honda, Peter J. Fitzgerald, J. Eduardo 
Sousa, Stanford University Medical Center, Stanford, CA, Institute Dante Pazzanese of 
Cardiology, Sao Paulo, Brazil
Background: Although sirolimus-eluting stenting (SES) reduces neointimal hyperplasia 
(NIH), the optimal dose of sirolimus has not been determined in human coronary arteries. 
The purpose of this IVUS study was to evaluate the efﬁ cacy of two reduced sirolimus 
doses (70% or 45% of sirolimus dose, compared to the current CYPHERTM coronary stent 
system) on in-stent NIH and late lumen area loss.
Methods: Serial IVUS analyses (Post stent, 4-month and 12-month follow-up) were 
performed in 44 patients treated with dose reduced SES (70% dose n=25, 45% dose 
n=19). At the stent site, volume index (volume/length) was calculated for stent, lumen, 
vessel and neointima. Percent neointimal volume (%NIV) was deﬁ ned as 100*(neointima 
/ stent volume). Cross-sectional analysis including in-stent minimum lumen area (MLA) 
and percent area loss, deﬁ ned as 100*(baseline MLA-follow-up MLA / baseline MLA), 
was also performed.
Results: At baseline, all IVUS parameters were similar between the groups. Slight 
increases of NIH and percent area loss were observed at two follow-up intervals (post-
stent to 4-month and 4- to 12-month), however, there was no signiﬁ cant difference in any 
IVUS parameter between the groups at 4-month or 12-month follow-up. One case of late 
incomplete stent apposition was observed in the 70% dose group at 12-month follow-up.
Conclusion: These IVUS analyses suggest that two different SES with reduced doses 
are equally effective in suppression of NIH and late lumen area loss during the 12-month 
follow-up.
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Overall
(n=44)
70% Dose
(n=25)
45% Dose
(n=19) p-value
4-month Follow-up
Neointimal Volume Index (mm3/mm) 0.13±0.28* 0.14±0.33 0.11±0.18 0.69
%NIV (%) 1.89±4.96* 2.37±6.33 1.38±2.21 0.50
MLA (mm2) 6.36±1.68† 6.41±1.93 6.30±1.32 0.83
Percent Area Loss (%) 3.49±10.38‡ 3.03±12.99 4.03±5.90 0.76
Late stent incomplete apposition 0 0 0
12-month Follow-up
Neointimal Volume Index (mm3/mm) 0.32±0.48* 0.37±0.56 0.24±0.34 0.69
%NIV (%) 4.36±7.96* 5.44±9.92 2.87±3.88 0.27
MLA (mm2) 6.15±1.71† 6.11±1.96 6.20±1.38 0.86
Percent Area Loss (%) 6.72±10.76‡ 7.64±12.56 5.47±7.70 0.51
Late stent incomplete apposition 1 1 0
*p<0.0001, †p=0.01, ‡p=0.02 (4-month vs. 12-month)
1065-26 Dose-Finding Study with a Novel Drug Eluting Stent 
System With the Use of an On-Site, Polymer-Free 
Coating with Rapamycin
Jörg Hausleiter, Adnan Kastrati, Rainer Wessely, Julinda Mehilli, Alban Dibra, Helmut 
Schühlen, Thomas Schratzenstaller, Boris Behnisch, Erich Wintermantel, Albert 
Schömig, Deutsches Herzzentrum München and I. Medizinische Klinik; Klinikum rechts 
der Isar, Munich, Germany, Zentralinstitut für Medizintechnik der TU München, Munich, 
Germany
Background. Drug-eluting stents are a major advance in interventional cardiology. Along 
with the success shown, current drug-eluting stents also present limitations related to 
the presence of polymer-coating, ﬁ xed drug and dose used. The objective of the ISAR 
(Individualized Drug-Eluting Stent System to Abrogate Restenosis) project is to develop a 
stent system that permits individualized choice of the drug and dose to use for the given 
patient. The system is based on stents with a microporous surface (more drug capacity) 
and a device that permits on-site drug coating in the cath lab.
Methods. In the clinical dose ﬁ nding study, bare stents with the microporous surface 
and coated stents with the use of a 0.5 % and 1 % rapamycin (R) solution were placed in 
patients with symptomatic coronary artery disease. A total of 487 patients were enrolled. 
The angiographic restenosis rate at 6-month follow-up is the primary study endpoint.
Results. The angiographic follow-up which is still ongoing, is currently available in 73% 
of enrolled patients. The table presents the preliminary results for treated lesions with an 
available angiographic follow-up.
Preliminary Study Results
Bare stent
(n=180)
0.5% R
(n=167)
1.0% R
(n=140) P
Late lumen loss, mm 1.05 ±0.74 0.71 ±0.70 0.36 ±0.54 <.001
Angiographic restenosis rate, % 28.4 16.8 10.9 <.001
Conclusion: The preliminary angiographic results indicate a dose-dependent prevention 
of restenosis. The ﬁ nal clinical and angiographic results will be presented.
1065-29 CYPHER™ Sirolimus-Eluting Bx Velocity Stent Is Safe 
and Effective For The Treatment Of In-Stent Restenosis
Fadi F. Alameddine, Marco Costa, Stanley Katz, Emerson Perin, Sidney Cohen, Steve 
Ramee, Peter Berger, Peter C. Block, Emory University Hospital, Atlanta, GA
Background: Brachytherapy is currently the only modality with proven efﬁ cacy for in-
stent restenosis (ISR), but failure rates approximate 25%. The efﬁ cacy of Sirolimus-eluting 
stent (SES) in native coronary arteries is proven, however its safety and efﬁ cacy in ISR 
treatment is unclear.
Methods: We evaluated SES efﬁ cacy in 142 ISR patients enrolled in the e-CYPHER 
Registry, a US internet registry on CYPHER™ SES.
Results: Out of 2067 patients treated with SES, 142 had placement of SES for treatment 
of ISR. Demographic, procedural, and follow-up data were collected. Mean patient age 
was 64 years, 47% of the patients had prior myocardial infarction, 35% were diabetic, 
37% had triple vessel disease, 23% had ostial disease and 28% of the lesions were class 
C. In- and out-of-hospital to 30 and 180 days events were adjudicated by an independent 
clinical events committee and are presented in the table below.
Conclusions: SES is a practical option for ISR with satisfactory safety and efﬁ cacy proﬁ le. 
A ~400 patient prospective randomized trial comparing SES to brachytherapy for ISR (the 
SISR Trial) has completed enrollment; results are expected in 2005.
Major Cardiac Events - Complications (In- and Out-of-Hospital to 30 and 180 days)
Adjudicated Events in 142 ISR patients from the eCYPHER registry
30 days 180 days
In- and Out-of-Hospital 
Complications % (number)
95% 
Conﬁ dence 
Interval
% (number)
95% 
Conﬁ dence 
Interval
MACE (Death, MI, Emergent 
CABG, TLR) 4.9% (7) 2.0-9.9% 16.9% (24) 11.1-24.1%
Death 0% 0% 2.1% (3) 0.4-6.0%
MI 3.5% (5) 1.2-8.0% 4.9% (7) 2.0-9.9%
Q Wave MI 2.1% (3) 0.4-6.0% 2.8% (4) 0.8-7.1%
Non-Q Wave MI 1.4% (2) 0.2-5.0% 2.1% (3) 0.4-6.0%
Emergent CABG 0% 0% 0% 0%
TLR 4.9% (7) 2.0-9.9% 15.1% (20) 8.8-20.9%
TL-CABG 0.7% (1) 0-3.9% 0.7% (1) 0.0-3.9%
TL-PTCA 4.2% (6) 1.6-9.0% 13.4% (19) 8.3-20.1%
TVR not involving Target 
Lesion 0% 0% 4.9% (7) 2.0-9.9%
TV/non-TL-CABG 0% 0% 0.7% (1) 0.0-3.9%
TV/non-TL-PTCA 0% 0% 4.2% (6) 1.6-9.0%
Target Vessel Failure 4.9% (7) 2.0-9.9% 18.3% (26) 12.3-25.7%
Stent Thrombosis 3.5% (5) 1.2-8.0% 3.5% (5) 1.2-8.0%
Acute Stent Thrombosis 1.4% (2) 0.2-5.0% 1.4% (2) 0.2-5.0%
Subacute Stent Thrombosis 2.1% (3) 0.4-6.0% 2.1% (3) 0.4-6.0%
Major (Hemorrhagic) 
Vascular Complications 3.5% (5) 1.2-8.0% 4.9% (7) 2.0-9.9%
Major Bleeding 
Complications 2.1% (3) 0.4-6.0% 3.5% (5) 1.2-8.0%
1065-30 Drug Eluting Stents Versus Repeat Vascular 
Brachythreapy for Patients With Recurrence of In-Stent 
Restenosis Who Failed Radiation Therapy
Ron Waksman, Rebecca Torguson, Andrew E. Ajani, Eduardo Cheneau, Rosanna C. 
Chan, Bill Bass, Dong-Hun Cha, Augusto Pichard, Lowell Satler, Kenneth M. Kent, Ellen 
Pinnow, Joseph Lindsay, Washington Hospital Center, Washington, DC
Background: Intracoronary Radiation Therapy (IRT) is effective to prevent recurrences 
of in-sent restenosis. However signiﬁ cant number of patients (pts) required repeat 
revascularization to the target irradiated site. This study examined the use of Drug Eluting 
Stents for failed IRT patients and compared their outcome to repeat IRT.
Methods: A cohort of 65 pts who failed IRT for the treatment of ISR was studied. Of 
these 14 patients were treated with DES either with Taxus or Cypher and 51 with repeat 
radiation using either beta or gamma sources. All patients prescribed at least 12 months 
of clopidogrel post-procedure The clinical outcome of these pts were compared at 9 
months by telephone contact or ofﬁ ce visit.
Results: The baseline characteristics of the patients were similar among the treated 
groups. At present mean follow-up available on the DES group is 8.9 ± 3.2 while the 
repeat radiation competed 9 months follow-up. Overall DES was resulted with higher 
events rate when compared to VBT at 9 months follow-up. (table)
Conclusions: DES and repeat VBT to the same site seems to be viable options for the 
treatment of ISR of failed VBT. This limited data suggest superiority of VBT over DES for 
the treatment of failed VBT patients. Complete 9 months clinical follow-up will be available 
at presentation to determine whether these differences sustained with larger cohort of pts 
and longer time of follow-up.
DES Group
(n=14) VBT Group (n=51) P value
MACE % 50.0 21.6 0.009
TLR MACE, % 50.0 19.6 0.02
Death, % 0 2.0 0.78
Q wave MI, % 0 0 --
NQWMI, % 9.0 2.0 0.38
TVR, % 50.0 21.6 0.03
TLR, % 50.0 19.6 0.02
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1066-9 Unstable Coronary Plaque is Not Soft But Has 
Inhomogeneous Compliance
Osamu Sasaki, Toshihiko Nishioka, Michiko Minai, Yoshirou Inoue, Mikio Yuhara, 
Shyunichi Sato, Toshiyuki Ando, Nobuyuki Masaki, Tetsuo Kamiyama, Hiroyuki Ito, 
Yoshiaki Maruyama, Nobuo Yoshimoto, Saitama Medical Center, Saitama Medical 
School, Kawagoe, Japan
Objectives: The purpose of this study was to examine the difference in coronary 
compliance between stable and unstable plaques using intravascular ultrasound imaging.
Methods: Thirty-six de novo coronary artery lesions of thirty-three patients (30 men, 
3 women, mean age 62±11) were imaged by IVUS and intracoronary pressure was 
simultaneously recorded. Systolic and diastolic lumen areas (LA) were measured at the 
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tightest lesion, and 5 evenly spaced sites between the proximal and distal reference sites. 
Lumen diameters (LD) were calculated with an assumption that the cross section was 
circular. Coronary compliance; {(LA change/diastolic LA) / (BP change)}×103 and stiffness 
index β; {ln (systolic BP/diastolic BP)}/(LD change/diastolic LD) were calculated at each site. 
The average, standard deviation and difference between maximum and minimum values 
of these 2 indices were calculated for each coronary lesion. Stable plaque and unstable 
plaque were deﬁ ned from patients’ clinical manifestations and angiographic ﬁ ndings.
Results: Coronary compliance at the tightest lesion and average compliance of the 
plaque showed no signiﬁ cant difference, however, maximum compliance, standard 
deviation and difference between maximum and minimum compliance within each 
segment were signiﬁ cantly higher (5.6±2.3 vs 3.7±1.8, 2.1±0.9 vs 1.1±0.6 and 5.3±2.3 vs 
2.8±1.5, p<0.001) in 17 unstable plaques than in 19 stable plaques.
Conclusions: These ﬁ ndings indicate that unstable coronary plaque is not soft but has 
more inhomogeneous vessel compliance than stable plaque, and could be related to 
plaque vulnerability.
1066-10 Detection of Coronary Plaques With Superﬁ cial Foam 
Cells Using Intrinsic Fluorescence at 308 and 480 nm 
Excitation Wavelengths
George O. Angheloiu, Irene Georgakoudi, Abigail S. Haka, Joseph T. Arendt, Markus G. 
Mueller, Jason T. Motz, Ramachandra R. Dasari, Maryann Fitzmaurice, John R. Kramer, 
Michael S. Feld, Massachusetts Institute of Technology, Cambridge, MA, University of 
Pittsburgh Medical Center, Pittsburgh, PA
Background: Foam cells are key players in plaque rupture. Apoproteins B100 and apo(a) 
are important moieties of oxidized low density lipoprotein, stored by foam cells. Both 
proteins contain tryptophan, whose remarkable ﬂ uorescent properties could be used for 
the identiﬁ cation of superﬁ cial foam cells (SFC).
Methods: In an in-vitro experiment we probed 120 human coronary segments with an 
intrinsic ﬂ uorescence spectroscopy (IFS) instrument equipped with a 1 mm diameter ﬁ ber 
optic probe, already in use in clinical studies. SFC area was histologically quantiﬁ ed on a 
region of interest represented by the top 50 µm of each specimen on a transversal width of 
1 mm. We extracted IFS data at excitation wavelengths 308 (IFS308) and 480 nm (IFS480), 
and ﬁ t them to a linear combination of basis spectra. The ﬁ gure attached illustrates the 
IFS308 basis spectra used, and the ﬁ t models in three specimens. A diagnostic algorithm, 
employing leave-one-out cross-validation and logistic regression, was built using the 
relative contribution of tryptophan basis spectrum to IFS308 and of ﬁ brous cap spectrum to 
IFS480 as diagnostic parameters.
Results: SFC were histologically noted in 23 specimens. The relative contribution of 
tryptophan to IFS308 correlated with the area occupied by SFC on the region of interest 
(r=0.47, P<0.01). The algorithm discriminated the specimens with SFC with sensitivity 
and speciﬁ city 87% and 92% respectively.
Conclusion: IFS of tryptophan accurately identiﬁ es SFC in coronary arteries. 
1066-11 In Vivo Human Temperature Measurements Of 
Atheromatous Plaques Are Related To The Severity Of 
The Target Lesion: New Implications Of The ‘Cooling 
Effect’ Of Coronary Blood Flow.
Konstantinos Toutouzas, Sophia Vaina, Maria Drakopoulou, John Mitropoulos, Virginia 
Markou, Eleftherios Tsiamis, George Latsios, Manolis Vavuranakis, Dimitris Tousoulis, 
Christodoulos Stefanadis, Hippokration Hospital, Athens, Greece
Background: Experimental ex-vivo and in-vivo models have demonstrated that thermal 
heterogeneity is underestimated due to the “cooling effect” of coronary blood ﬂ ow. 
However, the effect of the severity of the lesion in in-vivo thermography has not been 
studied. The aim of the present study was to investigate whether there are differences in 
temperature measurements between high-grade and mild to severe-grade stenoses, and 
the relation between the severity of the lesion with temperature measurements in human 
coronary arteries. 
Method: We performed thermography in 121 lesions from 105 patients scheduled for 
balloon angioplasty. Five minutes after the last contrast injection the lesion temperature 
was assessed using a thermography catheter (Medispes, Switzerland). Temperature 
difference (�T) was designated as the temperature of the culprit atherosclerotic plaque 
minus the temperature of the proximal healthy vessel wall. In all lesions quantitative 
computerized analysis (QCA) was performed using specialized software (Medcon, Israel) 
and the following parameters were calculated: Minimum lumen diameter (MLD), reference 
vessel diameter (RVD), length of lesion and percentage stenosis (%). 
Results: All procedures were successful and uncomplicated. Mean stenosis was 
75%±0,14% and MLD = 0,6±0,44mm. �T was greater in high-grade stenoses (n=23, >90%) 
compared to lower stenoses (n=98, 50-90%) (0.34±0.4 versus 0.18±0.23, p=0.01). In 5 
lesions (22%) of the high grade stenosis group thermal heterogeneity was not detected 
compared to 29 lesions (29%) of the second group. There was a good correlation of ΔΤ with 
percentage stenosis in the whole study population (r=0.23, p=0.02). However, no correlation 
was found when only mild to severe stenoses were included (ﬁ gure, r=0.6, p=0.59). Thermal 
heterogeneity was correlated with MLD in the whole study population (p=0,001). 
Conclusions: In atheromatic plaques causing mild to severe stenosis thermal 
heterogeneity is not correlated with percentage stenosis. When thermography is 
performed in occlusive lesions the ‘cooling effect’ of coronary blood ﬂ ow is eliminated and 
the pragmatic lesion temperature is measured.
1066-13 Assessment of Fibrous Cap Thickness in Lipid-rich 
Plaques by Optical Coherence Tomography Assisted 
with Attenuation Signal Analysis
Yuji Sakanoue, Brian K. Courtney, Debra L. Stamper, Yasuhiro Honda, Paul R. Herz, 
Susanne D. Giattina, Tony H. Ko, Samuel B. Adams, Mark J. Roberts, Frandics P. Chan, 
Paul G. Yock, Abel L. Robertson, Jr., James G. Fujimoto, Peter J. Fitzgerald, Mark E. 
Brezinski, Stanford University, Stanford, CA, Brigham and Women’s Hospital, Boston, MA
Although ﬁ brous cap thickness is thought to be an important factor in the likelihood 
of plaque rupture, no in vivo imaging methods with satisfactory resolution exist for its 
measurement. The aim of this study was to evaluate the accuracy of intravascular optical 
coherence tomography (OCT) for the assessment of ﬁ brous cap thickness using a newly 
developed signal analysis technique.
Methods: Twenty-two human coronary artery segments of 5-7 mm in length were collected 
from 20 cadavers at the time of autopsy and ﬁ xed using pressure ﬁ xation. The vessels 
were imaged in vitro using an intravascular OCT system. In the OCT image sequences, 
a thin ﬁ brous cap covering a lipid pool was identiﬁ ed, and its thickness was measured 
using a non-linear regression algorithm (Y=A0e
-�x) to which the OCT signal was ﬁ tted. 
As a gold standard, histological sections were made using Masson’s Trichrome stain, 
and the minimum cap thickness was compared between the OCT and corresponding 
histological sections.
Results: The minimum ﬁ brous cap thickness measured by OCT was 213±101 microns 
(n=22, range: 50 to 494 microns). Regression analysis showed a signiﬁ cant positive 
correlation between the OCT and histological ﬁ brous cap thicknesses (p<0.0001, r=0.88).
Conclusions: In this ex vivo evaluation model, quantitative assessment of a thin ﬁ brous 
cap by OCT was feasible. Signal analysis techniques for OCT may facilitate accurate and 
objective measurement of ﬁ brous caps in the evaluation of lipid-rich vulnerable plaques. 
1066-14 Impact of Optical Coherence Tomography on Visualizing 
Atherosclerotic Plaques in Patients with Acute 
Coronary Syndrome: Comparison with Intravascular 
Ultrasound
Yoshihiro Takeda, Osamu Katoh, Etsuo Tsuchikane, Koyo Satoh, Yasuyuki Suzuki, 
Ryouhei Kurokawa, Akira Murata, Kenya Nasu, Tatsuya Ito, Tomomichi Suzuki, Mariko 
Ehara, Hietoshi Satoh, Tetsuo Matsubara, Takahiko Suzuki, Toyohashi Heart Center, 
Toyohashi, Japan
Objectives: The aim of this study was to evaluate the ability of optical coherence 
tomography (OCT) to visualize the plaque morphology in patients with acute coronary 
syndrome (ACS)..
Background: The high resolution (of approximately 15 µm) of OCT may permit the 
identiﬁ cation of vulnerable plaques that cause ACS.
Methods: Corresponding OCT and IVUS images of 13 living patients with ACS (acute 
myocardial infarction: n=5, unstable angina pectoris: n=8) were compared to establish 
morphologic information of plaques.
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Results: In 13 culprit lesions, all thrombi (n=3) and ruptured plaque (n=2) identiﬁ ed by 
IVUS were seen in OCT images. Moreover, OCT identiﬁ ed 6 additional thrombi and 3 
additional ruptured plaques that were not discerned by IVUS. Thus, 9 thrombi (69%) 
and 5 ruptured plaques (38%) were detected by OCT in 13 culprit lesions. Echolucent 
regions, possibly representing large lipid pools, were identiﬁ ed in 11 (85%) corresponding 
OCT and IVUS image pairs. Comparison of the OCT and IVUS images of the signal-rich 
band overlying the echolucent regions demonstrates the potential for OCT to measure 
ﬁ brous cap thickness with a greater degree of precision than IVUS: the mean ﬁ brous cap 
thickness of 11 culprit lesions measured 91±35µm. 
Conclusions: In patients with ACS, as compared with IVUS, OCT may provide additional 
detailed information of atherosclerotic plaques, such as ﬁ brous cap thickness, thrombi 
and ruptured plaques.
POSTER SESSION
1067  Restenosis: Basic Research I
Monday, March 07, 2005, 9:00 a.m.-12:30 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 10:00 a.m.-11:00 a.m.
1067-3 Interleukin 1 Receptor Antagonist Gene Polymorphism 
And Restenosis After Percutaneous Coronary 
Intervention
Andrejs Erglis, Uldis Kalnins, Normunds Licis, Inga Narbute, Sanda Jegere, Gustavs 
Latkovskis, P.Stradins Clinical University Hospital, Riga, Latvia
Background: Besides the common restenosis predictors, possibly also genes may 
contribute to development of restenosis. Interleukin-1 beta (IL-1B) and IL-1 receptor 
antagonist are inﬂ ammatory mediators, cytokines and may play a key role in promotion 
of restenosis after PCI.
Method: Our study examined three DNA polymorphisms within interleukin-1 (IL-1) gene 
cluster: IL-1B (-511), IL-1B (+3954), IL-1RN (VNTR). We analyzed DNA samples from 
70 patients undergoing IVUS guided PCI based on “media to media” treatment principle. 
Patients were scheduled for clinical, angiographic and IVUS follow-up at 6 months.
Results: In the study IL-1B (-511) 1/1 genotype had 30 patients (42.9%), 1/2 -31 (44.3%) and 
2/2 -9 (12.8%), IL-1B (+3954) genotypes - 1/1 - 37 patients (52.9%), 1/2 - 28 (40.0%) and 2/2
-5 (7.1%) and IL-1RN (VNTR) genotypes - 1/1 -43 patients (61.4%), 1/2 -24 (34.3%) and 2/2
-3 (4.3%). Analysis consisted of comparing combined heterozygous and homozygous carriers 
of the allele 2 with homozygous carriers of the allele 1 in each DNA polymorphism.
IVUS results after PCI and at follow-up 
IL-1B (-511) 1/2 or 2/2 (n=40) IL-1B (-511) 1/1(n=30) p
Late loss MLD, mm 0.31±0.36 0.22±0.26 0.26
Late loss MSA, mm2 1.35±1.45 1.01±0.89 0.27
IL-1B (+3954) 1/2 or 2/2 (n=33) IL-1B (+3954) 1/1 (n=37) p
Late loss MLD, mm 0.30±0.29 0.24±0.35 0.43
Late loss MSA, mm2 1.14±0.95 1.27±1.47 0.67
IL-1RN (VNTR) 1/2 or 2/2 (n=27) IL-1RN (VNTR) 1/1 (n=43) p
Late loss MLD, mm 0.15±0.28 0.35±0.33 0.01
Late loss MSA, mm2 0.81±0.85 1.45±1.39 0.04
Conclusions: Allele 2 of IL-1RN (VNTR) polymorphism was associated with signiﬁ cant 
lower stented segment late loss in MLD and MSA at 6 months. That supports the 
hypothesis that genetic programming of the inﬂ ammatory response may be relevant to 
pathogenesis of restenosis after PCI. Association of IL-1B (-511) with degree of neointima 
did not reach statistical signiﬁ cance as reported previously for a smaller sample size in 
this cohort.
1067-4 l-Caldesmon Inhibits Neointimal Formation by 
Modulating the Phosphorylation of Focal Adhesion 
Kinase (FAK) and Extracellular Signal-Regulated Kinase 
(ERK1/2)
Kazuhiko Yokouchi, Yasushi Numaguchi, Hajime Imai, Ryuichiro Murakami, Hideo 
Matsui, Kenji Okumura, Toyoaki Murohara, Nagoya University Graduate School of 
Medicine, Nagoya, Japan
Background: In drug-eluting stent era, potent anti-prolierative and cytotoxic agents 
show efﬁ cacy to inhibit neointimal formation after PCI. However, some problems such as 
malapposition arised and other optimal agents or genes are required. We have shown that 
light type-caldesmon (l-CaD) is a potent anti-angiogenic gene which regulates cell growth 
and survival via modulation of cell shape and cytoskeleton in endothelial cells (ECs).
Methods and Results: To test this anti-proliferative function of l-CaD in vascular smooth 
muscle cells (VSMCs), we performed proliferation, apoptosis and migration assay in human 
aortic VSMCs, and evaluated its inhibitory effects on expression pattern of each marker 
protein (FAK, MAPKs) and neointimal formation in balloon-injured model. An adenoviral 
vector encoding GFP-l-CaD (AdGFP-l-CaD) was constructed to transfect to VSMCs. 
Increase in cellular GFP-l-CaD resulted in progressive loss of actin stress ﬁ bers and cell 
retraction in a similar manner as observed in ECs. Apoptosis was less induced in VSMCs 
than in ECs under similar transfection condition (EC : VSMC = 46±3%: 12±1%, p<0.01 at 24 
hrs). In migration assay, AdGFP-l-CaD transfection inhibited migration of VSMCs induced 
by PDGF-BB by 48% (control: GFP: GFP-l-CaD = 135±18.4 :119±6.12 : 68.5±7.30 cells/
HPF, p<0.05 between control and GFP-l-CaD, n=3 each). Immunoblotting analysis showed 
that l-CaD overexpression reduced PDGF-BB-induced phosphorylation of FAK by 83 % 
and that of ERK by 45%, but phosphorylation of p38 MAP kinase and that of SAPK/JNK 
were not inhibited. In Matrigel plug assay, gels with AdGFP-l-CaD (108PFU/gel) inhibited 
capillary formation with lower pericyte migraton (control: GFP: GFP-l-CaD=15.3±2: 12.1±3: 
5.2±2 vessels/area, p<0.01 vs. control and GFP, n=20 each). In balloon-injured rat carotid 
arteries, AdGFP-l-CaD transfection inhibited neointimal formation by 47% (control: GFP-l-
CaD=1.35±0.32: 0.72±0.12 in intima/media ratio, p<0.05, n=6) at 14 days.
Conclusions: Overexpression of l-CaD inhibits proliferation and migration of VSMCs 
by modulating focal adhesion formation and phosphorylation of ERK, and suppresses 
neointimal formation in balloon injured arteries.
1067-41 Herpes Simplex Virus-1 R7020 Strain Impairs Cellular 
Signaling In Low-Flow Experimental Vein Grafts
Amito M. Chandiwal, Zachary Baldwin, Wendy Huang, James Vosicky, Viji 
Balasubramanian, Bernard Roizman, Ralph Weichselbaum, Lewis Schwartz, University 
of Chicago, Chicago, IL, Illinois Institute of Technology, Chicago, IL
Introduction: The R7020 strain of Herpes Simplex-1 (HSV-1) virus has shown to be 
effective in reducing neointimal hyperplasia in animal models of vein graft failure. 
Extracellular-signal related kinases (ERK) are believed to be involved in regulating this 
thickening by regulating cell proliferation, differentiation, and migration of smooth muscle 
cells. The purpose of this study was to test the hypothesis that R7020 mutant reduces 
ERK 1/2 expression thereby reducing neointimal hyperplasia.
Methods: Using standard aseptic technique, the ipsilateral external jugular vein of New Zealand 
White rabbits was canulated and transfected with R7020 mutant (1.2 X 109 pfu/ml; n=3) or saline 
(PBS; n=3) at 80 mmHg for 30 min. The jugular vein was reversed and interposed between 
carotid arterial segments creating carotid interpostion vein bypass grafts. At the end of 3, 5 or 7 
days, the grafts were removed and ERK 1/2 expression determined using Western blot.
Results: ERK 1/2 expression increased from day 3 to day 7 in both groups. However, 
the expression of ERK 1/2 in HSV infected grafts was signiﬁ cantly lower (30-40%) than 
control rabbits for all the time periods (p<0.05).
Conclusion: The R7020 strain of HSV-1 reduces the expression of ERK 1/2 important 
in regulating the proliferation, differentiation and migration of smooth muscle cells. A 
decrease in the expression of this cell signaling kinases early in the course of remodeling 
may be important in reducing neointimal hyperplasia and vein graft failure.
1067-42 No Effect of the -455 G/A Polymorphism and 
Preprocedural Serum Levels of Fibrinogen on the Risk 
of Clinical Restenosis in Patients With Coronary Stent 
Placement
Pascalle S. Monraats, Jamal S. Rana, Moniek P.M. de Maat, Aeilko H. Zwinderman, 
Willem R.P. Agema, John J.P. Kastelein, Robbert J. de Winter, Rene A. Tio, Pieter A.F.M. 
Doevendans, Johannes Waltenberger, Rune R. Frants, Arnoud van der Laarse, Ernst E. van 
der Wall, J.Wouter Jukema, Leiden University Medical Center, Leiden, The Netherlands
Background: The relationship between increased level of ﬁ brinogen and risk for 
development of cardiovascular disease and restenosis after coronary balloon angioplasty 
is well known. However, the effect of preprocedural ﬁ brinogen levels on coronary 
stent restenosis is largely unknown. The -455 G/A polymorphism in the promoter of 
the ﬁ brinogen β-gene is associated with the plasma level of ﬁ brinogen. Therefore, we 
hypothesised that there may be a relationship between the -455G/A polymorphism or 
preprocedural ﬁ brinogen level and clinical restenosis at follow up among patients with 
coronary stent placement.
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Methods: The GENetic DEterminants of Restenosis (GENDER) project is a multicenter 
prospective study in patients who underwent a successful percutaneous coronary 
intervention (PCI). The primary end point is target vessel revascularization (TVR) and 
the secondary combined end point is clinical restenosis, which is deﬁ ned as death due 
to cardiac cause, myocardial infarction and TVR. A coronary stent was placed in 2,309 
patients. Of these patients, 2,255 (97.7%) were genotyped for the -455G/A polymorphism. 
Plasma ﬁ brinogen levels were measured at baseline in a subpopulation of 623 stented 
patients with the von Clauss method and patients were grouped into tertiles according to 
ﬁ brinogen levels.
Results: We did not observe an association between the -455G/A polymorphism and 
risk of restenosis (p=0.987). Furthermore, on follow up, no increase in TVR (9.8%, 
10.5%, 6.6%, respectively, P=0.32) and clinical restenosis rates (11.1%, 13.2%, 8.0%, 
respectively, P=0.22,) were observed across the tertiles of ﬁ brinogen levels. Multivariate 
regression analysis revealed that the risk of TVR and clinical restenosis were not higher in 
patients in the highest tertile for ﬁ brinogen levels, compared to the lowest tertile (RR 0.87, 
95% C.I= 0.62 - 1.21 for TVR and RR 0.87, 95% C.I= 0.63 - 1.19 for clinical restenosis).
Conclusions: In conclusion, we found that the presence of -455G/A polymorphism in 
the ﬁ brinogen β- gene or preprocedural ﬁ brinogen levels in the highest tertile are not 
associated with an increased risk of TVR and clinical restenosis in a patient population 
with coronary stent placement.
1067-43 Inﬂ ammatory Cytokine Release After Coronary Stenting 
And Its Contribution For Development Of In-stent 
Neointimal Hyperplasia In Porcine Coronary Arteries
Mariann Gyongyosi, Christoph Strehblow, Wolfgang Sperker, Csaba Csonka, Tamas 
Balint Csont, Peter Ferdinandy, Akos Hevesi, Rita Garamvolgyi, Zsolt Petrasi, Dietmar 
Glogar, Kurt Huber, University of Vienna, Vienna, Austria
Background. The aim of our study was to investigate the inﬂ ammatory cytokine release 
after stent implantation in pig coronary arteries and correlate with the degree of neointimal 
hyperplasia.
Methods. Seventy-six bare metal intracoronary stents were implanted in the left anterior 
descending and circumﬂ ex coronary arteries in 40 domestic pigs, after per os loading 
dose of aspirin (100 mg) and ticlopidine (2x250 mg). The stents were placed under 
general anaesthesia after intraarterial administration of 200 U/kg heparin. During the 4-
weeks follow-up (FUP), the animals were treated daily with per os aspirin (100 mg) and 
ticlopidine (2x250mg). After 1-month FUP, the development of neointimal hyperplasia was 
evaluated with 3D intravascular ultrasound (IVUS) by control coronary angiography and 
histomorphometry. Serum levels of interleukin (IL) 1-beta, IL-6 and tumor necrosis factor 
alpha (TNF-alpha) were measured before stenting, one hour after stent implantation and 
at FUP by using commercially available porcine ELISA kits.
Results. The serum levels of IL-1-beta (from 70.3±7.5 to 71.9±7.2 pg/ml), and IL-6 (from 
2.48±1.18 to 2.0±0.9 pg/ml) did not change shortly after stent implantation. The level 
of TNF-alpha increased signiﬁ cantly post-stenting (from 93.1±5.9 to 115.4±8.4 pg/ml, 
p<0.05). Based on the FUP results, the animals were divided into two groups: Group 1: 
at least one stent showed signiﬁ cant (at least 70% diameter stenosis) and Group 2: no 
signiﬁ cant in-stent stenosis. After 1-month, Group 1 pigs exhibited signiﬁ cantly elevated 
levels of FUP IL-1-beta (77.8±1.4 vs 29.3±0.4 pg/ml, p<0.05), FUP IL-6 (44.9±2.4 vs 
1.6±0.1 pg/ml, p<0.05) and FUP TNF-alpha (113.4±2.3 vs 73.3±0.3 pg/ml, p<0.05) as 
compared with Group 2. The FUP levels of IL-6 and IL-1beta exhibited signiﬁ cant (p<0.05) 
correlation with maximal neointimal area, maximal %area stenosis and maximal neointimal 
thickness, measured by histomorphometry, and with neointimal volume by 3D IVUS.
Conclusions. Increased inﬂ ammatory cytokine release of IL-1-beta, IL-6 and TNF-alpha 
resulted in corresponding vascular response to intracoronary stent implantation, leading 
to higher degree of neointimal hyperplasia.
1067-44 SiRNAs Targeting Serum Response Factor As Potential 
Tools To Interfere With In-stent Restenosis
Christian Herdeg, Daniela Werth, O. Heidenreich, A. Nordheim, Gabriele Grassi, 
University of Tuebingen, Tuebingen, Germany, University of Trieste, Trieste, Italy
Background: anti-proliferative drugs released from endo-vascular stents have substantially 
contributed to reduce in-stent restenosis rate in coronary arteries bearing single primary lesions 
by down regulating coronary smooth muscle cell (CSMC) growth. However, the considerably lower 
efﬁ cacies seen in more complex coronary lesions, such as long lesions and lesions present in 
small vessels, demonstrate the requirement of new alternative anti-proliferative approaches.
Methods and Results: we explored the use of siRNAs as tools to knockdown the serum 
response factor (SRF), a transcription factor that regulates the expression of numerous 
genes involved in cell growth and differentiation. SiRNAs targeting SRF were delivered 
to cultured human CSMCs by lipofection. SRF protein levels were determined by gel shift 
assay, and its mRNA amounts were evaluated by real time RT-PCR. The effects on cell 
proliferation and cell cycle distribution were measured by BrdU incorporation and 7-Amino-
Actinomycin D intercalation into DNA. Our siRNAs showed a sequence speciﬁ c and dose 
dependent reduction in the protein and mRNA amounts of SRF with a maximal effect at 
an siRNA concentration of 230 nM, which lasted at least for four days after transfection. 
SRF siRNAs dramatically reduced cell proliferation and the amount of S phase cells. 
Finally, SRF siRNAs were as efﬁ cient in proliferating as well as in resting VSMCs.
Conclusion: the selected SRF siRNAs may potentially contribute to reduce the in-
stent restenosis rate observed for stents applied to complex coronary lesions, where the 
exuberant proliferation of CSMCs still remains a major problem.
ORAL CONTRIBUTIONS
801  Drug-Eluting Stents in Complex 
Anatomy I
Monday, March 07, 2005, 9:15 a.m.-10:30 a.m.
Orange County Convention Center, Room 304A
9:15 a.m.
801-3 Sirolimus Eluting Stents Implantation in Bifurcational 
Coronary Artery Lesions Utilizing the ‘Crush’ Technique: 
Immediate and Mid Term Outcome
Flavio Airoldi, Antonio Colombo, Iassen Michev, Carlo Briguori, Alaide Chieffo, Ioannis 
Iakovou, Lei Ge, Mauro Carlino, Giuseppe Massimo Sangiorgi, Giancarlo Vitrella, Goran 
Stankovic, Matteo Montorfano, San Raffaele Hospital, Milan, Italy, EMO Centro Cuore, 
Columbus Clinic, Milan, Italy
Background: The “crush” stenting has been proposed as a novel technique for the 
treatment of coronary bifurcations with drug eluting stents. 
Methods: We report the clinical and angiographic results of 73 consecutive bifurcations 
from 70 patients treated using the “crush” technique with sirolimus eluting stents (Cypher, 
Cordis, Johnson & Johnson Company, NJ). 
Results: Angiographic success was reached in all lesions. Final kissing inﬂ ation was 
performed in 28 lesion (38%). During hospital stay no patient died; 4 (5.7%) patients had 
myocardial infarction. At 6-months follow-up no patients died, one patient who stopped 
double antiplatelets after 1 month had a ST-elevation MI. Target lesion revascularization 
(TLR) was performed in 16/70 (23%) patients. The 6-months angiographic FU rate was 
available in 61/73 (83%) lesions. Restenosis rate was 33% (20/61: 7% main and side 
branch and 26% only side branch). No difference was observed in restenosis rate on the 
main branch between lesions treated with ﬁ nal kissing balloon inﬂ ation (KY) and lesions 
without ﬁ nal kissing inﬂ ation (KN) (4% in the KY group vs 8% in the KN group, p=1.00). 
The restenosis rate on the side branch was lower in the KY group (17%) in comparison to 
the KN group (42%), p=0.046). 
Conclusions: “Crush” stenting of bifurcational lesions with sirolimus eluting stents gives 
a high rate of procedural success. The mid term clinical follow-up indicates a good safety 
proﬁ le of the procedure. The angiographic outcomes show a low rate of restenosis on the 
main branch and a relatively high restenosis rate on the side branch that could be lowered 
accomplishing the procedure with a ﬁ nal kissing inﬂ ation.
9:30 a.m.
801-4 Immediate and Mid-Term Outcome of Sirolimus-Eluting 
Stent Implantation for Chronic Total Occlusion Lesions
Lei Ge, Ioannis Iakovou, Giuseppe M. Sangiorgi, Alaide Chieffo, Gloria Melzi, Matteo 
Montorfano, Iassen Michev, Flavio Airoldi, Mauro Carlino, Nicola Corvaja, Antonio 
Colombo, EMO Centro Cuore Columbus, Milan, Italy
Background: Percutaneous coronary intervention of chronic total occlusion (CTO) is one 
of the major challenges in interventional cardiology. The effectiveness of sirolimus-eluting 
stent (SES) implantation for the treatment of CTO lesions has not been evaluated.
Methods: We identiﬁ ed 158 consecutive patients who underwent percutaneous 
revascularization in CTO lesion with SES from April 2002 to May 2004 (SES group). A control 
group for comparison was composed of 290 consecutive patients with CTO lesion treated 
with bare metal stents (BMS) in the same length period immediately before the introduction 
of SES (BMS group). The major adverse cardiac events (MACE) analyzed in this report 
were deﬁ ned as cardiac death, myocardial infarction, target lesion revascularization (TLR), 
and target vessel revascularization, either percutaneous or surgical.
Results: Compared with the BMS group, the patients of the SES group more frequently 
had established risk factors of coronary heart disease, more multivessel diseases, longer 
lesions and received more stents. Clinical follow-up at 6 months was complete for all 
patients and angiographic follow-up was complete for 85 patients in the SES group (71%) 
and 204 patients in the BMS group (70%). At 6 months follow-up, the cumulative rate of 
MACE was 17.5% in the SES group and 31.4% in the BMS group (P=0.005). The incidence 
of in-segment restenosis was 11% in the SES group and 33.9% in the BMS group(p<0.001). 
TLR at 6 months was 7.5% in the SES group and 23.4% in the BMS group (p<0.001), 
respectively. By multivariate logistic regression analysis, usage of BMS (OR: 5.46; 95% CI: 
2.33 to 12.8; P P<0.001) and multivessel coronary disease (OR: 2.17; 95% CI: 1.17 to 3.99; 
P=0.01) were identiﬁ ed as predictors of MACE during 6-month follow-up.
Conclusion: Compared to BMS implantation, SES implantation in CTO lesions appears 
effective in reducing the incidence of restenosis and the need of revascularization and 
improving the MACE-free survival at 6 months.
9:45 a.m.
801-5 Treatment of Chronic Total Occlusion With the 
Sirolimus-eluting Stent - Results From the e-Cypher 
Registry
Chaim Lotan, Anthony Gershlick, Giulio Guagliumi, Philippe Guyon, Ashok Seth, 
Joachim Schofer, Edouardo Sousa, Philip Urban, Hadassah-Hebrew University Medical 
Center, Jerusalem, Israel
Background and Aim: Despite the use of bare metal stents for Chronic Total Occlusion 
(CTO), the combined rate of restenosis and re-occlusion remains high (ca. 30-50%). The 
introduction of drug-eluting stents has markedly reduced restenosis rates for de novo, 
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non-occlusive lesions. However, there are no data concerning the use of drug-eluting 
stents in the challenging CTO lesion subset. The aim of this analysis is to assess the real 
life use and clinical outcome of the CYPHERTM stent in CTOs.
Method and Design: The present data were collected from a multi-center, international 
registry (the e-CYPHER Registry) since April 02. Patient inclusion is still ongoing, and 
clinical follow-up is being obtained at 1, 6 and 12 months.
Results: 367 centers enrolled a total of 14,316 patients. Among them, 415 patients (2.9%) 
had a chronic total occlusion of the target lesion (deﬁ ned as an occlusion > 3 months old). 
In this subset, mean patient age was 60.2 + 11.2 years, 79.5% were males and 30.4% 
were diabetic. 49.2% had a previous MI (63.7% Q wave) and 32.3% had previous PCI. 
Indication for PCI included stable angina 56.1%, unstable angina 20.5% and silent ischemia 
14.9%. Occlusive in-stent restenosis was noted in 13.7% of target lesions. Mean estimated 
occlusion length was 24.0 + 12.6 mm with a reference vessel diameter of 2.8 + 0.3 mm. A 
single stent was used in 79.2% of CTO lesions while 20.8% required multiple stenting.
Follow-up is ongoing, and is now available for 360 patients at 6 months (85% of those 
eligible). The overall rate of site-reported major adverse cardiac events (MACE) was 3.3%. 
This included 3 deaths (0.8%), 5 MIs (1.4%), 5 target lesion revascularizations (1.4%) of 
which 1 patient underwent CABG. Comprehensive 12-month follow-up data, including 
clinical status and adjudicated events, will be presented.
Conclusions: These highly encouraging preliminary results suggest that the use of the 
CYPHERTM stent is safe and appears effective in the treatment of CTO lesions.
10:00 a.m.
801-6 Comparison of Efﬁ cacy and Safety Between Sirolimus-
Eluting Stent (Cypher™) and Paclitaxel-Eluting Stent 
(TAXUS™) on the Outcome of Patients With Chronic 
Total Occlusions: Multicenter Registry in Asia
Sunao Nakamura, Tamil Selvan Muthusamy, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, New Tokyo Hospital, Matsudo, Japan
Background and Purpose: Both Sirolimus-eluting BX velocity stent (Cypher™, Cordis) 
and Paclitaxel-eluting Express stent (TAXUS™, Boston Scientiﬁ c) have been reported 
to be effective in preventing neointimal formation and in-stent restenosis. The aim of this 
study is to compare the safety and efﬁ cacy of these 2 stents on the outcome of patients 
with chronic total occlusions (CTO). Methods: A prospective analysis of 308 patients with 
358 CTOs (128 Cypher™ and 180 TAXUS™) in ﬁ ve high volume Asian centers after 
successful recanalization of CTO (deﬁ ned as TIMI ﬂ ow trade 0 and the age of occlusion 
was more than 3 months. Cypher™: LAD 53.3%, LCX 28.0%, RCA 18.7%. TAXUS™: 
LAD 52.4%, LCX 21.6%, RCA 26.0%) was performed. The study endpoints were major 
adverse cardiac events (MACE) at 30 days and restenosis rate at 12 months. 
Results: The baseline clinical characteristics between 2 groups were similar. See table 
for clinical results. Conclusion: The use of both stents in patients with CTO was equally 
safe with low acute complication and low incidence of restenosis. 
Cypher™ TAXUS™ p
Number of patients 128 180 -
Procedural success (%) 100 100 NS
MACE at 30 days (%) 0 0 NS
Reference diameter (mm) 2.90 ± 0.88 2.82 ± 0.90 NS
MLD post (mm) 2.80 ± 0.80 2.73 ± 0.81 NS
MLD at 12 months (mm) 2.73 ± 0.80 2.63 ± 0.77 NS
Restenosis rate (%) 1.5 1.7 NS
TVR (%) 2.3 2.2 NS
MACE at 12 months (%) 2.3 2.2 NS
10:15 a.m.
801-7 Drug-Eluting Stents for the Treatment of Left Main 
Lesions: Are the Results Different in High-Risk Patients 
for Cardiac Surgery? A Report From a Multicenter 
Registry
Philippe Garot, Thierry Lefèvre, Yves Louvard, Marc Silvestri, Olivier Darremont, Pierre 
Dumas, Marie-Claude Morice, Institut Cardiovasculaire Paris Sud, Quincy, France
Background: Left main stenting using DES has emerged as an alternative to cardiac 
surgery. However, whether the results of left main stenting using DES are different in 
high-risk patients for cardiac surgery is unknown.
Objectives: We sought to compare the results of DES for the treatment of left main 
lesions in high- (Euroscore≥6) vs. low-risk (Euroscore<6) patients for cardiac surgery.
Methods and results: A total of 174 consecutive patients treated by DES for left main 
lesion entered the present registry. Among them, the vast majority had unprotected 
left main stenosis (145/174, 83%). The clinical and angiographic characteristics are 
described. 
High-risk Euroscore≥6
Ν=64
Low-risk
Euroscore<6
N= 110
P
Estimated mortality rate 12% 5% < 0.01
Males 70% 80% NS
Age, y-o 75±9 64±10 < 0.0001
Unstable angina 49% 27% < 0.005
Post-MI 6% < 1% 0.06
Ejection fraction 59±13 63±13 NS
Distal left main stenting 73% 77% NS
Provisional T stenting 77% 82% NS
DES in both branches 23% 22% NS
Final kissing angioplasty 95% 96% NS
PCI success, N (%) 100% 99% NS
Non Q-wave MI 2% 2% NS
Q-wave MI 0% 0% NS
In-hospital MACE 4% 3% NS
In-hospital death 3% 1% NS
Conclusion: The in-hospital outcome of DES implantation in left main lesions shows 
that this treatment may be safe and effective both in low and high-risk patients for cardiac 
surgery. Six-month clinical and angiographic follow-up will be presented at the meeting.
ORAL CONTRIBUTIONS
804  Basic Research in Restenosis
Monday, March 07, 2005, 9:15 a.m.-10:30 a.m.
Orange County Convention Center, Room 414C
9:15 a.m.
804-3 Dual-action Combination Chemotherapy Drug 
Eluting Stent Reduces Restenosis, Plaque Mass, And 
Inﬂ ammation In Injured Hypercholesterolemic Rabbit 
Iliac Arteries
Vu-Hung Quan, Philip Seifert, Adam R. Groothuis, Anna Maria Spognardi, Jianbing 
Chen, Karl Qin, Paul Ashton, Elazer R. Edelman, Campbell Rogers, Brigham and 
Women’s Hospital, Boston, MA, Massachusetts Institute of Technology, Cambridge, MA
Background: Arterial inﬂ ammation is a common factor between atherosclerosis, vulnerable 
plaque, and restenosis. Given that stenting has been proposed as a treatment to prevent 
plaque rupture, we asked whether a stent releasing a co-drug (CDS-Tc32) combining anti-
inﬂ ammatory triamcinolone acetonide (TA) and anti-proliferative 5-ﬂ uorouracil (5-FU) could 
cause plaque regression without provoking excessive tissue growth.
Methods: Rabbits on 4 wks of 2% cholesterol diet then 4 wks of 0.2% cholesterol diet 
underwent iliac artery balloon denudation at 2 wks and stenting at 4 wks.
Results: Balloon denudation combined with high cholesterol diet resulted in intense 
intimal and medial macrophage inﬁ ltration with progressive luminal narrowing from four 
to eight wks. Bare metal stenting implantation at 4 wks accelerated plaque inﬂ ammation 
but not plaque thickening at 8 wks. In contrast, CDS-Tc32 stent, rather than causing 
plaque progression, induced frank regression by 8 wks, eliminated intimal and medial 
macrophages, enhanced smooth muscle cell content, and reduced the vulnerability index 
[macrophage (RAM-11) / SMC (α -actin)] by 100-fold.
Conclusion: 1) Bare stenting accelerates plaque inﬂ ammation. 2) Stenting with a stent 
releasing a co-drug combining 5FU and TA causes regression and markedly reduces arterial 
and plaque inﬂ ammation. 3) DES may not only reduce restenosis but also pacify vulnerable 
plaque by reducing inﬂ ammatory inﬁ ltrate and enhancing ﬁ bro-muscular components.
Diet + Injury at 
4 wks
Diet + Injury 
at 4 wks
Bare metal 
stent
CDS-Tc32 
stent
Bare 
metal 
vs. CDS-
Tc32 p 
Value
Intimal thickness 
(mm) 0.10 ± 0.03 0.51 ± 0.10 0.52 ± 0.02 0.32 ± 0.06 0.015
Stenosis (%) 31.5 ± 7.2 72.6 ± 8.0 59.6 ± 1.4 40.2 ± 5.8 0.002
Intimal 
Vulnerability 
Index
0.05 ± 0.03 1.24 ± 0.34 1.48 ± 0.32 0.03 ± 0.02 0.002
Medial
Vulnerability 
Index
0.43 ± 0.21 0.56 ± 0.24 14.16 ± 7.17 0.05 ± 0.04 0.004
9:30 a.m.
804-4 Stenting the Venous System: The Venous Response to 
Injury.
Arturo Garcia-Touchard, Theodore Lamson, Joshua Makower, Renu Virmani, Robert S. 
Schwartz, Minneapolis Heart Institute Foundation, Minneapolis, MN
Background: Stent placement in the venous system is becoming increasingly common. 
However, the venous response to stent placement remains poorly delineated. We sought to 
understand the venous response to stent placement and compare it with the well-known arterial 
response by examining results in porcine coronary arteries and veins at 30 days after implant.
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Methods: Six stents were implanted in anterior interventricular vein and six stents in the 
(homologous) LAD artery. Vessels were perfusion ﬁ xed and processed using standard methods. 
Histopathologic observation of injury, inﬂ ammation score, and histomorphometry were recorded 
using standard methods, and then correlated between coronary veins and arteries.
Results: Mean injury scores were similar across veins and arteries. Veins developed 
more inﬂ ammation than arteries (inﬂ ammation score: 1.9±0.9 vs 0.2±0.2, P=0.01). In 
both, inﬂ ammation was proportional to vessel injury (r:0.86, P=0.03 for arteries and 
r:0.87, P=0.02 for veins). In veins however, inﬂ ammatory reactions also occurred around 
the stent struts without signiﬁ cant injury. Veins and arteries both developed neointimal 
hyperplasia in response to stent placement. Neointimal thickness (mm) was 0.31±0.21 in 
veins and 0.48±0.25 in arteries (P=NS). Injury and inﬂ ammatory scores were predictors 
of neointimal thickness in arteries (r:0.85, P=0.03 and r:0.84, p=0.04 respectively ) but 
not in veins. Veins developed substantial neointimal neovascularization. Neointimal vessel 
density (vessels/0.5mm2) was 21± 3.5 in veins and 4.7±3.5 in arteries (P=0.0003). These 
intimal neovessels originated from the venous vascular lumen.
Conclusion: Compared with arteries, stented coronary veins develop more inﬂ ammation, 
and the neointimal response is poorly dependent on injury and inﬂ ammation. Stented 
coronary veins develop more neovascularization with neointimal vessels originated from 
the vessel lumen. Differences in histopathologic, physiologic and neointima perfused 
by blood from the venous lumen (with approximately 4-5 fold less oxygen content than 
arteries) may explain the differential vascular response between arteries and veins.
9:45 a.m.
804-5 Vessel-to-Vessel Dependence of Neointimal Hyperplasia 
After Stent Placement in a Porcine Coronary Restenosis 
Model
Robert J. Russo, Patricia D. Silva, Mark Yeager, Scripps Clinic, La Jolla, CA, The Scripps 
Research Institute, La Jolla, CA
Background: In the study of neointimal hyperplasia after stent placement in a porcine 
coronary restenosis model, animals often undergo multivessel stent placement in an effort 
to minimize research costs. The assumption is often made that vessels from the same 
animal are independent for the purpose of data analysis. This study tested the hypothesis 
that two arteries from the same animal in a porcine model respond independently after 
coronary stent placement.
Methods: Each of 22 nonatherosclerotic Yorkshire swine underwent stent placement in 
the left anterior descending and left circumﬂ ex coronary arteries. Vessels were randomized 
to balloon-to-artery (B:A) ratios ranging from 1.0-to-1 to 1.4-to-1. Intravascular ultrasound 
(IVUS) was used to determine preprocedure vessel diameter. At 28 days, automatic 
pullback IVUS was performed to determine in-stent neointimal area and volume. The 
correlation between vessels within the same animal (rwithin) was calculated, taking into 
account the achieved B:A ratio.
Results: There was a signiﬁ cant positive within-animal correlation for each of 4 variables (See 
table). P values <.05 indicate lack of independence between vessels in the same animal.
Conclusion: Vessels within the same animal do not respond independently after stent 
placement when neointimal hyperplasia is evaluated in a porcine model. This lack of 
independence needs to be considered when estimating sample size for stent studies 
involving swine and when analyzing the data from such studies.
Variable rwithin P
In-stent neointimal volume .70 <.001
Volume stenosis .60 .003
In-stent maximum cross-sectional area stenosis .69 <.001
Neointimal distance beyond stent edges .47 .03
10:00 a.m.
804-6 Evidence of Phenotypic Plasticity of Peripheral Blood 
and Bone Marrow-Derived Mononuclear Cells In Vitro 
and In Vivo at Sites of Vascular Injury
Randolph Hutter, Francine Carrick, Valentin Fuster, Juan Jose Badimon, Bernhard 
Sauter, Mount Sinai School of Medicine, New York, NY
Introduction: New evidence points to participation of bone marrow (BM) derived cells in 
vascular repair. However, the speciﬁ c identity of BM derived cells inserting into the injured 
arterial wall remains unclear.
Methods and Results:  We describe phenotypic plasticity of highly puriﬁ ed (>99.9%) 
human CD14+/CD34-/CD133-/ﬂ k- mononuclear cells. Upon exposure to lineage-
speciﬁ c growth factors these cells acquired phenotypes in vitro mimicking either key 
characteristics of endothelial cells (EC) (CD-14 positive cells becoming newly positive 
for CD31, Flk-1, Flt-1, Tie2, and vWF) or of smooth muscle cells (SMC) (CD-14 positive 
cells becoming newly positive for calponin, desmin, SM-alpha-actin, vimentin). Cells in 
control medium did not express these markers. Consistent with the changes in antigen 
expression cells exhibited dramatic morphologic changes from ﬂ at,rounded macrophage-
like cells to cobblestone EC-like cells or to elongated SMC-like cells growing in a hill and 
valley pattern. In the respective standard EC or SMC differentiation medium cell numbers, 
lineage-speciﬁ c antigen expression, and phenotypic changes were enhanced by the 
addition of GM-CSF and IL4. No clonal selection/growth pattern was observed. Rather 
a gradual shift in antigen expression of the total cell population over time was shown by 
FACS-analysis at 3, 7 and 10 days.
We further tested if monocytes could mimick a vascular cell phenotype in vivo. To this 
end we showed the homing of monocytes to the neointima of injured arteries of mice 
whose monocytes constitutively express GFP (c-fms-GFP). Remarkably, we identiﬁ ed 
GFP+ monocytes that either co-stained for SM-alpha-actin or for the EC-marker vWF in 
the injured arterial wall.
Conclusions: Monocytes are present in mechanical or metabolic vascular injury. Our data 
give in vitro and in vivo evidence that these cells are capable of a remarkable phenotypic 
mimickry of features traditionally associated with “true” SMC or EC. This indicates the 
presence of an arterial inﬂ ammatory cell population that is responsive to key vascular 
growth factors and chameleon-like blends into the surrounding tissue architecture by 
partially adapting its phenotype.
ORAL CONTRIBUTIONS
807  Drug-Eluting Stents: 
Clinical Outcomes I
Monday, March 07, 2005, 11:00 a.m.-12:15 p.m.
Orange County Convention Center, Room 304A
11:00 a.m.
807-3 Durability of the Polymer-Based, Paclitaxel-Eluting 
TAXUS Stent in Key Patient Subsets: Two-Year Results 
From the TAXUS-IV Trial
Stephen Ellis, Gregg W. Stone, David A. Cox, James Hermiller, Charles D. 
O’Shaughnessey, James Tift Mann, Mark Turco, Ron Caputo, Patrick J. Bergin, Joel 
Greenberg, Albert Raizner, Jeffrey J. Popma, Mary E. Russell, Mary E. Russell, The 
Cleveland Clinic Foundation, Cleveland, OH
Background. Drug-eluting stents have been shown to improve intermediate-term event-
free survival after implantation in de novo native coronary arteries, even in high-risk 
groups of patients. Whether these results are sustained is unknown.
Methods. In the TAXUS-IV trial, 1,314 patients undergoing stent implantation of a single 
de novo coronary lesion (vessel diameter 2.5 to 3.75mm, lesion length 10 to 28mm) at 73 
U.S. sites were randomized to receive either the slow-release, polymer-based, paclitaxel-
eluting TAXUS stent or a visually identical bare metal EXPRESS stent. Clinical follow-up 
was scheduled at 1, 4 and 9 months, and yearly thereafter for 5 years.
Results. The TAXUS and control stent groups were well-matched for baseline clinical 
and angiographic characteristics, including the presence of diabetes, reference 
vessel diameter and lesion length. Overall 2 year MACE rates were 14.8% and 25.2% 
respectively, p <.0001. Two year target lesion revascularization (TLR) rates in selected 
patient subsets are shown in the table. Between 1 and 2 years, TLR occurred in 1.6% of 
TAXUS pts vs. 3.5% of control pts, p=.03. 
TLR at 2-years TAXUS Control RR P
All (n=1314) 5.6% 17.5% .32 <.0001
Diabetics (n=318) 8.0% 22.0% .36 .0008
Insulin requiring diabetics (n=105) 6.0% 17.0% .35 .12
Non-diabetics (n=996) 4.9% 16.0% .30 <.0001
Vessel diameter 2.5 mm (n=415) 6.1% 25.4% .24 <.0001
Vessel diameter >3.0mm (n=396) 5.6% 11.9% .47 .03
Single stent 32 mm (n=203) 7.5% 22.3% .34 .004
Multiple stents (n=84) 0.0% 30.8% - <.0001
Conclusions. Two years after implantation the beneﬁ ts of the paclitaxel-eluting TAXUS 
stent in enhancing freedom from TLR continues to increase, and profound reductions in 
clinical restenosis are present in key high-risk patient subgroups.
11:15 a.m.
807-4 Long-Term Clinical Beneﬁ t of CYPHER™ Sirolimus-
eluting Coronary Stent: Three Year Follow-up of the 
SIRIUS Study
Martin B. Leon, Jeffrey W. Moses, David R. Holmes, Jr., Dean J. Kereiakes, Donald 
Cutlip, Sidney A. Cohen, Richard E. Kuntz, Columbia University, New York City, NY
Background: The SIRIUS Study is a multi-center, double-blind, randomized study comparing 
the Sirolimus-eluting stent (CYPHER) to a bare metal Bx VELOCITY™ control (BX) in the 
treatment of patients with de novo native coronary artery lesions. Analysis of the primary 
endpoint of target vessel failure (TVF) at 9 months demonstrated the safety and effectiveness 
of the CYPHER stent. Long term follow-up is planned annually out to 5 years.
Methods: Complete clinical follow-up at 3 years for 1058 patients enrolled at 53 centers 
is being analyzed. Target lesion revascularization (TLR), TVF and major adverse cardiac 
events (MACE) are adjudicated by an independent clinical events committee.
Results: TLR, TVF and MACE rates reported at 1 and 2 years are summarized below. 
Highly signiﬁ cant differences in outcomes between CYPHER and BX are preserved 
through the 2-year time point. Results of the 3-year follow-up will be presented. 
1 Year 2 Year
CYPHER
(n=533)
BX
(n=525) p-value
CYPHER
(n=533)
BX
(n=525) p-value
TLR 4.9 % 20.0 % <0.0001 5.8 % 21.3 % <0.0001
TVF 9.8 % 24.8 % <0.0001 12.0 % 26.7 % <0.0001
MACE 8.3 % 22.3 % <0.0001 10.1 % 24.4 % <0.0001
Conclusions: The 3-year clinical follow-up from SIRIUS will be presented and will 
contribute importantly to an understanding of safety and durability of the Sirolimus-eluting 
stent in patients with native coronary lesions.
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11:30 a.m.
807-5 Comparison Of Outcomes For Sirolimus-eluting 
Stent In The E-cypher Registry With Those From The 
Randomised Controlled Trials (sirius)
Anthony H. Gershlick, Giuglio Guagliumi, Philippe Guyon, Chaim Lotan, Jocham 
Schofer, Ashok Seth, Eduardo Sousa, Philip Urban, William Wijns, University Hospitals 
of Leicester, Leiceaster, United Kingdom
Background: While four randomised, placebo controlled clinical trials have demonstrated 
the safety and efﬁ cacy of the sirolimus-eluting coronary stent, there have been no 
comparisons of how this stent performs in real world patients as opposed to in selected 
patients in the controlled environment of clinical trials. Of 15, 573 enrolled in the e-
CYPHER registry (April 2002 and July 2004), 6-month follow-up data are available for 
14,316 patients.
Methods: Comparison of inclusion criteria and 6 mo clinical outcomes between those 
patients enrolled into e-CYPHER and those in the Sirolimus-arm of the SIRIUS trial (86% 
and 95% follow-up resp). Patient demographics are generally similar, although there are 
also several striking differences between the two groups. Table 1: 
Characteristic e-CYPHER(n=14,316) SIRIUS(n=533)
Male 77.7% 72.6%
Diabetes 28.6% 24.6%
B2/C lesions 85% 59%
Recent MI 7% 0 (Excluded)
Unstable angina 33.7% 0 (Excl)
Prior MI 34% 28.2%
Prior Revascularization 28.6% 26.3%
Overlapping stents 9.30% 28.5%*
Lesions >30 mm 11.7% 0 (Excl)
Vessels <2.5 mm 8.3% 0 (Excl)
Left Main Lesions 2.2% 0 (Excl)
Ostial Lesions 8.2% 0 (Excl)
SVG lesions 2.0% 0 (Excl)
Chronic Total Occlusions 8.8% 0 (Excl)
In-stent restenosis 12.1% 0 (Excl)
Bifurcation Lesions 11.3% 0 (Excl)
Excess overlapping stents in the SIRIUS trial due to unavailability of longer stents.
Results: Although patients entered into e-CYPHER consist of a more ‘high risk’ patient 
population with more challenging lesions, the Major Adverse Cardiac Events = 3.2% for e-
CYPHER vs. 4.7% for SIRIUS. Target Lesion Revascularisation and Target Vessel Failure 
are also similar (1.3% vs. 1.9% and 3.4% vs. 2.6% respectively).
Conclusion: This retrospective comparison indicates that outcome from real world 
practice that includes SES in higher risk patients can equal results to those from 
randomized, controlled, clinical trials.
11:45 a.m.
807-6 TAXUS Express Stent Usage Patterns and Clinical 
Outcomes: Twelve-month Results from the European 
subset of the Global MILESTONE-II Registry
Kari Niemelä, Bernard Chevalier, Hans Stoerger, Luc Bilodeau, Fabio Brito, Mary 
Russell, Tampere University Hospital, Tampere, Finland
Background: Randomized controlled trials established safety and efﬁ cacy of paclitaxel-
eluting TAXUS Slow Release (SR) stents in standard de novo lesions. The MILESTONE 
II registry was initiated to evaluate usage patterns and long-term clinical outcomes of the 
TAXUS SR Express Stent in real world clinical practice. Here we evaluate stent usage 
patterns and outcomes in the European population of the MILESTONE II registry.
Methods: MILESTONE II is a web-based, multi-center, global observational patient 
registry. Patient and lesion characteristics, plus stent implant procedural data, were 
collected at baseline. Follow-up was performed at 6- and 12-months post procedure, 
during which data on death, myocardial infarction (MI), stent thrombosis and target vessel 
(TV) re-interventions were obtained.
Results: Of 3689 patients (total) enrolled at 164 global sites, 1907 patients with 2240 
treated lesions were enrolled at 118 sites in Europe. Mean patient age is 61.8 ±11.2 years, 
76% are male, and 31% have diabetes. Prior PCI was performed in 32% and prior CABG in 
10% of patients. Fifty-two percent of the treated lesions were complex (AHA/ACC class B2 
or C). Approximately 4% of patients presented with acute MI, 8% with in-stent restenosis, 
5% with chronic total occlusions, and 3% underwent left main stenting. A single TAXUS 
stent was used in 89% of patients, while 2 TAXUS stents were used in 10% and >3 TAXUS 
stents in 1% of patients. Multiple vessels were treated for approximately 22% of all patients, 
10% received multiple TAXUS stents and 12% received a combination of TAXUS and 
other treatments. At the 6 month follow-up, 36 (2.1%) patients had experienced an MI, 71 
(4.2%) had TV re-interventions, and there were 25 (1.5%) cardiac deaths. Stent thrombosis, 
deﬁ ned as angiographically conﬁ rmed presence of thrombus and/or cases of death without 
obvious cause occurring <30 days from procedure, was observed in 26 patients (1.5%). 
Conclusions: Outcomes with the TAXUS SR Express stent at 6 months post-intervention 
demonstrate an excellent safety proﬁ le in “real world” interventional cardiology practice in Europe. 
Twelve-month follow up results from the same patient subset will be available in March 2005.
Noon
807-7 Sirolimus-Eluting Stents in Diabetic Patients: Integrated 
Analysis of Six Multicenter Trials
Alexandre Abizaid, Andrea S. Abizaid, Roxana Mehran, George D. Dengas, Marie-
Claude Morice, Joachim Schofer, Erick Schaempart, Jeffrey W. Moses, Jeffrey Popma, 
Richard Kuntz, Martin B. Leon, Bernhard Meier, Robert M. Siegel, Issam Moussa, 
Jeffrey W. Moses, Martin B. Leon, Jose Eduardo Sousa, Instituto Dante Pazzanese de 
Cardiologia, Sao Paulo, Brazil, Columbia University Medical Center, New York, NY
Background: Diabetes Mellitus is an independent predictor of recurrence after stenting 
(including drug-eluting stents). In several randomized trials sirolimus-eluting stents (SES) 
improved clinical events in the overall population. However the relatively small number of 
diabetic pts included in each trial precluded deﬁ nitive conclusions in diabetic patients.
Methods: We performed an integrated analysis of diabetic pts included in six prospective 
trials (n=525) to evaluate late angiographic (6-8 mos) and clinical outcomes (9 mos) after 
SES compared to bare metal stents. Of these, 292 pts received SES (RAVEL: 19 pts; 
SIRIUS: 131 pts; E-SIRIUS: 33; C-SIRIUS: 12; DIRECT: 70; SVELTE: 27) compared to 
233 pts treated with bare metal stents (RAVEL: 25 pts; SIRIUS: 148 pts; E-SIRIUS: 48; 
C-SIRIUS: 12). All trials included 6-8 month systematic angiographic follow-up, 9-month 
clinical follow-up, as well as adjudication of clinical events by an independent committee.
Results: There were no signiﬁ cant differences in patient demographics or lesions between 
groups. Overall, the mean age was 63±11 years, 64.3% male, 25.6% insulin-treated, 74% 
hyperlipidemic, and 75% hypertensive.
Sirolimus-Eluting Stents v. Bare Metal Stents: 
Angiographic and Clinical Outcomes among Diabetics
SES (292) Control (233) p-value
In-stent late loss (mm) 0.26±0.44 1.19±0.48 <0.0001
In-lesion late loss (mm) 0.32±0.45 0.96±0.49 <0.0001
In-stent restenosis (%) 5.7% 50.6% <0.0001
In-lesion restenosis (%) 11.8% 52.5% <0.0001
Death 2.1% 0.9% 1.00
MI: Q-wave
MI: Non-Q-wave
0.7%
1.0%
0.4%
4.7%
1.00
0.0123
TVR (non-TLR) 4.5% 3.0% 0.4934
TLR 5.8% 22.3% <0.0001
MACE 8.9% 24.0% <0.0001
Conclusions: Sirolimus-eluting stent implantation in diabetic patients is safe and 
associated with a signiﬁ cant reduction of angiographic (88.7%) and clinical (74%) 
restenosis compared to bare metal stents. These results are consistent with long-term 
beneﬁ ts observed in the overall study population treated with SES.
POSTER SESSION
1093  Drug-Eluting Stents and Endovascular 
Irradiation
Monday, March 07, 2005, 1:30 p.m.-5:00 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 2:30 p.m.-3:30 p.m.
1093-15 Incidence And Clinical Implication Of Hypersensitivity 
Allergic Reactions Following Cypher Stent Deployment
Fadi F. Alameddine, Sidney Cohen, Peter Berger, Peter Block, Emory University 
Hospital, Atlanta, GA
BACKGROUND: Allergic reactions during coronary stent procedures are a common event 
and are often attributable to the multiple drugs used prior to, during, and following PCI. Allergic 
reactions to coronary stents, speciﬁ cally to nickel, chromate, or molybdenum ions released from 
316L stainless steel, are believed to be uncommon but are feared to produce local effects that 
might be expressed clinically as restenosis. In order to evaluate whether allergic reactions might 
result from components of the Cypher stent, the incidence and, where available, causality of 
these reactions were examined in patients enrolled in the US E-CYPHER registry.
METHODS: We explored both the incidence of allergic reactions reported and the 
occurrence of major adverse cardiovascular outcomes, including TLR, in patients 
receiving Cypher stents using the Cypher stent post marketing surveillance registry.
RESULTS: Out of 2067 patients implanted with Cypher stents between 8/03 and 12/03 
and enrolled in the e-Cypher registry, 39 patients (1.9%) had what were believed to be 
allergic reactions. The causality in 28 patients with hypersensitivity reaction was attributed 
to a known non-Cypher stent related cause. In the 11 patients with hypersensitivity from 
an unknown cause, 6 had rash, 4 had hives or itching, and 1 had asthma. No respiratory 
distress, anaphylactic reactions, or death was reported. The combined in and out-of-
hospital death, MI, emergent CABG and TLR in those 39 patients was 5.1% at 30 days 
and 7.7% at 180 days; the combined endpoints of all 2067 patients were 1.4% at 30 days 
and 3.2% at 180 days. 180-day TLR in the patients experiencing hypersensitivity was 
0.0% vs. 2.3% in all registry patients.
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CONCLUSIONS: Hypersensitivity reactions occurred infrequently in patients enrolled in 
the Cypher post marketing surveillance registry. Most reactions were attributed to known 
non-Cypher stent related causes. Patients experiencing an allergic reaction had higher 
MACE rates than overall registry rates but had a 0.0% TLR, suggesting an absence of 
local allergic reaction to the Cypher stent or its components.
1093-16 Full Metal Jacket For De Novo Coronary Artery Lesions 
In The Drug Eluting Stent Era
Jiro Aoki, Andrew T.L. Ong, Gaston A. Rodriguez Granillo, Carlos A,G, van Mieghem, Marco 
Valgimigli, Keiichi Tsuchida, Hector Garcia, Eugene P. McFaden, Ron T. van Domburg, Pim de 
Feyter, Patrick W. Serruys, Erasmus Medical Center, Rotterdam, The Netherlands
Background Long stented segments are associated with a high incidence of restenosis 
with bare metal stents. We investigated the clinical effects of very long drug eluting stent 
(DES) implantation (stented length more than and equal 64mm), the full metal jacket. 
Methods Since April 2002, our center has adopted a policy of universal DES usage for all 
percutaneous coronary interventions requiring stents, irrespective of clinical presentation 
or lesion morphology. 122 consecutive patients with de novo coronary lesions who 
were treated with more than and equal 64mm of DES without any gaps in the same 
vessel. Results Among 122 consecutive patients, 81 patients were treated with sirolimus 
eluting stents (SES) and 41 patients with paclitaxel eluting stents (PES). Overall, the 
prevalence of diabetes was 19%. The incidence of chronic total occlusion was 40%. The 
mean number of stents per lesion was 3.3+/-1.1, and the average stented length was 
83.4+/-19.8 (64 to 168 mm). Glycoprotein IIb/IIIa inhibitor was used in 37% of patients. 
Periprocedural myocardial infarction occurred in 8 patients (6.6%) and subacute stent 
thrombosis occurred in 1 patient (0.8%). Table 1 shows the one-year clinical outcomes.
Conclusion The overall incidence of major adverse cardiac events was 20.5% at one 
year, not statistically different between the two stent groups with a low (7.6%) target 
revascularization rate. The use of DES for the treatment of long diffuse lesions is a 
feasible percutaneous alternative.
One year clinical outcomes
ALL (N=122) SES (N=81) PES (N=41) P value
Death,% 4.1 2.5 7.3 0.20
MI, % (CK >2 times) 10.8 11.2 9.9 0.81
TVR, % 7.6 7.5 7.6 0.97
MACE, % 20.5 21.0 19.5 0.86
1093-17 Angiomax Versus Heparin as an Antithrombotic Agent 
in Patients Treated With Sirolimus-Eluting Stents
Seung-Woon Rha, Pramod K. Kuchulakanti, William W. Chu, Zuyue Wang, Venkatesh 
Raman, Edouard Cheneau, Marcus McKenzie, Rebecca Torguson, Janice Lavoie, 
Rajbabu Pakala, William Suddath, Kenneth Kent, Lowell Satler, Augusto Pichard, Ron 
Waksman, Washington Hospital Center, Washington, DC
Background: Bivalirudin (Angiomax®) is increasingly used as a substitute for heparin in 
a variety of percutaneous coronary interventions (PCIs). This study aimed to evaluate the 
efﬁ cacy and safety of bivalirudin, as compared to heparin, as an antithrombotic regimen 
in patients treated with sirolimus-eluting stents (SES; CypherTM).
Methods: A total of 1022 pts with 1754 lesions underwent standard PCI with SES for various 
coronary artery lesions. Patients were treated with either bivalirudin (0.75 mg/kg bolus and 
1.75 mg/kg/hr infusion, n = 586) or heparin alone (40 U/kg bolus, n = 436) during PCI. The 
procedural, in-hospital, and 30-day clinical outcomes in both groups were compared.
Results: Baseline clinical and angiographic parameters were similar between both 
groups. Major bleeding and vascular complications were similar between both groups, 
although the bivalirudin group had a trend of lower pneudoaneurysm formation (0.3% 
vs. 1.4%, P=0.06). Periprocedural ischemic events (non-Q-wave MI with major CK-MB 
elevation) were signiﬁ cantly lower in the bivalirudin group. (Table).
Conclusions: Bivalirudin is clinically safe and feasible with lower periprocedural ischemic 
events and compatible complications compared with heparin when used in PCI with SES 
implantation.
Clinical Outcomes
Variables (%) Bivalirudin (n=586) Heparin (n=436) p Value
In-hospital CK-MB elevation
CK-MB >2X normal 15.0 26.4 <0.001
CK-MB >3X normal 10.7 20.0 <0.001
CK-MB >4X normal 7.9 16.6 <0.001
CK-MB >5X normal 6.3 13.9 <0.001
In-hospital complications
Any hematoma 5.3 6.1 0.604
Transfusion 3.8 5.4 0.290
Pseudoaneurysm 0.3 1.4 0.063
Vascular complications 2.2 3.2 0.328
Major bleeding 2.9 2.3 0.551
30-day outcomes
Death 1.5 0.8 0.525
Q-wave MI 0.0 0.8 0.053
Non-Q-wave MI 9.8 11.9 0.340
TVR-MACE 1.5 1.4 0.843
6-month outcomes
Death 2.8 2.1 0.554
Q-wave MI 0.8 2.1 0.122
Non-Q-wave MI 10.9 12.9 0.400
TVR-MACE 6.5 7.1 0.737
1093-18 Long-term Chronic Endothelial Dysfunction of Pig 
Coronary Arteries After Endovascular Irradiation
Jinsheng Li, Jeffrey Marshall, Jianhua Cui, Alka Redkar, Spencer B. King III, Nicolas A.F. 
Chronos, Keith A. Robinson, American Cardiovascular Research Institute, Norcross, GA
Background: Endocoronary irradiation (EI) and drug eluting stents (DESs) are now being 
widely applied in percutaneous coronary intervention. DESs and EI are associated with 
stent malapposition, echolucent vessel wall defects, uncovered stent struts, and vessel 
wall thinning; which may contribute to late thrombosis and other delayed complications 
related to endothelial healing and function. To elucidate long-term effects of EI on the 
endothelium we assessed pig coronary arteries 6 mo after irradiation (RAD) with or without 
angioplasty. Methods: Vasomotor function of pig coronary arteries was investigated after 
RAD (n=12; 20Gy β) or sham (S; n=8; inactive wire) and in naïve controls (C; n=8) in 
an organ chamber apparatus. Angioplasty was performed with a balloon/artery ratio of 
1.3:1, in two coronary arteries. One received RAD (P1; n=8) and the other sham (P2; 
n=8). Platelet recruitment was determined at 6 mo using autologous 111Indium platelet 
labeling. Endothelial macromolecular barrier function was assessed using the Evans blue 
dye technique and planimetric macroscopy. 
Results: Relaxation to a maximal dose of calcium ionophore A23187 (3µM) was 
decreased in RAD (29.8±9.4% vs. 86.0±7.0% in S and 90.2±11.0% in C; P<0.01). 
Relaxation to a maximal dose of substance P (0.1nM) was also less for RAD (29.7±5.4% 
vs. 65.0±3.9% in S and 67.4±6.8% in C; P<0.01). Contractile responses to both KCl and 
PGF2� with L-NAME were signiﬁ cantly decreased. Endothelium-independent relaxation to 
sodium nitroprusside was potentiated. Platelet recruitment in P1 was similar to P2 (429±70 
x103 vs. 347±67 x103 pl/vessel, P=NS). Coronary artery surface area with positive Evans 
blue staining in P1 was signiﬁ cantly higher than P2 (42.2±7.7% vs. 9.1±5.7%, P<0.01). 
Conclusion: These results demonstrate that EI induces very long-term delay of 
endothelial functional recovery, and suggests that adverse pathophysiologic effects 
might persist with clinical brachytherapy as well as DESs, which are also known to delay 
endothelial healing. These phenomena should be considered in the clinic when treating 
coronary disease patients with brachytherapy and DESs.
1093-19 Long-Term Outcomes of Diabetic Patients Undergoing 
Percutaneous Coronary Intervention in the Era of 
Drug-Eluting Stents and Contemporary Adjuvant 
Pharmacotherapy
Rachid A. Elkoustaf, Justin B. Lundbye, Haris Athar, Wajeeh Mohammed, Amir Ausef, 
Jeffrey F. Mather, Francis J. Kiernan, Jeffrey A. Hirst, Raymond G. McKay, William E. 
Boden, Hartford Hospital, Hartford, CT, University of Connecticut, Farmington, CT
Background: Although diabetes is an independent predictor of major adverse cardiac 
events (MACE) following percutaneous coronary intervention (PCI), clinical outcomes of 
diabetics in the setting of contemporary practice have not been fully described.
Methods: We assessed in-hospital and 9-month MACE in 2,424 consecutive patients 
undergoing elective and emergency PCI, including 660 patients with diabetes (185: 
insulin dependent; 475: diet/oral agents). Treatment strategies included use of Sirolimus 
DES in 55%, GP IIb/IIIa inhibitors in 72%, HMG-CoA reductase inhibitors in 81% and ACE 
inhibitors in 54% of patients.
Results: Compared to non-diabetics, diabetics were older, more likely to be female, and 
had a higher prevalence of hypertension, dyslipidemia, smoking, renal disease, chronic 
lung disease, prior MI and CABG. Diabetics with STEMI had worse in-hospital and 9-month 
mortality compared to non-diabetics, but there were no differences in clinical outcomes in 
patients with stable angina, unstable angina, non-STEMI, and cardiogenic shock.
Conclusions: Diabetics continue to represent an older subgroup of PCI patients with more 
females, cardiac risk factors and co-morbidities. With contemporary practice, diabetic and 
non-diabetic in-hospital and 9-month MACE are not signiﬁ cantly different. Compared to 
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non-diabetics, however, diabetics have an increased incidence of in-hospital renal failure 
and diabetic STEMI patients have a higher incidence of in-hospital and 9-month mortality.
In-Hospital No-Diabetes Diabetes P-Value
Death 1.7% 2.0% NS
Myocardial Infarction 3.1% 2.6% NS
Emergent CABG 0.3% 0.2% NS
Stroke 0.3% 0.3% NS
Renal Failure 0.5% 1.4% <0.02
9-Month
Death 2.9% 4.0% NS
Myocardial Infarction 2.0% 2.1% NS
Repeat Target Vessel PCI 8.3% 9.6% NS
1093-20 One Hundred Consecutive Unprotected Left Main 
Interventions: Latvian Centre Experience
Andrejs Erglis, Indulis Kumsars, Inga Narbute, Sanda Jegere, Iveta Dinne, Ilja Zakke, 
Uldis Strazdins, Uldis Kalnins, P.Stradins Clinical University Hospital, Riga, Latvia
Background: The role of PCI for left main (LM) coronary artery treatment is not completely 
clear yet. Lesion debulking prior to stenting reduces plaque burden as assessed by IVUS 
and may reduce the incidence of restenosis.
Purpose:
• To achieve maximum minimal square area (MSA) with reduced barotrauma using cutting 
balloons (CB) prior to stenting
• To improve intrahospital outcome
• To evaluate 6 months clinical, angiographic and IVUS outcome
Methods: Our on-going prospective study enrolls 100 patients with elective PCI 
on unprotected LM. After CB intervention 62 regular and 38 drug-eluting stents were 
deployed. Device sizes were selected by IVUS measurements following the “media to 
media” treatment principle.
Results: A total of 100 patients (mean age of 60.6± 10.7 ) were enroled. The procedural 
success was 100%. Mean hospitalisation - 4.3 days. During hospitalisation 1 patient (%) 
had Q-MI, 4 patients (%) had non- Q MI and one (%) re-PCI was performed. The in-
hospital mortality rate was 0%. At present 51 patients have 6-month follow up. During 
follow-up we observed 3 TLR (9.7%) - 2 PCI (6.5%) and 1 CABG (3.2%), 1 patient (3.2%) 
had Q-MI and 2 patients died one had MI other cancer.
Preliminary IVUS data (n=35) all bare metal stents. 
MLD (mm) MSA (mm2) Lumen volume (mm3)
Pre-intervention 1.70±0.23 3.00±0.73 104.6±15.0
Post intervention 3.18±0.20 8.96±1.49 203.6±22.8
At 6 months f-up (n=18) 2.89±0.23 9.01±0.78 182.3±26.9
Late loss 0.25±0.13 1.01±0.42 14.6±8.3
Loss index 0.18±0.08 0.17±0.07 0.16±0.10
Neointimal volume at follow-up was 16.8±6.7 mm3
Conclusions: IVUS guided CB intervention on LM followed by bare-metal stent or DES 
is safe with excellent acute gain and low 6 months MACE rate. Preliminary IVUS ﬁ ndings 
show very low neointimal growth at 6 months even in bare-metal stent group.
1093-21 5-Year Clinical Effect of Coronary Stenting and 
Coronary Artery Bypass Grafting in Renal Insufﬁ cient 
Patients With Multivessel Coronary Artery Disease -
Insights from ARTS Trial
Jiro Aoki, Andrew T.L. Ong, Lex A. van Herwerden, Eduardo Sousa, Adib Janete, 
Johannes J.R.M. Bonnier, Jacques P.M.A. Schonberger, Nigel Buller, Robert Bonser, 
Clemens Disco, Felix Unger, Patrick W. Serruys, Erasmus MC, Rotterdam, The 
Netherlands
Background Cardiovascular disease is the major cause of mortality in patients with renal 
dysfunction. However, there are no prospective randomized studies to compare coronary 
stent implantation and bypass surgery for multivessel coronary disease in patients with 
renal insufﬁ ciency.
Methods and results In the ARTS trial, 142 moderate renal insufﬁ cient patients (Ccr <60 
ml/min) with multivessel coronary disease were randomly assigned to stent implantation 
(n=69) or CABG (n=73), when there was consensus between the cardiac surgeon and 
interventional cardiologist as to an equivalent degree of revascularization. At ﬁ ve years, 
there was no signiﬁ cant difference between the two groups in terms of mortality (14.5% 
in the stent group vs. 12.3% in the CABG group (RR, 1.18; [95% CI, 0.51-2.72], p=0.81), 
or combined endpoint of death, cerebrovascular accident (CVA), or myocardial infarction 
(MI) (30.4% in the stent group vs. 23.3% in the CABG group (RR, 1.31; [95% CI, 0.76-
2.26], p=0.35). Among patients who survived without CVA or MI, 18.8% in the stent group 
underwent a second revascularization procedure, compared with 8.2% in the surgery group 
(RR, 2.29; [95% CI, 0.86-6.13], p=0.08). The event-free survival at ﬁ ve years was 50.7% in 
the stent group and 68.5% in the surgery group (RR, 1.56; [95% CI, 1.03-2.37], p=0.04).
Conclusions At ﬁ ve years, there were no differences in the mortality or combined incidence 
of death, CVA and myocardial infarction in either group. The presence of renal dysfunction 
should not in itself, inﬂ uence the choice of modality of revascularization treatment.
1093-22 Percutaneous Coronary Intervention Using 6 or 7 
French Guiding Catheters: Results of a Prospective 
Randomized Trial
Hisham Hallani, Adelina Wong, John Crozier, Jacqui Robinson, Andrew Hopkins, 
Dominic Leung, Sidney Lo, Craig Juergens, Liverpool Hospital, Liverpool, Australia
Background: The use of 7 French (Fr) guiding catheters may facilitate Percutaneous 
Coronary Intervention (PCI), but may be associated with increased vascular complications 
when compared to 6 Fr catheters. We prospectively compared procedural factors and 
vascular complications of 6Fr vs 7Fr systems.
Methods: Patients undergoing PCI considered suitable for either a 6 or 7Fr system were 
included. During the study, 414 patients (mean age 61 ± 11 years, 27% females) were 
randomly assigned to 6Fr or 7Fr sheath groups. All vascular sheaths were removed with 
assisted manual compression with the aid of a Femo-Stop device. Vascular ultrasounds 
were performed prior to hospital discharge and interpreted by a vascular surgeon blinded 
to treatment assignment. Procedural factors including contrast dose, screening time and 
operators’ opinion as to ease of use were noted.
Results: The two groups were well matched with regard to demographics and the use of 
glycoprotein IIb/IIIa inhibitors and heparin post sheath removal. Follow-up ultrasounds were 
obtained in 402 patients (204 6Fr and 198 7Fr). The rate of abnormal ultrasound (detection 
of arterial-venous ﬁ stula, pseudo-aneurysm, haematoma, thrombosis) was 7% in each 
group. The use of contrast volume was higher in the 7Fr group (157±58 ml vs 144±58 ml; 
P=0.029). There was no difference in screening time, radiation dose or procedure duration. 
There was a trend towards better satisfaction with the 7Fr guide (P= 0.08).
Conclusion: Sheath size did not inﬂ uence the incidence of vascular complications 
however less contrast was used in the 6Fr group and operators tended to prefer a 7Fr 
system.
1093-23 Postprandial Hypertriglyceridemia Is Powerful Predictor 
For Restenosis After Coronary Stent Implantation In 
Diabetics And Nondiabetics
Sugao Ishiwata, Minoru Yorozuya, Yoshinao Yazaki, Takanobu Yamamoto, Yo Fujimoto, 
Yoshiro Kamoi, Tetuya Seko, Haruo Mitani, Akiko Maehara, Shinichi Momomura, Tetu 
Yamaguchi, Toranomon Hospital, Tokyo, Japan
Background: The inﬂ uence of numerous polymorphisms on restenosis after coronary 
stenting is discussed controversially. Objectives: To evaluate the potential metabolic 
markers of restenosis after angioplasty and to identify whether some are predictive of 
restenosis. 
Methods: 84 consecutive patients underwent successful coronary stent implantation 
ingest test meal next morning after stenting. The test meal contains 75g ﬂ our starch, 
24g fat and 5.9g protein in a total 560 kcal, by which glucose intolerance, diabetes, 
postprandial dyslipidemia and insulin resistance would be detected. Measurements of 
several parameters were performed including triglyceride (TG), RLP (remnant lipoprotein), 
cholesterol, insulin and glucose at baseline, 1 hour, 2 hours and 6 hours following meal 
test. The primary end point was angiographic restenosis rate by 6months.
Results: 23 patients were diabetics and 14were impaired glucose tolerance (IGT). 
Coronary in-stent restenosis was documented in 36% of all patients; 55% in diabetics, 
41% in IGT and 26% in normal subjects (p<.05). 52subjects without restenosis had 
an early TG peak and 33 subjects with restenosis had a late peak. Thus, postprandial 
hypertriglyceridemia exhibited a bimodal response and a prolonged elevation and 
delayed clearance of TG was observed in patients with restenosis. In one-way analysis of 
variance (ANOVA), serum TG levels at 2 hours (164 + 56 vs. 210 + 97mg/dl; p<.05) and at 
6 hours (140+ 62 vs. 215 + 123mg/dl; p<.01) were signiﬁ cantly higher in restenosis group 
regardless of the presence of diabetes (p=ns).
Conclusions: Postprandial hypertriglyceridemia and delayed triglyceride clearance was 
an independent predictor for restenosis after coronary stent implantation.
1093-24 Stroke After Primary Angioplasty in Acute Myocardial 
Infarction: Analysis From the CADILLAC Trial
Eugenia Nikolsky, Cindy L. Grines, David A. Cox, Thomas Stuckey, Eulogio Garcia, 
Giulio Guagliumi, James E. Tcheng, Roxana Mehran, Manuela Negoita, Roopan Sikand, 
Alexandra J. Lansky, Gregg W. Stone, Cardiovascular Research Foundation, New York, 
NY, Columbia University Medical Center, New York, NY
Background. Compared to thrombolytic therapy, primary angioplasty reduces the 
occurrence of stroke after acute myocardial infarction (AMI). However, the correlates and 
implications of stroke after primary percutaneous coronary intervention (PCI) have not 
been examined.
Methods and Results. In the CADILLAC trial, 34 of 2,082 randomized patients (1.6%) 
developed a stroke during the 1-year follow-up period after primary PCI for AMI. 
Approximately one third of all strokes (29.4%) developed during the index hospitalization 
and 52.9% occurred within 30-days. Stroke was ischemic in 22 pts (64.7%), hemorrhagic 
in 8 pts (23.5%), and unidentiﬁ ed in 4 pts (11.8%). More than one third of all strokes 
(36%) were disabling (resulting in severe limitation of daily activities or inability to live 
independently). By multivariate analysis, 1-year stroke was predicted by low body mass 
index (<25.0 kg/m2) (HR 4.68, P=0.001), low ejection fraction (HR 0.95, P=0.008), 
randomization to stent (HR=3.50, p=0.02) and prior stroke (HR=4.89, p=0.03). 
Development of stroke was associated with strikingly increased 1-year mortality, recurrent 
ischemia and any major adverse cardiac event (Table). Mortality at 1-year was high for 
both hemorrhagic and ischemic stroke pts (37.5% vs. 31.8%, respectively; p=1.00).
Conclusions. Though uncommon, stroke after primary PCI for AMI is frequently disabling 
and associated with high rates of 1-year recurrent ischemia and mortality. 
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One-year events, %
Patients
P-value
With stroke
N=34
Without stroke
N=2048
Death 29.4% 3.9% <0.0001
Reinfarction 6.7% 2.3% 0.11
Recurrent ischemia 35.3% 22.4% 0.04
Any MACE 55.9% 17.1% <0.0001
1093-25 Value of the American College of Cardiology / American 
Heart Association Angiographic Classiﬁ cation of 
Coronary Lesion Morphology in Patients With In-Stent 
Restenosis
Fernando Alfonso, Angel Cequier, Juan Angel, Jose M Auge, Javier Zueco, Armando 
Bethencourt, Ramon Montilla, Jose R Lopez-Minguez, Cesar Moris, Manuel Gomez-
Recio, Maria J Perez-Vizcayno, Cristina Fernandez, Carlos Macaya, Hospital Clinico 
San Carlos, Madrid, Spain
Background: Treatment of patients with in-stent restenosis (ISR) remains a challenge. We 
sought to determine the implications of the American College of Cardiology / American Heart 
Association (ACC/AHA) angiographic classiﬁ cation of lesion morphology in patients with ISR.
Methods: 450 patients included in the Restenosis Intra-stent: Balloon angioplasty 
vs elective Stenting (RIBS) randomized study, were analyzed. A centralized core lab 
assessed 3 ISR classiﬁ cations: ACC/AHA, Mehran (M) and diffuse/focal (D/F). Logistic 
regression models were constructed for prespeciﬁ ed outcome measures including 1) 
unsatisfactory acute results (major complications, cross-over requirement, residual 
dissection >C or residual stenosis >35% by quantitative angiography and 2) recurrent 
restenosis rate.
Results: 5% of lesions were type A, 17% B1, 61% B2 and 17% type C. Complex (B2/
C) lesions obtained more frequently unsatisfactory acute results (20% vs 8%, p=0.007), 
smaller minimal lumen diameter after the procedure (2.45+0.5 vs 2.73+0.5 mm, p=0.001) 
and at follow-up (1.48+0.8 vs 1.94+0.8 mm, p=0.0001) and had a higher restenosis rate (43 
vs 24%, p=0.001) as compared with simple (A/B1) lesions. On logistic regression analysis 
all 3 classiﬁ cation schemes were useful to predict unsatisfactory initial results (AUC: 0.63, 
0.61, 0.59) and recurrent restenosis (AUC: 0.60, 0.64, 0.61). The predictive ability of these 
classiﬁ cation systems persisted despite adjustment for potential confounders. Although 
the ACC/AHA classiﬁ cation was a better predictor of acute results M was superior to 
predict recurrent restenosis.
Conclusions: The ACC/AHA classiﬁ cation provides a simple and useful tool to determine 
both the acute procedural result and the long-term angiographic outcome of patients with 
ISR. This classiﬁ cation scheme may be used for early patient triage.
1093-26 Pressure Wire Fractional Flow Reserve Assessment 
With a Decisional Value at 0.80: One Year Clinical 
Outcome
Francois Schiele, Marie-France Seronde, Pierre Legalery, Hu Wei, Nicolas Meneveau, 
Jean-Pierre L. Bassand, University Hospital Jean Minjoz, Besancon, France
Rationale and Aim: Pressure wire assessment of Fractional Flow Reserve (FFR) is 
helpful for decision-making in case of angiographic intermediate lesions. A cut-off value of 
0.75 for FFR is usually used, but values between 0.75 and 0.80 are considered as a “grey 
zone”. Outcome after decision based on FFR ±0.80 is poorly documented.
Methods: Single centre registry over three years. All patients with angiographic 
“intermediate” lesions (40 to 60% diameter stenosis by QCA) were submitted to FFR 
assessment . Revascularization was advocated when FFR was <0.80. Death, myocardial 
infarction, and target vessel revascularisation were recorded over 1 year.
Results: Out of 6415 patients submitted to coronary angiography and 2672 to angioplasty 
during the study period, FFR was performed successfully in 405 patients (6.3% of 
angiographies), using diagnostic catheters in 80%. Based on FFR, revascularisation was 
recommended in 33% (136 patients, mean FFR value 0.75±0.08) and medical treatment in 
67% (271 patients, mean FFR value 0.88±0.08).There was no difference in angiographic 
data between groups. Comparison of clinical outcome is displayed in the table. All but 4 
patients had clinical follow up (median 436 days). One year clinical outcome was comparable 
in both groups. FFR site-related clinical events occurred in 7.3% in group1 versus 8.1% 
in group 2.Conclusion: Decision-making based on FFR with a cut off value of 0.80 leads 
to revascularization in 33% of patients with comparable clinical outcome in both groups.
Group 1 (n=136) Group 2 (n=271) P value
FFR 0.75±0.08 0.88±0.08 0.001
%DS 57±12 53±16 0.12
MLD 0.97±0.4 1.12±0.5 0.08
Death 1 (1%) 5 (1.8%) 0.21
MI (Q or nonQ) 1 (1%) 4 (1.5%) 0.30
TVR 8 (5.9%) 13 (4.8%) 0.77
FFR site-related events 10 (7.3%) 22 (8.1%) 0.54
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1094-27 Unprotected Left Main Coronary Artery 
Revascularization With Sirolimus-Eluting Stents: Three 
and Nine Month Follow-up
Matthew J. Price, Neil Sawhney, Ecatarina Cristea, Yoshihiro Tsuchyia, Ricardo Costa, 
Richard A. Schatz, Alexandra Lansky, Paul S. Teirstein, Scripps Clinic, La Jolla, CA, CA
Background: The safety and efﬁ cacy of sirolimus-eluting stents (SES) to treat unprotected 
left main coronary artery (ULMN) stenosis is unknown.
Methods: All patients at Scripps Clinic who underwent implantation of SES within a 
ULMN stenosis were identiﬁ ed. Follow-up (FU) angiography was mandated at 3 and 9 
months. Quantitative coronary angiography (QCA) was performed by an independent 
core laboratory. Target lesion revascularization (TLR) was deﬁ ned as repeat intervention 
anywhere within the LMN or within 10 mm distal to the branch vessel ostia.
Results: To date, 51 pts have undergone SES implantation within the ULMN. Mean 
patient (pt) age was 69+13 years, diabetes was present in 13 patients (25%), and LVEF 
< 40% in 12 patients (24%). The distal LMN bifurcation was stented in 46 pts (90%), 
using the technique of double barrel (“V”) in 35, “crush” in 8, or a single stent spanning 
the circumﬂ ex (CIRC) or left anterior descending in 3 pts. The target lesion was due to 
LMN dissection in 2 (4%) and in-stent restenosis in 5 pts(10%). Angiographic FU was 
obtained at 3 months in 43 of the 45 (96%) eligible patients (mean FU 103+31 days). TLR 
occurred in 11 (26%) pts, of which 8 were asymptomatic. Restenosis was observed at the 
CIRC ostium only in 8 of the 11 pts (73%). To date, additional 9 month FU angiography 
has been obtained in 17 pts (mean FU 266+46 days). Two additional pts had TLR by 
9 months resulting in a cumulative TLR rate to date of 13 pts (30%). Of 10 patients 
who underwent repeat PCI for TLR at 3 months, 5 (50%) have required repeat TLR for 
symptomatic ischemia at a mean of 107+38 days after initial PCI for restenosis. There 
were 2 in-hospital acute stent thromoboses, one non-cardiac death at 4 months, and one 
cardiac death at 5 months. Complete FU and QCA will be presented.
Conclusions: Sirolimus stent implantation for unprotected left main lesions is feasible, 
but is limited by restenosis (30%) that may be silent and occurs most often at the left 
circumﬂ ex ostium. Treatment of recurrent left main restenosis with repeat PCI may be 
limited by a high rate of re-restenosis (50%). SES for unprotected left main stenosis 
should only be performed on selected patients with mandated angiographic follow-up, 
preferably at 3 and 9 months.
1094-28 Preliminary Results of the Left Main TAXUS Pilot Study
Thierry Lefèvre, Marc Silvestri, Olivier Darremont, Sergio Hernandez, Philippe Garot, 
Yves Louvard, Pierre Dumas, Jean-Louis Leymarie, Marie-Claude Morice, on behalf 
of the Left Main TAXUS Pilot Study Investigators, Institut Cardiovasculaire Paris Sud, 
Massy, France
Background: CABG is the gold standard treatment of unprotected left main (LM) stenosis. 
Percutaneous coronary intervention (PCI) using bare metal stents has been proposed as 
an alternative treatment in some centers with excellent in-hospital results. However, these 
results were partially impaired by the occurrence of restenosis leading to a relatively high 
rate of re intervention at follow-up compared to CABG.
Methods: A pilot study using the TAXUS stent was set-up in 3 French centers with a 
wide previous experience in LM stenting. PCI was proposed as an alternative to CABG in 
patients with de novo unprotected LM stenosis. Acute MI and cardiogenic shock were the 
only criteria for exclusion. prospective 1, 6 and 12 months clinical follow-up was set-up 
with a recommended angiogram at 6 months.
Results : Between March 2003 and August 2004, 130 Pts with unprotected LM were 
included. They were 68+11 years old, 75% male, unstable angina 27%, diabetes 30%. The 
ejection fraction was 62+13% and Euroscore 4.6+3.1 (estimated CABG mortality rate of 
7.6+17.9%). The number of other treated lesions was 1.1+0.9. Reference diameter of the 
LM was 3.76+0.49 mm. The lesion was distal in 76% of cases. All Pts were successfully 
stented on the LM with 1.1+0.3 stents (stent length 16.8+6.0 mm). In patients with distal 
LM, a second stent was used in 31% of cases (length 11+3mm) and a ﬁ nal kissing balloon 
inﬂ ation was performed in 98% of cases. The total MACCE rate at hospital discharge 
(4.5+3.1 days) was 3.1%. One Pt had acute stent thrombosis and died (0.8%) and 3 Pts 
had a non q-wave-MI (2.3%). There were no events between hospital discharge and 1 
month follow-up (n=112). A total of 46 Pts have reached the 6 month follow-up and 32 had 
a coronary angiogram. Two Pts died from non cardiac causes (total death rate 6.7%, total 
cardiac death 2.2%) and 1 Pt had restenosis of the circumﬂ ex artery ostium (3.1%).
Conclusion: Left main PCI using the TAXUS stent provided excellent angiographic 
results and in-hospital outcomes. Preliminary follow-up is promising. The complete 6-
month follow-up of the entire cohort will be presented at the meeting.
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1094-29 Early and Mid-term Results of Drug-Eluting Stents 
Implantation in Unprotected Left Main
Alaide Chieffo, Goran Stankovic, Erminio Bonizzoni, Eleftheria Tsagalou, Ioannis 
Iakovou, Gloria Melzi, Flavio Airoldi, Matteo Montorfano, Iassen Michev, Massimo 
Sangiorgi, Antonio Colombo, San Raffaele Hospital, Milan, Italy, EMO Centro Cuore 
Columbus, Milan, Italy
The safety and efﬁ cacy of percutaneous coronary intervention in unprotected left main 
(ULM) coronary arteries is still a matter of debate.Methods All consecutive patients (pts) 
who had sirolimus-eluting stent (Cypher, Cordis, Johnson and Johnson Company, Warren, 
NJ) or paclitaxel-eluting stent (Taxus, Boston Scientiﬁ c, Natick, MA) electively implanted 
in de novo lesions on unprotected left main (ULM) were analyzed.
Patients treated with DES were compared with the historical group of consecutive patients 
treated with BMS.Results 85 pts were treated with DES, 64 with BMS implantation. 
Patients treated with DES had lower ejection fractions (51.1±11 vs. 57.4±13, p=0.002), 
were more often diabetics (21.2% vs.10.9%, p=0.12) with more frequent distal left 
main involvement (81.2% vs. 57.8%, p=0.003). Furthermore, in the DES group, smaller 
vessels (respectively 3.33±0.6mm vs.3.7±0.7, p=0.0001) with more lesions (2.94±1.6 vs. 
2.25±1.3, p=0.004) and vessels (2.03±0.69 vs. 1.8±0.72, p=0.05) were treated with longer 
stents (24.3±12 vs. 15.8±8.6; p=0.0001). Despite the higher risk patients and lesions’ 
proﬁ le in the DES group, the incidence of MACE, at 6-month clinical follow-up, was lower 
in the DES compared to BMS group (respectively 20.0% vs. 35.9%, p=0.039).TLR was 
performed in 12 (14.1%) patients in DES group vs. 15 (24.2%) patients in BMS (p=0.13). 
TVR occurred in 16 (18.8%) patients in DES vs. 19 (30.6%) in BMS (p=0.11). Restenosis 
occurred in 12 (19%) in DES vs. 15 (30.6%) in BMS (p=0.18). All restenotic lesions in 
the group treated with DES were focal. Moreover, cardiac deaths occurred in 3 (3.5%) 
patients vs. 6 (9.3%) in BMS (p=0.17).Conclusions In this early experience with DES in 
ULM we can state that this procedure appears safe with favourable and improved clinical 
results compared to historical controls with BMS. A randomized study versus surgery 
appears justiﬁ ed at present.
1094-30 Initial US Experience on Treatment of Left Main Disease 
with Sirolimus-Eluting Stents: Insights from the e-
Cypher Post-Marketing Survelillance Study
Marco A. Costa, Emerson Perin, Peter Berger, Peter Block, Stanley Katz, Steven 
Ramee, Emily Keim, Linda Reynolds, Sidney Cohen, Dominick Angiolillo, Theodore A. 
Bass, e-CYPHER PMS study group, University of Florida, Jacksonville, FL
Left main (LM) coronary disease occurs in about 5% of patients undergoing cardiac 
catheterization. LM angioplasty or stenting have been associated with poor outcomes. 
As a result, bypass surgery remains the treatment of choice for LM disease. Clinical trials 
have demonstrated the effectiveness of sirolimus-eluting stents (SES) to treat native 
coronary disease. However, patients with LM disease were excluded from all major 
randomized trials. The aim of this study was to evaluate the clinical outcomes of patients 
with LM disease treated with SES.
Methods: The FDA mandated e-CYPHER Post Marketing Surveillance Registry included 
2067 patients (3245 lesions) treated with at least 1 SES. Enrollment was completed in 
December, 2003. Clinical events are adjudicated by independent committee. The present 
study population involves 46 patients (93 lesions) with LM disease treated with SES. 
Results: Mean age was 65.9 years, 65.2% were male, 45.5% were diabetics. Multivessel 
disease was present in 87% of patients, and additional 47 lesions (other than the LM) 
were treated. Clopidogrel was given to 93.3% and IIb/IIIa inhibitors were used in 41.3% 
and of patients. There were no in-hospital death, repeat revascularization or Q-wave 
myocardial infarction (MI). One patient had a peri-procedural non-Q wave MI. There 
was one death within 30 days post-procedure. There were no acute or subacute stent 
thromboses. Another patient died between 30-days and 6-month follow-up. The overall 
event-free survival rate was 93.5% at 6-month follow-up. There were 1 target lesion 
revascularization and no late stent thrombosis.
Conclusion: Treatment of LM disease with SES appears to be feasible and safe, with 
good mid-term outcomes, despite the high incidence of multivessel treatment of the 
present population. Adjudicated long-term (12-month) data are warranted and will be 
available for presentation.
1094-31 Drug Eluting Stent in the Treatment of Unprotected 
Left Main Disease: Immediate Results and Six-month 
Angiographic Follow-up
Maria Elena Di Salvo, Nadia Garro, Anna Petralia, Rossella Barbagallo, Carmelo 
Grasso, Alessio La Manna, Alfredo Ruggero Galassi, Bruno Francaviglia, Corrado 
Tamburino, Ferrarotto Hospital, Catania, Italy
Background: Unprotected left main (ULM) bare metal stenting (BMS) has become widely 
used, but restenosis rate remains high (20-to-40%).
Recently drug eluting stents (DES) have been introduced in clinical practice, but only 
few data concerning safety and reduction of restenosis in unprotected LM disease are 
available at the moment.
Methods: We report our series of 80 patients (pts) with ULM stenosis who underwent 
PCI with Sirolimus (31.3%) or Paclitaxel (68.7%) eluting stents from June 2002 to August 
2004. Seven pts (8.7%) were affected by in-stent restenosis after a previous bare metal 
stenting. Mean pt age was 65 + 9 y, the ejection fraction was 51 ± 12; 25 pts (31%) 
were diabetic, and 40 (50%) had unstable angina. Bifurcation was treated in 55% of pts. 
Stenosis in other vessels was in 89% of pts. The follow-up was at 1, 3 (clinical and stress 
test) and at 6 months (angiography).
Results: Procedural success was obtained in 98,7%. In-hospital MACCE were 3 (3.7%) 
deaths (1 acute thrombosis, 1 sub-acute thrombosis, 1 cardiac failure not related to 
stenting) and one CABG for ostial recoil. Non-Q wave AMI occurred in 1 pt (1,2%).
At 1-month clinical follow-up (76 pts) there was no recurrence of symptoms, 1 patient died 
for cardiac failure. At 6-month clinical follow-up 1 patient died for non-cardiac disease, 2 
patients (4.2%) had TLR (1 re-PTCA and 1 CABG). Six-month angiography achieved in 
58 pts showed restenosis in 4 pts (6.9 %).
No different outcome was observed between Sirolimus and Paclitaxel stents.
Conclusion: Our preliminary data are encouraging; immediate results and mid-term 
outcome conﬁ rm the safety of DES implantation in ULM stenosis with a low rate of 
untoward events.
1094-32 Durable Clinical Beneﬁ t Following Sirolimus-Eluting 
Stent Deployment on the Outcome of Patients With 
Unprotected Left Main Coronary Arteries: Multicenter 
Registry Two-Year Results
Sunao Nakamura, Tamil Selvan Muthsamy, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, New Tokyo Hospital, Matsudo, Japan
Background and Purpose: Sirolimus-eluting stent (Cypher™, Cordis) have been 
reported to be effective in preventing neointimal formation and in-stent restenosis in 
unprotected left main coronary arteries (LMT). However, late (≥2 years) durability of 
Cypher™ stent beneﬁ t is still unknown. 
Methods: Complete clinical follow-up to 2 years is being analyzed for 42 patients who 
received Cypher™ stent in patients with LMT (male 71.4%, mean age 68.8 yrs, average 
ejection fraction 50.5%). Lesion location of LMT was ostial 10 cases (23.8%), mid shaft 
12 cases (28.6%) and distal 22 cases (47.6%). 
Results: Angiographic and clinical success was achieved in all patients. See table for 
clinical results. 
Conclusions: Clinical beneﬁ t provided by the Cypher™ stent is durable and late beneﬁ t 
appears to be incremental.
Cypher™
Number of patients 42
MACE at 30 days (%) 0
Reference diameter (mm) 3.62 ± 0.78
MLD post (mm) 3.54 ± 0.72
1 stent / 2 stents 18 / 24
Follow-up angiography (mm)
MLD at 6 months 3.40 ± 0.77
MLD at 12 months 3.38 ± 0.82
MLD at 24 months 3.42 ± 0.88
Restenosis rate (%)
6-month 4.8
12-month 4.8
24-month 4.8
1094-33 Drug-Eluting Stents vs Bare Metal Stents in The 
Treatment of Unprotected Left Main Coronary Artery 
Disease: Immediate and Long Term Clinical Outcome
Imad Sheiban, Claudio Moretti, Premiano Lombardo, Maria Teresa Lucciola, Walter 
Grossomarra, Filippo Sciuto, Giuseppe Greco Luchina, Cristina Rolfo, Amedeo Chiribiri, 
Emanuele Meliga, Giampaolo Trevi, University of Torino, Torino, Italy
Background: Percutaneous coronary interventions (PCI) for left main coronary artery 
(LMCA) disease as alternative to coronary surgery is still debated . In the present study 
we report our experience in LMCA-PCI with bare metal stents (BMS) and drug eluting 
stents (DES). 
Methods: 148 consecutive patients (pts) with unprotected LMCA stenosis underwent 
PCI. 86 pts (Group I) LMCA stenosis were treated with BMS and 62 pts (Group II) were 
treated with DES. Demographic, clinical and angiographic characteristics were similar ion 
both groups.Clinical and angiographic follow up were planned in all pts. 
Results: Group I ( 86 pts): procedural success was 97.6%. There were 2 in-hospital deaths: 
(procedural and in-hospital mortality was 2.2%). There were 4 (4.4%) periprocedural non-
Q AMI all in multivessel PCI pts, stroke 0% and urgent CABG 0%. Clinical follow-up varied 
from 7 to 36 months. During the follow-up period there were 3 cardiac deaths (3.5%): due 
to heart failure in 2 pts with EF < 30% and 1 sudden death . A non cardiac death occurred 
in 10 pts (13,2%), all at least after 7 months following the procedure. Non-Q AMI occurred 
in 3 pts (3.5%), 15 pts (17,4 %) had recurrence of angina . Repeat revascularization was 
required in 14 (Re-PCI in all 14).At the end of follow up period 76% of contacted pts were 
free of events (65% of them with completed 6-month angiography and no restenosis). 
Group II ( 62 pts) Procedural success was 100%. One in-hospital death occurred (1,6 %) 
for renal failure . At least 6-month clinical follow up was completed in all . Recurrence of 
angina occurred in 3 pts (4.8%). TLR / TVR in one (1.6%) Total MCE was 5.7%. Clinical 
follow up ranged from 6 to 22 months : No death, no stroke, no CABG. During this period 
recurrence of angina occurred in 5 pts (8,1%), TLR/TVR in 3 pts ( 4.8% ), total MACE 
was 12.9% . 9-month angiographic follow up was completed in 31 pts (50%). In segment 
restenosis was 4.4%. 
Conclusions: These data suggest that PCI for LMCA stenosis is safe and effective 
alternative revascularization strategy with excellent immediate results and good mid term 
outcome .The most frequent MACE in survivors treated with BMS is re-PCI due to in-stent 
restenosis which seems to be dramatically reduced with the use of DES.
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1094-34 Acute and Late Outcomes of Unprotected Left 
Main Stenting in Comparison With Surgical 
Revascularization: LE MANS Case Controlled Study
Pawel E. Buszman, Jack Martin, Ewa Peszek, Marcin Debinski, Aleksander Zurakowski, 
Bozena Bialkowska, Michal Tendera, Stefan Kiesz, Silesian Medical School, Katowice, 
Poland, American Heart of Poland, Ustron, Poland
Background: The advent of coronary stenting provided more predictable acute and long 
term results making percutaneous intervention (PCI) a viable alternative to coronary 
bypass surgery (CABG) in patients (pts) with left main (LM) disease.
Methods: 289 consecutive patients with >50% LM stenosis were screened for eligibility 
for intent-to-stent PCI or CABG. One hundred and twenty two pts deemed suitable for 
both procedures were enrolled in this case matched study. PCI pts (n=61) had planned 
angiography within 4-6 months. LV function was evaluated by 2-D echo before and 12 
months after index procedure. Follow-up visit including tredmill stress test was scheduled 
after one year. Results: PCI vs CABG cohorts compared for age (60.8±10.8 vs 61.0±8.4, 
p=0.91), gender (79 vs 74% male, p=0.67), number of additional diseased vessels (2.04 
vs 2.3, p=0.12), CCS functional class (3.1±0.9 vs 3.0±0.9, p=0.67), ejection fraction 
(52.1±14.4 vs 53.9±7.5 %, p=0.35), presence of diabetes (17.3 vs 16.3%, p=0.99), 
Euroscore (3.1±2.5 vs 3.4±2.7, p=0.52) and distal LM involvement (54.1 vs 45.9%, 
p=0.137). LIMA was used in 66% of CABG pts and drug eluting stents in 15% of PCI pts. 
During the index hospitalization there were no deaths with PCI and 3 deaths with CABG 
(p=0.08). PCI was also associated with less major adverse events (MAE, 1.6 vs 29.5 %, 
p< 0.001) and hospital days (7.0±4.5 vs 11.0±4.2 days, p< 0.001). After 17.9±6.7 month 
follow up there was a death with PCI, no death with CABG and higher MAE with PCI 
(13.1 vs 32.7%, p= 0.018). Repeat revascularization was higher with PCI (20% vs 8%, 
p= 0.12) but CCS class after 12 month improved equally after PCI and CABG (1.3±0.9 
vs 1.0±1.2, ANOVA p=0.12 ). LM in-stent restenosis occured in 9 patients (14.7%) and 
was treated with repeat PCI. Ejection fraction improved slightly with PCI to 55.1±14.2%, 
(p=0.09), while after CABG remain unchaged (53.9±8,6, p=0.93). One year after the index 
procedure patients after PCI perfomed better on tredmill stress test (9.6±2.7 vs 7.5±3.9 
METs, p=0.001).
Conclusion: Stent supported PCI can be performed with favorable acute outcome in 
comparison to CABG in patients with LM disease. Improved late results would be expected 
with routine use of drug eluting stents.
1094-35 Impact of Sirolimus-Eluting Stents on the One 
Year Outcome of Patients with Bifurcation Lesions: 
Multicenter Registry in Asia
Sunao Nakamura, Tamil Selvan Muthusamy, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Treskosol, New Tokyo Hospital, Matsudo, Japan
Background: Previous clinical study utilizing Sirolimus-eluting stents (SES) in simple 
coronary lesions demonstrated an impressive reduction in intimal hyperplasia and restenosis. 
However, long-term efﬁ cacy of SES in treating patients with true bifurcation lesions is still 
unknown. A prospective Asian multicenter registry was set up in ﬁ ve high volumes Asian 
center to evaluate the efﬁ cacy of SES in the treatment of bifurcation lesions. 
Methods: A total of 292 patients, 332 lesions (male 68.2%, mean age 67.8) with 
bifurcation lesions (deﬁ ned as a more than 50% stenosis in both parent vessel and side 
branch, LMT/bifurcation 14.5%, LAD/diagonal 50.6%, LCX/OM 20.8%, and RCA/PD 
14.1%) were treated with 4 strategies: stenting both vessels utilizing SES with Y-stenting 
(n=102), stenting the parent vessel utilizing SES and balloon angioplasty of the side 
branch (n=70) and stenting both vessels utilizing SES with crushing stenting with (n=75) 
or without (n=45) post kissing ballooning (KB). We evaluated immediate and long-term 
clinical results by 6 and 12 months coronary angiography. 
Results: See table for clinical results. 
Conclusion: Our results suggest that stenting both vessels utilizing SES with Y-stenting 
or crushing stenting with post kissing ballooning can dramatically reduce the restenosis 
rate at follow-up.
Y-stenting Single stenting Crushing stenting (KB+)
Crushing 
stenting (KB-)
Number of patients 102 70 75 45
Procedural success (%) 100 100 100 100
MACE at 30 days (%) 0 0 0 0
Angiographic restenosis 
rate (12 mo)
Both vessels (%) 2.0 1.4 2.7 4.5
Parent vessel (%) 0 1.4 0 2.2
Side branch (%) 4.9 21.4 4.0 22.2
TLR: any vessels (%) 4.9 22.8 6.7 24.4
1094-36 The AST Petal Dedicated Bifurcation Stent: First-In-Man 
Experience
John A. Ormiston, Mark W. Webster, Seif El Jack, Greenlane Cardiovascular Unit at 
Auckland City Hospital, Auckland, New Zealand
Background: Outcomes following percutaneous treatment of coronary bifurcation lesions 
with current techniques remain inferior to those of non-bifurcation lesions. The AST Petal 
bifurcation stent gives security of side-branch access, allows provisional side-branch 
stenting, has 2 mm of stent protruding into and scaffolding the side-branch ostium (A), 
a common site for restenosis with both bare metal and drug-eluting stents. Endoscopic 
views (B, C) show unobstructed main and side-branches.
Aims: This ﬁ rst-in-man study tested the feasibiliy and safety of the Petal stent.
Results: Implantation of the Petal stent was attempted in 9 patients/bifurcation lesions. 
The age range was 43-76 years; 8 were men. Lesions were LAD (5), LCX (3), and RCA 
(1). Bifurcation lesion type was D in 6, A, C, F in 1 each. The Petal stent was successfully 
deployed in 8 of 9 lesions. Guidewire wrapping required repositioning of one of the wires 
in 3 lesions. In the1 failed delivery, the lesion was treated using the crush technique; this 
was the only patient with CK> 2x normal. There were no urgent revascularizations, Q 
MIs or deaths.
Summary: Deployment of the AST Petal bifurcation stent is feasible in selected patients 
with coronary bifurcation lesions. The Petal stent has a higher proﬁ le than a regular stent, 
and guidewire wrapping may hinder delivery if unrecognized and uncorrected. It is a 
promising platform for drug delivery, with unique scaffolding of the side-branch ostium. 
1094-37 Comparison of Simple Versus Complex Techniques 
With Sirolimus-Eluting Stent for Bifurcation Coronary 
Lesions
Bong-Ki Lee, Young-Hak Kim, Min-Kyu Kim, Bong-Ryong Choi, Mi-Jeong Kim, Kwan-Ho 
Ko, Seung-Whan Lee, Ki-Hoon Han, CheolWhan Lee, Myeong-Ki Hong, Jae-Joong Kim, 
Seong-Wook Park, Seung-Jung Park, Asan Medical Center, University of Ulsan College 
of Medicine, Seoul, South Korea
Background: Sirolimus-eluting stent (SES) implantation has dramatically decreased in-
stent restenosis(ISR) for simple coronary lesions. However, the efﬁ cacy for bifurcation 
lesions have not been satisfactory.
Methods: Between Jan 2003 and Jan 2004, 127 patients (127 lesions) with true bifurcation 
lesion treated by SES implantation were enrolled. Patients with acute myocardial 
infarction(MI) and ISR were excluded. The subjects were divided into two groups: the 
patients with stenting in both main branch (MB) and side branch (SB) concurrently (group 
A, n=57 ) and MB stenting and the balloon angioplasty in SB (group B, n=70). In the 
group A, 3 types of stenting techniques were used including kissing stenting (n=26), stent 
crushing (n=25), and T-stenting (n=6).
Results: Baseline clinical characteristics were not different. The procedural 
success(postprocedural % diameter stenosis < 30% in the MB and <50% in the SB; no 
periprocedural major complication) rate was 100% in the group A and 94.3% in the group 
B. The periprocedural CK-MB elevation occurred in 6 patients (10.5%) in group A and 7 
patients (10.0%) in group B (p=NS). Six-months angiographic follow-up was achieved in 
49 patients (86.0%) of group A and 52 patients (74.3%) of group B. Death, MI did not 
occur in the two groups during the follow-up period.
Conclusion: Simple stenting technique may remain an effective treatment strategy in the 
era of drug-eluting stent for bifurcation coronary lesions. 
Group A Group B
Acute gain (mm)
MB 1.91 ± 0.53 1.72 ± 0.59
SB 1.33 ± 0.44 * 0.74 ± 0.62
Late loss (mm)
MB 0.48 ± 0.60 * 0.24 ± 0.45
SB 0.40 ± 0.57 * 0.12 ± 0.52
Restenosis (p=NS)
MB 5 (8.8%) 1 (1.4%)
SB 5 (8.8%) 1 (1.4%)
Overall 9 (14.0%) 2 (2.9%)
MB=main branch, SB=side branch, * p<0.05
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1094-38 Provisional T Stenting Strategy for Coronary Bifurcation 
Lesions: Final Results of the Multicenter Tulipe Study
Philippe Brunel, Thierry Lefèvre, Olivier Darremont, Luc Maillard, Laurent Quillet, Hervé 
Lebreton, Marc Silvestri, Gilles Montalescot, Antoine Py, Yves Louvard, on behalf of 
the TULIPE Investigators, Nouvelles Cliniques Nantaises, Nantes, France, Institut 
Cardiovasculaire Paris Sud, Massy, France
Background: Previous prospective studies on the treatment of bifurcation lesions showed 
that a strategy of main branch (MB) stenting with provisional T-stenting of the side branch 
(SB) followed by kissing balloon inﬂ ation (Kiss) was associated with a high rate of success 
and a low target vessel revascularization rate (TVR) at follow-up in selected centers.
Objectives: To assess whether this strategy can be applied to a large multicenter study.
Methods: A total of 14 French centers included prospectively consecutive patients treated 
for de novo coronary bifurcation lesions with a MB > 2.8 mm and SB > 2.1 mm using the 
Penta stent for MB treatment. Wiring both branches at the beginning of the procedure and 
MB stenting with the “jailed wire technique” followed by provisional SB T-stenting and ﬁ nal 
kiss were strongly recommended. Were excluded, patients with left main disease >50%, 
acute MI and highly calciﬁ ed lesions. Acute angiographic results were assessed by a 
central core lab analysis and 7-month clinical follow-up was prospectively organized.
Results: 186 patients were included, mean age 66+11 years, diabetes 22%. The target 
was the left anterior descending coronary artery in 67%. Interpolated reference diameter 
of MB was 2.7+0.5mm and SB 2.4+0.5 mm. The jailed wire technique was used in 77% 
of cases. Stent length of the MB was 17.5+4.9mm. The SB was stented in 34% of cases 
(length 11.3+4.0mm). Final kiss was performed in 96 %. Angiographic success (% 
residual stenosis MB < 30% and SB < 50% by QCA) was obtained in 99% for MB, SB 
90%, both 89%. Only one non-Q-wave MI (0.54%) but no death, TVR, acute or subacute 
thrombosis occurred before hospital discharge. At 7 month follow-up: 3 patients (1.5%) 
died (only 1 from cardiac cause), 1 patient had non-Q-wave MI (0.54%) and TVR occurred 
in 15% (PTCA 13%, CABG 2%). By multivariate analysis, factors associated with TVR: 
lower EF (OR 0.934), moderate calciﬁ cations (OR 7.68) and non use of the “jailed wire 
technique” (OR 4.26).
Conclusion: This multicenter French study strongly suggests that a strategy of provisional 
T stenting using the Penta stent for the treatment of bifurcation lesions can be implemented 
widely with high success and low TVR rates.
1094-39 New Bifurcation Stenting Technology: BIfurcation 
Stenting With CORoﬂ ex (BISCOR) Registry, Results of 
491 Consecutive Patients
Sascha Rux, Stephanie Elisabeth Rückert, Sandra Lück, Steffen Mark Sonntag, 
Leonhard Bruch, Franz Xaver Kleber, UKB, Academic Teaching Hospital and Charité 
Medical School, Berlin, Germany
Background: Angioplasty of bifurcation lesions represents a continuing challenge. No ﬁ rm 
standards of treatment exist and most techniques are either complex and time consuming 
or are associated with a reduced success and increased early and late complication 
rate.
Methods: From June 2001 until August 2004 all bifurcation angioplasty cases were 
gathered that were done with stenting over a side branch (> 2mm) with a stent type 
(Coroﬂ ex ™ stent) with maximal ﬂ exibility, very low proﬁ le, small strut width and large 
lateral opening area, allowing direct stenting, easy side branch access without distortion 
of the distal stent end, and no need for two wire techniques and kissing balloons in most 
of the cases. Data on lesion location, stenosis morphology, procedural success, hospital 
and 6 months MACE rate were systematically collected.
Results: Immediate results of 491 patients (pts.) have been obtained (age 63 ± 11 years, 
26 % female). 63% of pts. underwent an elective intervention, while 22% had UAP / 
NSTEMI and 15% had STEMI. First step was direct stenting of the main vessel in 65%, in 
18% of cases the main vessel and in 17% the side branch was predilated.
In 16% of patients stenting of the main vessel alone was performed, in 68% stenting of 
the main vessel was complemented by side branch PTCA, in 13% of patients both vessels 
were stented and in 3% the stent was directed from the main vessel into the side branch. 
Kissing balloon was used in only 1.4% of pts. Technical success in both branches was 
achieved in 96%. MACE rate at discharge was 1.6% (6 deaths, 2 NSTEMI). Target lesion 
revascularization (TLR) rate at 6 months was 13.1% in 351 consecutive pts. followed for 6 
months so far. Within 180 days 7 additional late deaths (2.1%) were observed. 6 months 
total MACE rate was 21.4%.
Conclusions: In 96% of pts. successful bifurcation stenting was performed with a very 
low rate of immediate and inhospital MACE. The Coroﬂ ex™ stent was an excellent tool 
for this project. TLR with this technique is not higher than after stenting of non bifurcation 
lesions.
1094-40 Coronary Bifurcation Lesions Treated with the Crush 
Technique - An Intravascular Ultrasound (IVUS) 
Analysis
Ricardo A. Costa, Gary S. Mintz, Stephane G. Carlier, Kenichi Fujii, Hideo Takebayashi, 
Takenori Yasuda, Jose Costa, Jr., Masashi Kimura, Koichi Sano, Yoshihiro Tsuchiya, 
Alexandra J. Lansky, Roxana Mehran, George D. Dangas, Michael Collins, Edward M. 
Kreps, Issam Moussa, Antonio Colombo, Gregg W. Stone, Jeffrey W. Moses, Martin B. 
Leon, Columbia University Medical Center and Cardiovascular Research Foundation, 
New York, NY
Background: We report the IVUS ﬁ ndings of bifurcation lesions treated with crush 
sirolimus-eluting stenting. Methods: IVUS was completed in both main vessel (MV) and 
side-branch (SB) in 25 pts after successful crush stenting. IVUS analysis was performed 
in 5 distinct locations (Figure). Results: LAD/Diagonal lesions were prevalent (80%); ﬁ nal 
kissing balloon inﬂ ations were performed in 92% (balloon/artery ratio: 1.20 for MV and 1.22 
for SB). Reference external elastic membrane and lumen references were 13.9 and 9.0mm2
for the MV, and 8.6 and 5.9mm2 for the SB, respectively. Mean crush length was 4.8±1.6mm. 
The minimum stent cross-sectional area (CSA) in the MV was larger than in the SB (6.7±1.7 
vs. 4.4±1.4mm2, p<0.0001). The minimum stent CSA was found at the SB ostium in 68% 
of lesions. MV stent CSA measured <4mm2 in 8% of lesions and <5mm2 in 20% of lesions; 
the SB stent CSA measured <4mm2 in 44% of lesions and <5mm2 in 76% of lesions. Stent 
expansion (minimum CSA/distal reference lumen) was 89.3±18.4% for MV vs. 78.0±16.1% 
for SB, p=0.01. Conclusions: Bifurcation lesions treated with the crush technique presented 
the smallest minimum CSA at the SB ostium in the majority of cases. The small CSA of the 
SB ostium may contribute to a higher restenosis rate at this location. 
1094-44 Evaluation of Sirolimus Eluting Stents for the Treatment 
of Bifurcation Lesions: A Real World Study
Thierry Lefèvre, Yves Louvard, Pierre Dumas, Philippe Garot, Bernard Noël, Sergio 
Hernandez, Snehal Kothari, Marie-Claude Morice, Institut Cardiovasculaire Paris Sud, 
Massy, France
Background: Although bare metal stents have been a useful therapeutic modality for 
the treatment of bifurcation lesions using a “provisional T stenting strategy”, they have 
not eliminated the problem of restenosis. Sirolimus-eluting stents have been shown to 
markedly decrease restenosis in selected lesions.
Objectives of the study: to prospectively assess the immediate results and mid-term 
outcome of patients who underwent treatment with sirolimus-eluting stents.
Methods and Results: Between May 2002 and December 2003, a total of 252 patients 
underwent coronary stenting for the treatment of bifurcation lesions and of these 82 
patients were treated with a Cypher stent. Patients with distal left main disease or acute 
MI with cardiogenic shock were excluded. Patients were 62+12 years, 80% male, 34% 
diabetes mellitus, and 30% had unstable angina. Patients had multivessel disease in 
71% of cases and 0.69+0.71 lesions other than the bifurcation were treated during the 
same procedure. Bifurcations involved mainly LAD/ Diag (71%). The proximal reference 
diameter of the main branch was 2.92+0.46 mm, interpolated reference 2.33+0.50, side 
branch 1.96+0.34 mm. Stenting of the main branch with provisional T-stenting of the side 
branch was the strategy in 97% of cases (side branch was stented in 22.5% of cases). 
A ﬁ nal kissing balloon inﬂ ation was performed in 99% of cases. Angiographic success 
was obtained in 100% of cases for the main branch and 98% for main and side branch. 
In-hospital outcome was uneventful except for asymptomatic CPK elevation in 2 patients 
(2.5%). Seven month clinical follow-up was obtained in all cases. There were no cases 
of stent thrombosis, MI or death. Two patients (2.5%) had TVR (focal restenosis of both 
branches in 1 case and focal main branch restenosis in 1 case.
Conclusion: Implantation of the sirolimus-eluting stent at coronary bifurcations using a 
strategy of main branch stenting with provisional T stenting of the side branch followed 
by kissing balloon inﬂ ation is associated with a high rate of success and a very promising 
seven month outcome.
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1095-9 Intramyocardial Injection Of Autologous Bone Marrow 
Cells In Patients With Refractory Angina Pectoris And 
Chronic Ischemia Is Safe, Reduces Anginal Symptoms 
And Improves Myocardial Perfusion.
S. L.M.A. Beeres, K. Zeppenfeld, W. E. Fibbe, J. J. Bax, A. van der Laarse, T. de Vries, 
E. E. van der Wall, M. J. Schalij, D. E. Atsma, Leiden University Medical Center, Leiden, 
The Netherlands
Background: Patients with chronic myocardial ischemia despite optimal medical care 
and without options for revascularization have a diminished quality of life and a reduced 
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life expectancy. Stem cell therapy is a new therapeutic option for the repair of ischemically 
damaged myocardium through the induction of angiogenesis. We studied whether 
autologous bone marrow cell injection into ischemic myocardium is feasible, is safe, 
reduces symptoms and improves cardiac function.
Methods: In patients with refractory angina pectoris and chronic ischemia, bone marrow 
was aspirated from the iliac crest. After identiﬁ cation of the ischemic myocardial area 
using the NOGA system (Biosense Webster), 30-100x106 mononuclear cells were 
injected intramyocardially.
Results: In 15 patients (12 male, 64±2 yrs, AP class 3-4, EF 52%) the intramyocardial 
injection of autologous bone marrow cells was safe. Blood sample analysis revealed no 
myocardial damage nor raised inﬂ ammation parameters. No arrhythmias were recorded 
neither did echocardiography show pericardial effusion. Efﬁ cacy analysis showed a 
decrease in angina pectoris frequency (before 3.4/day, 3 months 0.9/day, p<0.05 ; 6 
months 0.2/day, p<0.05 ) and NTG usage (before 0.73/day, 3 months 0.14/day, p<0.05; 6 
months 0.04/day, p<0.05). Quality of life (before 56%, 6 months 85%, p=0.02) and exercise 
capacity increased after 6 months. Imaging techniques showed a reduced perfusion 
defect size and an 8±2.5% increased global left ventricular ejection fraction (p=0.03).
Conclusion: Autologous bone marrow cell injection in no-option patients with refractory 
angina pectoris and documented ischemia is safe. Moreover, anginal symptoms are 
reduced and myocardial perfusion and cardiac mechanical performance is enhanced.
1095-10 NOGA-guided Analysis Of Regional Myocardial 
Perfusion Abnormalities Treated With Intramyocardial 
Injections Of Plasmid Encoding VEGF A-165 In Patients 
With Chronic Myocardial Ischemia. Subanalysis Of The 
Euroinject-one Multicenter Randomized Study
Mariann Gyongyosi, Jens Kastrup, Birger Hesse, Christina Tagil, Eric Jorgensen, 
Aliasghar Khorsand, Sholeh Zamini, Dietmar Glogar, Hans Erik Botker, Witold Ruzyllo, 
Darius Dudek, Christer Sylven, University of Vienna, Vienna, Austria
Background. The aim of the EUROINJECT-ONE trial substudy was to analyse changes in 
myocardial perfusion in NOGA-deﬁ ned regions with intramyocardial injections of plasmid 
encoding VEGF A-165 in patients with chronic myocardial ischemia, not amenable for 
conventional revascularization.
Methods. Eighty patients with adenosin-induced ischemia by 99m-Tc myocardial 
perfusion scintigraphy were randomized to receive either active, VEGF-A-165-encoding 
(VEGF-plasmid, n=40) or inactive (Placebo-plasmid, n=40) plasmid. The injection points 
of the 3D NOGA images were projected to the baseline and follow-up (FUP) 2D polar 
maps of the perfusion images, and the treated areas (ROI) were delineated with the 
closest ellipse placed on polar maps including all injection points. The severity of the ROI 
perfusion abnormality was calculated as the mean normalized tracer uptake at rest and 
stress at baseline and FUP.
Results. The size of the treated area was similar in both groups (34.4±9.2% and 
35.1±8.2% of entire myocardium in plasmid and placebo groups). The baseline mean 
normalized tracer uptake at rest and stress, and the myocardial voltage and local linear 
shortening (LLS) values determined by NOGA of the ROI did not differ between the groups. 
At FUP, the mean tracer uptake of the ROI at stress increased signiﬁ cantly in patients with 
plasmid (from 62.7±10.7% to 67.9±9.5%, p<0.05), however, it has not normalized. The 
tracer uptake of ROI did not change in placebo group (from 62.8±10.0% to 63.7±9.9%). At 
FUP, a trend towards less severe perfusion defect at stress was observed in patients with 
plasmid as compared to placebo (p=0.089). The resting perfusion did not change in the 
groups during the FUP. Twenty-one patients (53%) in plasmid group and 8 patients (20%) 
in placebo group exhibited an improvement of stress defect, as more than 5% increase of 
normalized tracer uptake (p<0.005) of ROI was achieved.
Conclusions. NOGA-guided analysis of tracer-derived perfusion abnormalities enables 
exact evaluation of myocardial perfusion in regions treated with angiogenic substance. 
Injections of VEGF A-165 plasmid in chronic ischemic myocardium improve, but not 
normalize the stress-induced perfusion abnormalities.
1095-11 A Novel Injectable Polymeric Delivery System for 
Multiple Growth Factor Delivery Results in Stable 
Vasculature
Qinghua Sun, Eduardo A. Silva, David J. Mooney, Sanjay Rajagopalan, Paul Michael 
Grossman, University of Michigan Hospitals and Health System, Ann Arbor, MI, 
University of Michigan, Ann Arbor, MI
Background: Sequential and sustained delivery of multiple growth factors may be preferable 
for therapeutic angiogenesis. We hypothesized that an injectable, bio-degradable, alginate 
polymer system capable of sequentially delivering vascular endothelial growth factor 
(VEGF) followed by platelet derived growth factor (PDGF) would be superior to single 
growth factor delivery in promoting neovascularization and improving perfusion.
Methods: 3 groups of Apo E null mice (n = 18 each) underwent unilateral hind limb ischemia 
surgery and received ischemic limb intramuscular injections of alginate (Blank), alginate 
containing VEGF165 (VEGF), or alginate containing VEGF165 combined with microspheres 
containing PDGF-BB (V/P). Vascularity was assessed by morphologic (vessel number 
and diameter) and immunohistochemical [CD31 and alpha smooth muscle actin (�-SMA)] 
end-points. Blood ﬂ ow was determined by Laser Doppler Perfusion Index (LDPI, ischemic/
nonischemic limb %). Muscle VEGF and PDGF content was quantiﬁ ed.
Results: See table. In the V/P group, local tissue VEGF and PDGF levels peaked at week 
2 and 4 respectively, with PDGF still detectable at week 6.
Conclusion: Sequential delivery of VEGF and PDGF using an injectable, bio-degradable 
vehicle resulted in stable and sustained improvements in perfusion and larger, more 
mature appearing vasculature. This control-released, injectable, alginate polymer system 
is a promising approach for multiple growth factor delivery in clinical application.
Vascularity and Perfusion Indices
Group Time LDPI% CD31 (+/mm2) α-SMA (+/mm2) Mean vessel area (mm2)
Blank
Week 4 54 ± 10 80 ± 21 15 ± 6 11 ± 11
Week 6 71 ± 4 114 ± 19 23 ± 10 12 ± 10
VEGF
Week 4 61 ± 9 † 187 ± 42 † 32 ± 9 † 15 ± 11
Week 6 80 ± 4 † 242 ± 21 † 40 ± 11 † 19 ± 18
V/P
Week 4 67 ± 9 * 156 ± 35 * 43 ± 8 * 43 ± 70 *‡
Week 6 94 ± 5 *‡ 195 ± 15 * 61 ± 11 *‡ 52 ± 150 *‡
*p < 0.05, V/P vs Blank; †p <0.05, VEGF vs Blank; ‡p<0.05, V/P vs VEGF
1095-12 Percutaneous Transvenous Transplantation of 
Autologous Myoblasts in the Treatment of Postinfarction 
Heart Failure - One Year Follow-up of the POZNAN Trial 
series
Tomasz Siminiak, Dorota Fiszer, Olga Jerzykowska, Marcin Majewski, Maciej Kurpisz, 
District Hospital, Poznan, Poland
Background: Autologous skeletal myoblast (ASM) transplantation into the area of 
postinfarction left ventricular injury results in an increase in segmental contractile 
performance related to contraction of cells differentiated from transplanted myoblasts.
Objectives: We have established a phase I clinical trial to evaluate the feasibility and 
safety of ASM transplantation performed with percutaneous trans- coronary veins 
approach in patients with postinfarction left ventricular dysfunction.
Methods: Ten patients were included into the study on the basis of the following criteria: 
the presence of an akinetic of dyskinetic postinfarction injury with no viable myocardium; 
heart failure NYHA class 2 or 3. Skeletal myoblasts were obtained from a biopsy 
specimen and grown in cell culture. Patients were treated with prophylactic amiodarone 
infusion before and during the procedure, except one patient reporting allergic reaction 
to amiodarone in the past.
Results: In one patients the procedure was not performed due to inability of appropriate 
coronary sinus catheter positioning. Skeletal myoblast transplantations were performed 
uneventfully in 9 patients using Trans Access ® catheter system. In 5 patients anterior 
interventricular vein and in 4 patients the middle cardiac vein was used. The injections were 
performed in 2-4 channels 1.5-4.5 cm deep within the myocardial injured area, delivering up 
to 108 cells in 0.8 - 2.5 ml of saline. Patients were free from ventricular arrhythmia throughout 
10-16 days of continuous ecg monitoring except of one patient, not receiving prophylactic 
amiodarone, who had episodes of ventricular tachycardia and experienced 3 shots from his 
ICD. During initial 3 months follow-up NYHA class improved in all patients by 1-2 classes 
and ejection fraction increased 3-8 percent in 6 out of 9 cases. This effect maintained 
throughout 12 months follow-up and no important ventricular arrhythmia were noted.
Conclusion: These data suggest the feasibility and procedural safety of myoblast 
transplantation performed with trans-cardiac vein approach using Trans Access ® 
catheter system.
1095-13 Transcutaneous Local Sonotherapy Promotes 
Angiogenesis in Rabbit Hind-Limb Ischemia Model
Nicholas N. Kipshidze, George D. Dangas, Sriram Iyer, Mykola V. Tsapenko, Gary 
Roubin, Lenox Hill Hopstal, New York, NY
Objectives: Our previous studies have demonstrated that low power ultrasound therapy 
enhances production of different growth factors in vitro, which could induce new collateral 
growth in ischemic tissue. In this study we investigate the effect of transcutaneous local 
sonotherpy (TLS) on new collateral growth in a rabbit hind-limb ischemia model.
Methods: 18 rabbits were divided into 3 equal groups. In all animals created hind-limb 
ischemia with distal external iliac artery and femoral artery excision. Transcutaneous 
ultrasound (1MHz, 0.4 W/cm2) applied to adductor muscle near the site of the excised 
arteries for 2 (low dose, group 1) and 10 (high dose,group 2) min. daily for 4 weeks. Control 
animals (group 3) was not treated with TLS. Angiography, Doppler and morphological 
study were performed before, after surgery and at the time of sacriﬁ ce.
Results: After four weeks in the TLS series, 79.1±10.4 (low dose) and 91.7+8.4 (high 
dose) contrast medium opaciﬁ ed arteries (COAs) were counted crossing grid lines in 30 
squares on a grid section vs. 32.2±7.9 in controls (p<0.05 versus low and high dose); 
27.3±1.2 grids (low dose) contained COAs vs. 29.3±3.5 in (high dose) vs. 21+1.0 in 
controls (p<0.05). Capillary density was 283.7±24.5 mm2(low dose), 327+ 21.8 mm2 
(high dose) and 91.4±20.9 mm2 in controls (p<0.001).
Conclusion: Both low and high doses of TLS signiﬁ cantly enhanced and accelerated 
new collateral growth and may become a simple noninvasive method of treatment for 
peripheral arterial disease.
1095-14 Flow Cytometry Mediated Analysis of Fluorescent 
Dye Labeled Cardiomyocytes in a Rat Model of 
Intramyocardial Cell Transplantation
Christian Herdeg, M. Rihm, M. Alunni-Fabbroni, M. Lohmann, A. Duwe, K. Schröder, A. 
Kuhn, J.H. Kuepper, University of Tuebingen, Tuebingen, Germany
Background: heart regeneration by transplantation of differentiated cardiomyocytes, 
skeletal myoblasts or stem cells is considered to be a promising therapy option. However 
there is little information about the optimal cell type and number to be transplanted. Not 
much is known about the fate of transplanted cells either. 
Methods and Results: in this study we describe a procedure of cell labeling prior to 
intramyocardial transplantation and quantiﬁ cation of successfully transplanted cells. 
For this purpose a ﬂ uorescent label was used, the so-called Cell Tracker, that sticks to 
intracellular structures. We postulated that the best method for detection and counting of 
cells from heart tissue would be to perform ﬂ ow cytometry analysis (FACS) of labeled cells 
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that have been successfully transplanted. Adult rat cardiomyocytes were incubated with 
5-25 µM of Cell Tracker Green CMFSA in serum free medium for 45 minutes. Thereafter 
medium was changed and cells were incubated in routine medium for different time points 
before being analyzed by FACS. Already with the lowest concentration tested we found 
that almost 100% of the cells were stained 1 day after exposure of the dye. There was also 
a dose-dependent increase in mean ﬂ uorescence intensity values of stained cells. At day 
5 after staining cell labeling could still be detected in about 80% of the cell population with 
10 µM of dye concentration. Cell transplantation experiments with labeled cells foloowed. 
Cells were trypsinized on day 1, counted,and resuspended in serum-free medium and 
then immediately used for transplantation. Subsequently open-chest surgery of rats 
for intramyocardial cell injection was performed. One million cells/10µM were ditrectly 
injected into the myocardium. One day after transplantation rats were killed and heart 
muscle was prepared for FACS analysis. 
Conclusion: To our knowledge this is the ﬁ rst successful approach to detect ﬂ uorescence-
labeled cells after transplantation into a living heart by FACS. By use of this convenient 
technique it is now possible to investigate the yield of successfully transplanted cells and 
their distribution in heart tissue versus other organs.
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1096-3 Intravascular Ultrasound Study Of Patients Who 
Underwent Overlapping Of Paclitaxel And Sirolimus 
Stents: Comparison With The Results Obtained After 
Overlapping With Same-drug-eluting Stent. 
Juan M. Ruiz-Nodar, Sr., Pilar Carrillo, Araceli Frutos, Eloísa Felíu, Pedro Morillas, 
María Ibánez, Ramón Rubio, Juan Quiles, Daniel Nuñez, Vicente Bertomeu, Hospital 
Universitario de San Juan, Alicante, Spain
Background: The different clinical trials with drug-eluting stents (DES) that performed 
intravascular ultrasound (IVUS) during follow-up have demonstrated that there is not an 
increase in risk of restenosis in the areas of overlapping (OV). There is no information 
available about the response of patients who underwent OV with stents eluted with 
different drugs, being of such interest due to the different way sirolimus and paclitaxel 
achieve the reduction of the neointimal hyperplasia.
Methods: 8-month angiographic and IVUS study was performed in all those lesions 
treated by angioplasty with OV of DES, either same-drug of different-drug-eluting stents, 
between April-03 and January-04.
Results: 35 OV in 28 patients were performed. Angiographic and IVUS follow-up was 
achieved in 26 patients to which 32 OV with 58 DES. Out of these 32 OV, 9 were sirolimus-
paclitaxel (SP), 10 sirolimus-sirolimus (SS) and 13 paclitaxel-paclitaxel (PP). All the OV 
were identiﬁ ed with IVUS. There was not any subacute thrombosis. No aneurisms were 
observed either in the place of OV or in the rest of the stents. Restenosis were present in 
2 stents, being diffuse and affecting one TT and one ST overlapping (in the same patient). 
Only in 30% of the cases the maximum restenosis point was located at the OV.
Conclusion: Performing overlapping with DES with different drug-eluting stents is 
safe and results in such good outcome as OV with same-drug-eluting stent: Identical 
angiographic late loss and similar IVUS stenosis percentage.
IVUS measurements (CSA=cross sectional area)
SP (n=10) SS (n=12) PP (n=13) p value
Lumen CSA 6.74±2.58 6.55±1.99 7.84±1.59 0.38
Stent CSA 8.83±1.59 7.09±2.03 8.88±1.89 0.1
Intimal hyperplasia CSA 1.68±1.7 0.53±1.7 1.03±0.8 0.07
1096-4 The Intracoronary Ultrasound Attenuation behind 
coronary atheroma predicts embolic or event 
complication during Percutaneous Coronary 
Intervention.
Hisao Hara, Taro Tsunoda, Masaya Yamamoto, Masanori Shiba, Masamichi Iijima, 
Takahiro Tsuji, Rintaro Nakajima, Takashi Yoshitama, Masato Nakamura, Toho Ohashi 
Hospital, Tokyo, Japan
Objective: During intravascular ultrasound (IVUS) image analysis, a marked decrease 
of the back echo resulting failure of measurement (i.e., ultrasound attenuation: UA ) are 
sometimes experienced even in the absence of calciﬁ cation deposit within a coronary 
atheroma. This study investigated the frequency and clinical relevance of UA.
Subjects: Among 1,233 patients who received percutaneous coronary intervention 
(PCI) , a total of 701 patients who underwent IVUS during the early phase of PCI were 
examined. 
Results: The UA was observed in 84(12%) patients, including 44(52.3%) patients with 
stable angina pectoris and 40(47.7%) patients with acute coronary syndrome(ACS). The 
UA rate in each of these groups of patients was 8.4% and 22.2%, respectively, indicating 
a higher frequency in the ACS. UA was the most frequently observed at a proximal lesion 
(48.0%) characterized by positive remodeling (97.1%), nearby calciﬁ cation (91.0%). With 
regard to the outcome of treatment and the hospital prognosis of lesions associated with 
UA, up to 25.2% showed slow ﬂ ow during PCI, 4.1% of patients showed major advanced 
cardiovascular events in the hospital prognosis.
Conclusion: The cause of UA remains unknown, although it has been suggested that 
the phenomenon is caused by early intra-atheroma bleeding or by core calciﬁ cation. 
Considering that UA was observed in almost 12% of the PCI patients and that it is likely 
to affect coronary ﬂ ow during treatment, further evaluation of this phenomenon seems 
to be necessary.
1096-41 Microembolism of Plaque Debris Than Thrombus Is the 
Cause of Slow / No-reﬂ ow Phenomenon
Isamu Mizote, Yasunori Ueda, Atsushi Hirayama, Kazuhisa Kodama, Osaka Police 
Hospital, Osaka, Japan
Background: Slow / no-reﬂ ow phenomenon (SNRP) is more often caused in the PCI of 
SVG. SAFER trial demonstrated that SNRP is reduced by percusurge. Microembolism 
of thrombus or plaque debris is considered as the cause of SNRP. Therefore, we have 
tried to determine which of thrombus or plaque debris is the main cause of SNRP.
Methods: Consecutive 110 patients, from July 2000 to July 2002, with AMI treated 
without percusurge or thrombectomy (group 1) and consecutive 81 patients, from July 
2002 to July 2004, treated with percusurge (group 2) were included. Inclusion criteria 
were 1) within 12hrs from onset, 2) reference diameter >3.0mm, 3) treated with stent, and 
4) culprit lesion was assessed by angioscopy. In each group, patients were subdivided 
into two groups according to whether they had ruptured plaque (RP). RP was deﬁ ned 
as having at least two of the following criteria: 1) plaque disruption with much thrombus 
occupying >50% of lumen area, 2) large cavity / ulceration, 3) yellow or mixed thrombus 
with yellow plaque, and 4) distal embolism observed by angioscopy. Incidence of SNRP 
was compared between 4 groups. Microcirculation damage was evaluated by % ST 
resolution and MBG. Aspirated material was histrologically classiﬁ ed in three types, that 
is, thrombus and plaque, plaque only, and thrombus only. 
Results: SNRP was signiﬁ cantly frequent in group 1 RP (+) than other groups (group 1 
RP (+) vs. other group: p<0.05). % ST resolution and MBG were improved by percusurge 
in the patients with RP (group 1 RP (+) vs. group 2 RP (+): 68±15% vs. 40±21%; 2.6±0.5 
vs. 1.8±0.3, p=0.001), but not in the patients without RP (group 1 RP (-) vs. group 2 RP (-): 
61±14% vs. 58±17%, 2.3±0.4 vs. 2.2±0.6, p=ns). Aspirated material >1mm were detected 
more (97.3% vs. 78.5%, p=0.038) in the patients with RP and their aspiration materials 
were more plaque and thrombus than without RP(Thrombus and plaque: 90.6% vs 27.6% 
p<0.05 Plaque only: 4.7% vs 3.5% p=n.s Thrombus only: 4.7% vs 52.4% p<0.05)
Conclusions: SNRP was more often observed in the patients with RP and was reduced 
by distal protection, which also preserved myocardial microcirculation. Therefore, the 
cause of SNRP may be the microembolism of plaque debris rather than of thrombus.
1096-42 Fate of Acute Stent Malapposition After Sirolimus-
Eluting Stent Implantation: A Serial Intravascular 
Ultrasound Analysis
Hideo Takebayashi, Gary S. Mintz, Stephane G. Carlier, Koichi Sano, Masashi Kimura, 
Kenichi Fujii, Takenori Yasuda, Ricardo A. Costa, Jose R. Costa, Jr., Jeffrey W. Moses, 
Seiichi Haruta, Martin B. Leon, Cardiovascular Research Foundation, New York, NY, 
Fukuyama Cardiovascular Hospital, Hiroshima, Japan
Background: Serial intravascular ultrasound (IVUS) studies have shown that sirolimus 
eluting-stent (SES) reduce restenosis by inhibiting neointimal hyperplasia (IH). However, 
acute stent malapposition (SM) after SES implantation may lead to underdosing at the 
tissue level due to a lack of stent-vessel wall contact.
Method: We evaluated the long-term IVUS ﬁ ndings of acute SM after SES implantation 
in 60 consecutive pts (60 de novo lesions) in whom IVUS was performed at index and 
6-month follow-up. Acute SM was deﬁ ned as 1 or more stent struts clearly separated from 
the vessel wall with evidence of blood speckle behind the strut without overlapping side 
branch. “Large” acute SM was deﬁ ned as baseline stent malapposition area >2.0mm2.
Results: Acute SM occurred in 15 lesions (25% overall). Of 15 acute SM, 2 resolved, 9 
increased in size, and only 1 had neointimal proliferation at acute SM site. A signiﬁ cant 
increase in SM area was only observed in “Small” SM group; this increase was 
predominantly related to an increase in EEM area (Table).
2005_2_AngioInterCardio.indd   58 12/23/04   9:56:30 AM
JACC February 1, 2005 ABSTRACTS - Angiography & Interventional Cardiology  59A 
A
ngiography &
 Interventional C
ardiology
Conclusion: Acute SM after SES implantation usually does not resolve and often increases 
(slightly), especially when small. However, it rarely leads to signiﬁ cant IH at follow-up.
“Small” acute SM (n=10) “Large” acute SM (n=5) P
Baseline SM area, mm2 0.8±0.4 4.1±1.4 <0.01
Acute SM resolution (%) 10 20 NS
�SM area, mm2 0.4±0.8 -1.5±2.3 <0.05
�EEM area, mm2 1.4±1.4 -1.3±2.4 <0.05
�P&M area, mm2 1.0±1.2 0.1±0.5 NS
�intrastent lumen area, mm2 0.0±0.1 -0.5±1,2 NS
IH area, mm2 0.0±0.0 0.5±1.2 NS
SM=stent malapposition, EEM=external elastic membrane, IH=intimal hyperplasia
1096-43 Heterogeneity of Neointimal Distribution of Instent 
Restenosis in Diabetic Patients
Junya Ako, Hideaki Kaneda, Akiyoshi Miyazawa, Mamoo Nakamura, Shinjo Sonoda, 
Yoshihiro Morino, Paul G. Yock, Peter J. Fitzgerald, Yasuhiro Honda, Stanford University, 
Stanford, CA
Background: Diabetes mellitus is an independent predictor of restenosis after 
percutaneous coronary intervention. However, the pattern of restenosis in diabetics is not 
well documented with 3-D intravascular ultrasound (IVUS) analysis.
Methods: One hundred thirty four follow-up IVUS images with single bare metal stent 
implantation were available for analysis. Vessel, lumen, and stent areas were manually 
traced in stented segments. Average area was calculated as volume data divided by stent 
length. To measure the cross sectional and longitudinal severity of luminal encroachment 
by neointima, % obstruction was computed as neointimal area divided by stent area, and 
IH60 was calculated as the percentage of the stent length with % obstruction greater than 
60%. Values were compared between diabetics and non-diabetics.
Results: IVUS measurements were shown in table. Although average neointimal area 
is similar, there is a tendency toward higher maximal intimal hyperplasia and smaller 
minimum lumen area in diabetics. Signiﬁ cantly higher percentage of stent length was 
severely encroached by neointima in diabetics.
Conclusions: Despite a similar overall amount of neointimal hyperplasia, diabetic patients 
showed a more heterogenous pattern of neointima following bare metal stenting, resulting 
in longer high-grade obstruction segments. This may have important implications for stent 
design and pharmacokinetic properties of next-generation drug-eluting technology for this 
complex patient subset.
Non-DM (n=101) DM (n=33) p-value
Average Vessel Area, mm3/mm 17.0±4.3 17.2±5.9 NS
Average Stent Area, mm3/mm 8.8±2.2 8.4±2.3 NS
Average Lumen Area, mm3/mm 6.1±2.3 5.6±2.8 NS
Average Neointimal Area, mm3/mm 2.8±1.5 2.8±1.9 NS
Averalge % obstruction 32±16 35±21 NS
Minimum Lumen Area, mm2 4.2±2.0 3.5±1.9 0.06
Maximum Neointimal Area, mm2 4.6±1.8 5.0±2.0 NS
% Obstruction at maximum neointimal area 50±17 57±20 0.05
IH60, % 8±20 18±27 0.02
ORAL CONTRIBUTIONS
833  Intravascular Ultrasound Assessment 
of Atherosclerosis
Tuesday, March 08, 2005, 8:30 a.m.-10:00 a.m.
Orange County Convention Center, Room 304E
8:30 a.m.
833-3 Quantiﬁ cation And Qualiﬁ cation Of Coronary Plaque 
Using Multidetector row Computed Tomography In 
Diabetic Patients With Coronary Artery Disease. -a 
Comparative Study With Intravascular Ultrasound-
Akiko Sakuta, Noriko Nishii, Mayumi Noda, Atsushi Takagi, Yukio Tsurumi, Ryohei 
Kuwatsuru, Hiroshi Kasanuki, Tokyo Women’s Medical University, Tokyo, Japan
Background: MDCT is recognized as a useful tool for quantitative and qualitative 
assessment of coronary plaque in selected population. However, it is not clear whether 
MDCT affords diagnostic usefulness in patients with diabetes (DM), who often show 
diffuse and complex lesion morphology. Accordingly, we sought to determine whether 
coronary plaque detection and characterization by MDCT is reliable in diabetic patients 
by comparing intravascular ultrasound (IVUS) ﬁ ndings.
Materials and methods: In 14 diabetic patients, 35 lesions were analyzed regarding 
plaque burden assessment and tissue characterization by both 40MHz IVUS with 
automated pullback and 16-slice MDCT (Light Speed Ultra16 GE, Aquilion16 Superheart 
Toshiba, 0.5-0.625mm slice thickness, 0.4-0.5s rotation time, retrospective ECG-gating, 
100ml contrast media iv). MDCT images were evaluated based on multiplanar reformation 
images (short axis view of the vessel lumen). Quantitative assessment: The cross sectional 
vessel and plaque area were measured to calculate area stenosis, as plaque area divided 
by vessel area, by each modality. Qualitative assessment: Plaque components were 
separately evaluated by IVUS-derived plaque echogenity (soft, intermediate, calciﬁ ed) 
and by average CT attenuation values of three 1mm2-ROIs within the plaque areas.
Results: Area stenosis measured by MDCT and IVUS showed a signiﬁ cant correlation 
(r=0.81, p<0.001). The MDCT-derived attenuation value measurement signiﬁ cantly 
distinguished IVUS-derived plaque echogenity; soft (40±27HU; n=12), intermediate 
(86±19HU; n=11), and calciﬁ ed plaques (725±267HU; n=12, p<0.001). For detection of 
calciﬁ ed plaque, MDCT had the sensitivity of 92%, and speciﬁ city of 96%. For intermediate 
plaque (deﬁ ned as 50-130HU), sensitivity was 91%, speciﬁ city was 83%. For soft plaque, 
sensitivity was 67%, speciﬁ city was 100%.
Conclusions: The present study demonstrates the diagnostic signiﬁ cance of 16-slice 
MDCT for plaque quantiﬁ cation and qualiﬁ cation even in diabetic patients with CAD.
8:45 a.m.
833-4 An Intensive Lipid Lowering Strategy Halts Progression 
of Atherosclerosis at Coronary Arterial Branch Points
Stephen J. Nicholls, Paul Schoenhagen, Ilke Sipahi, Tim Crowe, Samir Kapadia, E. 
Murat Tuzcu, Steven E. Nissen, Cleveland Clinic Foundation, Cleveland, OH
Background: Altered shear stress at coronary arterial branch points predispose these 
regions to formation of atherosclerotic plaque. It is uncertain how these lesions respond 
to lipid lowering. We aimed to characterize the response of these lesions to moderate and 
intensive lipid lowering strategies.
Methods: Isolated matched lesions at coronary arterial branch points were identiﬁ ed in the 
baseline and followup intravascular ultrasound studies of 122 subjects who participated 
in the REVERSAL study, a comparison of moderate lipid lowering with pravastatin 40mg 
and intensive lipid lowering with atorvastatin 80mg for 18 months. Cross sectional areas 
were measured for the external elastic membrane (EEM CSA) and lumen (L CSA). 
Plaque+media (P+M) CSA was determined as the difference between EEM CSA and L 
CSA. The change in these parameters between baseline and followup was determined.
Results: Compared with baseline, P+M CSA increased with pravastatin by 4.1+/-1.8% 
but did not change (1+/-1.9%) with atorvastatin. In contrast, EEM CSA increased by 9.2+/-
2.9% with atorvastatin and 10.8+/-2.5% with pravastatin. Similarly, L CSA increased by 
9.4+/-3.1% with atorvastatin and 7.6+/-3% with pravastatin. 
ATORVASTATIN
(n=53)
PRAVASTATIN
(n=69)
BASELINE FOLLOWUP BASELINE FOLLOWUP
EEM CSA (mm2) 15.3+/-0.7 16.6+/-0.8** 14.5+/-0.5 16+/-0.7***
L CSA (mm2) 7.8+/-0.3 8.5+/-0.5** 7.8+/-0.3 8.4+/-0.4*
P+M CSA (mm2) 7.5+/-0.4 8.1+/-0.4 6.6+/-0.3 7.7+/-0.4*
Delta P+M CSA 1+/-1.9% 4.1+/-1.8%
*p<0.05, **p<0.01 and ***p<0.0001 for comparison with baseline
Conclusion: An intensive lipid lowering strategy halts progression of plaque area at branch 
points. This beneﬁ t was associated with a favourable impact on vascular remodeling. This 
highlights the beneﬁ cial properties of intensive lipid lowering on established atheroma.
9:00 a.m.
833-5 Association of Arterial Remodeling and Plaque 
Characterization by Intravascular Ultrasound Virtual 
HistologyTM Analysis
Kenichi Fujii, Stéphane G. Carlier, Gary S. Mintz, William Wijns, Antonio Colombo, 
Ricardo A. Costa, Jose de Ribamar Costa, Jr., Hideo Takebayashi, Takenori Yasuda, 
Masashi Kimura, Koichi Sano, Issam Moussa, George Dangas, Roxana Mehran, Gregg 
W. Stone, Jeffrey W. Moses, Martin B. Leon, Columbia University Medical Center and 
Cardiovascular Research Foundation, New York, NY
Background: Positive remodeling is characteristic of lesions in pts with acute coronary 
syndromes or vulnerable (rupture-prone) plaques. However, there is little data correlating 
plaque morphology and arterial remodeling. 
Methods: Fifty-four non-bifurcation native coronary lesions (36 patients) were imaged in 
vivo using 30-MHz intravascular ultrasound (IVUS) transducers. Radiofrequency signals 
were classiﬁ ed into 4 plaque types: calciﬁ ed; lipid-core; ﬁ brous; and ﬁ bro-lipidic. These 
algorithms have been derived and validated in vitro. The remodeling index (RI) was 
calculated as lesion divided by interpolated external elastic membrane area. Lesions were 
divided into two groups: 1) Positive remodeling (RI >1.05, 18 lesions) and 2) Intermediate/
Negative remodeling (RI ≤1.05, 36 lesions). 
Results: Although the reference segment plaque compositions were similar, lesion site 
plaque components were different between the 2 groups (Table) with more ﬁ brolipidic 
plaque in positive remodeling lesions. Furthermore, there were linear relationships 
between RI vs %ﬁ bro-lipidic plaque and %calciﬁ ed plaque (r=0.49, p=0.002, and r=-0.27, 
p=0.04, respectively). These ﬁ ndings were still signiﬁ cant when other common IVUS 
deﬁ nitions of remodeling were used. 
Conclusions: In vivo IVUS-based virtual histology demonstrates that positive remodeling 
occurs in lesions with more ﬁ bro-lipidic plaque.
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Virtual histology analyses
Positive 
remodeling 
(n=18)
Intermediate/
Negative 
remodeling 
(n=36)
P Value
Reference calciﬁ ed plaque area, % 1.8±4.2 2.6±6.4 NS
Reference lipid-core area, % 6.9±8.9 8.3±8.4 NS
Reference ﬁ brous plaque area, % 70.3±13.6 68.0±17.3 NS
Reference ﬁ bro-lipidic plaque area, % 20.9±9.7 21.1±17.3 NS
Lesion calciﬁ ed plaque area, % 2.3±3.5 4.1±4.8 NS
Lesion lipid-core area, % 5.8±7.2 9.0±6.9 NS
Lesion ﬁ brous plaque area, % 61.5±14.0 65.7±12.2 NS
Lesion ﬁ bro-lipidic plaque area, % 30.5±12.5 21.2±7.9 0.004
9:15 a.m.
833-6 Relationship Between Angiographic Extent Of Coronary 
Artery Disease And Severity Of Plaque Burden By 
Intravascular Ultrasound
Michael S. Chen, Chuan-Chuan Wun, Ilke Sipahi, David S. Lee, Paul Schoenhagen, E. 
Murat Tuzcu, Sorin J. Brener, Steven E. Nissen, Cleveland Clinic, Cleveland, OH, Pﬁ zer 
Pharmaceuticals, New York, NY
Background: Coronary angiography, the traditional means of assessing extent of coronary 
artery disease, views only the vessel lumen. Coronary intravascular ultrasound (IVUS) 
provides a more accurate analysis of plaque burden. Whether any relationship exists between 
disease burden as assessed by angiography and IVUS is poorly deﬁ ned. We aimed to 
determine whether angiographic severity of disease correlates with plaque burden by IVUS.
Methods: Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) was 
a randomized trial comparing effects of intensive versus moderate lipid-lowering therapy 
on percent atheroma volume by IVUS. IVUS was performed on one coronary artery (the 
left anterior descending artery where possible). Angiographic lesion severity was visually 
estimated and classiﬁ ed as < 50%, 51-90% and >90%. A vessel was diseased if any 
lesion >50% existed in either the parent vessel or its major branches. Of 502 subjects, 
389 subjects had complete coronary angiographic data for all native coronary vessels and 
interpretable IVUS images. Primary outcome of interest was correlation between baseline 
angiographic extent of disease and percent atheroma volume by IVUS.
Results: Number of diseased vessels was correlated with increasing percent atheroma volume 
(33.4 +/- 10.1, 39.4 +/- 10.8, 40.9 +/- 9.4 and 45.1 +/- 12.1 for 0, 1, 2, and 3 diseased vessels, 
respectively (p<0.0001, Spearman rank correlation r=0.32). In contrast, severity of disease, as 
measured by the number of diseased vessels with any lesion > 90%, had a weaker correlation 
with percent atheroma volume (p<0.0001, Spearman rank correlation r=0.23).
Conclusions: Extent of angiographic disease, as represented by number of moderately 
diseased vessels, appears to be a better predictor of plaque burden than severity of 
angiographic lesions.
9:30 a.m.
833-7 Tissue Characterization of Human Coronary Plaques 
by Spectral Analysis of Backscattered Intravascular 
Ultrasound Signal: Initial Experience in 400 Arteries
Stephane Carlier, Jose de Ribamar Costa, Jr., Gary Mintz, Kenichi Fujii, Koichi Sano, 
Masashi Kimura, Ricardo Costa, Edward Krepps, Jeffrey Moses, Gregg W. Stone, Martin 
B. Leon, Cardiovascular Research Foundation, New York, NY, Columbia Presbyterian 
Medical Center, New York, NY
Background: Characterization of atheroma composition by spectral analysis of backscattered 
intravascular ultrasound (IVUS) signal has been recently introduced. We sought to evaluate 
this methodology during IVUS guided percutaneous interventions (PCI).
Methods: Four hundred de novo native coronary arteries in 387 patients were imaged 
using ECG-gated acquisition. Virtual HistologyTM was applied using a new algorithm 
based on the blind deconvolution (BD) of the backscattered signal. This avoids tedious 
calibration of the catheter in plexyglass phantoms. Signals were classiﬁ ed into four plaque 
types: calciﬁ ed, ﬁ brous, ﬁ bro-lipidic, and lipid core.
Results: A majority of our recordings (>75%) were performed with 6-Fr compatible IVUS 
catheters (40 MHz CVIS and 20 MHz phased-array Eagle EyeTM) for which BD will soon be 
available. Complete data analysis will be presented. In our population that includes 73% 
of stable patients, the recordings performed with a 30 MHz CVIS catheter demonstrate a 
signiﬁ cant positive correlation between the % of lipid core and LDL, and between the % 
of calcium and HDL (see ﬁ gures). Blind deconvolution suppresses potential inaccuracies 
related to the variability of suboptimal phantom calibrations. The catheter may now remain 
sterile and pre-/post PCI analysis in the cathlab is possible.
Conclusion: Real time tissue characterization during PCI is possible. The histopathological 
information of the plaques will reveal important prognostic and clinical information.
9:45 a.m.
833-8 Infusion of Recombinant ApoA-I Milano Promotes 
Reverse Remodeling of Coronary Atherosclerotic 
Lesions
Stephen J. Nicholls, Ilke Sipahi, Paul Schoenhagen, Tim Crowe, Samir Kapadia, E. 
Murat Tuzcu, Steven E. Nissen, Cleveland Clinic Foundation, Cleveland, OH
Background: It has previously been demonstrated that infusing reconstituted high density 
lipoprotein (rHDL) containing recombinant apoA-I Milano (AIM) promotes regression of 
coronary atherosclerosis in humans. The aim of this study was to characterize arterial 
remodeling in response to this intervention.
Methods: 47 patients with acute coronary syndromes received 5 weekly infusions of 
placebo (n=11) or rHDL containing AIM at a dose of 15 mg/kg (n=21) or 45 mg/kg (n=15). 
Matched coronary intravascular ultrasound studies at baseline and followup were studied. 
Total external elastic membrane (EEM) and lumen volumes at baseline and followup 
were compared. Each artery was then characterized as either expansive (increase in 
both EEM and lumen volumes), reverse (decrease in both EEM and lumen volumes) or 
no remodeling.
Results: Infusion of rHDL promoted regression of plaque volume. Compared with 
baseline, infusion of rHDL was associated with a 5+/-3% reduction in total EEM volume. In 
contrast, total lumen volume did not change with any intervention (table). In those patients 
who were treated with rHDL, 86% of arteries demonstrated arterial remodeling, of which 
61% were classiﬁ ed as reverse and 39% as expansive. 
Placebo Combined rHDL Low dose AIM High Dose AIM
Base Foll Base Foll Base Foll Base Foll
Plaque Volume 
(mm3) 173±34 170±36 268±27 254±25**** 296±36 280±34** 231±40 218±38***
EEM Volume (mm3) 429±81 424±80 629±59 599±53** 677±80 661±75 561±87 512±70*
Lumen Volume 
(mm3) 273±44 265±44 375±34 366±32 403±48 404±47 336±46 313±39
*p=0.053, **p<0.05, ***p<0.01 and ****p<0.001 compared with baseline
Conclusion: The reduction in coronary plaque volume that is seen with infusions of 
recombinant apoA-I Milano is commonly associated with reverse remodeling of the 
arterial wall.
POSTER SESSION
1122  Chronic Total Occlusions, Cutting 
Balloon, GP IIb/IIIa Inhibitors in 
Percutaneous Coronary Intervention
Tuesday, March 08, 2005, 9:00 a.m.-12:30 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 9:00 a.m.-10:00 a.m.
1122-2 Effects of Antisense Oligodeoxynucleotides to PDGF A-
Chain on the Stent-Induced Stenosis of Pig a Coronary 
Artery Using a Coated Multipore Stent
Shin-Ichiro Yokoyama, Satoshi Saito, Noboru Fukuda, Yuxin Li, Satoshi Kunimoto, Kazuo 
Serie, Nihon University School of Medicine, Tokyo, Japan
Background: We have demonstrated that antisense oligodeoxynucleotides (ODN) or 
ribozyme to PDGF A-chain efﬁ ciently suppressed the restenosis of rat carotid artery after 
balloon injury. This study was undertaken to evaluate the efﬁ ciency of antisense ODN 
coated into multipore stent for the stent restenosis. This is a newly developed coated 
multipore stent. 
Methods: A coated multipore stent incubated with phosphorothiaote-linkaged antisense 
ODN with polyethylenimine (A-group) or incubated with saline (C-group) was implanted in 
the proximal LAD in 6 pigs (BW 25-30kg) in each group. Four weeks later, we performed 
CAG and intravascular ultrasound (IVUS), and sacriﬁ ced them to remove hearts. 
We calculated %-area-stenosis from IVUS and examined the pathological ﬁ ndings. 
Endothlization was also assessed using with coronary endoscpe.
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Result: There was no difference on coronary artery and blood data between two groups. 
Analysis with IVUS showed that %-stenosis was 18.4+/-11.9% VS 56.3+/-4.5% at the 
stent proximal edge (p=0.02) and 11.1+/-9.4% VS 62.6+/-20.8%(C-group) at the stent 
distal edge (P=0.02), and 15.2+/-10.9% VS 73.9+/-8.4% at the minimum lumen area of 
the in-stent-stenosis (P=0.002) (A-group VS C-group). Pathological ﬁ ndings also showed 
28.7+/-7.3% VS 57.3+/-9.3% at the proximal site of stent and 29.7+/-1.6% VS. 62.0+/-
10.7% at the center of the stent (A-group VS C-group). Multipore stent did not disturb 
endothelization from ecdoscopic study and pathological ﬁ ndings. 
Conclusion: The antisense ODN to PDGF A-chain was efﬁ ciently delivered and 
effectively suppressed the stent-induced stenosis of pig coronary artery, suggesting that 
the coated multipore stent might be also useful to delivery the nucleotide.
1122-3 Efﬁ cacy and Safety of Percutaneous Coronary 
Intervention in Acute Coronary Syndrome Patients 
Randomized to Enoxaparin or Unfractionated Heparin: 
Results of SYNERGY
Harvey D. White, Neal S. Kleiman, Derek Chew, John L. Petersen, Lisa G. Berdan, 
Louise Traylor, Kenneth W. Mahaffey, Marc Cohen, Renato Santos, Robert A. Harrington, 
Robert M. Califf, James J. Ferguson, Green Lane Hospital, Auckland, New Zealand, 
Duke Clinical Research Institute, Durham, NC
Background: An early invasive strategy is the standard of care in high-risk patients 
with non-ST-elevation acute coronary syndromes (ACS). With a conservative strategy, 
enoxaparin (enox) is superior to unfractionated heparin (UFH). Less is known about enox 
with an early invasive strategy, particularly with high rates of clopidogrel and glycoprotein 
(GP) IIb/IIIa antagonist use.
Methods: In SYNERGY, 9978 patients presenting with high-risk ACS were randomized 
to receive enox or UFH. All patients who had postrandomization percutaneous coronary 
intervention (PCI) were included by intention-to-treat. Analyses are unadjusted for potential 
differences in PCI patients across treatment groups and post-randomization confounders.
Results: Overall, 4687 (47%) patients had PCI a median of 22.6 (6.4, 48.6) hours after 
randomization. Clopidogrel was administered in 62.9% (upstream 30.5%) and GP IIb/IIIa 
antagonists in 57.3% of patients (upstream 23.4%). The primary efﬁ cacy endpoint was 
death and myocardial infarction (MI) at 30 days.
UFH (n=2364) Enoxaparin (n=2323) P-value
Stent placement 86.5% 86.2%
Abrupt closure during procedure 0.7% 0.6%
Death 1.8% 1.7% 0.80
MI 13.2% 11.9% 0.18
Death/MI 14.2% 13.1% 0.30
Any transfusion 5.4% 6.8% 0.05
Transfusion >2 units PRBC 1.8% 2.4% 0.15
GUSTO severe bleeding 1.6% 1.5% 0.69
TIMI major bleeding 2.5% 3.7% 0.03
Conclusions: Similar outcomes, including a low incidence of acute thrombotic closure, 
are achieved with an invasive strategy with either subcutaneous enox or UFH in high-risk 
ACS patients treated with a high rate of intensive anti-platelet therapy. TIMI major bleeding 
rates are modestly increased with enoxaparin without a signiﬁ cant difference in GUSTO 
severe bleeding.
1122-4 Emergency Coronary Bypass Surgery for Percutaneous 
Coronary Interventions: Changes in the Incidence, 
Clinical Characteristics, and Indications from 1979 to 
2003
Eric H. Yang, Ryan J. Lennon, Charanjit S. Rihal, David R. Holmes, Jr., Mandeep Singh, 
Mayo College of Medicine, Rochester, MN
Background: Emergency CABG (within 24 hours) after PCI is associated with a signiﬁ cant 
morbidity and mortality. The inﬂ uence of higher-risk patients and new technologies on the 
need for emergency CABG is not well studied.
Objective: To evaluate the changes in incidence, clinical characteristics, and indications 
for emergency CABG in patients undergoing PCI from 1979-2003.
Methods: Data from 23,087 patients who underwent PCI at Mayo Clinic from 1979-2003 
were analyzed. Patients were divided into three groups: the “pre-stent” era, 1979-1994 
(n=8905); the “initial stent era”, 1995-1999 (n=7605); and the “current stent era”, 2000-
2003 (n=6577). The incidence, clinical characteristics, and indications for emergency 
CABG in each of the three groups were compared.
Results: There was a signiﬁ cant decrease in the incidence of emergency CABG from 
2.9% to 0.7% to 0.3% across the groups (p < 0.001). Patients in the recent time periods 
had a higher prevalence of hypertension, prior revascularization, and left ventricular 
dysfunction (ejection fraction < 40%). There was a greater prevalence of patients 
presenting with urgent/emergent PCI and more complex lesions in the recent time periods 
and a reduction in coronary dissections.
Patients Requiring Emergency CABG
1979-1994
(n=258)
1995-1999
(n=56)
2000-2003
(n=21)
Age, yrs 62.4 + 10.7 64.6 + 10.0 53.5 + 14.9
Male, No. (%) 181 (70%) 36 (64%) 16 (76%)
Unstable angina, No.(%) 187 (72%) 31 (55%)* 13 (62%)*
Diabetes, No. (%) 23 (9%) 3 (5%) 2 (10%)
Hypertension, No. (%) 98 (39%) 28 (56%) 13 (65%)
Body mass index (kg/m2) 27.0 + 4.1 28.4 + 3.9 30.4 + 4.3 *
History of smoking, No. (%) 157 (62%) 44 (80%) 16 (76%)
Prior CABG, No. (%) 25 (10%) 3 (5%) 0 (0%)
Prior PCI, No. (%) 48 (19%) 19 (34%) * 5 (24%)
Ejection fraction <40%, No. (%) 14 (5%) 7 (13%) 5 (24%) *
Type of PCI, No.(%)
Elective
Urgent
Emergent
210 (81%)
10 (4%)
38 (15%)
14 (25%)*
17 (30%)*
25 (45%)*
5 (24%)*
8 (38%)*
8 (38%)*
Total Stents Placed 0.1 + 0.4 0.9 + 1.1 * 1.1 + 1.4 *
Glycoprotein 2b/3a inhibitor, No.(%) 0 (0%) 16 (29%)* 11 (52%) *
Type C lesion, No. (%) 15 (29%) 24 (56%) * 9 (50%)*
Calcium in any stenosis, No.(%) 54 (22%) 30 (61%) * 11 (65%) *
Indication for CABG
Abrupt Vessel Closure 21% 4% 14%
Dissection 34% 22% 14%*
Incomplete Revascularization 10% 13% 19%
Perforation .5% 2% 9%
Unsuccessful Dilation 26% 50% 33%
Other 8% 9% 9%
* p<0.017 vs. 1979-1994
Conclusion: There has been a signiﬁ cant decline in the incidence of emergency 
CABG after PCI in the last 25 years. Changes in the characteristics of patients requiring 
emergency CABG may be a reﬂ ection of the increase use of an invasive strategy in sicker 
patients.
1122-34 Can We Discharge Patients Following Percutaneous 
Coronary Intervention After Six Hours of Observation?
Abdul Rashid, Eliot Schechter, Jorge F. Saucedo, Mohammad K J Ghani, Thomas A. 
Hennebry, Oklahoma University Health Sciences Center, Oklahoma City, OK, Veterans 
Affairs Medical Center, Oklahoma City, OK
Background: Percutaneous coronary intervention (PCI) is performed routinely for chronic 
stable angina and acute coronary syndrome. It is common practice to keep patients 
overnight following PCI. The purpose of this study is to determine the time of onset of 
major complications following PCI and possibility of same day discharge after PCI.
Methods: A total number of 1251 patients underwent coronary angiography in a Veterans 
Affairs hospital from April 2003 to June 2004. Among 1251 patients, 478 underwent PCI. 
All major complications were tracked and the time elapsed from the procedure was 
recorded. All these patients were admitted and were monitored closely for twenty-four 
hours following PCI.
Results: Of the 478 patients, 15 (3.13%) had complications. All those complications 
were evident in the ﬁ rst six hours of observation: 1 (0.21%) death, 2 (0.42%) myocardial 
infarctions, 2 (0.42%) contrast reactions, 2 (0.42%) coronary dissections, 3 (0.63%) large 
hematomas, 2 (0.42%) hypotension and 3 (0.63%) retroperitoneal bleeds. The time of 
onset of these complications, 6 were evident at < 1 hour, 3 were evident between 1-3 
hours and 6 were evident between 4-6 hours.
Conclusion: Percutaneous coronary intervention is a safe procedure. All major 
complications were evident in the ﬁ rst six hours following the PCI. This observation 
suggests that discharging patients after six hours of PCI is feasible and supports the 
need for a prospective study.
1122-35 Contemporary Outcomes of Coronary Artery 
Perforation During Percutaneous Coronary Intervention: 
Insights From the REPLACE-2 Trial
Eugenia Nikolsky, Michael A. Lincoff, Roxana Mehran, Ian J. Sarembock, David J. 
Cohen, Douglass Spriggs, Gregg W. Stone, Cardiovascular Research Foundation, New 
York, NY, Columbia University Medical Center, New York, NY
Background. Coronary artery perforation is a serious complication of percutaneous 
coronary intervention (PCI). The contemporary outcomes of coronary perforation have 
not been reported from a large recent database.
Methods. In the multicenter, randomized, double-blind REPLACE-2 trial, 6,010 pts 
undergoing elective or urgent PCI were randomized to unfractionated heparin with routine 
GP IIb/IIIa inhibition (H+IIb/IIIa) vs the direct thrombin inhibitor bivalirudin (Biv) with 
provisional GP IIb/IIIa inhibition.
Results. Coronary artery perforation occurred in 25 pts (0.4%), with a similar incidence 
in both randomization arms. Patients with vs. without coronary perforation were older 
(p=0.001), more frequently female (p=0.10), had higher creatinine clearance (p<0.0001), 
and PCI performed more frequently in type B2/C lesions (p=0.01). By multivariate analysis 
older age was the only independent predictor of coronary perforation (hazard ratio 1.07, 
p=0.0005).As seen in the table, patients with perforation had markedly higher rates of 
in-hospital and 6 month major adverse cardiac events (MACE) including death, MI and 
repeat revascularization (mostly CABG). Coronary perforation also resulted in high rates 
of major bleeding and blood transfusion. Outcomes of pts with perforation were similar 
with the 2 antithrombotic regimens. Conclusions. Coronary perforation, while rare, is 
associated with a markedly adverse prognosis, independent of anticoagulant regimen.
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Events (%) PerforationN=25
No perforation
N=5,976 P-value
In-hospital
Death 8.0 0.2 0.001
MI 28.0 6.0 0.0005
Urgent revascularization 24.0 0.6 <0.0001
- by PCI 4.0 0.7 0.15
- by CABG 20.0 0.4 <0.0001
MACE 36.0 7.0 <0.0001
Major bleeding 28.0 3.1 <0.0001
Blood transfusion 24.0 2.0 <0.0001
At 6 months
Death 8.0 1.2 0.001
MI 36.0 7.7 <0.0001
Revascularization 36.0 9.2 <0.0001
1122-37 Does Revascularization Using The New Wiring 
Technique Of Chronic Total Occlusion (cto) Contribute 
To Improve The Long-term Prognosis?
Keisuke Hirano, Toshiya Muramatsu, Reiko Tsukahara, Yoshiaki Ito, Yoshiyuki Furuse, 
Takashi Tsubota, Shigeru Nishimura, Kawasaki social Insurance Hospital, Kawasaki, 
Japan
Purpose:In this study, we investigated the possible contribution of revascularization of 
CTO to the improvement of cardiac function and long-term prognosis.
Methods:The subjects were divided into GroupP, which included patients who underwent 
a successful revascularization and did not develop re-occlusion in the remote phase(577 
patients,66±11years) and GroupO, which included patients whose CTO was occluded in the 
remote phase(179patients,67±10years).We evaluate success rate of opening CTO lesion using 
by conquest tapering guide wire(new wire technique). The average follow up was 770±560days. 
Predictors of cardiac deaths were analyzed employing the Coxs proportional hazards model. 
Initial success rate comparing conquest wire period and before conquest period.
Results: Initial success rate was signiﬁ cantly higher in used the conquest wire 
period(86%) than before conquest period(73%).
The long-term survival rate was signiﬁ cantly lower in GroupO(69%) than that in 
GroupP(96%). The value of LVEF was higher in GroupP than in GroupO(p=0.01).The 
survival rate was signiﬁ cantly higher in EF>40%(95%) than that in EF<40%(71%). The 
patients without myocardial viability diagnosed by scintigraphy and ultrasound, the 
long term survival rate in the groupP was 89% showing signiﬁ cantly higher rate (p ≤
0.01) compared with 60% in the groupO. Univariate analysis revealed that occlusion, 
unimproved EF, high age(more than 75year old), low EF(less than 40%), and not success 
cases, were signiﬁ cant predictors of cardiac death.
Conclusions: Revascularization using the new wiring technique improved the Initial 
success rate of CTO and long-term prognosis, even in patients with no myocardial viability.
1122-38 The Inﬂ uence of Wire Cross Pattern on Subsequent 
Outcome in Chronic Total Occluded lesion - 
Percutaneous Coronary Intervention
Satoru Sumitsuji, Ken Kishida, Noriyuki Hayashi, Yuhei Nojima, Yoshiyuki Nagai, Rinku 
General Medical Center, Izumisano, Osaka, Japan
Background: In Chronic Total Occluded lesion - Percutaneous Coronary Intervention 
(CTO-PCI), there are two different wire cross pattern. One is true lumen cross and another 
is false lumen cross. It is still unclear the inﬂ uence of wire cross pattern on subsequent 
outcome. The purpose of this study is to evaluate the inﬂ uence of wire cross pattern on 
subsequent outcome. 
Method: To evaluate this point, we studied successful 111CTO lesions in 109 cases from 
1998/3 to 2003/3. We compared target lesion revascularization (TLR) ratio, ﬁ nal patency ratio 
and subsequent number of needed PCI to achieve ﬁ nal patency between true lumen wire 
cross pattern (true group) and false lumen wire cross pattern (false group). The wire cross 
pattern was classiﬁ ed by angiogram and intra vascular ultrasound (IVUS). Final patency was 
deﬁ ned as angiographic patent without restenosis at follow-up (more than 6month after PCI). 
Results: TLR ratio was 36.7% in true group and 60.0% in false group (p=0.057). Final 
patency ratio was 90.7% in true group and 78.1% in false group (p=0.103). Number 
of needed PCI was 0.51±0.74 in true group and 0.92±1.15 in false group (p=0.145). 
Conclusions: We concluded that the wire cross pattern possible to inﬂ uence on 
subsequent outcome. Especially for TLR ratio, false lumen wire cross pattern tend to 
increase TLR ratio.
1122-39 Recanalization of Chronically Occluded Coronary 
Arteries: Experience in 1250 Cases, Including Long-
Term Angiographic Follow-Up
Markus Lins, Gunhild Herrmann, Ruediger Simon, University Hospital Schleswig-
Holstein, Campus Kiel, Kiel, Germany
PCI of chronically occluded coronary arteries continues to be a challenge of interventional 
cardiology. To elucidate inital success and long-term angiographic follow-up a consecutive 
series of 1250 patients, who underwent recanalisation (R) procedure between 1988 
and 2002 in our department were investigated. Mean time of occlusion (TIMI 0) was 
documented for 21 weeks. There were R of RCA in 43.1%, RCX in 17.3%, LAD in 36.4%, 
SVG in 3.2%. For R a standard guidewire (14/1000 inch) was used in about 80% of 
the procedures, less often other techniques such as rotational wire or laser wire were 
performed. Overall success rate was 69% (866/1250) with residual stenosis <50% (QCA, 
Philips DCI): RCA 65.3%, LCX 71.6%, LAD 73.7% and SVG 76.9%. Mean ﬂ uroscopy time 
was 26 min in successful cases and 34 min in unsuccessful cases, total time of procedure 
was 61 and 65 min respectively. Complication rate was 2.7% (35/1250, in- and out- of- 
hospital): 11 pts developed AMI, 7 pts underwent emergency CABG due to perforation or 
imminent vessel occlusion (in pre stent era). In 13 stented pts SAT was documented, 3 pts 
suffered from intracranial hemorrhage and 3 pts died.
In 676/866 pts (78%) angiographic follow-up was available: 402/676 pts (60%) showed 
satisfying results with restenosis <50%, wheras restenosis was found in 187/676 pts 
(28%). Reocclusion was less frequent in 87/676 pts (12%). Those pts with restenosis 
underwent reintervention in 90% (168/187) and those with reocclusion in 30% (26/87). All 
other pts could be medically treated in most cases, however, bypass operation was rare.
This series of 1250 pts who underwent recanalisation of an occluded coronary vessel 
shows a high primary success rate with standard wire technique. The high angiographic 
follow-up rate of 78% shows a very acceptable long-term outcome.
1122-40 Predictors of Procedural Failure in Chronic Total 
Occlusion
Hiroyuki Tanaka, Kazuaki Mitsudo, Katsumi Inoue, Tsuyoshi Goto, Kazushige Kadota, 
Satoki Fujii, Hiroyuki Yamamoto, Yasushi Fuku, Sou Takenaka, Akitoshi Hirono, Masanao 
Taba, Keishi Saihara, Atsushi Ikeda, Yoji Kojima, Junpei Maekawa, Sachiko Maekawa, 
Natsuki Takahashi, Hajime Saeki, Yukinobu Nakamura, Kurashiki Central Hospital, 
Kurashiki, Japan
Background: Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) is 
still difﬁ cult, in spite of the technical developments and increased operator experiences. In these 
cases, the use of tapered-tip guide-wire, the so-called Neos Conquest™ guide-wire (NCG), is 
quite helpful. This study was to assess the determinants of procedural failure in CTO.
Methods and Results: Nine-hundred thirty four patients with 1039 lesions, who 
underwent PCI for CTO between 1995 and 2004, were divided into four periods. Period 
I: from January 1995 to September 1996, NCG was unavailable; Period II: from October 
1996 to October 1998, the guide-wire exchange strategy was stepwise; Period III: from 
November 1998 to March 2001, we introduced the advanced guide-wire exchange 
strategy of using the NCG to avoid the large subintimal space; Period IV: from April 2001 
to May 2004, we introduced the new double-wire techniques (parallel and seesaw wire 
methods). The success rate of the PCI for CTO was 64.6%, 67.9%, 81.0%, and 87.7% 
for Periods I, II, III and IV, respectively (Periods I, II vs. IV, p<0.001, III vs. IV, p=0.029). 
Independent predictors of procedural failure during Periods I and II were the length of 
the occlusion (odds ratio [OR]=3.23 [95% conﬁ dence interval, CI=1.48 to 7.06], p=0.003; 
OR=2.84 [CI=1.43 to 5.67], p=0.003, respectively) and the duration of the occlusion 
(>12months) (OR=2.88 [CI=1.05 to 7.92], p=0.040: OR=10.96 [CI=4.51 to 26.59], p<0.001, 
respectively). During Period III, the length of the occlusion (OR=4.90 [CI=1.71 to 14.04], 
p=0.003) was an independent predictor of procedural failure. On the other hand, during 
Period IV, calciﬁ cation (OR=5.30, [CI=2.11 to 13.36], p<0.001) and excessive tortuousity 
(OR=4.02, [CI=1.37 to 11.81], p=0.011) were independent predictors of CTO failure.
Conclusions: The use of the NCG and technical developments improved the success 
rate of PCI for CTO. However, PCI for CTO lesions with calciﬁ cation and excessive were 
still difﬁ cult.
1122-41 The Cutting Balloon Versus Conventional Balloon 
Angioplasty Prior to Stenting for the Treatment of Small 
Coronary Arteries (CUTBASS) Study - A Multicenter 
Randomized Trial in Japan
Yuji Sakanoue, Akira Itoh, Kazuo Haze, for the CUTBASS Investigators, Osaka City 
General Hospital, Osaka, Japan
Background: The Cutting Balloon (CB) has yet to be prospectively evaluated for use 
prior to stent implantation in small vessels, though it might reduce restenosis and improve 
clinical outcomes in this difﬁ cult lesion subset.
Methods: We randomly assigned 111 patients requiring intervention for a single lesion in 
a small vessel (<3.0 mm diameter) to either CB+stenting (CB group, n=56) or conventional 
balloon angioplasty (POBA)+stenting (POBA group, n=55). The primary angiographic 
end-point was restenosis (>50% stenosis) at 6-month follow-up.
Results: Follow-up angiography was performed in 97 patients (87%). There was no 
signiﬁ cant difference in mean vessel size in the 2 groups. There were signiﬁ cantly fewer 
post-stenting coronary complications (branch occlusion, coronary dissection) in the 
CB group than in the POBA group (2.0% vs. 14.3%, p<0.05). At 6-month angiographic 
follow-up, we observed similar percent diameter stenosis with 30.2±20.0% (CB) vs. 
36.8±23.4% (POBA); p=0.14, and similar binary restenosis rates (17% (CB) vs. 22% 
(POBA); p=0.50). The proportion of patients free of target lesion revascularization was 
also similar in both groups (83% (CB) vs. 82% (POBA), p = 0.86), as was the clinical 
events rate at 6 months. Conclusions: In these small lesions, use of the cutting balloon 
before stenting did not signiﬁ cantly reduce the 6-month restenosis or major adverse 
cardiac events rates compared to those for conventional angioplasty prior. Our Cutting 
Balloon patients did however present signiﬁ cantly fewer coronary complications (edge 
dissection and branch occlusion), which suggests that this strategy may be superior to 
conventional angioplasty.
1122-42 Tiroﬁ ban, Administered at High Dose Bolus During 
Coronary Angioplasty is Highly Effective in Preventing 
Periprocedural Ischemic Complications in Diabetic 
Patients. Insights Into The ADVANCE Trial
Marco Valgimigli, Gianfranco Percoco, Fabrizio Ferrari, Dario Barbieri, Gianluca Campo, 
Patrizia Malagutti, Giordano Cicchitelli, Gabriele Guardigli, Piefrancesco Agostoni, 
Roberto Ferrari, University of Ferrara, Ferrara, Italy
Background: Platelet reactivity is pivotal in the pathogenesis of complications after 
coronary angioplasty (PCI). In diabetic patients platelet aggregability is increased, thus 
partially explaining the higher rate of adverse events in this subset of patients during PCI. 
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As part of the ADVANCE trial, we sought to determine whether tiroﬁ ban, administered 
with the high-dose bolus (HDB), is able to reduce ischemic events in diabetic patients 
referred for elective or urgent PCI.
Methods: Ninety-nine patients (mean age 70±10 years; 70 males) affected by diabetes 
(65% non-insulin dependent), undergoing PCI on top of thienopyridines pre-treatment, were 
double-blinded randomised to placebo (n=45) or HDB tiroﬁ ban (n=54), given as a bolus 
of 25 µg/Kg/3-min and followed by an infusion of 0.15 µg/Kg/min for 24 to 48 h. Patients 
assigned to tiroﬁ ban received 50-70 U/Kg heparin (maximum 7000 U), while patients 
assigned to placebo received an initial bolus of 100U/Kg (maximum 10000 U). The rate of 
major cardiovascular adverse events (MACE) composed of death, myocardial infarction (MI) 
and target vessel revascularisation (TVR) during the index procedure were evaluated.
Results: Overall, 26% of population presented with non-ST segment elevation acute 
coronary syndromes (NSTACS), while stable angina (SA) was the indication to intervention 
in the remainders. After a median follow-up of 262 days (range: 143-398) the incidence 
of MACE was signiﬁ cantly reduced in the tiroﬁ ban group (17% vs. 40%, in the placebo 
group; HR 0.37 [95% CI: 0.11-0.58]; p=0.003), with a relative risk reduction of 58%. The 
difference in the incidence of events between the two groups was mainly due a lower rate of 
periprocedural MI (4% vs. 18%, p=0.048). In SA and ACS patients, MI rate was 0% and 13% 
in the tiroﬁ ban vs. 9% and 50% in the placebo group, respectively. The incidence of major 
and minor bleedings did not differ between the two groups. Conclusions: in unselected 
diabetic patients undergoing PCI, the use of tiroﬁ ban, given at HDB, by decreasing the 
incidence ischemic complications resulted to be both effective and safe, supporting the 
notion that diabetic population beneﬁ ts from a tailored drug regimen during PCI.
1122-43 Bolus Versus Bolus + Infusion of GP IIb/IIIa Inhibitor in 
Contemporary PCI Practice
Annapoorna S. Kini, Navin Budwani, Paul Lee, Michael C. Kim, Sajal Das, Tirumalesh 
Venkatesh, Madhu Prattipati, Mary-Beth Duffy, Samin K. Sharma, Mount Sinai Medical 
Center/ Cardiovascular Institute, New York, NY
Background: All randomized studies (except EPIC trial) of GP IIb/IIIa inhibitors (GPI) 
have incorporated bolus plus 12-18 hours infusion post-PCI. In the current PCI era of 
routine use of dual antiplatelet therapy and improved devices/techniques, prolonged 
infusion of the GPI may not be routinely required. Moreover, GPI bolus will give additional 
protection during device manipulation, the time of highest endothelial injury; also, GPI 
infusion is cumbersome, expensive and may cause increased vascular complications.
Methods: In Jan 2003 we changed the policy of GPI use to bolus only (except for procedural 
complications) and compared the results with 2002 policy of routine GPI bolus + infusion. 
Patient with MI, rest angina and rotablator were excluded. 960 pts of 2002 PCI done with GPI 
bolus + infusion were compared with 1112 pts of 2003 PCI done with GPI bolus only, for CK-
MB elevation, vascular complications (pseudoaneurysm, A-V ﬁ stula or vascular surgery) and 
30-day MACE (MI, urgent revascularization, stent thrombosis or death).
Results: Clinical and angiographic characteristics were similar in the two groups. In 2003, 
8.6% of GPI bolus cases required GPI infusion for some procedural events (Table).
Conclusions: The strategy of GPI bolus is associated with similar ischemic complications 
and 1-year survival as GPI bolus + infusion, but with reduced vascular complications and 
cost. Therefore, in the current era, GPI bolus only (with infusion as bailout) should be 
preferred over routine bolus + infusion.
2002
(n = 960)
2003
(n = 1112) P
Diabetes mellitus (%) 39 38 NS
ReoPro use (%) 22.4 21.5 NS
Clopidogrel preloading (%) 32 34 NS
Stent use (%) 93 94 NS
Procedural success (%) 98.4 98.5 NS
Any CK-MB elevation (%) 16.3 17.2 NS
Any Tn elevation (%) 30.8 31.4 NS
Length of hospital stay (days) 1.6 ± 0.2 1.7 ± 0.2 NS
Severe thrombocytopenia (%) 0.52 0.63 NS
30-day MACE (%) 3.0 3.2 NS
Vascular complications (%) 1.03 0.27 <0.01
GPI cost ($) 325 ± 150 706 ± 252 0.01
One-year mortality (%) 2.1 2.3 NS
1122-44 The First Clinical Experience of A Novel Penetration 
Catheter for Patients With Severe Coronary Artery 
Stenosis
Etsuo Tsuchikane, Osamu Katoh, Yasuyuki Suzuki, Koyo Sato, Ryohei Kurokawa, Akira 
Murata, Kenya Nasu, Yoshihiro Takeda, Tomomichi Suzuki, Mariko Ehara, Hidetoshi 
Sato, Tetsuo Matsubara, Takahiko Suzuki, Toyohashi Heart Center, Toyohashi, Japan
Recent development of conventional guide wires for percutaneous coronary intervention 
(PCI) provides the increase in success rate to cross the severe coronary artery disease 
such as chronic total occlusion (CTO) or severe calciﬁ ed stenosis. However, subsequent 
crossing by balloon or micro catheter is sometimes troublesome. We have developed a novel 
penetration catheter (Tornus, Asahi Intecc Co. Ltd, Aichi, Japan) for severe coronary artery 
stenosis which hinders crossing of conventional balloon or micro catheter. The main shaft of 
Tornus is a coreless stainless coil which is right handed lay (clockwise). Eight stainless wires 
are stranded in the coil. The outside diameter is 0.70 mm, and inside is 0.46 mm which is 
suitable for the 0.014 inch guide wire. Since the coil is stranded with 8 stainless wires and a 
length of 150 mm from the tip is tapered, the Tornus has desired ﬂ exibility and torquability. It 
can pass through the severe stenosis easily with counterclockwise rotation along the guide 
wire. The proﬁ le of the tip is 0.62 mm in diameter, and it is made of stainless-platinum alloy 
which provides the tip strength and radiopacity. We used Tornus in consecutive 14 patients 
(10 male, 68±10 years old) with severe coronary artery disease in which any 1.5mm balloon 
catheter or micro catheter could not cross through the lesion after successful 0.014 inch 
guide wire crossing. Of those, 10 patients had CTO (TIMI = 0, unknown occlusive duration) 
and 5 had severe calciﬁ ed stenosis. Tornus was successfully crossed through the lesion 
by manual counterclockwise rotation in all cases without any complication such as distal 
embolism, coronary perforation, or dissection. Device fracture by the handling was also not 
observed. For 5 patients the guide wire was exchanged to the rotational atherectomy wire 
through Tornus successfully and rotational atherectomy was performed. For others, Tornus 
made it possible to cross the lesion by 1.5 mm balloon catheter. Finally, subsequent stent 
implantation could be performed safely and optimal procedural result was obtained in all 
patients. In conclusion, this new device will enable the PCI procedures easier and more 
successful for patients with severe coronary artery diseases.
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1123  Drug-Eluting Stents in Complex 
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Orange County Convention Center, Hall E1
Presentation Hour: 9:00 a.m.-10:00 a.m.
1123-19 Use of Drug-Eluting Stents in Contemporary 
Interventions: A Comparison to Bare Metal Stent Use 
in the National Heart Lung and Blood Institute Dynamic 
Registry
Howard A. Cohen, David O. Williams, David R. Holmes, David P. Faxon, Spencer B. King, 
III, James Slater, Kevin E. Kip, Helen Vlachos, Faith Selzer, Sheryl Kelsey, Katherine 
Detre, University of Pittsburgh, Pittsburgh, PA
Background: Information regarding safety and effectiveness for drug-eluting stents(DES) 
are based on large randomized clinical trials of highly selected patients. Few data exist 
regarding the use of DES vs bare metal stents (BMS) in actual clinical practice. We sought 
to describe the clinical and procedural characteristics in a consecutive series of patients 
(pts) treated with a DES or BMS in 2004.
Methods: 1394 enrolled pts in the multi-center NHLBI Dynamic Registry 988 (71%) of 
whom received DES and 406 (29%)of whom received a BMS were analyzed.
Results: No differences were observed in gender, age, race, diabetes or prior coronary 
bypass (CABG) between DES and BMS pts. DES pts more often had severe non-cardiac 
disease (37.1% vs 27.7% p<0.001) and prior stenting (26.2% vs 15.6% p<0.001). DES 
pts were less likely (22.3% vs 41.1% p<0.001) to present as acute myocardial infarction 
(MI). Among attempted lesions, those receiving DES were less likely to be totally occluded 
(6.8% vs 13.5% p<0.001) and to have thrombus (9.9% vs 21.4% p<0.001) and were 
more likely to be calciﬁ ed (29.7% vs 23.7% p<0.05) or ostial in location (8.5% vs 4.8% 
(p<0.01). Lesion location differed with RCA (31.7% vs 36.6%) and CABG (5.5% vs 11.6%) 
less frequent and LAD more frequent (38.1% vs 30.3%) in DES vs BMS pts (p<0.001). 
Reference vessel diameter was smaller (3.02 mm vs 3.25 mm p<0.001) in DES vs BMS 
pts. Death (0.4% vs 2.0% p<0. 01) and Death/MI/CABG (2.6% vs 5.5% (p<0.001) were 
less frequent with DES vs BMS in hospital and at 30 days (Death: 0.51% vs 2.22% 
p<0.01) and (D/MI/CABG: 3.04% vs 6.40% p<0.01). There were no differences in sub-
acute stent thrombosis in DES and BMS pts.
Conclusion: In the NHLBI Dynamic Registry DES were used in 71% of stent procedures 
in a wide range of pts. DES were less common in MI and CABG possibly reﬂ ecting lack of 
proven efﬁ cacy at the time in these subgroups. DES were used more commonly in longer, 
calciﬁ ed and ostial lesions and in smaller vessels. In hospital and 30-day outcomes were 
better among DES pts although signiﬁ cant differences were observed in baseline risk. 
Importantly, there were no differences in sub-acute stent thrombosis in DES and BMS in 
this multi-center clinical practice.
1123-20 Is There Any Difference in Neointimal Hyperplasia 
Between Small and Large Vessels After Sirolimus-
Eluting Stent Implantation ? A 3D-Intravascular 
Ultrasound Study .
Eduardo Ferreira, Fausto Feres, Alexandre Abizaid, Vinicius Daher, Andrés Sánchez, 
Dimytri Siqueira, Rodolfo Staico, Luiz Mattos, Áurea Chaves, Luiz Tanajura, Amanda 
Sousa, J. Eduardo Sousa, Institute Dante Pazzanese of Cardiology, São Paulo, Brazil
Background: Small vessels (SV) are associated with increased levels of restenosis 
compared with large vessels (LV) even in the DES era. The purpose of this study is to 
compare neointimal hyperplasia (NIH) by intravascular ultrasound (3-D IVUS) in SV and 
LV after Sirolimus-Eluting Stent (SES) implantation. Methods: Eighty patients with de 
novo coronary lesions were successfully treated with SES (CypherTM) guided by IVUS. 
Patients were divided in two groups according to reference diameter (RD) by QCA: SV 
group (RD < 2.7mm) and LV group (RD > 2.7mm). 3D-IVUS analysis was performed at 
the stent segment at 6 months follow-up. QCA analysis was performed pre, post and 6 
months after stent implantation. Results: Mean age was 60 ± 11.6 and 63 ± 9.4 years 
(p=ns) and 42% and 30% were diabetics (p=ns) in SV and LV group, respectively. The 
mean lesion length was greater in SV group (13.51 ± 5.13 vs. 9.35 ±3.27 mm, p<0.001). 
There were no signiﬁ cant differences in baseline characteristics between groups. None 
of the pts had any major cardiac events at follow-up. QCA and 3D-IVUS analysis are 
shown below.
Conclusion: At follow-up, IVUS volumetric analysis post SES implantation showed 
similar NIH suppression in SV and LV. The pattern of NIH within SES was similar in both 
groups. Intimal proliferation was markedly localized at both edges and almost absent in 
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the central segments. Unrevealing mechanisms, such as focal NIH, should be evaluated 
to explain the signiﬁ cant difference in late-loss between groups.
Small vessel n=40 p Large vessel n=40p p
Reference diameter (mm) 2.48 ± 0.13 2.83 ± 0.39 <0.0001
In-stent Late loss (mm) 0.23 ± 0.16 0.10 ± 0.12 <0.001
Lumen obstruction volume (%) 5.13 ± 5.08 4.81 ± 5.12 0.8
NIH mm3/stent mm 0.25 ± 0.23 0.25 ± 0.28 0.9
1123-21 Long-Term Results After Sirolimus-Eluting Stent in 
Small Vessel Lesions: An Integrated Analysis of Six 
Multicenter Trials
Martin B. Leon, Roxana Mehran, Jeffrey Popina, Robert M. Siegel, Richard Kuntz, 
Alexandre Abizaid, Bernhard Meier, Marie-Claude Morice, Patrick Serruys, Jeffrey W. 
Moses, Erick Schaempart, Joachim Schofer, Amanda Sousa, Jose Eduardo Sousa, 
Columbia University Medical Center, New York, NY, Instituto Dante Pazzanese de 
Cardiologia, Sao Paulo, Brazil
Background: Previous trials have shown that vessel size is a signiﬁ cant independent 
predictor of restenosis after bare metal stenting. Trials with sirolimus-eluting stents (SES) 
have shown their long-term superiority compared to bare metal stents. However, the value 
of SES in pts with target lesions in small vessels is not known.
Methods: We performed an integrated analysis of pts in six prospective trials (n=1540) 
with lesions in small (<2.7mm in diameter by QCA) vessels to evaluate late angiographic 
(6-8 mos) and clinical outcomes (9 mos) after SES compared to bare metal stents. 909 pts 
were treated with SES (RAVEL: 90 pts; SIRIUS: 370 pts; E-SIRIUS: 152; C-SIRIUS: 44; 
DIRECT: 153; SVELTE: 100) compared to 631 pts treated with bare metal stents (RAVEL: 
87 pts; SIRIUS: 344 pts; E-SIRIUS: 152; C-SIRIUS: 42). All trials included 6-8 month 
systematic angiographic follow-up, 9-month clinical follow-up, and adjudication of clinical 
events by independent committee.
Results: There were no signiﬁ cant differences in pt demographics and lesions between 
groups. Overall, mean age was 62±10 years, 73% male, 25.5% with diabetes, 75% with 
hyperlipidemia, and 64% with hypertension. Stent thrombosis occurred in only 0.8% of 
patients with SES (compared to 0.5% of control, p=NS).
SES v. Bare Metal Stents: Angiographic and 
Clinical Outcomes in Small Vessel Lesions
SES (909) Control (631) p-value
In-stent late loss (mm) 0.18 1.02 <0.0001
In-lesion late loss (mm) 0.21 0.81 <0.0001
In-stent restesnosis (%) 3.2% 38.5% <0.0001
In-lesion restenosis (%) 6.9% 39.8% <0.0001
Death 1.0% 0.7% 0.6326
MI: Q-wave
MI: Non-W-wave
0.8%
1.9%
0.3%
2.9%
0.2593
0.1825
TVR (non-TLR) 2.8% 3.4% 0.4416
TLR 3.5% 17.1% <0.0001
MACE 6.4% 19.4% <0.0001
Conclusions: In CAD pts presenting with lesions in small vessels, treatment with SES is 
associated with a signiﬁ cant reduction of angiographic and clinical events. The superior 
efﬁ cacy of SES equalizes the outcomes across all vessel diameters.
1123-23 The Impact of Sirolimus-Eluting Stent Implantation in 
Small Vessel Angioplasty: A Report from the e-CYPHER 
Registry
Philippe Guyon, Philip Urban, Joachim Schofer, Chaim Lotan, Anthony Gershlick, Giulio 
Guagliumi, Edouardo Sousa, Ashock Seth, William Wijns, Centre Cardiologique du 
Nord, Saint-Denis, France
Background: To date, stent implantation in a small vessel (SV) PCI is generally 
questionable. Nevertheless, reports from recent clinical trials suggest that Sirolimus-
eluting stents (SES) are particularly effective in this setting. To assess the post-marketing 
SES performance in “a real-world” scenario and conﬁ rm the hypothesis that SES 
implantation is safe and beneﬁ cial in SV PCI, we evaluated the prospective results of the 
e-CYPHER international registry.
Methods: Among 14316 pts, 9% have received a SES in at least one lesion with a 
reference diameter ≤ 2.5 mm. The incidence of females, diabetics and multi-vessel 
disease was higher than for pts treated in larger vessels. Pts were older, with a higher 
proportion of previous cardiovascular history. The lesions were shorter with a lower 
number of restenotic lesions. In 50% of cases, the SV PCI was associated with another 
treated site, resulting in a larger number of stents used. Anti-platelet pre-regimen (included 
GIIbIIIa inhibitors) was similar in the two cohort groups. Clinical follow-up was obtained 
in 84% of this population and data were analysed after all events were adjudicated by an 
independent review committee.
Conclusion: In a “real world” registry, SES are effective in SV PCI, representing 9% 
of the total pts. Reference diameter is still a strong predictor factor of stent thrombosis 
and MI. In view of these conclusions, the duration of anti-platelet regimen may have an 
important impact in this speciﬁ c PCI.
Results at 180 days SV group(1333 pts) Other(12983 pts) p
MACE 4% 3.1% NS
Death 1.45% 1.49% NS
MI 1.83% 0.89% 0.0032
TLR 1.54% 1.22% NS
Stent Thrombosis 1.54% 0.85% 0.02
1123-24 Angiographic and Clinical Reduction in Restenosis with 
Polymer-based Paclitaxel-Eluting Stents as a Function 
of Lesion Length: Analysis from the TAXUS IV Study
William S. Sheldon, Charles D. O’Shaughnessey, David A. Cox, James Hermiller, 
James Tift Mann, Mark Turco, Ronald Caputo, Pattrick Bergin, Joel Greenberg, Jeffery 
J. Popma, Neil Weissman, Mary E. Russell, Stephen G. Ellis, Gregg W. Stone, EMH 
Regional Medical Center, Elyria, OH
Background: Historically, restenosis after bare metal stent implantation linearly 
increases with lesion and stent length. Polymer-based drug-eluting stents have been 
shown to reduce angiographic restenosis, though the relationship between lesion length 
and restenosis after DES has not been examined in depth.
Methods. We examined the 9-month angiographic and 1-year clinical outcomes of 
patients randomized to either the TAXUS stent (n=662) or a visually identical bare metal 
EXPRESS stent (n=652) in the pivotal TAXUS-IV trial. Lesion length (LL) subsets were 
categorized into three discrete categories: <10 mm (n=440 total randomized pts), 10-20 
mm (n=676), and >20 mm (n=188). Mean LL were 7.68 mm, 13.79 mm and 25.23 mm 
for the three strata respectively. The mean number of implanted stents was 1.03, 1.05, 
and 1.17 respectively, with mean stent lengths of 18.06 mm, 20.94 mm, and 31.78 mm 
respectively. Clinical and angiographic results are shown in the table.
Angiographic and Clinical Results
TAXUS Control RR P
Analysis segment restenosis
LL 10mm 5.6% 18.9% 0.29 [0.11, 0.76] 0.01
LL 10-20mm 7.2% 25.8% 0.28 [0.15, 0.53] <0.001
LL > 20mm 14.9% 41.5% 0.36 [0.17, 0.76] 0.004
1 year TLR
LL 10mm 4.1% 13.4% 0.22 [0.13, 0.60] 0.0005
LL 10-20mm 4.4% 14.1% 0.30 [0.16, 0.53] <0.0001
LL > 20mm 5.5% 22.1% 0.23 [0.09, 0.61] 0.0012
Conclusions: The TAXUS stent markedly reduces both angiographic and clinical 
restenosis in short as well as long lesions. The absolute reduction in restenosis is greatest 
in long lesions, though the relative reduction is independent of lesion length. 
1123-25 Stent Length as a Predictor of Restenosis After Long 
Sirolimus-Eluting Stent Implantation
Seung-Jung Park, Young-Hak Kim, Cheol Whan Lee, Myeong-Ki Hong, Seong-Wook 
Park, Hyeon-Cheol Gwon, Yang-Soo Jang, Myoung Mook Lee, Bon Kwon Koo, Dong 
Joo Oh, Ki Bae Seung, Seung-Jae Tahk, Junghan Yoon, Asan Medical Center, Seoul, 
South Korea
Background: The stent length of relatively short sirolimus-eluting stent (SES) is not 
associated with angiographic restenosis. However, the inﬂ uence of stent length on 
restenosis is not known well after long SES implantation.
Methods: This study included 336 de novo long coronary lesions which were treated with 
long SESs (total stent length≥28mm) in the “Long-DES” multicenter study from March 2003 to 
February 2004. Chronic total occlusion, acute myocardial infarction within 48 hours, and left 
main coronary lesions were excluded. All analyses were performed on a per-lesion basis.
Results: Of 233 lesions with 6-month angiography, in-segment restenosis occurred in 17 
lesions (7%). Compared to the group without restenosis, the group with restenosis had 
small reference diameter (2.6±0.4mm vs. 2.8±0.4mm, p=0.032), small postprocedural 
minimal lumen diameter (2.5±0.3mm vs. 2.7±0.4mm, p=0.021), long lesion length 
(43.1±13.1mm vs. 33.0±13.3mm, p=0.006), and long total stent length (49.4±15.3mm 
vs. 41.3±16.0mm, p=0.047) in univariate analysis. Clinical and procedural characteristics 
were similar in the two groups with or without restenosis. Total stent length (OR 1.04, 95% 
CI 1.01-1.07, p=0.018) and reference diameter (OR 0.18, 95% CI 0.03-0.92, p=0.039) 
were independent determinants of restenosis in multivariate analysis.
Conclusion: The stent length may remain a determinant of restenosis in long SES 
implantation for long coronary lesions. 
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1123-26 One-Year Clinical Outcome of Cypher Sirolimus-
Eluting Stents in Patients With Long Coronary Lesions: 
Multicenter Registry in Asia
Sunao Nakamura, Tamil Selvan Muthusamy, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, New Tokyo Hospital, Matsudo, Japan
Background and Purpose: Promising results with Cypher Sirolimus-eluting stent (SES) 
for relatively short de novo coronary lesions have been presented. However, long-term 
efﬁ cacy of SES for long lesions is still unknown. Methods: From April 2002, elective 
percutaneous coronary intervention (PCI) patients who had long (>25 mm) lesions with 
a single or multiple overlapped Cypher SES was included in this registry. The primary 
endpoint was the occurrence of major adverse cardiac events (MACE), the secondary 
endpoint included restenosis rate and target lesion revascularization (TLR). Results: See 
table. A total of 168 lesions were treated with 268 Cypher SES. The number of stents used 
was 1.6±0.6 per lesions. The maximum pressure used was 18.8±4.8 atm and balloon-
artery ratio was 1.1±0.1. Conclusion: Initial and long-term outcome for SES in long lesions 
seems to be favorable in terms of in-hospital clinical outcomes and long-term results.
Number of patients 168
In-hospital
Procedural success (%) 100
MACE at 30 days (%) 0
Reference diameter (mm) 2.90 ± 0.38
Post MLD (mm) 2.78 ± 0.44
Lesion length (mm) 35.8 ± 10
Angiographic follow-up at 12 months
Follow-up MLD (mm) 2.50 ± 0.50
Restenosis rate (%) 3.0
TVR (%) 3.0
1123-27 Impact of Body Mass Index on Restenosis After Bare-
Metal and Drug-eluting Stent Implantation: Analysis 
From the TAXUS-IV Trial
Eugenia Nikolsky, Edward Kosinski, Edward Kosinski, Gregory J. Mishkel, Thomas F. 
McGarry, Carey Kimmelstiel, Yingbo Na, Manuela Negoita, Roxana Mehran, Gregg 
W. Stone, Cardiovascular Research Foundation, New York, NY, Columbia University 
Medical Center, New York, NY
Background. The impact of body mass index (BMI) on restenosis after stent implantation 
has not been reported. We examined the database from the multicenter randomized 
TAXUS-IV trial to determine the impact of BMI on outcomes after bare metal and drug-
eluting stent implantation.
Methods. In TAXUS-IV, pts were randomized to treatment with either the slow-release, 
polymer-based, paclitaxel-eluting stent or a bare-metal stent. Outcomes were stratiﬁ ed 
by the baseline BMI.
Results. Of the 1,307 randomized pts, 233 (17.8%) were normal-weight (BMI<25 kg/m2), 531 
(40.6%) were overweight (≥25 to <30 kg/m2), and 543 (41.5%) were obese (≥30 kg/m2). Patients 
assigned to bare-metal stents who were overweight and obese compared to normal-weight 
had strikingly higher rates of 9-month binary restenosis (Figure); no such relationship was 
observed in patients treated with paclitaxel-eluting stent. By multivariate analysis, BMI≥30.0kg/
m2 independently predicted binary restenosis (HR=4.26, P=0.005) and 1-year TVR (HR=1.95, 
p=0.04) in pts treated with bare-metal stents but not with paclitaxel-eluting stents.
Conclusions. Obesity is an important risk factor for clinical and angiographic restenosis 
in pts treated with bare-metal stents. Paclitaxel-eluting stents reduce the increased risk 
associated with obesity such that the intermediate term prognosis after percutaneous 
coronary intervention is independent of weight.
1123-28 Efﬁ cacy of Drug-Eluting Stents in the Calciﬁ ed Lesions
Annapoorna S. Kini, Michael C. Kim, Sajal Das, Tirumalesh Venkatesh, Angelica M. 
Steinheimer, Samin K. Sharma, Mount Sinai Medical Center/ Cardiovascular Institute, 
New York, NY
Background: Randomized trials of drug-eluting stents (DES) have excluded patients 
with calciﬁ ed lesions requiring rotational atherectomy (RA) prior to stent implantation. 
Outcome with DES after RA in calciﬁ ed lesions is not known.
Methods and Results: We analyzed all PCI patients undergoing RA for de novo calciﬁ ed 
lesions in native vessels, followed by bare metal stents (BMS) from 5/02 to 4/03 and 
compared to patients undergoing RA followed by drug-eluting stents (DES) from 5/03 
to 4/04 at our institution. Procedural success (<30% diameter obstruction post), clinical 
success (procedural success in the absence of Q-wave MI, urgent revascularization or 
death), 30-day MACE (MI with CK-MB >3x, urgent revascularization or death) and target 
lesion revascularization (TLR) were compared between two groups (Table). Baseline 
clinical and angiographic characteristics (especially prior MI, diabetes mellitus, LVEF, 
multivessel disease, LAD lesion) were similar in two groups; GP IIb/IIIa inhibitors were 
used in >80% of cases. In the DES group, stenting the area that underwent balloon 
dilatation post-RA was routinely done. Multivariate predictors of TLR were diabetes (OR 
3.2; 95% CI 2.8-3.8), lesion length (OR 2.4; 95% CI 1.2-3.7) and use of DES (OR 0.5; 
95% CI 0.2-0.9).
Conclusion: Therefore, DES is superior to BMS even in the calciﬁ ed coronary lesions. 
Our non-randomized data supports the use of DES in calciﬁ ed lesions without concerns 
of vascular injury caused by RA burr.
Rota + BMS
(n = 284)
Rota + DES
(n = 246) p
Bifurcation lesion (%) 24 29 NS
Ostial lesion (%) 8 10 NS
Total occlusion (%) 8 9 NS
Lesion length (mm) 16.3 ± 4.5 15.1 ± 3.8 NS
RA ablation length (mm) 56.4 ± 15.3 58.4 ± 16.3 NS
Stent length (mm) 15.8 ± 6.3 24.4 ± 8.3 <0.01
Reference vessel size (mm) 2.86 ± 0.32 2.94 ± 0.42 NS
Procedural success (%) 98.2 99.2 NS
Clinical success (%) 96.8 97.7 NS
CK-MB elevation >3x (%) 6.3 3.3 0.09
30-day MACE (%) 6.7 5.3 0.62
Stent thrombosis (%) 0.4 0 NS
TLR (%) 15.5 5.3 <0.01
1123-29 The Impact of Culprit Lesion Calciﬁ cation in Patients 
Undergoing Paclitaxel-Eluting Stent Implantation: A 
TAXUS-IV Sub Study.
Issam Moussa, Stephen G. Ellis, Jeffery W. Moses, Michael Jones, Dean J. Kereiakes, 
Daniel McMartin, Barry Rutherford, Roxana Mehran, Micheal Collins, Martin B. 
Leon, Jeffrey J. Popma, Marry E. Russel, Gregg W. Stone, Cardiovascular Research 
Foundation, New York, NY, Columbia University Medical Center, New York, NY
Background: Randomized clinical trials have shown that paclitaxel-eluting stents 
signiﬁ cantly reduce restenosis after percutaneous coronary intervention (PCI). The 
impact of lesion calciﬁ cation on the efﬁ cacy of paclitaxel-eluting stents is unknown.
Methods: In the TAXUS-IV trial, 1,314 patients undergoing PCI were randomly assigned 
to a bare-metal or the paclitaxel-eluting TAXUS stent. By core lab analysis, 247 lesions 
(19%) were moderately or severely calciﬁ ed.
Results: Target lesion revascularization (TLR) at 1-year was reduced by 56% in TAXUS-
randomized patients with calciﬁ ed lesions (11.9 % vs. 5.1%, p=0.09), and by 75% in TAXUS-
randomized pts with non-calciﬁ ed lesions (15.7% vs. 4.3%, P<0.0001). By interaction testing, 
the efﬁ cacy of the paclitaxel-eluting stent in reducing 1-year TLR was similar in calciﬁ ed and 
non-calciﬁ ed lesions (p=0.30). The 9-month angiographic follow-up data are shown in the 
table. A non-signiﬁ cant trend was present (p=0.10) for interaction between the presence of 
calcium and treatment assignment on the occurrence of analysis segment restenosis.
Conclusion: Implantation of paclitaxel-eluting stents in lesions with and without 
calciﬁ cation reduces TLR to a similar extent. Further study is required to determine 
whether the absolute and relative reduction in angiographic restenosis with the TAXUS 
stent is similar in calciﬁ ed vs. non-calciﬁ ed lesions, and if the pattern of restenosis is more 
diffuse in calciﬁ ed lesions.
Calciﬁ ed lesions Non-calciﬁ ed lesions
TAXUS
n=53
Control
n=60 P-value
TAXUS
n=238
Control
n=207 P-value
Analysis segment 
restenosis 7.5% 18.3% 0.10 8.0% 29.0% <0.0001
ISR pattern n=4 n=11 n=12 n=54
Focal 0.0% 36% 0.12 84% 30% 0.15
Diffuse 50% 46% 0.44 8% 61% <0.0001
Proliferative 0.0% 9% 1.0 8% 7% 0.19
Total occlusion 50% 9% 0.60 0.0% 2% 0.46
ISR length (mm) 14.6+4.0 13.6+4.8 0.70 8.3+3.8 15.0+8.7 <0.0001
1123-30 Thrombosis After Drug-Eluting Stent Implantation in 
Bifurcational Lesions by Crush Stent Technique
Lei Ge, Ioannis Iakovou, Eleutheria Tsagalou, Giuseppe M Sangiorgi, Alaide Chieffo, 
Gloria Melzi, Matteo Montorfano, Iassen Michev, Flavio Airoldi, Mauro Carlino, Nicola 
Corvaja, Antonio Colombo, EMO Centro Cuore Columbus, Milano, Italy
Background: Although treatment of bifurcational lesions using crush stent technique is 
feasible, there is raising a concern about risk of thrombosis due to three layers struts at 
the site of carina. The aim of this study was to evaluate the frequency and the predictors 
of stent thrombosis after crush stenting.
Methods: We identiﬁ ed 178 consecutive patients who underwent percutaneous coronary 
intervention in bifurcational lesions by crush stent technique with either sirolimus eluting 
stent (SES)(SES group, n= 106) or paclitaxel eluting stent (PES)(PES group, n=72) 
between April 2002 to February 2004.
Results: There were no signiﬁ cant differences between the 2 groups in procedural 
complications and in-hospital outcome. Final kissing balloon was performed in 60% patients 
of the SES group and 78% patients of the PES group (P=0.01). During 6 months follow-
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up, the rate of target lesion revascularization on either branch was 6.6% in the SES group 
and 5.6% in the PES group (P=1.0). The cumulative major adverse cardiac events rate at 
6-month was 18% (18.9% of the SES group and 16.7% of the PES group, P=0.8). Five 
(2.8%) patients sustained stent thrombosis after the index procedure (2 [1.9%] patients of 
the SES group and 3 [4.2%] of the PES group, P=0.7). The 2 patients of the SES group 
had thrombosis after premature discontinuation of dual antiplatelet therapy (day 28 and 
55, respectively). No signiﬁ cant differences were observed in the incidence of subacute 
thrombosis (0.9% of SES group vs. 0% of PES group, P=1.0) and late thrombosis (0.9% of 
SES group vs. 4.2% of PES group, P=0.3) between the 2 groups. Independent predictors 
of thrombosis were: calciﬁ ed lesions (OR=4.71; 95%CI, 1.07 to 20.7, P=0.04), diabetes 
(OR=2.20; 95%CI, 1.15 to 4.23, P=0.02), lesions length (OR: 1.09; 95% CI: 1.01 to 1.19, 
P=0.03) and left main bifurcation (OR: 0.94; 95% CI: 0.90 to 0.94, P=0.004).
Conclusion: The incidence of stent thrombosis during 6 months after successful drug eluting 
stent implantation in bifurcational lesions by crush stent technique was 2.8%. Paticular attention 
will need to be directed to this complication when multiple predisposing factors are present.
1123-31 Treatment of Bifurcation Lesions With Sirolimus-
Eluting Stents Using the “Crush” and “V” Techniques. 
Procedural and Clinical outcomes.
Neil Sawhney, Matthew J. Price, Samir Damani, Steve S. Lee, Garrett Wong, Ashish 
Jani, Richard A. Schatz, Paul S. Teirstein, Scripps Clinic, La Jolla, CA
Background: The treatment of bifurcation lesions has both high procedural complication 
and restenosis rates. Recently, disappointing results with “T” stenting using Sirolimus-
Eluting Stents (SES) were reported with restenosis occurring primarily at the uncovered 
junction between the parent and side-branch vessel. It is hoped that “Crush” and “V” 
stenting using SES will improve clinical results for bifurcation lesions.
Methods: All patients with de novo bifurcation stenting using SES in our institution were 
analyzed. Only unprotected left main stenting was excluded. Clinical follow-up (FU) was 
obtained via chart review and patient phone contact. Patients were considered eligible for 
follow-up 5 months after the index procedure.
Results: To date 169 pts have undergone bifurcation SES implantation using either the 
Crush (n=111) or “V” (n=58) technique. A ﬁ nal kissing inﬂ ation was performed in 45% of 
Crush patients. The mean patient age was 65 years and 31% of have diabetes. Lesions 
involved the LAD 68%, LCx 17%, a protected LM 7%, and the RCA 8% of the time. 
Procedural success was 100% for both branches. Non-Q MI occurred in 12% patients post-
procedure. There was no in-hospital revascularization (TLR), thrombosis or deaths. There 
were 3 thrombosis - one resulting in cardiac death. FU was obtained in 97 eligible pts. TLR 
occurred in 14.4%. MACE (deﬁ ned as death, MI, TVR) occurred in 18.6%. TLR occurred in 
main branch alone in 0%, side branch alone in 79% and both branches in 21%. With FU still 
accruing, Crush stenting and V stenting had similar TLR (15.8% Vs 11.8%). Final kissing 
dilatation in Crush did not decrease TLR rates (14.8% no kiss Vs 22% with kiss).
Conclusion: Bifurcation stenting with SES can be performed with low procedural complications, 
and low 5 month TLR (14.4%). Complete follow-up of the entire cohort will be presented.
1123-32 Impact of Final Stent Dimensions on Restenosis After 
Crush Drug-Eluting Stent Implantation for Bifurcation 
Lesions
Ricardo A. Costa, Gary S. Mintz, Stephane G. Carlier, Kenichi Fujii, Hideo Takebayashi, 
Takenori Yasuda, Jose Costa, Jr., Masashi Kimura, Koichi Sano, Yoshihiro Tsuchiya, 
Alexandra J. Lansky, Roxana Mehran, George D. Dangas, Michael Collins, Edward M. 
Kreps, Issam Moussa, Antonio Colombo, Gregg W. Stone, Jeffrey W. Moses, Martin 
B. Leon, Columbia University Medical Center and the Cardiovascular Research 
Foundation, New York, NY
Background: The crush technique for treating bifurcation lesions is an attractive 
alternative for its predictability, high procedure success rate, and opportunity to fully cover 
the ostium of the side branch (SB). We report the 6 month follow-up (FU) of patients 
treated with crush sirolimus-eluting stent (SES) implantation to treat bifurcation lesions. 
Methods: 40 consecutive patients underwent successful crush bifurcation stenting 
using two SES. There were 5 left main and 35 left anterior descending (LAD)/diagonal 
bifurcation stenoses. Clinical FU at 6 months was available in all patients. 
Results: At 6 months, none of the patients with left main bifurcations presented with 
restenosis. However, among patients with LAD/diagonal bifurcations, the restenosis 
rate was 17%; and all restenoses were at the ostium of the SB. Intravascular ultrasound 
(IVUS) analysis of 41 MVs (40 post-implantation and 1 at follow-up), showed a minimum 
stent area of 6.4±1.7mm2; while IVUS analysis of 29 SBs (25 post-implantation and 4 
at follow-up), showed a minimum stent area of 4.2±1.4mm2 (p<0.0001 compared to the 
MV). In particular, in patients with SB restenosis, the minimum stent area measured 
3.5±0.6mm2 (p=0.16 compared to non-restenotic SB ostium in which the minimum stent 
area measured 4.4±1.4mm2). 
Conclusions: Restenosis in the SB ostium (1) occurs in 17% of patients after LAD/diagonal 
crush bifurcation SES stenting and (2) is the result of stent underexpansion. Conversely, 
MV stent expansion is consistently adequate and not associated with restenosis. In the 
bare metal stent era, primary attention was directed toward insuring adequate MV results. 
In the drug-eluting stent era, it may be necessary to refocus attention in order to obtain 
adequate SB stent expansion. 
1123-33 Sirolimus-Eluting Stents Versus Bare Metal Stents In 
Unselected Lesions: Follow-Up Results From the Milan 
Registry
Ioannis Iakovou, Lei Ge, Giuseppe Sangiorgi, Goran Stankovic, Matteo Montorfano, 
Eleftheria Tsagkalou, Gloria Melzi, Iassen Michev, Flavio Airoldi, Alaide Chieffo, Mauro 
Carlino, Nicola Corvaja, Antonio Colombo, EMO Centro Cuore Columbus, Milan, Italy, 
San Raffaele Hospital, Milan, Italy
Background: It is important to compare the results of sirolimus-eluting stents to the ones 
with bare metal stents in the same hospital and with similar operators in unselected lesions.
Methods: Consecutive patients treated with sirolimus-eluting stents over 24 months 
(SES group: 1020 patients, 2460 lesions) were compared with patients who received bare 
stents in the prior 24 months period (non-SES group: 1147 patients, 1784 lesions).
Result: Patients in the SES group more frequently had diabetes (23% vs. 9.5%, P<0.001) 
and multivessel disease (84% vs. 74%, P<0.001) and SES lesions were more frequently type 
B2 or C (72% vs. 68%, P= 0.008), restenotic (15% vs. 4.8%, P<0.001), bifurcational (25% 
vs. 19%, P<0.001), had smaller preintervention reference vessel diameter (2.60 ± 0.64 mm 
vs. 2.80 ± 0.67 mm, P<0.001) and longer length (14.95 ± 10.94 mm vs. 12.26 ± 7.47 mm, 
P<0.001). The were no signiﬁ cant differences regarding periprocedural, in hospital, and 
30-day outcome. At 240-day follow-up, the SES group compared to the non-SES, had lower 
target lesion revascularization (TLR) rate (5.5% vs.9.7%, P=0.001), TVR (10% vs. 13.9%, 
p=0.001 ) and cumulative rate of major adverse cardiac events (MACE=death, myocardial 
infarction, target vessel revascularization:10.3% vs. 14.2%, P=0.02)(Figure).
Conclusions: Unrestricted utilization of SES in the “real world” is safe and effective in reducing
both repeat revascularization and MACE at follow-up compared to bare stent implantation.
1123-36 TAXUS III Three-year Clinical Results: A Feasibility 
Study Of The Polymer-based, Paclitaxel-coated Stent 
For The Treatment Of In-stent Restenosis
Eberhard Grube, Patrick W. Serruys, Mary E. Russell, Heart Center Siegburg, Siegburg, 
Germany
Background: In-stent restenosis remains a key problem in a signiﬁ cant number of 
patients after treatment with coronary artery stents. Drug-eluting stent technology has 
shown promise in the reduction of restenosis after primary stenting of de novo lesions. 
Paclitaxel-eluting stents may also provide a mechanism for the treatment of in-stent 
restenosis and reduction of repeat restenotic events. The objective of the TAXUS III trial 
is to evaluate the feasibility of the NIRx paclitaxel-coated stent to treat and reduce the 
recurrence of restenosis in previously implanted stents.
Methods: TAXUS III, a non-randomized, prospective, single-arm clinical trial conducted 
at 2 sites, is designed to evaluate the safety of the NIRx paclitaxel-coated stent (slow-
release formulation) in patients (N=28) with in-stent restenosis (ISR) within a previously 
implanted stent. The primary endpoint was the Major Adverse Cardiac Event (MACE) rate 
at 30 days after placement of the study stent. Angiographic and intravascular ultrasound 
parameters were assessed at 6 months and target lesion revascularization (TLR) rate 
was measured at 6 and 12 months and annually thereafter out to 5 years.
Results: As reported previously, procedural success was achieved in 96% of patients 
with no stent thrombosis. Thirty-day and 6-month non-hierarchical MACE rates were 4% 
and 29% respectively, lower than the rates seen in historical bare-metal controls. MACE 
rate at 1-year was 32% due to one new TLR at 217 days. Two new MACE, a non-Q-
wave myocardial infarction in a non-target vessel and death due to ventricular ﬁ brillation, 
occurred in one patient at 688 days, resulting in a MACE rate of 39% at 2-years. A new 
repeat percutaneous transluminal coronary angioplasty in the target vessel outside the 
target lesion at day 883 increased the 3-year MACE rate to 43%. There has been no 
reported stent thrombosis to date.
Conclusion: The results of the TAXUS III trial have shown that the paclitaxel-eluting NIRx 
stent is safe and potentially efﬁ cacious in the treatment of ISR. The safety and beneﬁ ts of the 
paclitaxel-eluting stent in reducing recurrence of restenosis are sustained out to 3 years.
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1124-9 The Safety and Efﬁ cacy of the 40mm Amplatzer Septal 
Occluder
Keila N. Lopez, Bharat Dalvi, John Cheatham, David Balzer, Tarek Momenah, Qi-ling 
Cao, Ziyad Hijazi, University of Chicago Hospitals, Chicago, IL
Background: The safety and efﬁ cacy of the Amplatzer septal occluder (ASO) devices 
size 4 to 38 mm has been fully evaluated which led to the United States FDA approval. 
However, the safety and efﬁ cacy of the 40mm ASO has not yet been evaluated.
Objective: Our purpose is to report on the safety and efﬁ cacy of the 40 mm ASO in 
closing large secundum atrial septal defects (ASD).
Methods: Thirty-two patients (21F; 11M) underwent an attempt of device closure of their 
ASD’s at a median age of 39 years (range 14-81) and median weight of 64 kg (range 
48-98) using the 40 mm ASO device. The median size of the ASD as assessed by 2D 
transesophageal echocardiography (27 patients) or intracardiac echocardiography (5 
patients) was 30mm (range 24-39mm). The median balloon stretched diameter of the ASD 
was 37.7mm (range 32-43.7mm). The median Qp:Qs ratio was 3.2:1 (range 1.4-6.2).
Results: In 5 patients, the attempt was unsuccessful (in two patients devices embolized 
after release requiring surgical removal; in two patients, the device could not be seated well 
and therefore the procedure was aborted; and in one patient there was a perforation of the 
left atrium during placement of the sheath). The attempt was successful in the remaining 27 
patients, resulting in complete immediate closure in 13 patients and trivial residual shunt in 
14 patients. Median patient procedure time was 96 minutes and median ﬂ uoroscopy time was 
12.2 minutes. At twenty-four hour follow-up 2D transthoracic color Doppler echocardiography 
revealed complete closure in 22 patients and 5 patients had trivial residual shunt. At a median 
follow up interval of 6 months (range 4 wks to 1 year), 17 patients had no residual shunt, and 
3 patients had trivial residual shunt. There were no patient complications, and all patients are 
doing well with no evidence of thromboembolic episodes or any signiﬁ cant arrhythmias.
Conclusion: The use of the 40 mm Amplatzer septal occluder is safe and effective for 
most patients with a large secundum atrial septal defect. Further follow-up is underway to 
assess the long term safety and efﬁ cacy of this device.
1124-10 Angiograhic and Pathological Studies of Late Vascular 
Responses to Successful Carotid Artery Stenting
Keita Odashiro, Hiroyoshi Yokoi, Masashi Iwabuchi, Hiroyoshi Yokoi, Hitoshi Yasumoto, 
Hideyuki Nosaka, Katsumi Inoue, Kokura Memorial Hospital, Kitakyushu, Japan, 
Kurashiki Central Hospital, Kurashiki, Japan
Aim: The purpose of this study was to assess the long-term efﬁ cacy of carotid artery 
stenting (CAS) angiographycally and histopathologically.
Methods: From Aug.1996 to Aug. 2004, we performed CAS for 97 patients(pts.) and 108 
lesions (mean age 73 years). Out of 31 patients with 38 lesions undergoing 6 months follow-
up angiography, 1-2 years follow-up angiography was available in 17 patients with 24 lesions 
and 3-8 years follow-up angiography was available in 10 patients with 12 lesions. Quantitative 
angiographic analysis was performed. Minimal luminal diameter(MLD), interpolated 
referense diameter and % diameter stenosis were measured. Stent sites were divided into 
10 segments. At each segments, minimal diameter and mean diameter were measured. 
Histopathologic examination was performed in patients undergoing antemortem CAS. 
Temporal canges in histologic pattern between 8 months and 3 years were examined.
Results: Follow-up angiography of 24 lesions at 6 months and 1-2 years revealed a 
decrease in MLD from 4.41±0.55mm immediately after stent implantation to 3.45±0.39mm 
at 6 months, but no further decrease in diameter after 6 months (in patients with paired 
angiograms, 3.45±0.39mm at 6 months and 3.78±0.3mm at 1-2 years: P=0.015). Luminal 
diameter stabilization was observed at 3-8 years (in patients with paired angiograms, 
3.65±0.76mm at 6 months and 4.00±0.53 mm at 3-8 years; P=0.085). Micrographs of 
the stented segment revealed ﬁ brotic maturation and decrease of extracellular matrix 
substance of the neointima inside the stent during 3 years.
Conclusion: Angiographic long-term outcomes after CAS were favorable. Late 
improvement of neointimal hyperplasia appears to occur after 6 months. Temporal 
changes in histologic patterm provide a pathologic backgound for angiographic results.
1124-11 Absence of Gender Effect on Late Outcomes after 
Carotid Artery Stent Placement
Umesh Arora, Dat Do, Jitesh Vasadia, Robert Chilton, Michael Wholey, Mark Wholey, 
Walter Tan, Steven Bailey, University of Texas Health Science Center at San Antonio, 
San Antonio, TX
Background: It is reported that there is a gender difference in cardiac morbidity and mortality 
in women undergoing percutaneous interventions. In this study, we compared the late 
neurological events of men versus women after undergoing carotid artery stent placement.
Methods: We performed a retrospective review of 495 patients (291 men and 204 women) 
who underwent carotid artery stent placement from 3/95 to 11/01, with a mean follow-up 
of 21 months. Past medical history and medications were reviewed and 3-year event rate 
for each variable was calculated. The primary endpoints were neurological events including 
TIA, CVA and neurologically related deaths during the three-year follow up.
Results: There was no difference in mean age between male (mean age 71 years) and 
female (mean age 71 years) in the study. Strikingly, women composed nearly 45% of the 
study group, compared to 20% of most coronary PCI studies. Women who underwent 
carotid artery stent had more hyperlipidemia, less history of tobacco use and taking more 
diuretics compared to their male counterparts. However, the three-year neurological event 
rate is similar between each gender.
The 3-year neurological event rate of male versus female
Male Female p-value
Count (%) 3-Year Event Rate (%) Count (%)
3-Year Event 
Rate (%)
Hypertension 224 (77%) 2.7 164 (80%) 6.1 0.09
Hyperlipidemia 161 (55%) 3.1 140 (69%) 5.0 0.40
Diabetes 91 (31%) 6.6 61 (30%) 8.2 0.71
Current tobacco used 55 (19%) 5.5 43 (21%) 4.7 0.86
Past or current tobacco used 248 (85%) 4.0 127 (62%) 6.3 0.33
History of CHF 42 (14%) 7.11 30 (15%) 3.3 0.49
History of MI 74 (25%) 6.8 49 (24%) 4.1 0.53
History of prior TIA or CVA 141 (48%) 5.0 94 (46%) 4.3 0.80
History of PVD 63 (22%) 4.8 36 (18%) 5.6 0.86
Aspirin 210 (72%) 2.9 140 (69%) 5.7 0.18
Clopidogrel or Ticlopidine 219 (75%) 3.2 137 (67%) 5.8 0.22
Statins 55 (19%) 0.0 40 (20%) 2.5 0.24
Beta-blocker 72 (25%) 2.8 54 (26%) 5.6 0.43
Calcium channel blocker 76 (26%) 3.9 68 (33%) 2.9 0.74
ACE-Inhibitors 97 (33%) 3.1 69 (34%) 8.7 0.12
Diuretics 83 (29%) 6.0 82 (40%) 7.0 0.74
Conclusions: In this “real world” registry, women are as likely as men to receive carotid 
Stent placement Unlike coronary PCI, the three year neurological event rate is similar 
between men and women undergoing carotid artery stent placement.
1124-12 Increased Late Event Rate in Diabetic Patients 
Undergoing Carotid Artery Stent Placement Compared 
to Non-diabetic Patients.
Dat T. Do, Jitesh Vasadia, Steven Bailey, Robert Chilton, Michael Wholey, Mark Wholey, Walter 
Tan, Umesh Arora, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background: Diabetes, considered a preclinical cardiac ischemic state, is a well-recognized 
risk factor for future cerebrovascular events. In this study, we compared the rate of neurological 
events occurring in diabetic and non-diabetic patients after carotid artery stent placement.
Methods: We performed a retrospective review of 495 patients (291 men, 204 women) 
who underwent carotid artery stent placement from 3/95 to 11/01, with a mean follow-up 
of 21 months. Past medical history and medications were reviewed and the 3-year event 
rate for each variable was calculated. The primary endpoints were neurological events 
including TIA, CVA and neurologically related deaths.
Results: There were 152 diabetic and 343 non-diabetic patients. Diabetic patients taking 
ASA and Clopidogrel/Ticlopidine had 7.3% and 7.4% 3-year event rate, respectively. These 
were signiﬁ cantly higher than non-diabetic patient. Also, diabetic patients with a prior history 
of MI or a prior cerebrovascular event had 12% and 8% 3-year event rate, respectively. 
These were higher than the non-diabetic patients, but were not statistically signiﬁ cant.
Table: The 3-year neurological event rate of diabetic versus non-diabetic patients
Diabetic Non-diabetic P-value
Count (%) 3-Year Event Rate (%) Count (%)
3-Year 
Event Rate 
(%)
Hypertension 127 (84%) 5.5 261 (76%) 3.4 0.34
Hyperlipidemia 95 (63%) 6.3 206 (60%) 2.9 0.16
Current tobacco used 24 (16%) 8.3 74 (22%) 4.1 0.41
Past or current tobacco used 112 (74%) 8.0 263 (77%) 3.4 0.06
History of CHF 43 (28%) 7.0 29 (8%) 3.4 0.53
History of MI 42 (28%) 12.0 81 (24%) 2.5 0.03
History of prior TIA or CVA 72 (47%) 8.3 163 (48%) 3.1 0.08
History of PVD 45 (30%) 6.7 54 (16%) 3.7 0.51
Aspirin 110 (72%) 7.3 240 (70%) 2.5 0.03
Clopidogrel or Ticlopidine 108 (71%) 7.4 248 (72%) 2.8 0.05
Statins 35 (23%) 0.0 60 (17%) 1.7 0.45
Beta-blocker 44 (29%) 2.3 82 (24%) 4.9 0.48
Calcium channel blocker 51 (34%) 3.9 93 (27%) 3.2 0.83
ACE-Inhibitors 55 (36%) 7.3 111 (32%) 4.5 0.46
Diuretics 64 (42%) 9.4 101 (29%) 5.0 0.27
Conclusions: Diabetic patients who have a prior history of myocardial infarction 
or neurologic events are more likely to experience recurrent events compared with 
non-diabetic patients. Anti-platelet therapy may be less effective at preventing future 
neurologic events in diabetic patients compared with non-diabetic patients who undergo 
carotid stenting.
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1124-13 Impact of Diabetes Mellitus on Clinical Adverse 
Outcomes During Percutaneous Carotid Artery 
Interventions
M. Habeeb Ahmed, Aravinda Nanjundappa, Donna J. Whitman, Tracey Bersnahan, 
Regina Deible, Rebecca Canos, Augusto D. Pichard, Ron Waksman, Lowell Satler, John 
R. Laird, Jr., Washington Hospital Center, Washington, DC
Background: Diabetes Mellitus (DM) is usually associated with co-morbidities that exist with 
atherosclerosis in other vascular beds including carotid arteries. This study aimed to analyze 
the impact of DM on adverse clinical outcomes of patients (pts) who underwent percutaneous 
carotid artery intervention (PCAI) using cerebral distal protection devices (DPD).
Methods: The records of 151 pts who underwent PCAI from 2000 to 2004 were reviewed. 
Of these 48 pts were diabetic. Patients who underwent PCAI included those with high 
risk characteristics such as prior CEA or radiation therapy, >75 years of age, Diabetes 
Mellitus (DM), Hypertension, high cervical lesion, contra-lateral occlusion and CVA/TIA. 
All pts were pretreated with clopidogrel and ASA. The in-hospital and 30 day outcomes 
were compared between the diabetic and the non-diabetic groups.
Results: Baseline demographics were similar between the groups except for the 
presence of diabetes. Periprocedural there was a trend for a higher stroke in the diabetic 
group. However, this was not seen at 30day and at 6 month and the overall complications 
rate was low in both the diabetic and the non-diabetic groups. (Table)
Conclusions: Diabetic pts undergoing PCAI have a trend towards periprocedural 
intracerebral events despite the use of DPD. This warrants special precautions during 
PCAI involving diabetic patients. However, at later follow-up there is not difference in 
outcome out of hospital following carotid stent implantation among diabetic pts.
DM (n=48) non-DM (n=103) p value
Peri-Procedure
CVA, % 6.25 0.9 0.09
Intracranial Hemorrhage, % 0.0 1.9 0.46
In-Hospital
TIA, % 6.25 0.9 0.09
CVA, % 2.0 1.9 0.28
Death, % 0.0 0.9 0.68
1 month
TIA, % 2.0 0.0 0.32
CVA, % 0.0 0.9 0.68
Death, % 0.0 0.9 0.68
1124-14 Percutaneous Revascularization of Femoropopliteal 
Arteries with Self-Expanding Nitinol Stents - Immediate 
Success and One-Year Results
Sepideh Kazemi, Ramagopal Tumuluri, Suhail Allaqaband, Anjan Gupta, Yoseph 
Shalev, Rami Gal, Tanvir Bajwa, Aurora Sinai/St. Luke’s Medical Centers, University of 
Wisconsin Medical School-MCC, Milwaukee, WI
Background: Previous studies of percutaneous revascularization of femoropopliteal 
(FP) arteries with balloon-expanding or self-expanding stainless steel stents have been 
disappointing with low patency rate of about 40%. No long-term data is available for self-
expanding (SE) Nitinol stents in FP arteries. We evaluated the immediate and long-term 
patency rate of SE Nitinol stents in FP arteries.
Methods: We retrospectively identiﬁ ed patients at our institution who underwent 
percutaneous revascularization of FP arteries with SE Nitinol SMART stents (Cordis 
Corp., Miami Lakes, FL). Follow up duplex scans were performed in all patients. Primary 
patency was deﬁ ned as ≤ 50% in-stent restenosis by duplex scan. In more than 90% of 
patients, in-stent restenosis by duplex, was reconﬁ rmed by angiography.
Results: 69 patients (34 men and 35 women; mean age, 60 yr ±10) presented with severe 
claudication (80% - Fontaine stage ΙΙb) or critical limb ischemia (20% - Fontaine stage 
ΙΙΙ or ΙV). 35 patients had diabetes mellitus and 34 were smokers. 14 (20%) patients 
presented with total occlusion and 55 (79%) with high-grade stenosis (80-99%). Pre-
dilatation was performed in 44 patients. All patients received aspirin and plavix post-
procedure. Procedural and follow-up results are shown in the angiographic data Table.
Conclusion: Percutaneous revascularization of femoropopliteal arteries with self-
expanding Nitinol stents provides excellent immediate and promising one-year results. 
Angiographic Data
initial technical success 100%
average number of distal vessel run-off 2
average stent length 63 mm (range 20-100)
patients with > 60mm stents 52 (75%)
patients with >1 stent 41 (59%)
mean follow up 11 months (range 3-52 months)
primary patency 51 (76%)
primary assisted patency 59 (86%)
binary in-stent restenosis (>50%) 17 (24%)
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1125-15 Long-Term Follow-up of Patients Undergoing 
Intravascular Ultrasound-Guided Revascularization for 
Angiographically Indeterminate Left Main Coronary 
Artery Disease
Amir-Ali Fassa, Kenji Wagatsuma, Stuart Taylor Higano, Amir Lerman, Mayo Clinic, 
Rochester, MN
Background: The assessment of left main coronary artery (LMCA) lesions by 
angiography is often challenging. The purpose of this study is to evaluate the efﬁ cacy 
of an intravascular ultrasound (IVUS) guided strategy for angiographically indeterminate 
LMCA disease.
Methods: IVUS was performed on 121 patients with angiographically normal LMCAs to 
determine the lower range of normal minimum lumen area (MLA), deﬁ ned as the mean 
- 2 standard deviations. We conducted IVUS studies on 214 patients with angiographically 
indeterminate LMCA lesions, and deferral of revascularization was recommended when 
the MLA was larger than the pre-determined value.
Results: The lower range of LMCA MLA was 7.5 mm2. Of the patients with angiographically 
indeterminate LMCAs, 83 (39%) had a MLA<7.5 mm2 (group 1), and 131 (61%) had 
a MLA≥7.5 mm2 (group 2). LMCA revascularization was performed in 86% (71/83) of 
group 1, and was deferred in 87% (114/131) of group 2. Long-term follow-up (Figure) was 
available for 185 patients (86%) for a mean period of 3.5 ± 2.1 years (range 0-8.4 years). 
The patients with a MLA<7.5 mm2 who underwent revascularization and those with a 
MLA≥7.5 mm2 who were deferred for revascularization had a similar rate (p=0.28) of major 
adverse events (target vessel revascularization, acute myocardial infarction and death).
Conclusions: IVUS is an accurate method to assess angiographically indeterminate 
lesions of the LMCA. Moreover, deferral of revascularization for patients with a MLA≥7.5 
mm2 appears to be safe.
1125-16 Extent of Angiographic Disease Predicts Response to 
Statin Therapy
Michael S. Chen, Chuan-Chuan Wun, Ilke Sipahi, David S. Lee, Paul Schoenhagen, E. 
Murat Tuzcu, Sorin J. Brener, Steven E. Nissen, Cleveland Clinic, Cleveland, OH, Pﬁ zer 
Pharmaceuticals, New York, NY
Background: Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) 
demonstrated halting of coronary atherosclerosis progression, as assessed by 
intravascular ultrasound (IVUS), with intensive lipid lowering therapy. It is uncertain 
whether baseline angiographic extent of disease correlates with plaque progression.
Methods: REVERSAL subjects received 40 mg pravastatin (moderate regimen) or 80 mg 
atorvastatin (intensive regimen) daily. Baseline and 18-month angiograms and IVUS were 
performed. Of 502 subjects, 389 had complete IVUS and angiograms. Angiographic lesion 
severity was visually estimated as <50%, 51-90% and >90%. A vessel was diseased if 
any lesion >50% existed in the parent vessel or its major branches. Primary outcome was 
change in percent atheroma volume.
Results: Less atheroma progression occurred with increasing extent of angiographic 
disease (p=0.020). When analyzed by treatment, progression occurred in the moderate 
regimen irrespective of angiographic disease burden. In contrast, with intensive therapy, 
halting of plaque progression existed with increasing extent of angiographic disease 
(p=0.003) (Table).
Conclusions: Contrary to expectations that more angiographic disease would be more 
resistant to statin therapy, we found that a higher angiographic disease burden correlated 
with less atherosclerosis progression. Our results imply that subjects with a larger extent 
of angiographic disease beneﬁ t more from aggressive lipid-lowering therapy.
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Relationship between extent of angiographic disease and 
change in percent atheroma volume
Nominal change in percent atheroma volume
Number of diseased 
vessels
Pravastatin (n=195) Atorvastatin (n=194) Total (n=389)
(n) mean +/- sd (n) mean +/- sd (n) mean +/- sd
0 (50) 1.9 +/- 4.2 (64) 2.0 +/- 4.3 (114) 1.9 +/- 4.2
1 (62) 2.7 +/- 5.7 (67) -0.6 +/- 6.4 (129) 1.0 +/- 6.3
2 or more (83) 1.5 +/- 4.4 (63) -0.1 +/- 3.8 (146) 0.8 +/- 4.2
Spearman rank 
correlation (r) -0.065 -0.21 -0.12
p-value 0.36 0.003 0.021
1125-17 Volumetric Intravascular Ultrasound Assessment 
Of Coronary Artery Disease In Patients With Renal 
Insufﬁ ciency: The Impact Of End Stage Renal Disease 
On Atherosclerosis Morphometry
Prithviraj B. Rai, Gary Mintz, Luis Gruberg, Daniel Canos, Chrysoula K. Pappas, Lowell F. 
Satler, Augusto D. Pichard, Kenneth K. Kent, Ron Waksman, Neil J. Weissman, Medstar 
Rsearch Institute, Washington, DC, Cardiovascular Research Foundation, New York, NY
Background: Renal failure accelerates coronary artery disease; however, the impact of 
mild to moderate vs severe renal insufﬁ ciency on atherosclerosis is not known.
Methods: We performed pre-intervention, total arterial, 3-D intravascular ultrasound 
(IVUS) assessment in 110 patients with a wide range of creatinine clearances (CrCl). 
Patients were matched for age, gender, and diabetes and grouped as follows: (A) 
CrCl>70ml/min (n=31); (B) CrCl=50-69ml/min (n=30); (C) CrCl<50ml/min (n=26) and (D) 
end stage renal disease (ESRD, n=23). Volumetric assessment of non-stenotic segments
were performed every 1mm including external elastic membrane (EEM), lumen, plaque, 
plaque burden (plaque/EEM), and arc and surface area of calcium (Ca); results were 
normalized for measured segment length.
Results: Patients in the ESRD Group had a larger EEM, more plaque, and more calcium 
compared to the other groups. However there were no signiﬁ cant differences in any of the 
parameters between patients with mild to moderate renal insufﬁ ciency (Groups A thru C).
Conclusion: Volumetric IVUS analysis indicates that mild to moderate renal insufﬁ ciency 
does not affect overall atherosclerosis morphometry. It is the transition to ESRD that is 
associated with increased plaque burden and arterial calciﬁ cation.
Group-A Group-B Group-C Group-D P value
Length analyzed 16.0mm 17.2mm 23.1mm 15.4mm 0.025
Mean EEM 14.40mm2 14.59mm2 13.85mm2 18.32mm2 0.003
Mean lumen 7.80mm2 7.33mm2 7.53mm2 9.0mm2 NS
Mean plaque 6.58mm2 7.25mm2 6.37mm2 9.66mm2 <0.001
Mean plaque burden 46% 49% 45% 53% 0.01
Mean Ca arc 87° 109° 102° 128° 0.028
Mean Ca surface 3.54mm2 4.53mm2 4.15mm2 6.3mm2 0.001
1125-18 Cross-Sectional Versus Serial Assessment of Coronary 
Arterial Remodeling in Mildly Stenotic Atherosclerotic 
Lesions Undergoing Progression. An Intravascular 
Ultrasound Study
Ilke Sipahi, Paul Schoenhagen, Stephen J. Nicholls, Timothy Crowe, Deborah Hansen, 
Aaron Loyd, Samir Kapadia, E. Murat Tuzcu, Steven E. Nissen, The Cleveland Clinic 
Foundation, Cleveland, OH
Background: Arterial remodeling is the process by which an increase in arterial 
area delays luminal narrowing during progression of atherosclerosis. Cross-sectional 
intravascular ultrasound (IVUS) studies deﬁ ne remodeling by comparing the external 
elastic membrane (EEM) areas of lesion and reference sites. Serial IVUS studies allow 
determination of remodeling by measuring EEM and atheroma area at two or more time 
points. We examined the relationship between static and serial assessment of arterial 
remodeling.
Methods: From the cohort of the REVERSAL study, we identiﬁ ed 224 patients with a 
mildly stenotic coronary lesion (<50% diameter stenosis on angiogram) and a relatively 
normal proximal reference site on baseline IVUS. 118 lesions showing >5% increase in 
atheroma area at the 18-month follow-up IVUS were included. Fiduciary branches and 
automatic pullback were used to match the lesion and reference sites at baseline and 
follow-up. Static remodeling at baseline and follow-up was described by the remodeling 
index (RI), calculated as lesion EEM area/reference EEM area. Serial assessment of 
remodeling was calculated as (EEM area at follow-up - EEM area at baseline)/(atheroma 
area at follow-up - atheroma area at baseline). A ratio of >1 was considered as expansive, 
<0 as constrictive, 0-1 as no remodeling.
Results: EEM area at lesion site increased from 14.9±4.9 to 17.8±6.1 mm2 (p<0.001). 
Serial assessment revealed expansive remodeling in 74%, no remodeling in 16% and 
constrictive remodeling in 10% of the lesions. In contrast, static assessment demonstrated 
no signiﬁ cant change in the RI between baseline and follow-up (1.055±0.155 and 
1.042±0.147, p=0.38). On serial assessment, the reference segments also had expansive 
remodeling in 87% of the occasions. Simultaneous expansive remodeling of lesion and 
reference sites was the main reason for the discrepancy between static and dynamic 
methods.
Conclusions: Arterial remodeling is a dynamic process involving the entire coronary 
tree. Cross-sectional static measurements misrepresent the actual extent of coronary 
remodeling and provide limited insight into remodeling patterns during progression of 
atherosclerotic lesions. 
1125-22 Local Geometrical Determinants of Vascular 
Remodeling in Coronary Atherosclerosis : 
A Serial Intravascular Ultrasound Study
Yusaku Fukumoto, Takafumi Hiro, Genata Hashimoto, Koji Imoto, Jutaro Yamada, 
Takayuki Okamura, Takashi Fujii, Masunori Matsuzaki, Yamaguchi University Graduate 
School of Medecine, Ube Yamaguchi, Japan
Background and Methods: This study hypothesized that coronary remodeling pattern 
is determined in part by local vascular geometrical architecture. No previous studies 
examined this hypothesis with a serial obstruction of vessel remodeling. To clarify the local 
geometrical determinants of coronary remodeling by intravascular ultrasound(IVUS), we 
imaged 107 proximal coronary segments at the baseline and at the follow-up period(10±5 
months after the baseline). We measured vessel area(VA), lumen area(LA), plaque 
area(PA), maximum(Mx) and minimum(Mn) thickness of plaque, plaque distribution 
index(Pd=Mn/Mx), vascular perimeter(L) and the degree of cross-sectional roundness of 
the vessel(Rd=4πVA/L2). Then, percent change(%d-) of each parameter during the follow-
up period was calculated.
Results: Coronary segments analyzed had a % area stenosis of 51±12%. During the 
follow-up period, 45% of segments showed a progression in PA, while 55% showed a 
regression in PA. %d-VA was correlated signiﬁ cantly with %d-PA (r=0.57, p<0.0001), but 
there was no signiﬁ cant correlation between %d-PA and %d-LA. %d-VA was inversely 
correlated with baseline Pd (r=-0.32, p<0.001). %d-Mx was signiﬁ cantly correlated with 
%d-Rd(r=0.31, p<0.005).
Conclusions: The serial IVUS study of the same coronary segments with a mild stenosis 
showed that vessel area changed in parallel with the change of plaque area. The more 
eccentric the plaque distribution was at baseline , the more vessel area increased at 
follow-up period(positive remodeling). When the maximum thickness of the eccentric 
plaque increased, vascular cross-section became more elliptical, which represented the 
heterogeneity of vascular remodeling within the same cross-section. These data suggest 
that coronary remodeling pattern is partly determined by local arterial geometry.
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839-3 Endothelial Progenitor Cell Capture By Stents Coated 
With Antibody Against CD34The HEALING-FIM (Healthy 
Endothelial Accelerated Lining Inhibits Neointimal 
Growth-First In Man) Registry
Jiro Aoki, Andrew T.L. Ong, Eugene P. McFaden, Willem J. van der Giessen, Georgios 
Sianos, Evelyn Regar, Pim de Feyter, Michael J.B. Kutryk, Patrick W. Serruys, Erasmus 
medical center, Rotterdam, The Netherlands
Background A Pro-healing approach for prevention of post stenting retenosis is 
theoretically favored over the use of cytotoxic or cytostatic local pharmacological therapies. 
It is a widely held belief that the central role of the vascular endothelium is to maintain 
quiescence of the underlying media and adventitia. As a result, it has been hypothesized 
that rapid endothelialization of stainless steel stents with a functional endothelium will 
prevent stent thrombosis and reduce the occurrence of restenosis.
Methods and results Sixteen patients with de novo coronary disease were successfully 
treated with the implantation of endothelial progenitor cell (EPC) capture stents. Complete 
procedural and angiographic success was achieved in all 16 patients. Six-month composite 
major adverse cardiac and cerebrovascular events (MACCE) rate was 6.3% as a result 
of a symptom-driven target vessel revascularization in a single patient. There were no 
other MACCE nor stent thrombosis despite only one month clopidogrel treatment. At six 
month follow-up, mean angiographic late luminal loss was 0.63±0.52mm and percent 
stent volume obstruction by intravascular ultrasound analysis was 27.2±20.9%.
Conclusions This ﬁ rst human clinical investigation of this technology demonstrates that 
the EPC capture coronary stent is safe and feasible for the treatment of de novo coronary 
artery disease. Further developments in this technology is warranted to evaluate the 
efﬁ cacy of this device for the treatment of coronary artery disease.
10:45 a.m.
839-4 Paclitaxel In-Stent Controlled Elution Study. 
The PISCES study
Patrick Serruys, Georgios Sianos, Peter Den Heijer, Dougal McClean, Stefan Verheye, 
Eduardo Sousa, Jose Antonio Condado, Jorge Belardi, Conor Medsystems Inc., Menlo 
Park, CA, Cardialysis, Rotterdam, The Netherlands
Background: The Conor stent with intra-strut wells and erodable polymer is speciﬁ cally 
designed for drug delivery with programmable pharmacokinetics. Methods: 244 patients 
with single vessel disease received either a bare metal Conor stent (n=53) or a Paclitaxel-
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eluting Conor stent with one of six release formulations (n=191) varying in dose and elution 
kinetics, direction and duration. The endpoints at 6 months (bare stent group) and at 4 
months (eluting stent groups) were angiographic late loss and neointimal tissue volume 
by IVUS and the rate of Major Adverse Cardiac Events (MACE). Baseline characteristics:
age 59.1± 9.2y, male 70%, history of smoking 76%, diabetes 19%, hypertension 53%, 
dyslipidemia 66%, prior MI 38%, prior CABG 3%, prior PCI 12%. Baseline characteristics 
were comparable in all doses. The technical success rate was 95% and the procedural 
success rate 93%. 
Results:
At 6 months (bare metal group D0) and 4 months 
(Paclitaxel-eluting groups D1-D6):
D0 D1 D2 D3 D4 D5 D6
Dose(ug)/ 
duration(days)/ 
direction(*)
Bare stent 10/5/b 10/10/b 10/10/m 30/10/b 10/30/m 30/30/m
N 50 30 29 30 30 39 29
Clinical
Any MACE 4 (8.0%) 5 (16.7%) 5 (17.2%) 2 (6.7%) 2 (6.7%) 1 (2.6%) 1 (3.4%)
QCA
Late loss
(mm) 0.88±0.41 0.72±0.39 0.70±0.56 0.67±0.52 0.48±0.47§ 0.38±0.34§ 0.30±0.35§
Restenosis rate (%) 11.6 10.3 10.7 3.6 6.9 0.0 3.8
IVUS
Obstruction volume 
fup (%) 26±13 22±13 20±17 17±13
¶ 12±13§ 8±7§ 5±7§
* b=bidirectional (luminal and abluminal), m=mural (abluminal)
¶ p value <0.05 compared to bare stent group
§ p value <0.01 compared to bare stent group
Conclusion: This novel eluting stent platform, using an erodable polymer with complete 
elution of low doses of Paclitaxel, is safe. The inhibition of the in-stent neointimal 
hyperplasia was best in the long release groups. The principal ﬁ nding of this study is that, 
for Paclitaxel, differing release kinetic proﬁ les at similar doses appears to have profound 
impact on efﬁ cacy. Twelve-month data will be presented.
11:00 a.m.
839-5 Efﬁ cacy and Tolerability of Oral Rapamycin to 
Prevent Restenosis After Coronary Stent Implantation: 
The Prospective, Randomized ORAR II Study
Alfredo E. Rodriguez, Maximo Rodriguez-Alemparte, Carlos Fernandez-Pereira, 
Antonio Pocovi, Jorge Tronge, Gregg Kaluza, Albert Raizner, Gregg W. Stone, Otamendi 
Hospital, Buenos Aires, Argentina, Columbia University Medical Center, New York, NY
Background. Previous non-randomized data suggested that oral rapamycin may reduce 
angiographic restenosis and late loss in patients (pts) undergoing stent implantation in de 
novo coronary lesions.
Methods. Between September 2003 and August 2004, 100 pts undergoing coronary 
stenting in two centers in Buenos Aires, Argentina were randomized to either oral rapamycin 
(pre-treated 2 hrs before intervention with a 6 mg loading dose, followed by 3 mg per day for 
15 days) vs. control. Primary endpoints were angiographic binary restenosis and late loss 
determined by an independent core laboratory blinded to treatment allocation. Secondary 
end points were target lesion revascularization (TLR), target vessel revascularization ( TVR) 
and incidence of major adverse cardiovascular events ( MACCE).
Results. Fifty pts were randomized to oral rapamycin and 50 pts to control . The two groups 
were well matched for baseline clinical, angiographic and procedural characteristics.
Minor side effects related to oral rapamycin were present in 22% of pts, two (4%) requiring 
medication discontinuation at days 3 and 8. Clinical follow-up to date, complete in all 100 
pts (100%) at a mean time of 190 days is shown in the table.
Conclusions. The results of this prospective randomized trial suggest that the 
administration of oral rapamycin in pts undergoing bare metal stent implantation reduces 
clinical measures of restenosis. Long term clinical data and angiographic follow-up will be 
complete for presentation in March 2005.
Clinical Follow Up
Rapamycin Control p
TLR (lesions) 2/67 (3%) 10/59 (17%) 0.018
TVR(vessels) 2/62 (3.2%) 9/55 (16.4%) 0.039
MACCE(pts) 4/50 (8%) 12/50 (24%) 0.06
11:15 a.m.
839-6 Impact of Direct Coronary Stenting on Neointimal 
Distribution Within Sirolimus-Eluting Stents - IVUS 
Subanalysis From the DIRECT Trial
Atsushi Hirohata, Junya Ako, Ryota Sakurai, William F. Fearon, Ronald Caputo, Gregory 
Mishkel, Michael Mooney, Charles O’Shaughnessy, Albert Raizner, Robert Wilensky, 
David Williams, Shing Chiu Wong, Steven Karas, Paul G. Yock, Yasuhiro Honda, Jeffrey 
Moses, Peter J. Fitzgerald, The DIRECT investigators, Stanford University Medical 
Center, Stanford, CA
Background: Neointimal distribution within sirolimus-eluting stents (SES) has been 
reported to favor the stent edges. Direct coronary stenting without pre-dilatation may 
reduce vessel trauma and subsequent neointimal hyperplasia (NIH) compared to stenting 
with pre-dilatation. The aim of this IVUS study was to clarify the impact of this strategy on 
extent and distribution of NIH within SES.
Methods and Results: This analysis enrolled all cases from the DIRECT (stenting 
without pre-dilatation) and the SIRIUS (stenting with pre-dilatation) trials, in which a single 
18-mm SES was implanted and 8-month volumetric IVUS was performed (DIRECT 34, 
SIRIUS 39). Average lumen, vessel, stent and neointimal area (volume/length, mm3/mm) 
in DIRECT and SIRIUS were similar (lumen 6.71±2.04 vs. 6.81±2.07, stent 6.83±2.02 
vs. 6.94±2.04, vessel 14.01±4.15 vs.15.16±3.98, neointima 0.14±0.24 vs. 0.16±0.23, 
p=n.s. for all). On average, there was no signiﬁ cant difference in overall distribution 
pattern of NIH between the groups. At the distal 3mm of the stent edge, however, NIH 
was signiﬁ cantly higher in SIRIUS compared to DIRECT (0.22 vs. 0.098 mm2, p=0.01 
for average neointimal area within 3mm from distal stent edge, Figure). There was no 
difference in NIH at the proximal stent edges.
Conclusion: Direct coronary stenting with SES appears to be associated with less NIH 
near the distal stent edge, suggesting this strategy may provide further beneﬁ t compared 
to a conventional strategy of pre-dilatation prior to stenting. 
11:30 a.m.
839-7 The Diabetes (DIABETes and Sirolimus Eluting Stent) 
Trial: One-year Clinical Results.
Pilar Jiménez-Quevedo, Manel Sabaté, Dominick J. Angiolillo, J. Antoni Gómez-Hospital, 
Rosana Hernández-Antolín, Javier Goicolea, Fernando Alfonso, Camino Bañuelos, 
Javier Escaned, Raul Moreno, Francisco Fernández-Avilés, Carlos Macaya, Hospital 
Clinico San Carlos, Madrid, Spain, Hospital do Meixoeiro, Vigo, Spain
The DIABETES (DIABETes and sirolimus Eluting Stent) trial is a prospective, multicenter, 
randomized, controlled trial aimed to demonstrate the efﬁ cacy of sirolimus-eluting stent 
(SES) as compared to bare metal stent (BMS) on the inhibition of neointimal hyperplasia 
in diabetic patients (pts).
Methods: From January to November 2003, 160 pts (222 lesions) were included in 
the trial: 80 pts randomized to SES and 80 pts to BMS. Patients were eligible for the 
study if they were identiﬁ ed as non-insulin or insulin-dependent diabetics, with signiﬁ cant 
coronary stenoses in 1, 2 or 3 vessels and signs or symptoms of ischemia. There was 
a sub-randomization according to the type of diabetes. The use of abciximab during 
the procedure was recommended per protocol, and dual antiplatelet therapy (aspirin 
indeﬁ nitely and clopidogrel for 1 year) was routinely prescribed. Clinical follow-up was 
scheduled at 1, 9 and 12 months and angiographic follow-up at 9 months.
Results: Baseline clinical and angiographic characteristics were comparable between 
groups. To date, 153 pts (95%) have completed 9-month angiographic follow-up and 
117 pts (73%) one-year clinical follow-up. At 9 months, the rate of clinically-driven target 
lesion (stent+edges) revascularization (TLR), was signiﬁ cantly lower in SES group as 
compared with BMS group (7.6% vs. 33.8%, respectively; p<0.0001). This beneﬁ cial effect 
was extended to 1-year follow-up (TLR: 11.1% in SES group vs. 41.3% in BMS group, 
p<0.0001). There were no differences between groups (SES vs. BMS) in death (1.9% vs. 
3.2%; p=NS) or myocardial infarction rates (3.8% vs. 6.5%; p=NS) at 1-year. The need 
for new revascularization due to progression of atherosclerosis in non-target segments 
was higher, but not signiﬁ cant, in the SES group (11.1% in SES group vs. 3.2% in BMS 
group; p=0.14).
Conclusion: As compared with BMS, SES implantation in diabetic pts with de novo 
stenoses appears to signiﬁ cantly reduce the need to repeat revascularization at 1 year.
11:45 a.m.
839-8 Impact of Sirolimus-Eluting Stents on the Outcome 
of Patients With Diffuse Type In-Stent Restenosis: 
Multicenter Registry in Asia
Sunao Nakamura, Tamil Selvan Muthusamy, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, New Tokyo Hospital, Matsudo, Japan
Background and Purpose: Diffuse In-stent restenosis (D-ISR) remains the major limitation 
of percutaneous coronary intervention. The efﬁ cacy of Sirolimus-eluting stent (SES) for 
treatment of D-ISR is still under evaluation. A prospective Asian multicenter registry was set 
up in ﬁ ve high volume Asian centers to evaluate the SES in treatment of D-ISR. Methods: A 
total of 126 patients with 176 D-ISR lesions (male 71.4%, mean age 69.5, LMT 3.4%, LAD 
43.8%, LCX 27.8%, RCA 25.0%) in native coronary arteries were treated with SES (mean 
lesion length 24.5±10.5 mm). We evaluate immediate and long-term clinical result by 6 and 
12 months angiography. Results: See table for clinical results. Conclusion: These results 
showed utilizing SES can dramatically suppress the restenosis rate of D-ISR.
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Number of patients 126
Procedural success (%) 100
MACE at 30 days (%) 0
Reference diameter (mm) 2.82 ± 0.55
MLD pre (mm) 0.63 ± 0.38
MLD post (mm) 2.78 ± 0.60
MLD at 6 months (mm) 2.55 ± 0.88
MLD at 12 months (mm) 2.58 ± 0.88
Restenosis rate (%) 3.2
TVR (%) 4.8
MACE at 12 months (%) 4.8
ORAL CONTRIBUTIONS
841  Intravascular Ultrasound Insight in 
Coronary Stenting
Tuesday, March 08, 2005, 10:30 a.m.-Noon
Orange County Convention Center, Room 304E
10:30 a.m.
841-3 The Impact of Stent Area in Patients Treated with Drug-
eluting Stents versus Brachytherapy: an Intravascular 
Ultrasound Analysis
Sang-Wook Kim, Gary S. Mintz, Pramod K. Kuchulakanti, Esteban Escolar, Patrick 
Ohlmann, Augusto D. Pichard, Lowel F. Satler, Kenneth M. Kent, William O. Suddath, 
Ron Waksman, Neil J. Weissman, Washington Hospital Center, Washington, DC, 
Cardiovascular Research Foundation, New York, NY
Background: We used intravascular ultraound (IVUS) to compare pts who presented with 
drug-eluting stent (DES) vs brachytherapy (BT) failure. 
Methods: IVUS measures were performed each 1 mm within the stent. Stent, lumen, 
and intimal hyperplasia (IH) areas were measured, and %IH was calculated as IH/stent 
area. Absolute volumes and %volume obstruction (IH/stent volume) were calculated using 
Simpson’s rule. 
Results. Between September 2003 and June 2004, 19 pts presented with DES failure 
and 15 pts presented with BT failure. Pt age was 60±8 yrs in DES and 58±7yrs in BT; 
58% of DES and 53% of BT were males; 42 % of DES failures and 46% of BT failures 
were diabetic; and the time to presentation was 179±79 days in DES and 290±255 days 
in BT failures (p=0.12). IVUS analysis (Table) revealed that the minimal stent area was 
signiﬁ cantly larger in BT vs DES failures (p=0.0002); this was associated with more 
neointimal hyperplasia compared to DES failures (P=0.01). Conversely, DES failures were 
associated with a smaller minimum stent area and less neointimal hyperplasia.
DES Brachytherapy p-value
Stent length (mm) 33.7±10 26.7±11 0.8
Minimal stent area (mm2) 4.65±1.38 6.58±1.32 0.0002
Mean IH area (mm2) 0.90±1.00 2.56±1.03 0.0004
IH volume (mm3) 29±35 69±48 0.01
% Volume obstruction 13±12 31±11 0.0001
Conclusion: BT failures are caused by signiﬁ cant recurrent intimal hyperplasia in the 
setting of adequate stent expansion while DES failures are caused by only modest intimal 
hyperplasia in the setting of DES underexpansion. Therefore, DES failures may be more 
amenable to convention catheter-based techniques compared to BT failures since it appears 
to be mostly a mechanical problem, rather than resistant intimal hyperplasia proliferation.
10:45 a.m.
841-4 The Impact of Pre-procedural Plasma C-Reactive 
Protein on the Neointimal Hyperplasia after Successful 
Coronary Artery Stenting
Young Joon Hong, Myung Ho Jeong, Hyung Wook Park, Weon Kim, Ju Han Kim, Young 
Keun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang, Chonnam National 
University Hospital, Gwangju, South Korea
Background: It has been shown that pre-procedural C-reactive protein (CRP) could 
predict late clinical restenosis after stent implantation. However, the relation between 
pre-procedural CRP and in-stent neointimal hyperplasia (NIH) after successful stent 
implantation was not clearly demonstrated.
Objectives: This study assessed the relation between pre-procedural CRP levels and 
in-stent NIH after successful stent implantation.
Methods: This study included 100 patients who underwent stent implantation for 
angiographically signiﬁ cant stenosis. Patients were divided into a normal CRP group (< 
0.5mg/dL) and elevated CRP group (≥ 0.5mg/dL) on the basis of serum CRP levels. All 
patients underwent angiographic and intravascular ultrasound (IVUS) follow-up at six 
months.
Results: The baseline CRP level was 0.29±0.08 mg/dL in the normal CRP group and 
2.90±2.31 mg/dL in the elevated CRP group. The levels of ﬁ brinogen and monocyte 
were higher and the ejection fraction was lower in the elevated CRP group. On coronary 
angiogram, the complex lesion was observed more frequently in the elevated CRP group. 
On follow-up angiogram, the late loss was signiﬁ cantly larger in the elevated CRP group 
(0.54±0.34 mm vs. 0.95±0.42 mm, p=0.013). The plaque plus media cross sectional 
area (P&M CSA) and plaque burden in the minimal lumen CSA at pre-intervention were 
signiﬁ cantly larger in the elevated CRP group (8.3±3.2mm2 vs. 11.5±3.1mm2, 66.2±7.7% 
vs. 72.1±6.6%, p<0.001, =0.032, respectively). The NIH CSA in the minimal lumen CSA at 
follow-up was signiﬁ cantly larger in the elevated CRP group (1.9±1.3mm2 vs. 3.0±1.5mm2, 
p=0.001). A signiﬁ cant positive correlation was found between pre-interventional CRP 
levels and pre-interventional P&M CSA and follow-up NIH area (r=0.37, p<0.001, r=0.52, 
p<0.001, respectively).
Conclusion: Elevated CRP may be related to the development of NIH after stent 
implantation and measuring pre-interventional CRP may be helpful to predict in-stent 
restenosis after stent implantation.
11:00 a.m.
841-5 Sirolimus-eluting Stent to Prevent Restenosis in 
Diabetic Patients with de Novo Coronary Stenoses: 
The Diabetes Trial. Nine-month Intravascular Ultrasound 
Results
Pilar Jiménez-Quevedo, Manel Sabaté, Dominick J. Angiolillo, Rosana Hernández-
Antolin, David Bass, Javier Goicolea, Fernando Alfonso, J. Antoni Gómez-Hospital, 
Marco Costa, Camino Bañuelos, Javier Escaned, Raul Moreno, Theodore Bass, 
Francisco Fernández-Avilés, Carlos Macaya, Hospital Clinico San Carlos, Madrid, 
Spain, Hospital de Bellvitge, Barcelona, Spain
Background: The DIABETES (DIABETes and sirolimus Eluting Stent) trial is a 
prospective, multicenter, randomized, placebo-controlled trial aimed to demonstrate the 
efﬁ cacy of the sirolimus eluting stent (SES) on the inhibition of neointimal hyperplasia in 
diabetic patients (pts) as compared to bare metal stent (BMS). An intravascular ultrasound 
(IVUS) substudy was performed to determine the mechanistic effect of SES both at target 
site and stent edges.
Methods: A total of 160 pts and 222 stenoses (112 in SES group and 110 in BMS 
group) were treated in this trial. Patients were eligible for the study if they were identiﬁ ed 
as diabetics (according to the WHO 1999 report), and had signiﬁ cant coronary stenoses 
in 1, 2 or 3 vessels with signs or symptoms of ischemia. The study also considered a 
sub-randomization according to the type of diabetes: insulin or non-insulin-dependent. In 
a subset of 165 lesions (SES=85, BMS=80) serial IVUS analysis (automated motorized 
pullback at a speed 0.5 mm/sec) was performed after stent implantation and at 9-month 
follow-up. Vessel, luminal and stent mean areas and volumes were evaluated at proximal 
and distal edges and within the stent.
Results: To date, 69 lesions have been analyzed by an independent core lab. At 9-month 
follow-up, a signiﬁ cant reduction in mean in-stent luminal area was evidenced in the BMS 
group as compared with SES group (8.2±2.8 mm2 vs. 6.3±2.3 mm2; p=0.003) due to a 
signiﬁ cant increase in mean neointimal hyplerplasia in the BMS group (2.3±1.6 mm2 
vs. 0.3±0.8 mm2; p<0.001). At distal edges, mean lumen area was signiﬁ cantly reduced 
in the BMS group (delta lumen: -1.3±2.1 mm2, p=0.004), whereas it showed a trend 
to increase in the SES group (delta lumen: 0.9±2.3 mm2, p=0.07). At proximal edges 
no signiﬁ cant changes were observed in either group. Acquired stent malapposition was 
observed more often in the SES group (p=0.03).
Conclusions: SES implantation is effective in preventing neointimal proliferation in this 
high risk group of patients without apparent deleterious effect at stent edges. Clinical 
consequences of acquired malapposition of those stents remain to be elucidated.
11:15 a.m.
841-6 Neointima Thickness: A Direct Intravascular Ultrasound 
Measure of Late Lumen Loss from the TAXUS IV and VI 
IVUS Substudy
Esteban Escolar, Gary S. Mintz, Joerg Koglin, Peter Lam, Jeffrey J. Pompa, Mary 
Russell, Steve Ellis, Gregg W. Stone, Eberhard Grube, Keith Dawkins, Neil J. Weissman, 
Cardiovascular Research Institute, Washington, DC
Background: Late lumen loss (LLL) is a primary endpoint in drug eluting stent (DES) trials. 
Angiographic LLL is a comparison of minimum lumen diameter (MLD) post-intervention 
and follow-up. The location of the MLD can migrate during follow-up; therefore, LLL is 
not a direct measure of intimal hyperplasia (IH) thickness. This study determined the 
degree to which LLL correlated with actual intravascular ultrasound (IVUS) measured 
IH thickness.
Methods: We analyzed the subset of 112 TAXUS IV and VI and 107 control stents with 
post-intervention and follow-up IVUS and angiography. IH thickness was measured each 
degree and every mm throughout the stent. Maximum (Max) IH thickness per stent was 
calculated and compared with angiographic LLL.
Results: At 9 mos, Max IH thickness was lower in TAXUS than in controls (0.43± 0.38 
vs. 0.73±0.31 mm, p<0.0001). This difference was also seen in Mean IH area (IH volume/
stent length) (0.84±1 vs. 2.39±1.37mm2 p<0.0001), %IH [IH/stent volume] (11.08±11.96 
vs. 29.73±13.67% p<0.0001), and LLL (0.42±0.62 vs. 0.87±0.45 p<0.0001). There was a 
good overall correlation between Max IH thickness and LLL (r=0.52 p<0.0001) (ﬁ gure). 
This correlation was maintained in the control group (r = 0.51 p<0.0001), but was less 
strong in the TAXUS group (r=0.39 p<0.0001).
Conclusion: There is a good correlation between angiographic LLL and IVUS-based 
measurements of Max IH thickness in bare metal stents. However, when the neointima is 
suppressed by DES, the relation becomes weaker.
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11:30 a.m.
841-7 A Critical Appraisal of Stent Diameters Derived from 
Manufacturer’s Compliance Charts: an Intravascular 
Ultrasound Study
Jose de Ribamar Costa, Jr., Stephane Carlier, Gary Mintz, Ricardo Costa, Kenichi Fujii, 
Koichi Sano, Hideo Takebayashi, Takenori Yasuda, Masashi Kimura, Jeffrey W. Moses, 
Gregg W. Stone, Martin B. Leon, Cardiovascular Research Foundation, New York, NY, 
Columbia Presbyterian Medical Center, New York, NY
Background: Many interventional cardiologists rely on the manufacturer’s compliance 
charts to select stent size and optimize stent diameters according to inﬂ ation pressures. 
However many factors inﬂ uence stent expansion in vivo compared to the in vitro conditions 
of the compliance charts.
Methods: We randomly selected 212 patients with de novo coronary lesions treated with 
a single, bare-metal, >3.0mm stent (Bx velocity®, NIR®, TETRA®/PENTA®, S660®/S670®/
S7®) and intravascular ultrasound (IVUS) guidance. Cases of stent overlap and post 
dilatation with another balloon were excluded. Predicted stent diameters were derived 
from the manufacturer’s compliance charts and the ﬁ nal maximal deployment pressures. 
IVUS minimum stent diameters (MSD) were measured from motorized pullback performed 
with a 40MHz CVIS system.
Results: All IVUS minimal stent diameters (1.4-4.0mm, mean 2.79mm) were smaller than 
the predicted ones (3.1-4.57mm, mean 3.78mm). The ratio of IVUS to predicted diameters 
ranged from 44% to 97% (mean 73.8±10%). Only 4% of the stents achieved 90% of their 
predicted size. However, most stents (65%) did achieve 70% of their predicted size. These 
ﬁ ndings were common to all manufacturers, types and lengths of stent studied.
Conclusions: In human coronary arteries, minimal diameter of deployed stents are 
signiﬁ cantly smaller than the prediction from the compliance charts, which should, at 
least, inform physicians about these discrepancies and, perhaps, be eliminated entirely.
11:45 a.m.
841-8 Intravascular Ultrasound Assessment of the Safety and 
Efﬁ cacy of Heparin-Coated Sirolimus-Eluting Stent in 
Small Vessel Stenting
Yoichiro Hongo, Junya Ako, Ryota Sakurai, Akiyoshi Miyazawa, Eduardo J. Sousa, 
Ernest Ban Hayashi, Charles Chan, Stefan Verheye, Franz J. Neumann, Dieter 
Horstkotte, Philippe Guyon, Ali Hassan, Yasuhiro Honda, Peter J. Fitzgerald, Stanford 
University, Stanford, CA, Institute Dante Pazzanese of Cardiology, Sao Paulo, Brazil
Background: Small vessel stenting remains a challenging category despite the 
prevalence of drug-eluting stents in contemporary percutaneous coronary intervention. 
The purpose of this study was to assess the safety and efﬁ cacy of the newly developed 
heparin-coated sirolimus-eluting cobalt chromium alloy stent in small vessel stenting 
using intravascular ultrasound (IVUS).
Methods: Fifty-one patients with a de novo coronary lesion in a reference vessel between 
2.0 and 2.5mm in diameter were enrolled in this study. The stent was either 2.0 or 2.5mm 
in diameter and 18mm in length. Serial baseline and 6-month follow-up IVUS analyses 
were available for 38 cases.
Results: No stent edge dissection was found except for one that was treated with 
additional stenting. One tissue protrusion and one intraluminal thrombus was detected, 
without adverse follow-up phenomenon. Six persistent, 3 resolved and 1 late incomplete 
apposition were found. Minimum lumen area within the stented segment did not change 
during the 6-month period (3.1 ± 0.7 to 3.0 ± 0.7 mm2, P=NS). Percent neointima volume 
(neointima volume * 100 / stent volume) was 2.5 ± 3.5 % (Median = 1.0 %).
Conclusion: This IVUS study showed the safety and minimum neointimal proliferation 
of the new heparin-coated sirolimus-eluting stent for small vessel stenting, warranting 
further trials to compare the efﬁ cacy of this stent system to previous ones. 
POSTER SESSION
1150  Drug-Eluting Stents: 
Clinical Outcomes II
Tuesday, March 08, 2005, 1:30 p.m.-5:00 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 1:30 p.m.-2:30 p.m.
1150-27 Drug-eluting Vs. Bare-metal Stents: A Meta-analysis Of 
Hard Clinical Outcomes
Demosthenes Katritsis, Evangelia Karvouni, John PA Ioannidis, Athens Euroclinic, 
Athens, Greece, University of Ioannina School of Medicine, Ioannina, Greece
Aim. To examine whether there is evidence for differences in death, myocardial infarction 
(Q wave and non-Q wave), and stent thrombosis between drug-eluting stents with 
sirolimus or paclitaxel and bare-metal stents.
Methods. We performed a meta-analysis of 10 randomized trials on 5066 patients with 
6-12 months follow-up.
Results. The summary risk differences excluded any major differences between the 
two types of stents for death (0.12%, 95% CI, -0.34% to 0.58%, p=0.60) and overall 
myocardial infarction (0.04%, 95% CI, -0.72% to 0.81%, p=0.91). There was a modest 
increase in the risk of Q wave myocardial infarction with drug-eluting stents (0.36%, 95% 
CI -0.04% to 0.77%, p=0.080), but no difference for non-Q wave myocardial infarction 
(-0.26%, 95% CI, -0.95% to 0.43%, p=0.47). The trend for increased risk of Q wave 
myocardial infarction was seen for both paclitaxel and sirolimus stents (risk differences 
0.28% and 0.58%, respectively). Drug-eluting stents also had a non-signiﬁ cant trend for 
higher risk of thrombosis (0.29%, 95% CI, -0.08% to 0.66%, p=0.13).
Conclusion. Sirolimus- and paclitaxel-eluting stents are equivalent to bare-metal stents 
in terms of mortality and overall myocardial infarction risk for the ﬁ rst year of follow-up; 
the meta-analysis excludes with considerable conﬁ dence the presence of large, clinically 
relevant differences for these outcomes. The observed trend for increased risk of Q wave 
myocardial infarction needs further study.
1150-28 Final Report of the Cypher Stent U.S. Post Marketing 
Surveillance Registry
Marco A. Costa, Emerson Perin, Peter Berger, Peter Block, Steve Ramee, Stanley Katz, 
Emily Keim, Linda Reynolds, Sidney Cohen, e-Cypher US-PMS study group, University 
of Florida, Jacksonville, FL
Randomized trials have demonstrated the effectiveness of sirolimus-eluting stents (SES) to 
treat native coronary disease in selected patients. The primary aim of the FDA-mandated 
CYPHER™ Post Marketing Surveillance (PMS) study was to assess safety and clinical 
outcomes associated with the use of the SES in routine clinical practice and identify uncommon 
device-related adverse events that may not have been noted during clinical trials. 
Methods: The CYPHER™ PMS Registry included 2067 patients (3245 lesions) treated with 
at least 1 SES in 38 US hospitals. No exclusionary criteria were applied. Enrollment was 
completed in December, 2003. An independent committee adjudicates all clinical events.
Results: Mean age was 63.7 years, 69% of patients were male, 32% had diabetes, 
59% had multivessel disease. Treated vessels were: right coronary (33%), left anterior 
descending (36%), left circumﬂ ex (29%), left main (1.5%) and vein grafts (5.5%). There 
were 15.4% ostial, 10.4% bifurcation and 6.7% total occlusion lesions treated. Clopidogrel 
was given to 95% and IIb/IIIa inhibitors were used in 42% of patients. Procedural success 
was obtained in 93.8% of patients. Acute plus subacute thrombosis rate was 0.6%.
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6-MONTH OUTCOMES
Clinical Event Estimates (n=2067)
Death 0.9%
Myocardial Infarction (MI) 1.2%
Target Lesion Revascularization (TLR) 2.3%
MACE( death, MI, TLR) 3.7%
Conclusion: The CYPHER™ PMS Registry demonstrates the safety and effectiveness 
of the use of SES to treat unselected patients in routine clinical practice, with excellent 
mid-term outcomes. Long-term (12-month) data are warranted and will be available for 
presentation.
1150-29 Methodological Implications of the Relocation of the 
Minimal Luminal Diameter in the Drug-Eluting Stent Era
Marco A. Costa, Dominick J. Angiolillo, Manel Sabate, Pilar Jimenez-Quevedo, Carlos 
Macaya, Jacques Guillaume, Paula Hu, Martin M. Zenni, Paul Gilmore, Theodore A. 
Bass, University of Florida, Shands Jacksonville, Jacksonville, FL, Cardiovascular 
Imaging Core Laboratories, Jacksonville, FL
Late loss (LL = post procedural minus follow-up [FU] minimal lumen diameter (MLD)), 
is a pivotal angiographic parameter to determine anti-proliferative effects of drug-eluting 
stents. However, accurate calculation of LL may be affected by the mismatch between MLD 
locations (post vs FU), as reported after angioplasty and brachytherapy. This phenomenon 
has not been assessed following stent implantation. The aim was to assess the implications 
of MLD relocation after bare metal and sirolimus-eluting stent (SES) implantation.
METHODS: Customized angiographic methodology was used. This included sub-
segmental analysis (5-mm/subsegment) of the target segment. MLD, Acute Gain (AG= 
post minus pre MLD) and LL were determined for each subsegment. Relocation of in-
stent MLD (post MLD located >2 standard deviations of the mean stent length away 
from FU MLD site) were compared between post and FU. Only matched projections and 
segment lengths were considered. Angiographic data from 2 SES trials were analyzed: 
STLLR (946 pre and post data) and DIABETES (172 post and FU data). STLLR only 
involved SES. DIABETES randomized patients to SES or bare stent (stent assignments 
will remain blind until Oct/04).
RESULTS: MLD relocation (pre MLD located >1 subsegment away from post MLD site) 
occurred in 76% of cases from pre to post assessments. MLD was located distally in 
61.7% and proximally in 14.3%. Conventional AG was 0.91mm, while AG considering a 
matched location of post-procedure MLD was 1.39mm. Post-procedure vs FU relocation 
occurred in 56.7%, moving distally in 16.5% and proximally in 26.8% of assessments. 
Conventional LL was 0.08±0.43mm, while LL considering a matched location of FU MLD 
was 0.34±0.52mm. In in-stent analyses, incidence of MLD relocation between post and 
FU was 70.9%. Whether the occurence of MLD relocations varies between bare metal 
and SES will be determined after unblinding the DIABETES trial. 
CONCLUSIONS: Relocation of the MLD is a frequent phenomenon after stenting and 
affects both in-segment and in-stent analyses. This phenomenon impacts the accurate 
calculation of both LL and AG, and should be taken into account during assessment and 
report of data from DES clinical trials.
1150-30 Clinical and Financial Impact of Drug-Eluting Stents: 
The US Academic Experience
David S. Marks, Thomas A. Ratko, Karl A. Matuszewski, Michael J. Oinonen, Joseph 
P. Cummings, Medical College of Wisconsin, Milwaukee, WI, University HealthSystem 
Consortium, Oak Brook, IL
Background: Drug-eluting stents (DES) have changed the clinical and ﬁ nancial impact 
of coronary intervention. The impact of DES following the initial US rollout, including the 
entry of competitive stents, has not been described.
Methods: The University HealthSystem Consortium (UHC) is an alliance of 87 academic 
health centers in the US. The UHC clinical database was queried for DES implantation 
compared to bare stent implantation from the second quarter (Q2) of 2003 to Q2 of 2004. 
This database contains a comprehensive collection of procedure-speciﬁ c data derived from 
discharge abstract summaries and UB-92 data for all inpatients at participating centers.
Results: 73,484 procedures involving coronary stents from 74 institutions were analyzed. 
Penetration of DES increased monthly and reached 85% in non-AMI procedures by 
Q2 2004. Mean length of stay was lower for DES procedures compared to bare stent 
procedures both with myocardial infarction (MI) and without MI (p<0.01). Overall 
procedural costs increased each quarter for DES both with MI and without MI; Costs for 
bare metal stent procedures plateaued in the last two quarters. The incremental cost for 
using drug-eluting stents in Q2 2004 is $3,787 with MI and $2,384 without MI. This ﬁ nding 
demonstrates an erosion in initial control of cost seen by academic health care centers.
Conclusion: The introduction of DES demonstrated rapid adoption and increased costs 
to health care centers. Yet, retrospective database analysis suggests initial cost controls 
have eroded despite continued reduction in the length of stay for patients receiving DES. 
Further investigation is required to understand the patient and physician characteristics 
that have determined DES utilization and stent/non-stent cost savings.
1150-31 Six Month Clinical Outcome Using Sirolimus Eluting 
Stents in Clincal Practice: Results from the US Post 
Marketing Surveillance Registry (the e-CYPHER Study)
Peter B. Berger, Marco A. Costa, Sidney Cohen, Peter C. Block, Duke Clinical Research 
Institute, Durham, NC
Background: After approval of the CYPHER sirolimus-eluting stent in the US, a post 
marketing surveillance registry was initiated at 38 centers to study the safety and efﬁ cacy 
of CYPHER outside the narrow clinical and anatomic groups studied in randomized trials. 
There were no exclusion criteria.
Methods: In the registry, 2067 pts were enrolled, and 3103 lesions (1.5/pt) treated 
with 2993 CYPHER and 304 non-CYPHER stents(1.6 stents/pt). Adverse events were 
adjudicated by an independent events committee. Enrollment was completed 12/31/03. 
Results: Mean age was 64 yrs; 32% had diabetes, 31% had 2 and 28% had 3 vessel 
disease; 32% had unstable angina. Procedural success (residual stenosis <50% without 
death, Q or non-Q [WHO deﬁ ned CK 2X > upper limits of normal with an elevated CK-MB], 
or TLR) was achieved in 97.0% of pts. In-hospital and post-discharge MACE was rare; the 
cumulative 30 day event rate was 1.3%, and stent thrombosis occurred in 0.7%. Off-label 
useage of the CYPHER stent was commmon. MI in the 24 hr and 24-72 hr before stenting 
(7.4%, 7.4%), and deployment in a left main (1.5%), vein graft (5.4%), restenotic lesion 
(6.8%), and occlusion were common. Event rates at 180 days are presented below.
Conclusions: In this registry, the CYPHER stent was frequently deployed in clinical 
situations and anatomic subgroups not studied in randomized trials. Cumulative 6 mo 
event rates were higher in these subgroups than the entire population but lower than 
previously reported in trials and registries of bare metal stents.
N= Death(%)
Q-MI 
(%)
Non-Q-MI 
(%)
TLR
(%)
Any event 
(%)
Stent 
thrombosis
(%)
All pts 2067 0.9% 0.5% 0.7% 2.3% 3.7% 0.7%
MI <24 hr 171 2.35 3.55 1.8% 8.2% 11.1% 4.7%
MI <72 hr 322 1.2% 2.25 1.2% 5.3% 7.1% 2.8%
Left main 46 4.3% 0.0% 2.2% 2.2% 6.5% 0.05
Vein graft 126 1.6% 0.0% 0.8% 4.0% 6.3% 0.0%
Restenotic
lesion 142 2.1% 2.8% 2.1% 14.1% 16.9% 3.5%
Occluded
artery 182 0.5% 3.3% 2.2% 8.8% 11.0% 4.4%
1150-32 Drug-Eluting Stents in Diabetic Patients: Clinical 
Outcomes from the Strategic Transcatheter Evaluation 
of New Therapies (STENT) Group
Barrett Cheek, Steven Rohrbeck, Darryl Kalil, Henry Jennings, Navin Gupta, Ian Smith, 
Christopher Metzger, Stanley Juk, Charles Simonton, High Point Regional Hospital, High 
Point, NC, R. Stuart Dickson Institute for Health Studies, Charlotte, NC
Background: In clinical trials, diabetes mellitus (DM) has been a predictor for increased 
adverse outcomes following percutaneous coronary interventions (PCI). However, “real- 
world” PCI outcomes in diabetics receiving drug-eluting stents (DES) in the U.S. have not 
been reported.
Methods: The STENT Group is an independent multicenter registry with prospective 
enrollment of all consenting patients undergoing PCI. All DM patients were included for 
this study from May 2003 - June 2004 and stratiﬁ ed according to insulin-dependence. 
Primary endpoints of analysis included MACE (death, myocardial infarction, and target 
vessel revascularization) and subacute thrombosis at 3 and 9 month follow-up.
Results: Three month clinical follow-up was completed for a total of 1339 DES procedures, 
of which 399 (30%) were DM patients (69% NIDDM, 31% IDDM). For DM patients with DES 
procedures, the average age was 63, with coronary artery bypass surgery in 15%, acute 
coronary syndrome in 71%, ST-elevation myocardial infarction in 8%, urgent or emergent 
PCI in 75%, and mean ejection fraction 51%. Patients received 1.4 DES per procedure 
with an average total stent length of 27.4mm. In-hospital procedural success was 98%. 
Cumulative MACE at 90 days was 3.8% for all DM, including 4.9% for IDDM and 3.3% for 
NIDDM. Target vessel revascularization at 90 days occurred in 1.0% for all DM, with 0.8% 
for IDDM and 1.1% for NIDDM. In-stent subacute thrombosis was 1.3% (n=5) for DM.
Conclusion: Diabetic patients receiving DES appear to have favorable early clinical 
outcomes in this diverse “real-world” population. Complete 9-month outcomes will be 
available at the time of presentation.
1150-33 Impact of Treatment of Coronary Artery Disease with 
Sirolimus-eluting Stents on Outcomes of Diabetic 
Compared with Non-diabetic Patients
Pramod Kuchulakanti, Daniel A. Canos, Sang-wook Kim, Rajbabu Pakala, Lowell F. 
Satler, William O. Suddath, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman, 
Washington Hospital Center, Washington, DC
Background: Sirolimus-eluting stents (SES) have shown lower rates of restenosis after
PCI. We aimed to determine the impact of treatment of coronary artery disease with SES 
on outcomes of diabetic compared to non-diabetic patients.
Methods: A total of 1407 patients (1618 lesions) underwent PCI with SES for treatment 
of various lesions including complex lesions and vein grafts at our institution. Among 
them, 160 (11.4%) were insulin-dependent diabetics (IDM), 332 (23.6%) were non-
insulin-dependent diabetics taking oral agents and/or on dietary control (NIDDM), and 
the remaining 915 (65.1%) were non-diabetics (Non-DM). The in-hospital, 1-month, and 
6-month outcomes of the 3 groups were compared and analyzed.
Results: Baseline characteristics were similar except that a higher number of patients 
in the IDM group were women and diabetic patients had higher body mass indexes and 
concomitant traditional coronary risk factors. IDM patients had higher history of renal 
insufﬁ ciency and in-hospital complications including death and CABG. (Table) Six-month 
follow-up showed higher incidence of TLR-MACE and combined rate of death and Q-wave 
MIs (p=0.03) in diabetic patients.
Conclusion: Sirolimus-eluting stents continued to perform well in diabetic patients in 
terms of overall cardiac events and lower revascularization rates. Special care should be 
undertaken for all diabetic pts following SES implantation regardless to insulin therapy 
due to higher rates of death and MI when compared to non-diabetics.
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Clinical Characteristics, Procedural Complications, 1-month and 6-month 
Outcomes
Parameter IDDM (n=160)
NIDDM 
(n=332)
Non-DM 
(n=915) p Value
Clinical characteristics
Males, % 49.4 57.4 68.7 <0.001
Body mass index (kg/m2) 32.5± 7.3 34.3± 7.2 29.7± 5.7 <0.001
H/o renal insufﬁ ciency, % 22.3 11.0 5.5 <0.001
Procedural complications
IABP usage, % 4.5 1.5 1.5 0.02
Acute renal failure, % 5.1 1.8 0.9 0.001
Death in hospital, % 1.3 0.0 0.0 <0.001
CABG in hospital, % 1.3 0.3 0.1 0.04
1-month outcomes
TLR-MACE, % 3.1 2.2 1.2 0.22
TVR-MACE, % 3.1 2.2 1.4 0.31
Death, % 3.1 2.2 0.8 0.03
Non-Q-wave MI, % 10.8 9.9 11.2 0.85
Subacute Thrombosis, % 0.6 0 0.2 0.55
6-month outcomes
TLR-MACE, % 5.4 6.3 2.7 0.03
TVR-MACE, % 8.0 7.9 6.2 0.50
Death, % 4.5 3.8 2.3 0.28
Q-wave MI, % 2.7 3.0 0.9 0.06
Death and Q-wave MI,% 5.4 6.3 2.7 0.03
1150-34 Does the Dose of Sirolimus Effect Outcomes After 
Drug-Eluting Stenting in Diabetic Patients? Final 
Results of the Double Dose Diabetes (3D) Study
J. Eduardo Sousa, Alexandre Abizaid, Giulio Guagliumi, Basil Lewis, Roxana Mehran, 
Alexandra Lansky, Sidney Cohen, Peter J. Fitzgerald, Aurea Chaves, Luiz A. Mattos, 
Amanda Sousa, Martin Leon, Institute Dante Pazzanese of Cardiology, Sao Paulo, Brazil
Background: Recurrence after drug-eluting stents for treatment of CAD in diabetic 
patients has shown varying results. The relationship between drug dosage and response 
to therapy after DES in diabetic patients in not known. We assessed the safety and 
efﬁ cacy of a double dose (280µg/mm2) compared to the commercially available single 
dose (140µg/mm2) sirolimus-eluting BX VELOCITY™ stent (SES) in diabetic patients with 
CAD.
Methods: A prospective, randomized, double blinded, feasibility study involving 3 sites 
enrolled 56 diabetic patients with lesion length < 30mm and vessel size between 2.5 and 
3.5mm randomized 1:1 to the two treatment arms: single dose versus double dose. All 
patients required angiographic follow-up at six months for assessment of late loss as the 
primary endpoint.
Results: Baseline demographics (mean age=59±9 years, 68% male) were similar 
between both groups,36.4% of the patients required insulin treatment. The 6-month 
angiographic and clinical outcomes are shown in table. By multivariate model, the only 
independent predictor of late loss was number of SES used (Estimate=0.36, Hazard 
Ratio=1.0, p=0.0047).
Conclusions: SES with both single and double dose is safe and equally effective 
resulting in low angiographic (8%), and clinical (7.7%) recurrence in diabetic patients. 
There appears to be no additional beneﬁ t to the double dose of Sirolimus in this subset.
Single dose Double dose Combined p-value
Angiographic Results
RVD 2.77+/-0.41 (30) 2.83 +/-0.40 (29) 2.80+/-0.40 (59) 0.58
Lesion Length 13.43+/-4.65 (30) 14.58 +/-5.09 (29) 14.00 +/-4.86 (59) 0.37
In-stent binary restenosis 0.0% (0/23) 7.4% (2/27) 4.0% (2/50) 0.49
In-lesion binary restenosis 4.3% (1/23) 11.1% (3/27) 8.0% (4/50) 0.61
In-stent late loss 0.18+/-0.29 (24) 0.24+/-0.56 (27) 0.21+/-0.45 (51) 0.67
In-lesion late loss 0.19+/-0.51 (24) 0.23+/-0.49 (27) 0.21+/-0.49 (51) 0.79
Clinical Outcomes
Death 0.0% (26) 0.0% (26) 0.0 (0/52) N/A
Myocardial Infarction 0.0% (0/26) 3.8% (1/26) 1.9% (1/52) 1.00
TLR 3.8% (1/26) 11.5% (3/26) 7.7% (4/52) 0.61
TVR 0.0% (0/26) 3.8% (1/26) 1.9% (1/52) 1.00
Total MACE 3.8% (1/26) 11.5% (3/26) 7.7% (4/52) 0.61
1150-35 Hypersensitivity Reactions in Patients With Drug 
Eluting Stents
Marc D. Feldman, Jonathan R. Nebeker, Renu Virmani, June M. McKoy, Charles J. Davidson, 
Jennifer M. Hoffman, Denis W. Raisch, Steven M. Belknap, Dennis P. West, Matthew H. 
Samore, Paul R. Yarnold, Laura Davidson, Charles L. Bennett, University of Texas Health 
Science Center at San Antonio, San Antonio, TX, University of Utah, Salt Lake City, UT
Background: Six months after the approval of the drug-eluting coronary stents (DES), the 
Food and Drug Administration (FDA) reported 50 hypersensitivity reactions following stent 
placement. Subsequently, FDA ofﬁ cials concluded that these reactions were probably due 
to concomitantly prescribed medications such as Plavix.
Methods: All adverse device event reports for hypersensitivity-like reactions associated 
with CYPHER and TAXUS stents, included in the FDA’s adverse event reporting system, 
the published literature, or from the Research on Adverse Device and Reports (RADAR) 
project between April 2003 and August 2004 were reviewed. Causality was evaluated 
using standardized World Health Organization criteria.
Results: Of 2,607 adverse event reports for the CYPHER stent, 234 cases of hypersensitivity 
were identiﬁ ed. Only two cases were judged certainly due to clopidogrel; otherwise clopidogrel 
and aspirin were judged to be only possible (85%, 92%) or unlikely (15%, 8%) causes (see 
Table). For 15 probable cases of CYPHER and TAXUS stent induced hypersensitivity clinical 
manifestations included rash, hives, dyspnea, persistence of hypersensitivity ﬁ ndings following 
clopidogrel dechallenge, eosinophilia, elevated IgE levels, and/or Gallium-scan or autopsy 
ﬁ ndings consistent with inﬂ ammation at the stent site.
Conclusion: Rash, hives, dyspnea, and catastrophic cardiac events may represent local 
and systemic hypersensitivity reactions from DES.
Putative Causative Agent Certain Probable Possible Unlikely
Clopidogrel 2 (1%) 0 198 (85%) 34 (15%)
Aspirin 0 0 216 (92%) 18 (8%)
Agents administered during implantation 0 0 63 (27%) 171 (73%)
Drug Eluting Stent 0 7 (3%) 214 (91%) 13 (6%)
1150-36 Sustained Neointimal Suppression in TAXUS II: 2-Year 
Angiographic Substudy to Evaluate Long-Term Results 
for Standard Risk De Novo Lesions
Dariusz Dudek, Janusz Drzewiecki, Krzysztof Zmudka, Adrian Banning, Francois 
Schiele, Joerg Koglin, Mary E. Russell, Jagiellonian University, Krakow, Poland
Background: The clinical safety and efﬁ cacy of paclitaxel-eluting stents are well 
established through TAXUS II, IV, and VI, but long-term angiographic outcomes are 
unknown. A 2-year quantitative coronary angiography (QCA) substudy was conducted 
in TAXUS II to evaluate long-term vascular responses and the longevity of safety and 
efﬁ cacy outcomes. This study represents the ﬁ rst drug-eluting stent trial with a large, 
comparative analysis of 2-year angiographic data.
Methods: The randomized, double-blinded TAXUS II trial enrolled patients at 38 sites to 
evaluate the efﬁ cacy of TAXUS slow-release (SR, n=131) and TAXUS moderate-release 
(MR, n=135) stents with bare control stents (BMS, n=270). QCA was conducted post-
procedure and at 6 months. The original protocol was amended to add a 2-year QCA 
follow-up with 231 patients.
Results: Patients with a target vessel revascularization prior to 6 months were excluded 
from the analysis, resulting in a self-selected study population of successful cases. In a 
matched subset of patients, in-stent minimum lumen diameter was stable over time (SR: 
2.32 ± 0.39 vs. 2.32 ± 0.45 mm and MR: 2.34 ± 0.38 vs. 2.35 ± 0.37 mm, at 6 months 
and 2 years, respectively) and superior to BMS at 2 years (BMS: 2.11 ± 0.44 mm, overall 
P=0.0012). Late lumen loss was also unchanged in TAXUS (SR: 0.26 ± 0.31 vs. 0.27 ± 
0.49 mm and MR: 0.26 ± 0.39 vs. 0.25 ± 0.38 mm, at 6 months and 2 years, respectively) 
and lower than in BMS at 2 years (BMS: 0.54 ± 0.36 mm, overall P<0.0001). The same 
pattern of stability (SR: 17.51 ± 8.88% vs. 16.69 ± 14.10% and MR: 15.86 ± 8.79% vs. 
15.56 ± 9.19%, at 6 months and 2 years, respectively) and superiority at 2 years (BMS: 
21.28 ± 11.73%, overall P=0.0081) was seen in percent diameter stenosis. There were 
no new cases of binary restenosis or aneurysms, and all three aneurysms present at 6 
months in TAXUS substudy patients resolved by 2 years.
Conclusions: The beneﬁ ts in QCA parameters observed in TAXUS at 6 months are 
preserved at 2 years despite the smaller sample size and the excellent performance of 
the controls. Paired analysis demonstrates the long-term stability of TAXUS technology 
and indicates that TAXUS stents prevent, rather than merely delay, in-stent restenosis.
1150-37 Two Year Outcome of the RESEARCH Registry
Ron T. Van Domburg, Andrew T. Ong, Pedro A. Lemos, Patrick W. Serruys, Erasmus 
Medical Center, Rotterdam, The Netherlands
Background: Sirolimus-eluting stents (SES) have been proven to reduce both repeat 
revascularization and major adverse cardiac events at 1 year compared with bare stent 
implantation in the daily practice. We investigated whether this beneﬁ t is sustained up to 
2 years follow-up. Methods: SES implantation has been utilized as the default strategy 
for all procedures in our institution, as part of the Rapamycin-Eluting Stent Evaluated At 
Rotterdam Cardiology Hospital (RESEARCH) registry. Results: Consecutive patients with 
de novo lesions (n=508) treated exclusively with SES were compared with 450 patients 
who received bare stents in the period just before (pre-SES). Patients in the SES group 
more frequently had multivessel disease, more type C lesions, received more stents, 
and had more bifurcation stenting. The cumulative rates of major adverse cardiac events 
(death, myocardial infarction or target vessel revascularization) were 9.4% and 14.2% in 
the SES group at 1- and 2-years, respectively and 14.7% and 21.2% in the pre-SES group 
(p=0.002). The 1- and 2-year risk of target vessel revascularization in the SES group were 
3.8% and 5.9%, respectively, and 10.5% and 14.0% in the pre-SES group (p<0.0001). 
Conclusion: The beneﬁ cial effect of unrestricted utilization of sirolimus-eluting stents in 
the “real” world is sustained, and even continued to increase in the second year. 
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1150-38 Cypher™ versus Taxus™ Stent in Very Complex 
Coronary Lesions. A Volumetric Analysis of In-stent 
Intimal Hyperplasia.
Fausto Feres, Vinicius Daher, Alexandre Abizaid, Andrés Sánchez, Ricardo Silva, 
Rodolfo Staico, Luiz Mattos, Galo Maldonado, Ana Cristina Seixas, Marinella 
Centemero, Amanda Sousa, J .Eduardo Sousa, Institute Dante Pazzanese of 
Cardiology, São Paulo, Brazil
Background: Sirolimus (Cypher™) and paclitaxel (Taxus™) stents have proven to be 
effective in suppressing neointimal hyperplasia ( NIH ). However, little is known about 
which DES could be superior in terms of in-stent NIH inhibition, especially in complex 
lesions subsets. The aim of this study was to evaluate this issue by 3D-intravascular 
ultrasound (IVUS) in a randomized cohort.
Methods: 52 pts with 76 de novo coronary complex lesions were randomized for PCI with 
Cypher™ or Taxus™ stent implantation. Twenty-ﬁ ve pts with 38 lesions were treated with 
Cypher™ and 27 pts with 38 lesions were treated with Taxus™. More than one stent per 
lesion was allowed. QCA and 3D-IVUS evaluations were performed at the time of stent 
implantation and 8 months post procedure.
Results: Up to date, 36 patients (44 lesions) had the follow-up completed. Mean age was 
56±19.6; 10 (23%) patients were diabetics, 25 (56%) were men and 6 (18%) patients had 
unstable angina. The mean reference diameter was 2.62± 0.38mm, lesion length was 
22.1± 10.0mm, the mean stent per lesion ratio was 1.4 and the stent/lesion length ratio 
was 1.53.. The full data will be completed for presentation, including clinical outcomes.
Cypher™ (lesions=21) Taxus™ (lesions=23) p value
QCA
Reference Diameter, mm 2.75±0.37 2.68±0.33 0.49
Lesion Length, mm 22.7±9.4 22.8±7.6 0.96
Stent Length, mm 33.7±12 33.7±9.5 0.99
Binary restenosis 1(4.8%) 1(4.3%) 1
Late Loss, mm 0.22±0.54 0.39±0.57 0.37
3-D IVUS
NIH mm3 / stent mm 0.38±0.32 0.96±0.88 0.006
Stent Obstruction Volume, % 6.2±4.0 14.7±13.4 0.008
Conclusion: In the preliminary analysis of this randomized comparison between 
Cypher™ versus Taxus ™ there were no differences in terms of angiographic restenosis 
and late loss, however the amount of NIH was signiﬁ cantly higher in the Taxus™ group. 
Whether these IVUS ﬁ ndings will impact clinical results is yet to be demonstrated.
1150-39 Direct Stenting Using the Sirolimus-Eluting Bx 
VELOCITY Stent: One Year Clinical and Angiographic 
Outcomes
Jeffrey Moses, Martin Leon, Jeffrey Popma, Peter Fitzgerald, Sidney Cohen, Richard 
Kuntz, Columbia University, New York City, NY
Background: Preliminary results suggest direct stenting leads to improved outcomes 
due to reduced arterial injury, edge restenosis and procedure time. Results testing this 
hypothesis will be presented from patients in the DIRECT trial who received direct stenting 
using the Cypher™ stent in native coronary lesions; the comparison group is a matched 
set of patients from the SIRIUS trial treated with predilatation.
Methods: This prospective, non-randomized study involved 16 sites and enrolled 225 
patients. Enrollment criteria matched the SIRIUS trial. The primary endpoint was in-lesion 
late loss at 8 months. Additional endpoints included procedure time, delivery strategy 
success, 8 month binary restenosis, and 9 and 12 month major adverse cardiac events.
Results: Direct Stenting vs Predilatation (SIRIUS Cypher™ Angiographic Cohort - SCAC)
DIRECT 
(N=225)
SCAC 
(N=412) p-value
Procedural
Lesion Success 100.0% 99.8% 0.95
Device Success 99.6% 98.3% 0.21
Procedure Success 99.1% 97.3% 0.15
Delivery Strategy Success 85.8% N/A N/A
Procedural Time (minutes) Median* 33 45 <0.01
Clinical - 9 months
(Combined In and Out of Hospital)
MACE* 4.9% 7.3% 0.42
MI (Q Wave or Non- Q Wave)* 1.3% 2.9% 0.30
Target Lesion Revascularization* 3.1% 4.4% 0.63
Target Vessel Failure* 8.4% 9.0% 0.78
Stent Thrombosis* 0.4% 0.2% 0.58
Angiographic - 8 months
In-Stent Late Loss (mm) 0.18 0.17 0.89
In-Lesion Late Loss (mm) 0.22 0.24 0.72
Combined Edge Restenosis 2.6% 7.2% 0.03
Angiographic - Tercile Sub-Analysis
In-lesion Binary Restenosis (Small Vessels ≈ 2.3mm) 9.1% 18.3% 0.13
In-lesion Binary Restenosis (Medium Vessels ≈ 2.8mm) 4.8% 7.4% 0.75
In-lesion Binary Restenosis (Large Vessels ≈ 3.3mm) 3.0% 1.8% 0.63
Angiographic - Diabetic Sub-Analysis
In-Stent Binary Restenosis (All Diabetics) 3.2% 8.3% 0.22
In-Lesion Binary Restenosis (All Diabetics) 4.8% 18.8% 0.02
In-Lesion Binary Restenosis (IDDM) 0.0% 35.0% 0.01
*Adjustment made for pre-procedure lesion length
Conclusion: In eligible patients, direct stenting with the CypherTM stent resulted in 
procedural outcomes that were at least as good as those obtained with predilatation, 
with 85.8% of patients successfully treated with direct stenting. Procedure time deﬁ ned 
as xylocaine administration to removal of catheter sheath was signiﬁ cantly reduced. Nine 
month clinical endpoints were similar in the 2 groups. Statistically signiﬁ cant improvement 
in edge restenosis was seen. Statistically signiﬁ cant decrease in in-lesion restenosis was 
seen, with no restenosis in IDDM patients. Twelve month clinical and complete 8 month 
angiographic/IVUS data will be presented.
1150-40 The Changing Incidence and Patterns of In-Stent 
Restenosis: Impact of Drug-Eluting Stents
Roxana Mehran, George D. Dangas, Srinivas Kesanakurthy, Robert M. Siegel, Andrea 
Abizaid, Alexandre Abizaid, Issam Moussa, Gary S. Mintz, Alexandra J. Lansky, 
Michael B. Collins, Edward Kreps, Eugenia Nikolsky, Allan Schwartz, Gregg W. Stone, 
Jeffrey W. Moses, Martin B. Leon, Columbia University Medical Center, New York, NY, 
Cardiovascular Research Foundation, New York, NY
Background: The patterns and incidence of in-stent restenosis (ISR) after bare metal 
stents have been well established. Drug-eluting stents (DES) have practically eliminated 
ISR, however the patterns and incidence of ISR with use of DES remain unknown.
Methods: From April, 24, 2003 (DES approval by FDA) to October, 24, 2003, 1895 
consecutive patients (mean age-61, 62% male, 34% diabetics) with 3307 lesions 
underwent implantation of sirolimus-eluting stents (SES). All patients had 30-day and six-
month telephone contact for assessment of major adverse cardiac events.
Results: ISR occurred in 44 lesions in 39 patients. Of the 44 ISR lesions, only one 
presented with diffuse ISR-type II, two with diffuse ISR-type III, 39 with focal-type I, and 
two with total-occlusion-type IV (see ﬁ gure). ISR lesions were treated by repeat stenting 
using SES (84%), repeat balloon alone (13.6%), and heparin-coated stenting in one 
patient (2.3%). In contrast, in the previous 6 months (10/02 to 4/03), 282 patients with 311 
lesions were treated for ISR after bare metal stents. This represents an 86% reduction in 
ISR cases for this six-month period after DES approval. 
Conclusions: SES are associated with a major reduction in ISR and a change in the 
pattern of ISR from diffuse (with bare metal stents) to a focal, more easily treatable 
pattern. These data support the important impact of DES in effectively treating CAD, 
and changing the paradigm of PCI cases in catheterization laboratories, where DES is 
a mainstay therapy. 
1150-44 Drug-Eluting Stent For Complex Lesions: Latest 
Angiographic Data From the Randomized Rapamycin 
Versus Paclitaxel CORPAL Study
José Suárez de Lezo, Alfonso Medina, Manuel Pan, Miguel Romero, Antonio Delgado, 
José Segura, Enrique Hernández, Djordje Pavlovic, Soledad Ojeda, Jaime Fernández-
Dueñas, Javier Ariza, Francisco Melián, Reina Soﬁ a Hospital, Cordoba, Spain, Dr. 
Negrín Hospital, Las Palmas, Spain
Background and aims: Rapamycin- and Paclitaxel-eluting stents have been shown 
to signiﬁ cantly decrease restenosis rates. The purpose of this study was to compare 
both stent types in a large series of patients (pts) with coronary lesions at high risk for 
restenosis.
Methods: Since May/03 to August/04, 667 lesions have been treated in 515 consecutive 
pts with documented myocardial ischaemia secondary to coronary lesions prone to 
restenosis with at least one of the following conditions: 1) Long-diffuse stenosis (>20mm; 
mean 31±11mm); 2) small vessel size (<2.5mm; mean 2.4±0.2mm); 3) bifurcated lesions 
; 4) in-stent restenosis and 5) recanalized chronic total occlusion. Pts were randomly 
assigned to receive either Rapamycin- (Group I, n=261) or Paclitaxel- (Group II, n=254) 
eluting stents. After treatment, major adverse cardiac events were recorded at 6-month. A 
follow-up cardiac catheterization was scheduled at 6-month follow-up.
Results: There were no signiﬁ cant differences in clinical, angiographic and procedural 
characteristics between groups. Primary success and in-hospital course was similar in 
both groups of pts. Minimal lumen diameter post stent implantation was near identical 
in both groups (2.55±0.4 vs 2.56±0.5 mm). Post procedural myocardial injury markers 
were similar in both groups either (CK:141±442 vs 149±429 iu/l; p:ns). One patient died in 
group I and 2 in group II. We obtained 6-month follow-up angiographic revaluations in 154 
pts (30%) and ultrasound study (IVUS) in 51 of them. Angiographic late loss was 0.30±0.4 
mm in group I vs 0.59±0.8 mm in group II (p<0.01). The incidence of binary restenosis per 
lesion was 12% in group I vs 19% in group II (ns). Follow-up IVUS neointimal area was 
0.41±0.4 in group I vs 1.37±1.4 mm2 in group II (p< 0.01). Target lesion revascularization 
took place in 12 pts (4%) from Group I and 18 (5%) from Group II . Angiographic and 
clinical follow-up will be updated at the time of presentation.
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Conclusions: 1) No signiﬁ cant differences in restenosis rate or late cardiac events were 
observed between groups. 2) Quantitative coronary angiography showed less late loss in 
group I pts, that was conﬁ rmed by a less late neointimal proliferation in the IVUS study.
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1152-9 Plasma Matrix Metalloproteinase-9 Level Is a Predictor 
for Restenosis After Coronary Artery Stenting
John W. Chu, Greg Jones, I. Patrick Kay, Michael J. Williams, Gerard T. Wilkins, Victoria 
Philips, Maree McCormick, Andrea M. Van Rij, University of Otago, Dunedin, New 
Zealand
Background: Plasma matrix metalloproteinase (MMP)-9 levels are elevated in patients 
with severe coronary stenoses and predict cardiovascular mortality in patients with 
coronary artery disease (CAD). However, the inﬂ uence of MMP-9 on in-stent restenosis 
(ISR) is unknown. The aim of this study was to assess the role of plasma MMP-9 level as 
a predictor for ISR in patients having percutaneous intervention.
Methods: 165 CAD patients with coronary stent placement were recruited retrospectively: 
82 patients with angiographically proven ISR, 83 patients without clinical restenosis (angina 
free). Clinical and demographic data was collected and analysed. Plasma total MMP-9, high 
sensitivity C-reactive protein (hs-CRP), lipoprotein(a) and lipid proﬁ le were measured.
Results: The baseline clinical and demographic characteristics of both groups were 
similar. There were no statistically signiﬁ cant differences in plasma hs-CRP, lipoprotein(a) 
and lipid proﬁ le. Mean level of MMP-9 was 78% higher in the restenosis compared with 
the control group (14.9 versus 8.4 ng/ml; P<0.0001). MMP-9 was also a predictor for ISR 
with crude odds ratio (OR) of 1.11 (95% CI, 1.06-1.17; P<0.0001). Confounder effects 
were observed for severity of CAD, plasma high density lipoprotein cholesterol and body 
mass index. After adjustment for these confounders, the OR was 1.09 (95% CI, 1.02-1.17; 
P=0.011). By categorizing the MMP-9 concentrations into high or low rank and setting cut-
off levels of 10, 15 or 20 ng/ml, the ORs were 2.83 (95% CI, 1.20-6.65; P=0.02), 5.57(95% 
CI, 1.70-18.31; P=0.005), and 6.85 (95% CI, 1.43-32.75; P=0.02) respectively.
Conclusion: The total plasma MMP-9 level appears to be a novel independent predictor 
of risk for ISR in CAD patients undergoing percutaneous coronary stent placement.
1152-10 Use of  Nanoparticles for Targeted Delivery of 
Antirestenotic Therapeutics in the Porcine Coronary 
Restenosis Model
Nicholas N. Kipshidze, Patrick Iversen, David Hellinga, Fermin Tio, Feng Xie, Mykola V. 
Tsapenko, Derek Knapp, George D. Dangas, Sriram Iyer, Gary Roubin, Tomas R. Porter, 
Lenox Hill Hopstal, New York, NY, AVI-Biopharma, Portland, OR
Hypothesis: Sirolimus and antisense phosphorodiamidate Morpholino oligomer, AVI-
4126 (PMO), both have been effective in reducing neointimal formation in animal models 
following delivery by coated stents. Greater ﬂ exibility of repeated dosage regimens and 
reduced procedure complexity may be provided by systemic injection of the therapeutics 
bound to Perﬂ ourobutane Gas Microbubble Carrier (PGMC). The purpose of this study 
was to investigate the effectiveness and fesability of PGMC-nanoparticles for targeted 
delivery of antirestenotic therapeutics (Sirolimus or PMO) in prevention of restenosis in 
porcine coronary arteries after stent implantation.
Methods: Twelve pigs underwent stent implantation (3 stents/animal). Four pigs received 
IV injection of PGMC and 2mg of antisense. Five pigs were treated with IV injection of 
PGMC with 2mg of Sirolimus and three animals served as control. Four hours later 3 
pigs were sacriﬁ ced and vessels were analyzed by HPLC and western blot. In chronic 
experiments, 9 pigs were sacriﬁ ced at 28 days.
Results: HPLC of the treated arteries demonstrated high drug concentration in the 
vessel tissue, and Western blot analysis showed elevated expression of p27 at 4 hours 
post-procedure in the Sirolimus , and inhibition of c-myc in the antisense treated vessels, 
accordingly. Histomorphometry revealed signiﬁ cantly reduced neointimal formation in the 
PGMC/Sirolimus group (1.84+0.84 mm2, p<0.001) and PGMC/Antisense group (2.83 ± 
1.99 mm2 , p=0.05) compared with control (4.77+1.71 mm2).
Conclusion: Targeted systemic delivery of Sirolimus or antisense using nanoparticle 
carrier resulted in signiﬁ cant inhibition of neointimal formation.
1152-11 Impact Of Statins On Atherosclerotic Plaque 
Temperature In Patients With Diabetes Mellitus.
Virginia Markou, Konstantinos Toutouzas, Maria Drakopoulou, Sophia Vaina, John 
Mitropoulos, Eleftherios Tsiamis, Manolis Vavuranakis, Costas Tsiouﬁ s, Christodoulos 
Stefanadis, Hippokration Hospital, Athens, Greece
Statin administration has favorable effect on atherosclerotic plaque temperature. In 
patients (pts) with diabetes mellitus (DM) widespread inﬂ ammatory activation is observed, 
combined with increased local thermal heterogeneity in culprit lesions. The aim of this 
study was to investigate the effect of statin administration on heat production in the culprit 
lesions of pts with DM.
Method: We included 45 pts with DM and 63 pts without DM undergoing percutaneous 
coronary interventions. The latter group was matched for age, type of clinical syndrome, 
and angiographic stenosis(%). Fifty-four patients were under statin treatment and 54 pts 
did not receive statins. Treated patients were considered if they were under statins ≥ 4 
months. In all patients coronary thermography (Medispes, Switzerland) was performed. 
We measured temperature difference (DT) between the atherosclerotic plaque and the 
proximal vessel wall.
Results: Pts treated with statins had lower DT compared to untreated pts (DT: 0.07±0.01 
vs 0.20±0.04ºC, p<0.01). In pts with DM 23 were under statins and 22 were untreated. 
In pts with DM under statin treatment DT was lower compared to untreated pts (DT: 
0.11±0.03 vs 0.27±0.06ºC, p=0.02). Interestingly, pts with DM under treatment had similar 
DT to pts without DM (0.11±0.03 vs 0.15±0.03ºC, p=NS).
Conclusion: Statin administration has favorable effect on atherosclerotic plaque 
temperature in pts with DM. The results of this study provide new insights in the pleitropic 
effect of statins in pts with DM. 
1152-12 Plasma Tissue Factor Level Predicts Collateral 
Development in Humans With Occluded Coronary 
Arteries: A Study-Based on 364 Consecutive Patients
Guillaume Rosey, Sophie Susen, Cuilleret François, Frédéric Mouquet, Arnaud Sudre, 
Jean-Marc Lablanche, Jean Dallongeville, Christophe Bauters, Brigitte Jude, Eric Van 
Belle, INSERM ESPRI -EA 2693, Lille, France
PURPOSE: Regulation mechanisms of collateral circulation are not well described, and 
collateral circulation remains variable from one patient to another. Because previous 
animal in vitro and in vivo studies have demonstrated that Tissue Factor (TF) seems to 
have a pro-angiogenic effect, it has been hypothesized that TF pathway could modulate 
collateral circulation in humans. Our purpose was to investigate the relation between the 
different biological parameter of TF pathway and human collateral coronary circulation 
evaluated by angiography.
METHODS: 364 consecutive patients with at least at least one coronary artery occlusion 
of a major branch detected by angiography were analyzed. Blood sample for TF and 
biological analyses was performed at the time of angiography. Collateral coronary 
circulation was analyzed in a semi-quantitative way by angiographic score (collateral ﬂ ow 
grade). Clinical parameters were recorded.
RESULTS: In univariate biological analysis of collateral coronary circulation variation, 
mean collateral ﬂ ow grade were 2,36 ± 1,10 for low plasma TF plasma (< 173 pg/ml) and 
2,76 ± 1,04 for high plasma TF value (> 173 pg/ml) (p=0.0004). In multivariate analysis 
of collateral coronary circulation variation, we found 5 factors with a negative signiﬁ cant 
effect: recent coronary occlusion (<15 days) (p<0.0001), diabetes mellitus (p=0.005), 
female sex (p=0.006), tobacco (p=0.008), number of coronary arteries occlusion (p=0.01) 
and a low plasma TF value (p=0.007). We found no relation with all other biological 
markers, including activated Factor VII, free Tissue Factor Pathway Inhibitor and CRPus.
CONCLUSION: A high plasma TF level independently predicts a better coronary 
collateral development in patients with occluded vessels. Our ﬁ ndings suggest that TF 
pathway play a critical role in collateral development in humans and support the use of 
FT modulation to increase collateral coronary arteries for non-revascularisable patient 
with coronary occlusion
1152-13 Serum Hepatocyte Growth Factor Levels Predict Long-
Term Clinical Outcome After Percutaneous Coronary 
Revascularization
Karine Sautiere, Sophie Susen, François Cuilleret, Frédéric Mouquet, Akram Chmaït, 
Arnaud Sudre, Jean-Marc Lablanche, Eugène Mc Fadden, Jean Dallongeville, 
Christophe Bauters, Brigitte Jude, Eric Van Belle, INSERM ESPRI -EA 2693, Lille, 
France, Department of Cardiology, Lille, France
Background Contradictory results regarding the value of serum levels of angiogenic 
growth factors, hepatocyte growth factor (HGF) in particular, to predict cardiovascular 
events have recently been published. In addition, while it is well established that serum 
level of HGF is highly dependent of heparin administration, its predictive value in patients 
with coronary artery disease but without heparin treatment is unknown.
Aims Therefore our purpose was to evaluate, in patients referred for elective percutaneous 
coronary revascularisation (PCR) without heparin pretreatment, the relationship between 
baseline serum levels of the angiogenic growth factors; vascular endothelial growth factor 
(VEGF) and HGF and clinical outcome. We also examined the clinical and biological 
covariates of baseline levels of VEGF and HGF.
Methods In 488 consecutive patients undergoing elective coronary angioplasty, hsCRP, 
HGF and VEGF levels were measured before heparin administration. The primary 
endpoint, a composite of death and myocardial infarction, occurred in 44 patients (9.0 
%) at 14.3±5.3 months.
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Results At baseline, VEGF levels were related to CRP levels and inversely related 
to age; HGF levels were related to CRP levels, diabetes and recent clinical instability. 
By univariate analysis, HGF serum levels were signiﬁ cantly higher in patients who 
experienced a clinical endpoint (median : 2105 pg/mL [1627-2573] versus 1554 pg/mL 
[1266-2018]; p=0.001). A similar trend was observed for VEGF (median : 520 pg/mL [335-
751]; versus 435 pg/mL [285-674]; p=0.07). After adjustment for covariates and other risk 
factors, HGF levels were independently predictive of clinical events (2nd tertile hazard ratio 
3.70 [95% CI, 1.03-13.24]; 3rd tertile hazard ratio 5.18 [95% CI, 1.51-17.87]).
Conclusion Our results demonstrate that in patients, without heparin pretreatment, 
referred for PCR a high serum level of HGF is an independent predictor of clinical 
events during follow-up and is correlated with other surrogate measures of the activity 
of atherosclerosis.
1152-14 Temporal Analysis of Cellular Constituents 
of Intracoronary Thrombi Aspirated Through 
Thrombectomy
Hiroshi Iwata, Masataka Sata, Toshihiro Morita, Masao Yamasaki, junko Honye, 
Daigo Sawaki, Yasunobu Hirata, Ryozo Nagai, The Graduate School of Medicine, The 
University of Tokyo, Tokyo, Japan
Background: Accumulating evidence suggests that intracoronary thrombus plays a 
crucial role in the pathogenesis of acute coronary syndrome (ACS). However, cellular 
contents and its pathophysiology are remained unknown. We performed this study to 
clarify the pathogenesis of intracoronary thrombi. 
Methods: We examined cellular constituents of the aspirated intracoronary thrombi 
of consecutive patients who admitted to the Tokyo University Hospital and underwent 
emergent PCI for ACS (n=21). Thrombi were obtained with thrombectomy devices. Frozen 
sections were stained with anti PECAM-1, CD34, CD45, vWF, smooth muscle myosin 
heavy chain (SMMHC) and smooth muscle alpha actin antibodies. 
Results: The thrombi from the patients with acute onset of chest pain contained CD34-
positive cells as well as PECAM-1 positive cells. As the duration after the onset of chest 
pain prolonged, the proportion of CD34 or PECAM-positive cells decreased with increased 
content of smooth muscle alpha actin-positive cells. Conclusions: Our ﬁ ndings suggest 
that acute thrombus formation and accumulation of hematopoietic cells may play a role in 
the pathogenesis of ACS and lesion progression. 
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1153-15 A Prospective, Randomized Trial to Determine the Early 
and Late Reactions After the Use of Iopamidol 340 
(Niopam™) and Iomeprol 350 (Iomeron®) in Cardiac 
Catheterization
Kunadian Vijayalakshmi, Michel Stewart, Adrian Davies, Robert Wright, James Hall, 
Mark de Belder, The James Cook University Hospital, Middlesbrough, United Kingdom
Background: A new generation of intravascular contrast agents, the non-ionic monomers 
have safety proﬁ les that are superior to those of older ionic compounds. There are, 
however, signiﬁ cant differences between these agents.
Aim: The aim of this study was to determine the incidence of early (< 24 hours) and late (>24 
hours to 7 days) reactions to 2 contrast agents currently used during cardiac catheterisation: 
iopamidol 340 (Niopam™ Bracco UK Ltd.) and iomeprol 350 (Iomeron® Bracco UK Ltd.)
Methods: This was a prospective, randomised, double-blinded trial. One thousand nine 
hundred and eighty ﬁ ve patients undergoing cardiac catheterisation received one of 
the following contrast agents: iopamidol 340 (Niopam™) and iomeprol 350 (Iomeron®). 
Reactions that were possibly related to the contrast agents were recorded during 
hospital admission (early reaction) and after discharge (late reaction) by means of a 
questionnaire.
Results: The baseline characteristics were matched in both the groups. There was 
no signiﬁ cant difference in the incidence of heat sensation experienced between the 
two groups, (p=0.1). Early non-heat reactions occurred in 2.6% of patients receiving 
iopamidol 340 (Niopam™) and 4.7% of those receiving iomeprol 350 (Iomeron®), 
(p=0.01). Electrocardiographic changes were recorded in 1.7% of patients who received 
iopamidol 340 (Niopam™), and 1% of those who received iomeprol 350 (Iomeron®), 
(p=<0.2). Late reactions (post discharge symptoms) occurred in 23% of those receiving 
iopamidol 340 (Niopam™) and 32% of those receiving iomeprol 350 (Iomeron®) (p=0.01). 
This is attributed to the fact that nausea reported by patients after discharge from the 
hospital was more frequent in the iomeprol 350 (Iomeron®) group (6.2%) compared to the 
iopamidol 340 (Niopam™) group (3.7%), p=0.01.
Conclusions: The incidence of adverse reactions was similar with the 2 non-ionic contrast 
agents. Nausea was reported more commonly following discharge from the hospital in 
patients receiving Iomeron 350. Although these adverse effects were rarely troublesome, 
patients should be advised accordingly.
1153-16 High Resolution Ex Vivo Magnetic Resonance Imaging 
ofHuman Coronary Arteries: A Comparison with 
Intravascular Ultrasound Imaging
Yoshihisa Shimada, Brian K. Courtney, Michael V. McConnell, Debra L. Stamper, 
Susanne D. Giattina, Mark E. Brezinski, Paul G. Yock, Peter J. Fitzgerald, Yasuhiro 
Honda, Stanford University, Stanford, CA, Brigham and Women’s Hospital, Boston, MA
Background: Accurate characterization of coronary atherosclerotic composition, as well as 
precise measurements of plaque burden and lumen narrowing, may allow the stratiﬁ cation 
of risk for future cardiovascular events and help direct therapeutic management. Both 
high-resolution magnetic resonance imaging (MRI) and intravascular ultrasound (IVUS) 
have the potential to accurately characterize and quantify atherosclerosis; however, these 
technologies have not been systematically compared in human coronary arteries.
Methods: Fifty-one human coronary artery segments were obtained at autopsy from 
20 patients who had died of noncardiovascular diseases, and subjected to ex vivo MRI, 
IVUS, and histological examination. A standard clinical MRI scanner (1.5-T) was used to 
generate proton density- and T2- weighted images using a fast spin-echo sequence with 
160 × 160 × 1500 µm spatial resolution. IVUS was performed using a standard 30-MHz 
imaging catheter. One hundred and forty-two cross sections were matched and studied 
by MRI, IVUS, and histology.
Results: Measurement of vessel area (r=0.93, P<0.001) and lumen area (r=0.91, P<0.001) 
correlated well between MRI and IVUS. For plaque characterization, overall accuracy of 
detecting plaque calciﬁ cation was higher with IVUS (sensitivity 100%, speciﬁ city 86%) 
than with MRI (sensitivity 52%, speciﬁ city 92%). However, IVUS detection of the extent of 
calcium was impaired by acoustic shadowing, whereas MRI identiﬁ ed the extent and depth 
of calcium. Nineteen lipid/necrotic cores were identiﬁ ed on histology, and the accuracy of 
detecting lipid core was higher with MRI (sensitivity 84%, speciﬁ city 94%) than with IVUS 
(sensitivity 11%, speciﬁ city 97%). In cases with a lipid core, MRI could differentiate the 
plaque components, whereas IVUS showed homogeneous echo density in most cases.
Conclusions: This study demonstrates that high resolution ex vivo MRI accurately 
quantiﬁ es and characterizes atherosclerotic lesions in human coronary arteries and is a 
promising technique to complement IVUS.
1153-17 In-Vivo Color Mapping Of Shear Stress Of Coronary 
Atherosclerotic Plaque Using Three-Dimensional 
Intravascular Ultrasound
Yusaku Fukumoto, Takafumi Hiro, Takashi Fujii, Koji Imoto, Genta Hashimoto, Jutaro 
Yamada, Takayuki Okamura, Masunori Matsuzaki, Yamaguchi University, Ube, Japan
Backgrounds and Methods: Various in-vitro studies have demonstrated that the 
shear stress of vascular lumen is one of the important determinants for coronary plaque 
vulnerability. However, in-vivo relationship between shear stress and plaque rupture is still 
unclear. Three-dimensional intravascular ultrasound (3D-IVUS) was used to obtain the 
spatial information of luminal geometry from 15 patients with acute coronary syndrome 
having a distinct ulcerative lesion. These three-dimensional contours for each lumen 
were ﬁ rst divided into mesh polygons, and was analyzed by a calculation program of ﬂ uid 
dynamics. The ﬂ ow was considered to be a constant laminar one. Then, colorized mappings 
of distribution of streamline, wall-distending pressure and shear stress were performed. The 
luminal contour for each ruptured lesion was obtained by smoothing and extrapolation.
Results: All patients had a coronary plaque rupture at the proximal or the top of plaque 
hill. In the color-mapping, concentration of wall-distending pressure and shear stress 
could be observed on each plaque surface. The area of shear stress concentration was 
almost corresponded to the rupture point for each case in 12 cases (80%), whereas the 
area of concentration of wall-distending pressure was not related to the rupture point in 
12 cases (80%)..
Conclusions: Although the absolute value of shear stress is not enough for directly 
provoking mechanical destruction of ﬁ brous cap, the concentration of shear stress might 
be a trigger of ﬁ brous cap rupture. Therefore, this in-vivo study using color mapping of 
shear stress with 3D-IVUS suggested that the modiﬁ cation of endothelial function by the 
shear stress concentration might be important in acute coronary events.
1153-18 Transcoronary Transplantation of Autologous 
Mesenchymal Stem Cells and Endothelial Progenitors 
Into Infarcted Human Myocardium
Demosthenes Katritsis, Panagiota Sotiropoulou, Evangelia Karvouni, Ilias Karabinos, 
Socrates Korovesis, Sonia Perez, Eutychios Voridis, Michael Papamichail, Athens 
Euroclinic, Athens, Greece, St Savas Hospital, Athens, Greece
Background: To investigate whether a combination of mesenchymal stem cells able 
to differentiate into cardiac myocytes, and endothelial progenitors that mainly promote 
neoangiogenesis, might be able to facilitate tissue repair in myocardial scars.
Methods: Eleven patients with an anteroseptal myocardial infarction (MI) underwent 
transcoronary transplantation of bone marrow-derived mesenchymal stem cells (MSC) 
and endothelial progenitor cells (EPC) to the infarcted area through the left anterior 
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descending artery. Eleven age- and sex-matched patients served as controls.
Results: Wall motion score index was signiﬁ cantly lower at follow-up in the transplantation 
(p=0.04) but not in the control group. On stress echocardiography, there was improvement of 
myocardial contractility in one or more previously non-viable myocardial segments in 5 out 
of 11 patients (all with recent infarctions), and in none of the controls (p=0.01). Restoration 
of uptake of Tc99m sestamibi in one or more previously non-viable myocardial scars was 
seen in 6 out of 11 patients subjected to transplantation and in none of the controls (p=0.02). 
Cell transplantation was an independent predictor of improvement of non-viable tissue.
Conclusion: Intracoronary transplantation of MSCs and EPCs is feasible, safe, and may 
contribute to regional regeneration of myocardial tissue early or late following MI.
1153-19 Interim PLAATOTherapy Results Suggest Marked 
Stroke Rate Reduction
Peter C. Block, Mark Reisman, William Gray, Paul Kramer, Ray Matthews, Heyder 
Omran, Horst Sievert, Antonio Bartorelli, Antonio Colombo, Paul Casale, Jeffrey Moses, 
David Williams, Bernhard Meier, Allan Skanes, Paul Teirstein, Emory University Hospital, 
Atlanta, GA, Swedish Heart Institute, Seattle, WA
Background: The PLAATO™ (Percutaneous Left Atrial Appendage Transcatheter 
Occlusion) Trials evaluate safety and efﬁ cacy of left atrial appendage occlusion in patients 
in atrial ﬁ brillation at high risk for stroke. We report on 30-day major adverse events 
(MAE) and follow-up (f/u) in trials conducted in Europe (EU) and North America (US/CA). 
Methods: A total of 111 patients were enrolled, 47 in EU and 64 in US/CA. Mean age 
was 71±9 years. 59% were male; 38% had history of TIA/stroke. Mean number of stroke 
risk factors was 3.5±1.2; mean CHADS2 score was 2.5±1.3. Average f/u was 12.5 months. 
Total f/u through July ‘04 was 116 patient years. An events committee adjudicated adverse 
events. MAE is deﬁ ned as cardiac or neurological death, stroke, myocardial infarction, or 
cardiovascular surgery related to the PLAATO procedure. Results: By 30 days 110/111 
patients were free of MAEs (1 US patient had 2 MAEs: tamponade requiring surgery 
and later death). See table for a summary of the MAEs. In total there were 6 deaths at 1 
year; none were device/procedure related; 4 deaths were adjudicated as MAEs. At 1 year 
there were 2/111 strokes (1.8%) and 3/111 TIA’s (2.7%). Based on the patients’ baseline 
CHADS2 score a 4.2% annual rate was expected. The observed annual incidence of stroke 
was 2/116 patient years of f/u or 1.7%, which represents an estimated 59% reduction. 
Conclusion: PLAATO therapy for stroke prophylaxis in atrial ﬁ brillation has a low MAE 
rate. Results suggest a marked reduction in expected stroke rate in high risk pts.
Major Adverse Event Timing
US/CA EU
0-30 days 2 of 64 pts. (surgery, death) 0 of 47 patients
1-6 months 0 of 60 patients 1 of 47 patients (stroke)
6-12 months 2 of 49 patients (stroke, death) 1 of 47 patients (death)
> 12 months 1 of 14 patients (death) f/u closed
1153-20 A Comparison Of Continuous Intravenous Infusion Of 
Arginine Vasapressin To Dopamine In The Treatment Of 
Cardiogenic Shock
Masahisa Yamane, Osamu Kinebuchi, Akiko Yamane, Kentarou Hayashida, Hitoshi 
Yokozuka, Ashikaga Red Cross Hospital, Ashikaga City, Japan
Background: The objective was to compare the safety and efﬁ cacy of arginine 
vasopressin (AVP) to dopamine (DOA) in the treatment of cardiogenic shock.
Methods: We enrolled 32 consecutive patients with acute myocardial infarction (AMI) 
complicated by cardiogenic shock within 24 hours from symptom onset. Continuous IV 
AVP or DOA was randomly assigned to the patients (n=16 in each group) in the emergency 
room and the infusion dose was adjusted to maintain mean arterial pressure (MAP) of 80 
mmHg or more. The patients underwent emergent primary angioplasty. Treatment with 
mechanical ventilation, intraaortic balloon pump (IABP) and stent placement for the infarct-
related artery was kept constant throughout the study. Primary end points were changes 
in hemodynamic parameters over the 24 hours after primary angioplasty and secondary 
end point was weaning time from mechanical support and intravenous medication.
Results: During the mean of 21 to 24 minutes administration of AVP ( mean ± standard 
deviation of 13± 10 IU/hour) or DOA (12± 7mcg/kg/min), MAP increased comparably over 
the baseline in both groups (181± 80 % vs. 187± 99 %, p=0.8677), but signiﬁ cant increase 
in heart rate was noted in the DOA group (84± 4 bpm vs.110± 6 bpm, p=0.0024). Primary 
angioplasty achieved TIMI 3 ﬂ ow of the infarct-related artery in 94% vs. 81% of the patients, 
respectively (p=0.285). Decrease in systemic vascular resistance and pulmonary capillary 
wedge pressure were also comparable with no group differences. Coronary perfusion 
pressure and cardiac index progressively improved more in the AVP group (p=0.0329 and 
0.0169, respectively) and weaning from the support was signiﬁ cantly shorter in the AVP 
group (142± 110 hours vs. 505± 452 hours, p=0.0092). No adverse events were detected 
during AVP administration. At 3-month follow-up, 13 patients (81.2%) were alive in the 
AVP group and 10 patients (62.5%) in the DOA group (p=0.2382).
Conclusions: Continuous IV administration of AVP is safe and might have some clinical 
and hemodynamic advantage over DOA in the treatment of cardiogenic shock.
1153-21 Achieving Perfect Coronary Bypass Patency with 
Intraoperative Angiography
Nimesh Desai, Senri Miwa, David Kodama, George Christakis, Gideon Cohen, Bernard 
Goldman, Marc Pelletier, Stephen Fremes, Sunnybrook and Women’s College Health 
Sciences Centre, Toronto, ON, Canada
Background: Intraoperative graft angiography would be a valuable aid for optimizing 
coronary surgery. We report comprehensive assessment and validation of the Novadaq 
Spy™ intraoperative angiography system.
Methods: Fluorescent indocyanine green(ICG) dye, is excited with dispersed LASER light 
to create an angiogram. 120 patients underwent ICG angiography of 336 bypass grafts. 
40 grafts were also studied with x-ray angiography to determine agreement between the 
techniques.
Results: 2.8±0.6 grafts and 3.6±0.9 ICG angiograms were performed per patient. ICG 
angiography found 4% of patients required major anastomotic revision and another 4% 
needed minor revisions. Quality of visualization was rated by surgeon according to a 7-
point likert scale(1=worst,7=best). Among conduits, saphenous veins were best visualized 
(mean score±sd) 6.4±1.5 vs. 5.5±1.9 for internal mammary arteries and 4.4±2.3 for radial 
arteries(p=0.02). Location of distal anastomosis did not inﬂ uence quality of visualization. 
Inter-rater agreement among 2 surgeons was 100%(kappa=1.0) for graft patency and 
94%(kappa=0.8) for graft revision. There was 96% agreement (kappa=0.9) between ICG 
and X-ray angiography. (See Figure)
Conclusions: Information from ICG angiograms led to graft revisions for technical 
problems in 8% of cases that would have otherwise gone unrecognized. Given the 
anatomic complexity of current coronary bypass patients, ICG angiography can reliably 
ensure intraoperative technical perfection. 
1153-22 Plasma Interleukin-6 Level Correlates with C-Reactive 
Protein Level across Coronary Circulation and Modiﬁ es 
Coronary Vascular Resistance
Haruhiko Date, Takuroh Imamura, Takahiro Sumi, Tetsunori Ishikawa, Hisamitsu 
Onitsuka, Junji Kawagoe, Kazuya Mishima, Yasuko Nagoshi, Toshiro Nagoshi, Tanenao 
Eto, First Department of Internal Medicine Miyazaki Medical College University of 
Miyazaki, Kihara 5200, Kiyotake Miyazaki, Japan
Background: Interleukin-6 (IL-6) is a major determinant of CRP production and may 
modify coronary vasomotor tone in cardiac transplant recipients through endothelial 
dysfunction. The gene and protein of interleukin-6 are expressed in human atherosclerotic 
lesions. We have already demonstrated that CRP mRNA is expressed in coronary plaque 
and may be released into coronary circulation. However, whether IL-6 affects plasma 
CRP level through coronary circulation and native coronary microvascular function is still 
unknown. 
Methods: We examined 35 consecutive patients (17 men and 18 women; mean age 
63.3 years) with coronary atherosclerosis on the left anterior descending artery who 
had undergone coronary intervention (CAD group; n=11) and angiographically normal 
coronary artery (ANCA group; n=24). Plasma levels of IL-6 and CRP were measured in 
blood samples collected simultaneously from the oriﬁ ce of the left coronary artery (CA) 
and the great cardiac vein (GCV) after control coronary angiography and before coronary 
intervention. Coronary blood ﬂ ow was measured using a 15-MHz Doppler wire in the 
ANCA group. Coronary resistance deﬁ ned as coronary pressure divided by coronary 
blood ﬂ ow during maximum coronary vasodilation and this value was automatically 
measured at real time using a computer system. 
Results: Plasma IL-6 level was signiﬁ cantly higher in the GCV than in the CA (p= 
0.0002). The difference in plasma IL-6 level between the GCV and CA in the CAD group 
was signiﬁ cantly higher than that in the ANCA group. Not only plasma IL-6 level at the 
GCV but also the difference in plasma IL-6 between the GCV and CA positively correlated 
with plasma CRP levels at the GCV (r=0.484, p=0.003) and the difference in plasma 
CRP level between the GCV and CA (r=0.595, p=0.0022), respectively. The difference 
in plasma IL-6 level between the GCV and CA was signiﬁ cantly correlated with coronary 
resistance (r=0.444, p=0.0385).
Conclusions: These data suggest that an intimate link between plasma IL-6 level and 
CRP level across the coronary circulation and that the locally produced IL-6 may modify 
native coronary vascular resistance.
1153-26 Prevalence Of Heparin/Platelet Factor 4 Antibodies In 
Patients Pre- And Post- Cardiac Catheterization
Shi Yin Foo, Brendan Everett, David Criss, Iris McNulty, Elizabeth M. Van Cott, Michael 
Laposata, Ik-Kyung Jang, Massachusetts General Hospital, Boston, MA
Background: With the increasingly widespread use of heparin, heparin-induced 
thrombocytopenia (HIT) is becoming epidemic. The prevalence of heparin/platelet factor 
4 antibodies (HIT antibodies) and the relationship between antibodies and platelet counts 
are unknown in patients presenting for cardiac catheterization.
Methods: An ELISA-based assay (Diagnostica Stago) was used to examine the presence of 
HIT antibodies in patients presented for cardiac catheterization. HIT antibodies and concurrent 
platelet counts were measured at two time points: at catheterization and 5 days thereafter. 
Thrombotic complications were assessed via telephone interview 30 days after the procedure. 
Management of HIT antibody-positive patients was at the discretion of the patient’s physician.
Results: A total of 340 consecutive patients were enrolled. The prevalence of HIT 
antibodies was 7.7% (26/336 patients) before catheterization and 16.8% (40/238 patients) 
after catheterization. Of the patients with an initial positive HIT test, only one had clinical 
HIT syndrome (platelet count <150,000/mm3 or drop of ≥ 50%.) The platelet count at the 
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time of catheterization did not differ signiﬁ cantly between patients with or without an initial 
positive HIT antibody test (mean 236,200/mcL versus 224,800/mcL respectively; p=0.54.) 
Platelet count at time of catheterization also did not correlate with the development of the 
second positive HIT test (mean values of 222,700/mcL vs 221,200/mcL in patients with 
versus without a second positive HIT antibody; p=0.61.)
Conclusions: The prevalence of HIT antibodies is high in patients undergoing cardiac 
catheterization and more than doubles after the procedure. Platelet counts do not indicate 
or correlate with the development of HIT antibodies, hence emphasizing the importance 
of empiric testing in this population.
POSTER SESSION
1154  Restenosis: Basic Research II
Tuesday, March 08, 2005, 1:30 p.m.-5:00 p.m.
Orange County Convention Center, Hall E1
Presentation Hour: 1:30 p.m.-2:30 p.m.
1154-2 Reduced Coronary Stent Restenosis in Chronic Kidney 
Disease Patients Treated with Cilostazol
Jovonne K. Foster, Claudine T. Jurkovitz, Karen M. Parker, Grant T. Anderson, Paul Kolm, 
Nancy V. Murrah, Ziyad Ghazzal, John S. Douglas, Jr., Emory University, Atlanta, GA
Background: In the Cilostazol for RESTenosis (CREST) trial, patients treated with 
cilostazol after percutaneous coronary intervention (PCI) with stent had a signiﬁ cantly 
lower rate of restenosis than those treated with placebo. The effect of cilostazol on 
restenosis in patients with chronic kidney disease (CKD) is unknown. The purpose of this 
study is to determine whether cilostazol prevents restenosis after stenting in patients with 
CKD. Methods: A total of 705 patients were enrolled in CREST. Baseline serum creatinine 
(Scr) was available for 697 of them. Patients with Scr ≥ 2.5 mg/dL were not included in 
the trial. Glomerular ﬁ ltration rate (GFR) was calculated using the Modiﬁ cation of Diet 
in Renal Disease equation. CKD was deﬁ ned as GFR <60 ml/min/1.73m2. Restenosis 
was deﬁ ned as >50% diameter stenosis at the 6-month angiogram. Results: Respectively 
14.0% and 17.3% of the patients had CKD in the treatment and placebo group (p = 0.23). 
Six-month angiograms were available for 74 patients with CKD and 449 patients without 
CKD. The in-segment restenosis rate among the CKD patients was 36.6% for those 
treated with placebo whereas it was 15.2% for those treated with cilostazol (p=0.04). The 
difference remained signiﬁ cant in the patients without CKD (33.0% versus 23.1%, p=0.02). 
Conclusion: Patients with moderate CKD may beneﬁ t from treatment with cilostazol after 
PCI. This could be of public health importance considering the high prevalence of CKD 
and poor long-term outcome of CKD patients following PCI.
Baseline Characteristics of the CREST Population
CKD
n=109
No CKD
n=588 P
Mean Age ± SD 67 ±9 59 ±10 <0.001
Mean GFR ± SD 53.0 ±5.9 87.0 ±18.3 <0.001
Mean Hemoglobin (g/dL) ± SD 13.4 ±1.7 14.0 ±1.5 <0.001
Female (%) 35.8 24.3 0.01
African-American (%) 4.6 6.6 0.40
Diabetes (%) 31.2 24.8 0.20
Hypertension (%) 74.3 64.4 0.04
Prior PCI (%) 30.3 23.5 0.12
Prior CABG (%) 16.5 9.5 0.03
1154-3 The Inﬂ uence of Prolonged Inﬂ ammation and Insulin 
Resistance on In-stent Neointimal Hyperplasia and 
Restenosis
Aleksander Zurakowski, Pawel Buszman, Marek Cienciała, Wojciech Wojakowski, Jack 
Martin, Michal Tendera, Upper-Silesian Center of Cardiology, Katowice, Poland
The aim of the study was to evaluate the correlation between serum IL-6, Il-10, hs-CRP 
and insulin resistance on intimal hyperplasia and restenosis six month after coronary 
stent implantation.
Methods. Seventy three consecutive patients (57% males, age 55,6±10, diabetes 
18,2%) with coronary artery disease suitable for PCI and stenting were included into 
the study. A total number of 74 coronary segments were covered with bare stents. Six-
month angiographic study together with the evaluation of the serum level of IL-6 [pg/ml], 
IL-10 [pg/ml], hs-CRP [mg/l], fasting Insulin [µIU/ml] and glucose [mg%] were obtained. 
Hemostasis Model Assessement Insulin Resistance (HOMA) was calculated as fasting 
serum Insulin [µIU/ml] multiplied by fasting serum glucose [mg%] and divided by 22.5. 
QCA analysis of stented segments was performed at baseline, after the intervention and 
at 6 month follow-up.
Results. The % diameter stenosis at follow-up was 29±20%, late loss was 0.77±0,60 
mm and restenosis rate was 18,8%. There was a trend toward more late loss (1,2±0,7 vs 
0,65±0,74 mm, p=0,070) and signﬁ cantly bigger %diameter stenosis at follow-up (42,4±32,3 
vs 24,3±32,3%, p=0,015) in patients with hs-CRP>3 mg/l. Hs-CRP correlated well with a 
remodelling of reference diameter (r=0,12 , p=0,005). Fasting glucaemia was elevated in 
pts with restenosis (137±47,0 vs 101,7±29,3 mg%, p=0,015). Percent diameter stenosis at 
follow-up was bigger in pts with HOMA>5 (34,0±26,8 vs 22,0±26,8%, p=0,045). Furthermore, 
we found a correletion between negative vessel remodelling and serum IL-6 (p=0,038) and 
that the level of IL-10 was signiﬁ cantly higher in patients with late loss > 1.2mm (2,99±1,43 
vs 4,99±3,92, p<0.05). There was no correlation between the lipid proﬁ le and renarrowing 
of the stented segments. Multivariate analysis showed that from demographic, angiographic 
and biochemical parameters only hs-CRP and HDL serum concentration have independent 
inﬂ uence on lumen late loss and risk of restenosis (p<0.001).
Conclusions. Prolonged inﬂ ammation play important role in re-narrowing of stented 
coronary segments
1154-4 Association Between Level of Platelet Inhibition After 
Early Use of Abciximab and Myocardial Reperfusion in 
Primary Percutaneous Coronary Intervention
Armando Perez de Prado, Felipe Fernandez-Vazquez, J. Carlos Cuellas, Cristina Olalla, 
Alejandro Diego, Antonio De Miguel, Raul Carbonell, Norberto Alonso-Orcajo, Hospital 
de Leon, Leon, Spain
Background: Substantial interpatient variability in platelet inhibition (PI) with abciximab 
has been described. Our objective is to test the relationship between level of PI after early 
use of abciximab and optimal reperfusion obtained with primary angioplasty in patients 
with ST-segment elevation acute myocardial infarction (STEMI).
Methods: 62 consecutive patients with STEMI (<12 h. of evolution) treated with primary 
angioplasty were prospectively included. Levels of PI were measured with Ultegra Rapid 
Function Assay (Accumetrics, Inc.): the PI level (PI%) was calculated dividing the end-
procedure by the basal value (basal reference values are 125-330 platelet aggregation 
units, PAU). We deﬁ ned optimal myocardial reperfusion as the presence of myocardial 
blush grade 2 or 3 (MBG 2-3) and ST-segment resolution > 50% (sum of ST-segment 
elevation at 60 minutes compared with baseline).
Results: 4 patients did not receive abciximab because of contraindication. PAU levels 
were: baseline 186 ± 57, end-procedure 8 ± 11; the global calculated PI% was 94 ± 9%. 
A level of PI% > 80% was obtained in 90.4% of the cases. MBG 2-3 was detected in 82%, 
ST-segment resolution > 50% in 79% and both in 66% of patients. The table describes the 
relationship between PI% levels and reperfusion parameters.
PI% and myocardial reperfusion
YES NO p
ST resolution > 50% 96 ± 6% 89 ± 15% 0.02
MBG 2-3 95 ± 9% 94 ± 8% 0.5
ST resolution > 50% AND MBG 2-3 96 ± 6% 90 ± 13% 0.023
Conclusion: Our series links higher levels of platelet inhibition after early use of 
abciximab in primary angioplasty with optimal myocardial reperfusion as assessed by 
ECG and angiography.
1154-41 Acute Coronary Syndromes as Clinical Presentation of 
In-Stent Restenosis
Rita Fernandes, Antonio Fiarresga, Joana Feliciano, Nuno Pelicano, Rui Ferreira, Jorge 
Quininha, Hospital de Santa Marta, Lisbon, Portugal
Although many studies have been performed to increase our understanding of this major 
late complication of coronary stenting, the clinical manifestation of in-stent restenosis 
remains incompletely characterized.
OBJECTIVES: To assess the incidence, clinical and angiographic characteristics of Acute 
Coronary Syndromes (ACS) as clinical presentation of in-stent restenosis. METHODS: 
We retrospectively studied 121 patients who had in-stent restenosis angiographically 
diagnosed between February 2002 and May 2004, and divided them in two groups: 
Those whose clinical presentation were ACS (Group A) and those with other clinical 
manifestations (Group B). Several parameters were analysed in both groups, including 
localization of the lesion, time of restenosis to occur and patient-related factors, such as 
age, gender, hypertension, diabetes, and smoking status. 
RESULTS: 51 patients were included in group A, of which 31 (60,9%) were admitted 
with rest angina, 11 (21,4%) with acute myocardial infarction without ST elevation and 9 
(17,6%) with acute myocardial infarction with ST elevation. Group B included 70 patients, 
of which 21 (30,0%) were assymptomatic and had positive results in exercise stress 
test and/or Tl scintigraphy, and 49 (70,0%) presented with stable angina. Hypertension 
was more frequent in group B (83,6%vs63%, p=0,015), while no signiﬁ cant differences 
between the two groups were found in the analysis of the baseline variables, or the 
localization of the lesion. Time of development of restenosis, estimated by the interval 
between coronary stenting and appearance of symptoms was 93,6±156,4 days in group 
A and 235,3±357,1 days in group B.
CONCLUSIONS: ACS were shown to be a common presentation of in-stent restenosis 
and our ﬁ ndings suggest that they occur earlier in the course of restenosis than other 
clinical manifestations.
1154-42 A Recombinant Neutrophil Inhibitory Factor Attenuates 
Neointimal Formation in Zucker Diabetic Rat Model
Zhongmin Zhou, James S. Lee, Valentin Ustinov, Kai Wang, Farhad Forudi, Eric J. Topol, 
Edward Plow, Marc S. Penn, The Cleveland Clinic Foundation, Cleveland, OH
Background: Enhanced inﬂ ammatory and proliferative responses to vascular injury are 
central pathogenic mechanisms for restenosis in diabetes; recruitment of leukocytes plays 
a major role in the process. The effects of a recombinant neutrophil inhibitory factor (NIF) 
on neutrophil binding in vitro and vascular smooth muscle cell (VSMC) proliferation in vivo 
and neointimal formation were evaluated in a Zucker diabetic rat model. 
Methods: The binding of NIF with neutrophils from diabetic rats was assessed by FACS analysis.
Balloon injury of left common carotid artery was performed in twenty-one Zucker diabetic rats 
using standard procedure, a recombinant NIF was administered 10 mg/kg intravenously every 
other day beginning one day prior to and continued for the next 7 days. VSMC proliferation was 
evaluated at 3 days, and neointimal formation was assessed at 21 days after injury. 
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Results: In spite of only 57% of diabetic rats leukocytes compare with human leukocytes 
were bound with the NIF in vitro by FACS analysis. Bromodeoxyuridine (BrdU)-labeled 
proliferating VSMC was markedly decreased in NIF treated rats in vivo (34.00 ± 3.65 
vs 49.33 ± 10.26, P < 0.05), neointimal area was signiﬁ cantly suppressed in the treated 
rats compared with controls (0.11 ± 0.03 vs 0.17 ± 0.03, P < 0.01), and a reduction of 
intima/media ratio was also observed in treated versus control group (1.03 ± 0.28 vs 1.49 
± 0.41, P < 0.05). Conclusion: These data demonstrate that a recombinant NIF binds and 
suppresses neutrophil activation, decreases VSMC proliferation and reduces neointimal 
formation in Zucker diabetic rats.
1154-43 High Plasma Levels of Osteopontin in Patients With 
Restenosis After Percutaneous Coronary Intervention
Yukihiko Momiyama, Reiko Ohmori, Ryuichi Kato, Hiroaki Taniguchi, Haruo Nakamura, 
Fumitaka Ohsuzu, National Defense Medical College, Saitama, Japan, Mitsukoshi 
Health and Welfare Foundation, Tokyo, Japan
Background: In vitro, osteopontin (OPN) promoted endothelial cell migration and smooth 
muscle cell proliferation. Increased OPN mRNA expression was reported in rat arteries after 
balloon injury. Moreover, OPN transgenic mice had markedly increased neointimal formation 
and medial thickening after arterial injury, suggesting that OPN may play a role in the 
development of restenosis after percutaneous coronary intervention (PCI). In humans, OPN 
mRNA was shown to be highly expressed in atherosclerotic plaques. We recently reported 
plasma OPN levels to be high in patients (pts) with coronary artery disease (CAD). However, 
no association between plasma OPN levels and restenosis has yet been elucidated.
Methods: We measured plasma OPN levels by ELISA in 90 CAD pts (age 63±10 yrs) who 
had coronary angiography for suspected restenosis. All of them had undergone PCI 0.6±0.4 
yrs ago, of whom 36 (40%) had been treated with stent. OPN levels were also measured in 
45 age and gender-matched controls who had normal coronary arteries on angiograms.
Results: Of the 90 pts, 42 had restenosis (>50% stenosis). Compared with 48 pts without 
restenosis, 42 with it tended to have a lower rate of current smoking (10% vs 21%) and 
a higher rate of diabetes (38% vs 23%). The percentage of pts taking statin did not differ 
between pts with and without restenosis (60% vs 48%). Plasma OPN levels were higher in 
both pts with and without restenosis than in controls (567±164 and 483±119 vs 399±134 
ng/ml, p<0.002), but OPN levels were much higher in pts with restenosis than in those 
without it (p<0.01). Moreover, pts with restenosis more often had OPN level of >600 ng/ml 
than those without it and controls (38% vs 15% and 9%, p<0.025). However, plasma C-
reactive protein levels did not differ between pts with and without restenosis. In multivariate 
analysis, plasma OPN levels as well as diabetes and smoking were independent factors 
associated with restenosis. The odd ratio for restenosis was 1.7 (95%CI=1.2-2.5) for a 100 
ng/ml increase in OPN levels (p<0.01).
Conclusion: High plasma levels of OPN in pts with a history of PCI were found to be 
associated with the presence of restenosis, suggesting that OPN may play a role in the 
development of restenosis after PCI.
ORAL CONTRIBUTIONS
848  Primary and Rescue Percutaneous 
Coronary Intervention for Acute 
Myocardial Infarction
Tuesday, March 08, 2005, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room 304A
2:00 p.m.
848-3 Association of Primary Percutaneous Coronary 
Intervention Door-to-Balloon Time and Mortality 
in Elderly Patients Hospitalized With ST-Elevation 
Myocardial Infarction
Saif S. Rathore, Jeptha P. Curtis, JoAnne Micale Foody, Yongfei Wang, Mikhail 
Kosiborod, Robert L. McNamara, Frederick A. Masoudi, Edward P. Havranek, Harlan M. 
Krumholz, Yale University School of Medicine, New Haven, CT, Colorado Foundation for 
Medical Care, Aurora, CO
Background: Current ACC/AHA guidelines recommend ST-elevation MI (STEMI) patients 
receive primary PCI within 90 minutes of admission.
Methods: The Cooperative Cardiovascular Project database was used to assess the 
association between door-to-balloon time and mortality in STEMI patients age ≥65 years 
undergoing primary PCI in 1994-96 for whom time to treatment data were available 
(n=1,932). Logistic regression models utilizing fractional polynomials for time were used 
to assess the unadjusted association between door-to-balloon time and mortality at one 
year. Analyses were repeated adjusting for patient age, race, sex, symptoms, admission 
presentation, electrocardiographic data, medical history, and hospital MI volume (c-
statistic 0.81, goodness of ﬁ t P=0.46).
Results: Median door-to-balloon time was 128 minutes (interquartile range 92-178, 24.2% 
within 90 minutes). Overall one-year mortality was 21.1%. Multivariable logistic regression 
models indicated any increase in door-to balloon time was associated with successive 
increases in patients’ adjusted risks for one year mortality (Figure). Results were similar 
excluding patients admitted >6 hours after symptom onset. 
Conclusion: Our ﬁ ndings suggest that any delay in primary PCI is associated with higher 
one year mortality in elderly patients hospitalized with STEMI. Efforts should focus on 
reducing time to treatment as much as possible, even among those centers currently 
providing primary PCI within 90 minutes.
2:15 p.m.
848-4 Angiographic Predictors of Unsuccessful Rescue 
Coronary Intervention for Failed Thrombolytic Therapy 
for Acute Myocardial Infarction
Pertha S. Chowdhury, Simon R. Dixon, Kishore J. Harjai, Razvan M. Chirila, Saroj K. 
Chowdhury, Judith A. Boura, William W. O’Neill, William Beaumont Hospital, Royal Oak, MI
Background: Previous studies demonstrated a high incidence of infarct vessel re-
occlusion and in-hospital death in patients undergoing rescue angioplasty (PCI) after 
failed thrombolytic therapy for myocardial infarction (AMI). There are few data in the 
contemporary era of rescue PCI for AMI with the use of stenting and GP IIb/IIIa antagonists. 
We sought to identify the predictors of unsuccessful rescue PCI for failed thrombolytic 
therapy in order to help identify patients who are at higher risk for intervention. 
Methods: We studied 166 patients who failed thrombolytic therapy and were transferred 
to William Beaumont Hospital for rescue PCI between Jan. 1995 and June 2001. PCI was 
performed using available techniques. In-hospital clinical outcome data were collected 
prospectively. We additionally analyzed angiographic data for these patients. Patients with 
cardiogenic shock were excluded in our analysis. Successful PCI was deﬁ ned as TIMI 3 
ﬂ ow and <50% residual stenosis in the infarct related artery. 
Results: Successful PCI was accomplished in 136/166 (82%) of patients. The overall 
incidence of in-hospital events was: death 3.0%, re-occlusion 4.2%, stroke 0.6%, 
transfusion 6.0%. Patients who had initial occlusion had a trend towards higher PCI failure 
(60 vs 42%, p=0.07). Multivariate analysis demonstrated that failure of rescue PCI was 
independently predicted in more patients with LAD infarction (60 vs 36%, OR=3.26), more 
severe initial stenosis (96 vs 91%, OR=1.98), eccentric lesions (82 vs 66%, OR=4.97), 
and multivessel disease (67 vs 52%, OR=2.03) (all p<0.05). 
Conclusion: Our observations in this series demonstrate high risk characteristics for 
patients presenting for rescue PCI for failed thrombolytic therapy. Consideration should 
be made for adjunctive therapy when undertaking intervention in this subset of patients.
2:30 p.m.
848-5 Reperfusion Success and Clinical Outcomes After 
Rescue Compared to Primary Angioplasty: Results 
from the EMERALD Trial
George D. Dangas, Roxana Mehran, John Webb, David A. Cox, Bruce R. Brodie, 
Mansoor Qureshi, Daniel Dulas, Anna Kalynych, Mark Turco, Heinz P. Schultheiss, Barry 
Rutherford, Mitch Krucoff, Raymond Gibbons, Alexandra Lansky, Carmen Spatareanu, 
Ramona Popp, Denise Jones, Allan Schwartz, Gregg W. Stone, Columbia University 
Medical Center, New York, NY, Cardiovascular Research Foundation, New York, NY
Background. Rescue percutaneous coronary intervention (PCI) after failed thrombolytic 
therapy has lower reperfusion success rates as assessed by TIMI ﬂ ow and worse 
clinical outcomes compared to primary PCI. To examine the validity of these results, we 
investigated the clinical outcomes of rescue vs. primary PCI in the multicenter randomized 
prospective EMERALD trial.
Methods. In EMERALD, 501 pts within 6 hrs of chest pain onset with ≥2 mm ST elevation 
or LBBB undergoing primary or rescue PCI were prospectively randomized at 38 sites 
in 7 countries to intervention with vs. without distal protection with the 0.028” GuardWire 
Plus system. Results. Rescue and primary PCI pts had similar baseline characteristics, 
target artery location and symptom onset to ER time. Pts undergoing rescue PCI more 
frequently were tachycardic, tachypnic, and had lower blood pressure. Although TIMI 2/3 
ﬂ ow at baseline was more common in pts undergoing rescue compared to primary PCI, 
normal TIMI-3 ﬂ ow was less frequently achieved at procedure end. However, myocardial 
reperfusion as assessed by myocardial blush grade and ST segment resolution were 
similar between primary and rescue PCI, as were measures of infarct size and event-free 
survival. Conclusions. Despite lower rates of post procedure TIMI-3 ﬂ ow after angioplasty 
for failed thrombolytic therapy, contemporary PCI techniques achieve comparable 
myocardial reperfusion success and clinical outcomes in rescue and primary PCI. 
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Primary PCI (n=408) Rescue PCI (n=93) P value
Pre TIMI ﬂ ow 2 or 3 29.1% 56.2% <0.0001
Final TIMI ﬂ ow 3 92.6% 80.9% 0.002
Final Blush grade 3 58.2% 51.8% 0.33
Infarct size tc-99m (%LV) 16.9 ± 18.9 19.1 ± 20.5 0.35
ST resolution >70% 62.3% 58.1% 0.54
30 day mortality 2.5% 2.2% 0.89
6 month mortality 3.7% 2.4% 0.60
30 day MACE 6.8% 5.6% 0.72
6 month MACE 10.7% 11.4% 0.89
2:45 p.m.
848-6 Relationship Between Vessel Size And Mortality 
After Primary Angioplasty For ST-Segment Elevation 
Myocardial Infarction
Giuseppe De Luca, Harry Suryapranata, Jan Paul Ottervanger, Arnoud WJ van’t Hof, 
Jan-Henk E. Dambrink, At Marcel Gosselink, Jan CA Hoorntje, Menko-Jan de Boer, De 
Weezenlanden Hospital, Zwolle, The Netherlands
Background. The prognostic impact of vessel size in STEMI has yet to be investigated. 
The aim of current study was to evaluate the impact of vessel size on mortality in patients 
undergoing primary angiolasty for STEMI.
Methods. Our population is represented by 1478 patients with STEMI undergoing 
primary stenting from 1997 to 2001. All clinical, angiographic, and follow-up data were 
prospectively collected. No patient was lost to 1-year follow-up. Patients were divided in 4 
groups according to quartiles of vessel size.
Results. Vessel size was linearly associated with gender, diabetes, previous infarction, 
anterior infarction location, and multivessel disease, the rate of stenting. Smaller vessels 
had poor myocardial blush grade, impaired ST-segment resolution and subsequently 
larger enzymatic infarct size and lower predischarge ejection fraction (Figure 1). After 
adjustment for all baseline confounding factors, we found a relative risk [95% CI] of 1-year 
mortality of 1.44 [1.08-1.92] (p = 0.012) for each 0.5 mm reduction in vessel size.
Conclusions. This study shows that vessel size is a main determinant of mortality 
in patients with STEMI treated with primary angioplasty, mainly related to impaired 
myocardial perfusion and subsequently larger infarct size. Future randomized trial should 
evaluate the beneﬁ ts from additional use of pharmacological and mechanical therapies in 
order to improve myocardial perfusion in small infarct related arteries. 
3:00 p.m.
848-7 Is Late. . . Too Late for Primary Angioplasty in Acute 
Myocardial Infarction?
Jorge L. Szarfer, Miguel Angel Riccitelli, Alejandro Garcia Escudero, Sergio Centeno, 
Miguel Payaslian, Ricardo Sarmiento, Gerardo Gigena, Silvia Massone, Luis Alberto 
Vidal, Hospital General de Agudos CosmeArgerich, Buenos Aires, Argentina
Background: Myocardial salvage has been shown to be dependent on the time elapsed 
from the onset of Symptoms (SO) to thrombolysis. We sought to evaluate the importance of 
time to reperfusion on the early recovery of left ventricular function (LVF) in an unselected 
series of patients (p.) after myocardial infarction treated with primary PCI.
Methods: End diastolic (EDV), end systolic (ESV) volumes and Ejection Fraction (EF) 
angiographicaly assessed through the area-length method, were evaluated pre procedure 
and 24 hs. after (post) an accomplished Primary PCI, in 161 consecutive p. performed <12 
hs. of SO. Corrected Timi Frame count was evaluated immediately and 24 hours after; 
Timi ﬂ ow grade pre procedure. Patients were allocated to 4 groups according to the time 
interval between SO and reperfusion on a quartile distribution basis, A: ≤ 180 min., B: 180 
to 270 min., C: 270 to 370 min. and D: ≥ 370 min.
Results: No differences were found between groups on demography; previous medical 
history; pre procedure IRA patency; pre and post procedure LVF; localization, extension 
and severity of lesions; Corrected Timi Frame Count evaluated immediately and 24 hours 
after; and pre procedure Timi Flow Grade. 
p values for intra group pre/post pci differences
Group A: 41p. 
prePCI < 
25%ile
Group A: 41p. 
postPCI < 25%ile
Group B: 39p. 
prePCI 25%ile 
- median
Group B: 39p. 
postPCI 25%ile 
- median
Group C: 40p. 
prePCI Median 
- 75%ile
Group C: 40p. 
postPCI Median 
- 75%ile
Group D: 
41p. prePCI > 
75%ile
Group D: 41p. postPCI 
> 75%ile
EDV ml/m2 65,1+18,5 68,3+12,5 P=NS 72,3+29,9 71,9+22,7 P=NS 73,6+22,2 66,7+18,5 P<0,001 73,7+18,2 69+18,5 P< 0,02
ESV ml/m2 35,4+ 9,9 31,7+12,8 P<0,001 40,4+15,5 34,7+17 P<0,001 42,5+17 35,6+15,3 P<0,001 40,5+16,8 34,3+15,8 P<0,0001
EF % 44,1+11,1 52,3+14,1 P<0,0001 43,9+13,1 52,7+12,7 P<0,0001 42,1+13,2 46,9+14,2 P<0,001 44,7+12,9 51,4+11,9 P<0,0001
Conclusion: We found that myocardial salvage can be achieved in patients reperfused 
within 12 hs with primary PCI. Improvement of LVF variables became apparent only 24 
hours after the procedure. Despite a different SO to reperfusion time all groups showed 
similar LVF early recovery and coronary ﬂ ow velocity.
3:15 p.m.
848-8 The Safety and Efﬁ cacy of Percutaneous Coronary 
Intervention for STEMI with Off-site Surgical Back-up
Gishel New, Julian Castro, Swati Mukherjee, Louise Roberts, Leonie Johnston, George 
Proimos, Yew Mun Cheong, Christopher Goods, Michael Rowe, Box Hill Hospital, Box 
Hill, Australia
Background: The advantages of primary PCI for STEMI include higher initial reperfusion 
rates, lower recurrence rates of ischaemia/ infarction, less residual stenosis, intra cranial 
bleeding. The safety of primary PCI without on site cardiac surgery is controversial.
Aims: To document the safety and effectiveness of primary angioplasty for STEMI in a 
centre without onsite cardiac surgery.
Methods: Data was prospectively collected for all STEMI patients referred to the 
cardiology unit at Box Hill Hospital (BHH), Melbourne Australia, since the inception of the 
primary angioplasty programme from 1st July 2002 to 30 June 2004.
Results: Two hundred & eighty-three patients presented with a STEMI; 198 from BHH 
and 83 were transferred from other hospitals to BHH (SHIPEM Registry). Two hundred 
& eight-one underwent angiography, two hundred & sixty-four underwent primary PCI. 
Seventeen were transferred for CABG as they were not suitable for PCI or developed a 
mechanical deﬁ cit. Two patients were treated conservatively & 1 patient was thrombolysed. 
Of the SHlPEM patients 83 had angiograms 78 had primary PTCA; no patients were 
transferred for CABG due to a PCI complication. One patient experienced a stroke after 
a facilitated PCI. 
30 Day Outcomes BHHn=186
SHIPEM
n=78
TOTAL
n=264
Procedural success 180/186 (97%) 75/78 (96%) 255/264 (97%)
Death 12 (6.5%)* 5 (6.4%)* 17 (6.4%)*
MI (x3 ULN CK) 2 (1%)* 1 (1.3%) 3 (1.1%)
TVR 0 2 (2.6%) 2 (0.8%)
30 D MACE TOTAL 14/186 (7.5%) 7/78 (9%) 21/264 (8%)
30 D MACE excluding cardiogenic 
shock 9/178 (5%) 5/74 (6.8%) 14/252 (5.6%)
* Cardiogenic Shock
Conclusion: Our ﬁ ndings indicate that primary angioplasty for STEMI without on 
site cardiothoracic surgery is safe and effective, for patients who present direct to the 
emergency department and those that are transferred from surrounding hospitals.
ORAL CONTRIBUTIONS
852  Coronary Stents: Adjunctive Measures
Tuesday, March 08, 2005, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room 230B
2:00 p.m.
852-3 Reduction in Mortality and Other Procedural 
Complications Following Percutaneous Coronary 
Angioplasty in Patients with Hyperlipidemia is Largely 
Due to Statin Treatment
Mandeep Singh, Charanjit Rihal, Ryan Lennon, Sean Halligan, Amir Lerman, Mayo 
Clinic, Rochester, MN
Background Long-term administration of statin therapy has been shown to reduce major 
coronary events and cardiac mortality within randomized clinical trials. We hypothesized 
that statin therapy may reduce major cardiovascular complications among patients 
undergoing PCI.
Methods and Results Patients with (n=3702) hyperlipidemia (cholesterol ≥240mg/dl) 
were stratiﬁ ed into those taking (group 1,n=2052) and not taking (group 2, n=1650) statins 
at the time of the PCI. The results of procedure success and major adverse complications 
(death, Q-MI, CK-MB >3×ULN, stroke, and emergent CABG) were compared with 
patients with normal levels of cholesterol (group 3, n=726). Group 1 patients on statins 
had high-risk variables. The procedural success was high and similar (94-95%) in the 3 
groups. The in-hospital mortality, and MACE were signiﬁ cantly reduced in patients on 
statins as compared with other 2 groups. After adjusting for other risk factors, patients 
with high cholesterol on statins had fewer complications (OR 0.72; 95% CI 0.56, 0.92; 
p=0.009) than patients without high cholesterol. Patient with high cholesterol but not on 
Statin medication had similar outcomes as patients with normal cholesterol.
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Conclusions Despite higher prevalence of characteristics associated with procedural 
complications, patients with hyperlipidemia on statins have signiﬁ cantly lower in-hospital 
mortality, and procedural complications during PCI. 
Variable Group 1 (%) Group 2 (%) Group 3 (%) P
Age, yr 67.1±11.2 66.6±12.2 67.6±13.3 0.19
MI<24 hr 9 26 23 <0.001
Diabetes 29 26 20 <0.001
Hypertension 79 75 60 <0.001
PVD 14 9 8 <0.001
Multivessel disease 70 72 65 0.006
Mortality 0 2 2 <0.001
Q-MI 2 2 1 0.14
CK-MB elevation 16 31 32 <0.001
PCI complication 15 30 30 <0.001
2:15 p.m.
852-4 The Incidence of Clopidogrel Resistance is Strongly 
Inﬂ uenced by Dose
Paul A. Gurbel, Kevin P. Bliden, Udaya Tantry, Sinai Center for Thrombosis Research, 
Baltimore, MD
BACKGROUND: We have previously reported clopidogrel resistance following a 300 mg 
loading dose. However, the effect of dose on the incidence of resistance is unknown
METHODS:  We have previously deﬁ ned resistance as the absolute change in aggregation 
by light transmittance aggregometry in response to 20 µM ADP (Δ A ) < 10%, where Δ A = 
pretreatment aggregation minus post-treatment aggregation. Patients undergoing elective 
stenting were randomly assigned to 300 mg vs 600 mg clopidogrel administered 0-1 hr pre-
stenting and both groups received 75 mg qd maintenance. All patients received aspirin ( 325 
mg qd ). Samples were drawn immediately pre-stenting and at day 5 post-stenting.
RESULTS: Average age was 66 ± 14 years; (n=194). Baseline aggregation was the same 
between groups ( 80 ± 16 % vs. 78 ± 7 % for 300 mg and 600mg, respectively). Δ A was 23 
± 12% in the 300 mg group vs. 36 ± 18 % in the 600 mg group (p<.0004). The incidence of 
resistance was markedly lower in the 600 mg group (7% vs. 30%, p<.0007)
CONCLUSIONS: The incidence of clopidogrel resistance is strongly affected by the 
loading dose administered for stenting . Higher dosing strategies and methods to conﬁ rm 
platelet inhibition should be further investigated in order to optimally use this drug.
2:30 p.m.
852-5 Hypercoagulability Measured by TEG Strongly Predicts 
Recurrent Ischemic Events Post Coronary Stenting
Kevin P. Bliden, Udaya S. Tantry, Kevin M. Hayes, Kazi Zaman, Jason A. Yoho, Paul A. 
Gurbel, Sinai Hospital, Baltimore, MD
Background: The thromboelastogram (TEG) is a useful tool in the management of 
perioperative hemostasis.Its utility for platelet inhibition monitoring and risk stratiﬁ cation 
in coronary stenting is unknown.
Methods: We prospectively studied 120 patients undergoing elective stenting pre- and 
24 hours post-procedure, followed up to 6 months for recurrent ischemic events (death, 
MI, stroke, and angina requiring hospitalization ) and grouped into ischemic and non-
ischemic groups based on the occurrence of at least one event. The incidence of normal 
haemostasis (NH); clopidogrel responsiveness; enzymatic hypercoaguability (EH); a 
marker of ﬁ brin generation, and platelet hypercoaguability (PH); a marker of ﬁ brin-platelet 
interaction strength were determined.
Results: Events occurred in 17 % of the population and 88 % with ischemic events were 
non-responsive to clopidogrel by TEG as compared to 12 % of patients without events , 
p < 0.001. 90% of patients with events had EH , PH, or both (Table). The probability of an 
ischemic event was 35% in the presence of one or more abnormal TEG parameters.
Conclusion: The TEG is a powerful point of service tool for identifying patients at risk for 
recurrent ischemic events following coronary stenting. This technique is currently being 
investigated to tailor antiplatelet and anticoagulant therapy in patients with coronary disease. 
2:45 p.m.
852-6 Relationship Between Activated Clotting Times 
and Procedural Outcomes in Patients Undergoing 
Coronary Intervention With Unfractionated Heparin and 
Glycoprotein IIb/IIIa Inhibitors
Giora Weisz, Michael Lincoff, Issam Moussa, Ramin Ebrahimi, Gad Keren, Jeffrey Carr, 
Frederick Feit, Roxana Mehran, Jeffrey W. Moses, Martin B. Leon, Gregg W. Stone, 
Center for Interventional Vascular Therapy , Columbia University Medical Center, New 
York, NY, Cardiovascular Research Foundation, New York, NY
Background: The relationship between ACT levels and ischemic and hemorrhagic 
complications in pts undergoing percutaneous coronary intervention (PCI) with 
unfractionated heparin (UFH) and IIb/IIIa inhibitors is still a matter of debate.
Methods: We studied 3,011 pts from the REPLACE-2 trial who were assigned to UFH 
(65 U/kg bolus) plus IIb/IIIa inhibition (abciximab or eptiﬁ batide, n=3011). ACT was 
measured 5 minutes after the drug was administered (data available in 2,772 (92%) pts), 
and additional heparin bolus (20 U/kg) was given if the ACT was less than 225 seconds. 
Outcomes were examined based on the 5 minutes post drug ACT level in 3 strata: <250, 
250-300, and >300 seconds.
Results: Ischemic and hemorrhagic adverse events rates at 30-days are shown in 
the Table. Freedom from the primary net clinical beneﬁ t endpoint of REPLACE-2, the 
composite 30-day incidence of death, MI, urgent revascularization or major bleeding, 
was lowest in the cohort of patients with an ACT of 250-300 seconds, both by univariate 
analysis (Table) and multivariate analysis (Hazard Ratio=0.71, p=0.04).
Conclusions: In patients receiving UFH plus IIb/IIIa inhibitors during PCI, optimal 
outcomes are achieved when the ACT level measured 5 minutes after drug administration 
is 250-300 seconds. Both higher and lower ACT levels are associated with increased 
rates of adverse events.
*p=0.03 vs. <250sec, and p=0.02 vs. ACT>300
ACT<250
n=567
ACT 250 - 300
n=613
ACT>300
n=1592 p-value
ACT at 5 minutes 207±39 276±15 375±65 <0.0001
Peak procedural ACT 264±79 290±69 380±74 <0.0001
Final ACT 246±75 260±83 300±66 <0.0001
Outcomes at 30-days
Death / MI 7.4% 5.1% 6.8% 0.22
Urgent revascularization 2.3% 0.7% 1.3% 0.046
Death/MI/urgent revascularization 8.0% 5.4% 7.6% 0.16
Major bleeding 4.4% 2.4% 4.5% 0.08
Death/MI/urgent revasc/major 
bleeding 11.1% 7.4%* 10.7% 0.045
3:00 p.m.
852-7 High Dose Clopidogrel and Eptiﬁ batide: The Optimum 
Strategy to Prevent Myocardial Necrosis in Elective 
Stenting: Results from the CLEAR PLATELET Study.
Paul A. Gurbel, Kevin P. Bliden, M. Fissha, K. Plantholt, R. Kreutz, Udaya Tantry, Sinai 
Center for Thrombosis Research, Baltimore, MD
BACKGROUND: The optimum antiplatelet strategy remains contoversial in elective 
coronary stenting. Concern has been raised for pretreatment given bleeding risk with 
CABG. Insufﬁ cient platelet inhibition may be a cause of myocardial necrosis after 
stenting. However, the relation of platelet reactivity to myocardial necrosis has never been 
established in a prospective randomized investigation.
METHODS: In a 2 x 2 factorial randomized investigation (The CLEAR Platelet Study) 
patients ( n = 118 ) were treated with 300 mg clopidogrel ( C ); 300 mg C + eptiﬁ batide ( 
E ); 600 mg C; and 600 mg C + E. Serial assessment of platelet reactivity to ADP for 24 
hours was measured by light transmittance aggregometry (LTA). CPK-MB, troponin I, and 
myoglobin were measured every 8 hours. 
RESULTS: Demographics and baseline LTA were the same between groups. Patients 
receiving 600 mg C + E had consistently the lowest platelet reactivity over 24 hours and 
the lowest marker release ( p < 0.05) (Table).
CONCLUSION: Patients with the greatest platelet reactivity post-stenting are at greatest 
risk for the development of myocardial necrosis. A strategy of 600 mg C + E administered 
at the time of stenting provides the greatest platelet inhibition and protection against 
myocardial necrosis.
Table
CKMB Trop-I Myoglobin LTA (20µΜ ADP)
2-5X B >5X B > ULN >2X B 2-3 h 8h 18-24h
% of Patients % Inhibition
300C 35 10 25 30 16 19 19
300 C+E 5 0 0 5 99 99 84
600 C 30 5 10 20 22 36 32
600 C+E 5 0 0 0 100 100 94
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852-8 Thirty Day and Six Month Outcomes after Saphenous 
Vein Graft Stenting with Distal Protection in Patients 
Excluded From Randomized Trials: The FilterWire EX 
High Risk Registry
Gregg W. Stone, Bruce R. Brodie, Ronald Caputo, Robert Feldman, Campbell Rogers, 
David A. Cox, David K. Roberts, A. Zaki Masud, James Hermiller, Patrick Cambier, 
Richard Kovach, Manuela Negoita, Allan Schwartz, Ramona Pop, Martin Fahy, 
Roopan Sikand, Roxana Mehran, Columbia University Medical Center, New York, NY, 
Cardiovascular Research Foundation, New York, NY
Background. In the randomized SAFER and FIRE trials, 30-day MACE (death, MI and 
TVR) following saphenous vein graft (SVG) stenting with distal protection devices (DPD) 
occurred in 9.6% - 11.6% of pts. These trials, however, excluded pts with high risk features. 
The outcomes of SVG stenting with DPD in an unselected population are unknown.
Methods. In the FilterWire EX High Risk Registry, 255 pts undergoing SVG stenting 
with exclusion criteria for enrollment in the randomized FIRE trial (creatinine >2.5 mg/dL, 
recent MI with elevated CK-MB, LVEF <25%, occluded SVG, single remaining vessel) 
were treated with the FilterWire EX ﬁ lter-based DPD and followed for 6 months.
Results. Mean age was 71 yrs (range 44-90). High risk features included 66% prior MI, 
38% diabetes, 29% CHF, 39% PVD, and 25% with LVEF <25%. Thrombus was present in 
54% of grafts, and TIMI ﬂ ow <3 in 17%. Following stenting (mean length 34 mm) with the 
FilterWire EX, TIMI-3 ﬂ ow was present in 97%. CPK-MB levels were elevated in 27.8% of 
pts. Outcomes appear in the table.
Conclusions. In this high risk population undergoing SVG stenting with FilterWire EX 
distal protection excluded from prior randomized trials such as FIRE, the 30-day and 
6-month MACE rates are higher than previously reported, and mortality at 6 months is 
considerable. These data emphasize the poor prognosis of this high risk group despite 
distal protection, and the need for additional treatment approaches.
30 days cumulative 30-180 days 180 days cumulative
Death 3.5% 4.5% 7.9%
MI 12.9% 3.6% 16.1%
TVR 2.0% 4.5% 6.4%
MACE 16.1% 11.7% 25.9%
ORAL CONTRIBUTIONS
857  Drug-Eluting Stents: Treatment 
of In-Stent Restenosis
Tuesday, March 08, 2005, 4:00 p.m.-5:00 p.m.
Orange County Convention Center, Room 304E
4:00 p.m.
857-3 A Prospective, Multicenter Randomized Trial of the 
Paclitaxel-Eluting Stent Versus Vascular Brachytherapy 
in Patients with Coronary In-stent Restenosis: The 
TAXUS-V ISR Trial
Gregg W. Stone, Stephen G. Ellis, Charles D. O’Shaughnessy, Lowell Satler, Steven 
Martin, Thomas McGarry, Marc Turco, Dean J. Kereiakes, William C. Jacobs, Mary E. 
Russell, Columbia University Medical Center, New York, NY, Cardiovascular Research 
Foundation, New York, NY
Background. Vascular brachytherapy is the only therapy proven to reduce the high 
recurrence rate after repeat percutaneous intervention for in-stent restenosis. Though 
drug-eluting stents represent a logistically less complex and therefore desirable 
alternative to brachytherapy, their safety and efﬁ cacy for this application have not been 
demonstrated.
Methods In the TAXUS-V ISR trial, 488 patients with in-stent restenosis of bare metal 
stents in a single native coronary artery are being randomized at 38 centers to either 
beta brachytherapy with either of the two FDA approved systems vs. the polymer-based, 
slow-release, paclitaxel-eluting TAXUS stent. For study inclusion the target lesion length 
must be ≤46 mm, and the reference vessel diameter is ≥2.5 and ≤3.75 mm. Patients 
are treated with clopidogrel for 6 months after both treatments, or 12 months after 
brachytherapy if new bare metal stents are implanted. Clinical follow-up occurs at 1, 4 and 
9 months, and then yearly for 5 years. The primary endpoint is the 9 month rate of target 
vessel revascularization for ischemia. Angiographic follow-up is planned in all patients 
at 9 months, additionally with intravascular ultrasound in the ﬁ rst 250 patients. The trial 
is powered for both non-inferiority and superiority using sequential testing. A biomarker 
sub-study will prospectively test the prognostic value of post procedural troponins, high 
sensitivity CRP and HgbA1C.
Results. Enrollment will be complete by December 2004, and the 30-day results ready 
for presentation in March 2005.Conclusions. A large-scale, prospective, randomized 
trial of the polymer-based, slow-release paclitaxel-eluting TAXUS stent compared to beta 
vascular brachytherapy in patients with coronary in-stent restenosis has been performed. 
The 30-day results will provide important insight into the relative safety of these two 
approaches in this complex patient cohort
4:15 p.m.
857-4 Results of the Restenosis Intrastent: Balloon 
Angioplasty Versus Rapamycin-Eluting Stent 
Implantation Randomized Study
Fernando Alfonso, Juan Angel, Angel Cequier, Jose M Auge, Jose R Lopez-Minguez, 
Armando Bethencourt, Javier Goicolea, Maria J Perez Vizcayno, Alfonso Suarez, Carlos 
Macaya, RIBS II Investigators, Hospital Clinico San Carlos, Madrid, Spain
Background: Treatment of patients (P) with in-stent restenosis (ISR) remains a challenge. 
Drug-eluting stents (DES) are considered an attractive strategy in this setting but currently 
there is only limited information, from observational studies, on the value of DES in P 
with ISR.
Methods: The RIBS II study (Restenosis Intra-stent: Balloon angioplasty [BA] vs elective 
rapamycin-DES) is a multicenter, randomized trial designed to determine the efﬁ cacy of 
rapamycin-DES in P with ISR. Main inclusion criteria included ISR producing symptoms or 
myocardial ischemia, ﬁ rst ISR, anatomy suitable to both therapeutic strategies, reference 
vessel diameter >2.5 mm and ISR length <33 mm. From February 2003 to April 2004, 
150 P with ISR were enrolled (computer-generated code, central randomization) at 7 
university hospitals in Spain, 74 allocated to BA and 76 to DES. All P were treated with 
dual antiplatelet therapy and repeat angiography was scheduled at 9 moths. The primary 
end-point was the recurrent restenosis rate by QCA. A composite of major adverse events 
(death, myocardial infarction and target vessel revascularization) constituted a secondary 
end-point of the study.
Result: Mean age was 64+11 years and 33 P (25%) were female. Baseline clinical 
characteristics (unstable angina 44%, diabetes 35%, median time to ISR 6.6 months) and 
angiographic ﬁ ndings (diffuse ISR 60%, LAD location 52%), were similar in both groups. 
All P obtained initial angiographic success but 1 P died during hospitalization. Currently, 
all P have completed the 1 month clinical follow-up and 45 P the 9 moth follow-up. During 
this time, no further P died, 1 P (DES) suffered a Q-wave myocardial infarction following 
acute vessel closure and 13 symptomatic P required target vessel revascularization (11 
BA group, 2 DES group) (1 surgery, 1 BA, 5 brachytherapy and 6 DES). The complete 
(150 P) 9-month clinical and angiographic follow-up will be presented.
Conclusion: The RIBS II randomized study will determine whether DES are superior 
(both clinically and angiographically) to conventional BA in P with ISR.
4:30 p.m.
857-5 Superior Acute and Follow-Up Results of Sirolimus-
Eluting Stents Compared to Vascular Brachytherapy for 
In-Stent Restenosis.
Ekaterina Ioﬁ na, Paul Skurzewski, Peter Radke, Rüdiger Blindt, Andreas Franke, Peter 
Hanrath, Jürgen vom Dahl, Rainer Hoffmann, University Aachen, Aachen, Germany
The effectiveness of sirolimus-eluting stents (SES) in comparison with vascular 
brachytherapy (VB) for treatment of in-stent restenosis (ISR) is not deﬁ ned. 
Methods and results: This analysis evaluated acute procedural, 6-months angiographic 
results and target lesion revascularization (TLR) rates @> 6 months in 124 patients with 
ISR (ISR lesion length<30 mm, vessel diameter <3.5 mm) treated with VB or SES. 62 
patients with 62 ISR lesions were treated with VB (� -radiation, Novoste) and 62 patients 
with 62 lesions with SES (CypherTM, Cordis). Reference vessel diameter, lesion length, 
minimal lumen diameter (MLD) before intervention and frequency of diabetes mellitus 
were similar. Clinical follow-up was obtained in all patients and angiographic follow-up in 
53 SES and 53 VB patients.
SES were used in 16 lesions after failed VB and in 46 lesions for ﬁ rst time ISR. Late loss 
was higher after use of SES for failed VB than after use of SES for ﬁ rst time ISR (0.61 mm 
vs 0.24 mm; p=0.018). In a multivariate analysis prior failed VB was the only independent 
predictor for recurrent restenosis after SES for ISR (P=0.052; OR=5.8). 
Conclusion: SES achieves superior acute and follow-up results compared to VB for 
treatment of ISR even if cases with failed VB are included. Failed VB is a predictor of 
impaired SES effectiveness.
SES vs VB
VB SES P
Reference(mm) 2.57±0.41 2.57±0.35 n.s.
Lesion length (mm) 12.4±4.8 12.1±5.2 n.s.
MLD preintervention (mm) 0.74± 0.28 0.68± 0.39 n.s.
Acute gain (mm) 1.32±0.47 1.52±0.45 0.032
Late loss (mm) 0.60±0.67 0.35±0.53 0.044
Net gain (mm) 0.74±0.60 1.16±0.56 <0.001
Restenosis rate (%) 30 11 0.033
TLR (%) 25 11 0.069
4:45 p.m.
857-6 Comparison of Efﬁ cacy and Safety between Sirolimus-
Eluting Stent (Cypher™) and Paclitaxel-Eluting Stent 
(TAXUS™) on the Outcome of Patients with Diffuse In-
Stent Restenosis: Multicenter Registry in Asia
Sunao Nakamura, Tamil Selvan Muthusamy, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Treskosol, New Tokyo Hospital, Matsudo, Japan
Background and Purpose: Both Sirolimus-eluting stent (Cypher™, Cordis) and 
Paclitaxel-eluting stent (TAXUS™, Boston Scientiﬁ c) have been reported to be effective 
in preventing neointimal function and reducing restenosis. The aim of this study is to 
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compare the safety and efﬁ cacy of these two types of stents on the outcome of patients 
with diffuse in-stent restenosis (D-ISR). Methods: A prospective analysis of 260 patients 
with 304 D-ISR lesions (126 Cypher™ and 134 TAXUS™) in the high volume Asian 
centers after successful stent implantation (Cypher™: LMT 3.2%, LAD 43.7%, LCX 
27.8%, RCA 25.3%) (TAXUS™: LMT 3.7%, LAD 44.8%, LCX 22.4%, RCA 29.1%) was 
performed. The study endpoints were major adverse cardiac event (MACE) at 30 days 
and restenosis rate at 12 months. Results: See table for clinical results. Conclusion: The 
use of both stents in patients with D-ISR was equally safe with low acute complications 
and low incidence of restenosis.
Cypher™ TAXUS™
Number of patients 126 134
MACE at 30 days 0 0
Reference diameter (mm) 2.78 ± 0.68 2.60 ± 0.70
MLD post (mm) 2.68 ± 0.66 2.50 ± 0.70
MLD at 12 months (mm) 2.50 ± 0.86 2.68 ± 0.60
Restenosis rate (%) 7.4 13.4
TVR (%) 7.4 13.4
MACE at 12 months (%) 7.4 13.4
ORAL CONTRIBUTIONS
866  Drug-Eluting Stents: 
Higher-Risk Patients
Wednesday, March 09, 2005, 8:30 a.m.-10:00 a.m.
Orange County Convention Center, Room 304A
8:30 a.m.
866-3 WISDOM High-risk Subgroups: 12-Month Outcomes 
With The Slow-release, Polymer-based, Paclitaxel-
eluting Taxus Stent
Alexandre Abizaid, Charles Chan, Tean-Teng Lim, Upendra Kaul, Tejas Patel, Huay 
Cheem Tan, Nakul Sinha, Julio Lopez, Efrain Gaxiola, Saligram Ramesh, Alfredo 
Rodriguez, Milena Adamian, WISDOM Investigators, Instituto de Cardiologia Dante 
Pazzanese, São Paulo, Brazil
Background: Diabetes mellitus (DM), smaller vessel size, and long lesion length (LL) have been 
identiﬁ ed as predictors of unfavorable outcomes post percutaneous coronary interventions. The 
global WISDOM registry evaluated 12-month outcomes in “real world” patients who received the 
slow-release (SR) paclitaxel-eluting TAXUS™ (Boston Scientiﬁ c Corp., Natick, MA) stent.
Methods: Twelve-month clinical outcomes were evaluated in high-risk subgroups 
(diabetics, acute coronary syndrome [ACS], longer lesions, and smaller vessels) of 
patients enrolled in the WISDOM global registry. The clinical outcomes were monitored 
and follow-up was performed at 3, 6, 9, and 12 months post stent implant procedure.
Results: A total of 778 patients with 907 de novo or restenotic lesions were treated with 996 
TAXUS SR stents. Out of the entire study population, 33% (n=260) of the patients were diabetics, 
18% (n= 142) presented with acute coronary syndrome (ACS), 15% had lesions >20 mm 
(n=116), and 12% (n=94) of the patients received a TAXUS stent in smaller vessels (reference 
vessel diameter [RVD] <2.50 mm). Twelve-month clinical follow up was available for 92% of the 
patients at a mean of 346 days post procedure. Results are shown in the table below.
Overall 
WISDOM Overall DM 
Insulin 
requiring DM 
Lesion 
length 
>20mm 
RVD 
<2.5mm ACS
Mean RVD (mm) 3.0±0.5 2.9±0.5 2.9±0.5 2.9±0.4 2.1±0.4 3.0±0.5
Mean lesion length (mm) 15.9±6.6 16.5± 6.5 16.4±6.6 28.1±6.0 13.8±5.8 15.5±6.0
Mean stent length (mm) 22.1±9.0 22.7±9.2 22.0±7.9 35.2±13.3 22.1±8.7 22.3±7.6
Overall reported events 
(%)* 5.4 10.0 12.9 2.9 4.2 4.1
Repeat intervention (%) 1.9 3.5 2.7 2.8 1.3 1.4
Stent thrombosis (%) 0.6 1.4 0.0 0.0 0.0 0.8
*Overall reported events = death, myocardial infarction, repeat intervention on target vessel
Conclusions: Reported 12-month clinical outcomes for higher risk patient subgroups are 
consistent with overall reported event rates and demonstrate an acceptable safety proﬁ le 
for the TAXUS stent in real world clinical practice.
8:45 a.m.
866-4 Comparing Cypher vs Taxus in Patients With St-
elevation Acute Myocardial Infarction Undergoing 
Primary Percutaneous Coronary Intervention: a Sub-
analysis From the Real-world Eluting-stent Comparative 
Italian Retrospective Evaluation (RECIPE) Study
Elena Falchetti, Guido Vittori, Umberto Signorini, Massimo Margheri, Giuseppe Biondi 
Zoccai, Enrico Remigi, Giuseppe Sangiorgi, Antonio Colombo, Azienda Ospedaliero-
Universitaria Careggi, Florence, Italy, San Raffaele Hospital, Milan, Italy
Background: Few data are available concerning the comparison of the two FDA - 
approved drug eluting stents (DES), Sirolimus (SES) and Paclitaxel eluting stent (PES), in 
patients presenting with ST-elevation acute myocardial infarction (AMI).
Methods: Consecutive patients undergoing DES at 4 high-volume and high-expertise Italian 
centers were enrolled in the Real-world Eluting-stent Comparative Italian retrosPective 
Evaluation (RECIPE) Study. The aim of this analysis was to assess short-term (in-hospital and 
1-month follow-up) safety and efﬁ cacy of DES in patients with ST elevation AMI. The clinical 
events of interest were Major Adverse Cardiac and Cerebrovascular Events (MACCEs: 
Death, AMI, CABG, Target Vessel Revascularization, Target Lesion Revascularization and 
Stroke); documented stent thrombosis was also explicitly adjudicated.
Results: Across the 2495 patients enrolled in the RECIPE study, 216 (8.7%) patients had 
AMI and underwent primary angioplasty with DES implant. At baseline, diabetes mellitus 
was present in 25.7% (30% for SES and 23% for PES), multivessel disease in 58 (66 vs 
53) %. In 61.9% (66% of SES vs 59% of SES) the culprit lesion was located in the left 
anterior descending coronary artery. Direct stenting was performed in the 19.6% and GP 
IIb/IIIa Inhibitors were used in the 36.3% of cases (23% in SES vs 44% PES p=0.002). 
Peak post - procedural CK was 1433 (1240 vs 1545) U/L. In hospital mortality was 1.4 (3 
vs 1) %, one patient (0.5%) needed CABG; TVR occurred in 3.1% (5% vs 2% p=NS). At 1 
month follow-up death occurred in 2.3% of cases (2% vs 3% p=NS) , TVR in 5.4% (8% vs 
4% p=NS), TLR in 4.7% (8% vs 3% p=NS), stroke in 1 patient (0.46%). Angiographically 
documented sub-acute stent thrombosis (deﬁ ned within 30 days) occurred in 1.4% (1% vs 
2% p=NS).Continuous follow-up is in progress and will extend to 6 and 12 months.
Conclusion: In this study DES implant in patients with AMI was safe with an early outcome 
comparable to the published experience with bare metal stents and a very low rate of 
adverse events related to acute and subacute thrombosis. No signiﬁ cant difference was 
observed between the two FDA - approved DES in the early occurrence of MACCEs.
9:00 a.m.
866-5 The CYPHER U.S. Post Market Surveillance Registry 
(e-Cypher) - Six Month Results in Acute Myocardial 
Infarction Patients
Stanley Katz, Marco A. Costa, Peter B. Berger, Linda Reynolds, Emily Keim, Sidney 
Cohen, Northshore Hospital, Manhasset, NY
Background: Little is known about the clinical outcome of patients (pts) receiving a 
CYPHER stent in acute myocardial infarction (AMI).
Methods: The Cypher Post Market Surveillance study enrolled 2067 pts prospectively 
at 38 sites in the U.S. by December 31st 2003. There were no exclusion criteria; 171 pts 
received >1 Cypher stent with an AMI within 24 hours. Interim 6 month clinical outcomes 
are presented; 12 month event rates will be presented.
Event AMI ( N=171)N (%)
No AMI (1896 )
N (%) P value
MACE (Death, Q Wave or Non Q Wave 
MI, Em CABG, TLR) 19 (11) 58 (3.1) <0.001
Death 4 (2.3) 15 (0.8) <0.05
TLR 14 (8.2) 34 (1.8) <0.001
TL-CABG 2 (1.2) 6 (0.3) ns
TL-PTCA 12 (7) 28 (1.5) <0.001
Target Vessel Failure 19 (11.1) 66 (3.5) <0.001
Stent Thrombosis 8 ( 4.7) 6 (0.3) <0.001
Cerebrovascular Accident (CVA) 1 (0.6) 6 (0.3) ns
Major Bleeding 7 (4.1) 26 (1.4)% <0.01
Conclusions: The 6 month adverse event rates in AMI patients are higher than those 
in non-infarct patients treated with Cypher stents. Of note, stent thrombosis occurred in 
4.7%, TLR occurred in 8.2%, and TVF occurred in 11.1% of infarct patients, accounting 
for the increased rate of clinical events observed in these patients.
9:15 a.m.
866-6 First Randomized Trial Comparing Sirolimus Eluting 
versus Bare Metal Stents in Severely Diseased 
Saphenous Vein Graft Treatment. Six Month Clinical and 
Angiographic Outcome
Paul H. Vermeersch, G. Van Langenhove, S. Verheye, C. Convens, D. Stockman, F. Van 
den Branden, P. Van Den Heuvel, AZ Middelheim, Antwerp, Belgium
Introduction: Percutaneous treatment of saphenous vein graft disease (SVGD) with drug 
eluting stents (DES) remains controversial. Since the mechanism of in stent restenosis 
in saphenous vein grafts differs from native coronary arteries, the beneﬁ t of DES as yet 
remains to be shown in randomized trials. We therefore initiated the ﬁ rst randomized trial 
comparing DES and BMS in SVGD
Methods: 70 patients presenting with severe SVGD were randomized in a double-blind 
fashion between DES and bare metal stenting (BMS). Groups A and B ( one being the DES 
group, the other the BMS group) received the same postprocedural standard of care. Clinical 
and 6 month angiographic and intravascular ultrasound (IVUS) follow-up was scheduled.
Results: 30 patients have reached the 6 month angiographic folllow-up date. The following 
table shows clinical and angiographic outcomes.
Group A Group B p-value
Initial stenosis (% ± SD) 71.0 ± 10.5 69.1 ± 11.5 NS
Postprocedural angiographic success (%) 100 100 NS
MACE at 6 months (%) 11 44 NS
Binary restenosis (%) 0 50 0.001
Total stent length (mm ± SD) 30.8±14 25.3±11 NS
Diameter stenosis at follow-up (% ± SD) 21.8 ± 14.8 58.8 ± 24.3 0.007
Late loss (mm ± SD) 0.49 ± 0.72 1.48 ± 0.65 0.005
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Conclusion: This ﬁ rst randomized non-industry sponsored data shows far better 
outcomes in patients allocated to group A, in both clinical as well as angiographic 
outcome. Complete data sets including angiographic and IVUS with unblinding of the 
treatment allocation will be available for all 70 patients by jan 2005.
9:30 a.m.
866-7 The Effect of Everolimus-Eluting Stents in Different 
Vessel Sizes - Results From the FUTURE 1 & 2 Trials
Yoshihiro Tuschiya, Alexandra J. Lansky, Ricardo A. Costa A, Cody Pietras, Roxana 
Mehran, Ecaterina Cristea, Raquel Sanchez, Bahran Sahid, Manuela Negoita, Yeal Gilutz, 
Martin Fahy, George Dangas, Stephane Carlier, Issam Moussa, Gregg W. Stone, Jeffrey 
W. Moses, Martin B. Leon, Ralf Muller, Michael Rink, Hans Storger, Karl E. Hauptmann, 
Eberhard Grube, Columbia University Medical Center and the Cardiovascular Research 
Foundation, New York, NY, Siegburg Heart Center, Siegburg, Germany
Background: In both FUTURE I (single center safety and feasibility study) and FUTURE 
II (larger multicenter randomized study, with inclusion of diabetics) trials, the everolimus-
eluting stent (EES) demonstrated safety and efﬁ cacy to inhibit neointimal proliferation in 
de novo coronary lesions compared to the metallic stent (MS). The results of the EES in 
different vessel sizes have not been reported yet. 
Methods and Results: 106 patients with 107 de novo coronary lesions were randomized 
to EES (n=48) vs. MS (n=58). Patients were divided into 3 groups based on pre-
procedure reference diameter (RD): small (<2.75mm), medium (2.75mm-3.25mm), and 
large (>3.25mm) vessels. Baseline clinical and angiographic characteristics were similar 
between EES vs. MS in all groups. Angiographic follow-up was performed at 6 months. 
Quantitative coronary angiographic results are shown in the Table. 
Conclusions: In the FUTURE I and II trials, 6 months angiographic follow-up showed 
that EES was associated with signiﬁ cant increased MLD and reduced diameter stenosis 
in small, medium and large vessels, both in-stent and in-segment, compared to the 
MS. In addition, EES signiﬁ cantly reduced in-stent late loss, a surrogate of neointimal 
proliferation, by 78-94%, independently of vessel size. 
Variable (N of Pts) Small vessels (N=37) Medium vessels (N=38) Large vessel (N=31)
Number of Lesions EES (N=13) MS (N=25) EES (N=22) MS (N=16) EES(N=14) MS (N=17)
pre RD, mm 2.49+0.20 2.51+0.17 3.01+0.13 3.01+0.14 3.50+0.25 3.61+0.31
Stent Acute Gain, mm 1.96+0.43 1.83+0.44 1.77+0.40 1.83+0.40 2.04+0.45 1.85+0.50
Stent Late Loss, mm 0.19+0.22 0.86+0.68* 0.05+0.23 0.90+0.44† 0.14+0.29 0.77+0.39†
Stent Restenosis, % (N) 0.0 (0/12) 26.3 (5/19) 0.0 (0/21) 13.3 (2/15) 0.0 (0/13) 7.7 (1/13)
Segment Restenosis, % (N) 8.3 (1/12) 36.8 (7/19) 0.0 (0/21) 26.7 (4/15)‡ 7.7 (1/13) 15.4 (2/13)
*P=0.003 vs. EES. †P<0.0001 vs. EES. ‡P=0.05 vs. EES.
9:45 a.m.
866-8 Comparison of Efﬁ cacy and Safety Between Sirolimus-
Eluting Stent (Cypher™) and Paclitaxel-Eluting Stent 
(TAXUS™) in Unprotected Left Main Coronary Arteries: 
Multicenter Registry in Asia
Sunao Nakamura, Tamil Selvan Muthusamy, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, New Tokyo Hospital, Matsudo, Japan
Background and Purpose: Both Sirolimus-eluting BX velocity stent (Cypher™, Cordis) 
and Paclitaxel-eluting Express stent (TAXUS™, Boston Scientiﬁ c) have been reported 
to be effective in preventing neointimal formation and in-stent restenosis. The aim of this 
study is to compare the safety and efﬁ cacy of these 2 stents on the outcome of patients 
with unprotected left main coronary arteries (LMT). 
Methods: A prospective analysis of 138 patients with LMT stenosis (72 Cypher™ and 
66 TAXUS™) in ﬁ ve high volume Asian centers after successful stenting in LMT was 
performed. Lesion location of LMT was ostial 28 cases (20.3%), mid shaft 33 cases 
(23.9%) and distal 77 cases (55.8%). The study endpoints were major adverse cardiac 
events (MACE) at 30 days and restenosis rate at 12 months. 
Results: The baseline clinical characteristics between 2 groups were similar. See table 
for clinical results. Conclusion: The use of both stents in patients with LMT was equally 
safe with low acute complication and low incidence of restenosis.
Cypher™ TAXUS™ p
Number of patients 72 66 -
Age (mean/yrs) 68.8 69.8 -
Procedural success (%) 100 100 NS
MACE at 30 days (%) 0 0 NS
LV ejection fraction (mean/%) 50.5 52.8 NS
Reference diameter (mm) 3.52 ± 0.94 3.38 ± 0.92 NS
MLD post (mm) 3.38 ± 0.88 3.29 ± 0.88 NS
MLD at 12 months (mm) 3.28 ± 0.77 3.19 ± 0.80 NS
Restenosis rate (%) 2.7 3.0 NS
TVR (%) 1.4 1.5 NS
MACE at 12 months (%) 1.4 1.5 NS
ORAL CONTRIBUTIONS
867FO  Featured Oral Session...Distal 
Embolization Protection
Wednesday, March 09, 2005, 8:30 a.m.-10:00 a.m.
Orange County Convention Center, Room 304E
8:45 a.m.
867-4 Severity of Thrombus Score Predicts Adverse Events 
After Stenting in Saphenous Vein Grafts with Distal 
Embolic Protection: The FIRE Trial
Giora Weisz, Campbell Rogers, James Hermiller, Robert Feldman, Patrick Hall, 
Robert Haber, Zaki Masud, David Cox, Patrick Cambier, Ronald Caputo, Mark Turco, 
Roxana Mehran, Jeffrey Popma, Gregg W. Stone, Center for Interventional Vascular 
Therapy, Columbia University Medical Center, New York, NY, Cardiovascular Research 
Foundation, New York, NY
Background: Distal embolization of atherothrombotic material and peri-procedural 
adverse events after stent implantation in saphenous vein grafts (SVG) are reduced with 
distal protection devices. Whether the severity and extent of thrombus is predictive of 
adverse events after SVG stenting with distal protection devices is unknown.
Methods: In FIRE trial, 651 pts undergoing SVG stenting were randomized to distal 
protection with FilterWire EX (FW) vs. GuardWire (GW) balloon occlusion and aspiration 
system. Thrombus was graded in the angiographic core laboratory in 5 categories: 
none, possible (haziness), mild, moderate, or severe. Data on angiographic thrombus 
appearance was available on 600 patients.
Results: Thrombus was absent in 210 pts (35.0%), possible in 237 pts (39.5%), mild in 99 
patients (16.5%), moderate in 51 pts (8.5%) and severe in 3 pts (0.5%). The rates of major 
adverse cardiac events (MACE; death, MI, or target vessel revascularization) as a function 
of the severity of thrombus at 30-days are summarized in the Table.
Conclusions: The presence of thrombus, especially when extensive, is a strong correlate 
of adverse events after SVG stenting with GuardWire distal protection. In contrast, event 
rates when the FilterWire EX is used for distal protection are not impacted by the presence 
or degree of thrombus. These data suggest that the FilterWire may be preferred for distal 
protection in thrombotic vein grafts.
GW MACE FW MACE p-value
Thrombus score N=290 N=310
None 5.9% 7.4% 0.78
Possible 10.1% 12.7% 0.55
Mild 18.2% 5.5% 0.057
Moderate-severe 32.0% 13.8% 0.32
Mild-severe 23.2% 8.3% 0.01
P value for trend 0.002 0.36
9:00 a.m.
867-5 Incidence, Predictors, and Sequelae of Embolic 
Complications during Saphenous Vein Graft 
Interventions before Distal Protection Device Use: An 
Analysis of the NHLBI Dynamic Registry
Ruchira Glaser, Faith Selzer, Warren K. Laskey, Howard A. Cohen, Sheryl F. Kelsey, 
Robert L. Wilensky, University of Pennsylvania, Philadelphia, PA
Introduction: Distal protection devices have reduced embolic complications of saphenous 
vein graft (SVG) intervention. Examination of the incidence, predictors and associated 
adverse outcomes of embolic complications in a contemporary PCI cohort may provide a 
basis for selective use of protection devices.
Methods: Using 3 recruitment waves (1997-8, 1999, 2001-2) of consecutive patients 
undergoing PCI in the NHLBI Dynamic Registry, we examined the incidence, predictors, 
and associated outcomes (in hospital and one year death and MI) of procedural 
complications suggestive of embolization during SVG interventions (no/slow reﬂ ow, 
embolization, vessel closure, reduced TIMI ﬂ ow). Procedures were performed before wide 
use of distal protection devices.
Results: A total of 499 SVG interventions were performed, 54 of which had embolic 
complication as deﬁ ned above (incidence 10.8%, 95% CI 8.2-13.9%). Risk of embolic 
complication decreased over time (1999 v. 1997 Adj OR 0.64 p=0.2; 2001 v. 1997 Adj 
OR 0.42 p=0.04). Baseline characteristics were similar amongst patients with and 
without embolic complications, and the majority (78%) had stent implantation. Patients 
with embolic complication had higher risk of in hospital death and MI than those without 
complication (death 3.7% v. 0.9%, MI 13.0% v. 3.6%, OR D/MI 4.25, 95% CI 1.83-9.89). 
By 1 year, patients with embolic complication had a more modest increase in adverse 
events (adj HR D/MI 1.78 95% CI 0.87-3.64). Presence of thrombus and total occlusion 
were strong independent predictors of embolic complication (adj OR thrombus 2.94, 
adj OR occlusion 5.94, p<0.001). Amongst the 470 patients without thrombus or total 
occlusion, the incidence of embolic complication was only 2.1%.
Conclusions: In an era of SVG intervention utilizing stents and improved anticoagulation, 
embolic complication remains an important consideration, with a higher associated rate of early 
death and MI. However, the risk for these complications has declined considerably over time. 
The presence of thrombus and total occlusion are the only independent predictors of embolic 
complications; in the absence of these factors, the incidence of embolic complication is low.
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9:15 a.m.
867-6 Efﬁ cacy Of Thrombosuction Using The Export 
Aspiration Catheter Before Or During Primary 
Percutaneous Coronary Intervention In Acute 
Myocardial Infarction
Woong Chol Kang, Tae Hoon Ahn, Seung Hwan Han, Eak Kyun Shin, Cardiology division, 
Cardiovascular Center, Gil Hospital, Gachon Medical School, Incheon, South Korea
Background: Effective myocardial reperfusion after primary PCI for AMI in lesions with 
a large thrombus is limited by distal embolization and slow/no reﬂ ow phenomenon. We 
evaluated the safety, feasibility, and efﬁ cacy of a thrombus reduction technique in using 
the EAC for thrombosuction before primary PCI in AMI. 
Method: We analyzed 61 patients with AMI who underwent primary PTCA and had a 
large thrombi burden using EAC(group I ; n=31, 25 males) or without EAC using(group 
II ; n=31, 20 males). After primary PCI, angiographic ﬁ ndings and clinical outcomes at 1 
month and 6 months were recorded.
Results: Angiographic success rate were 100%(31/31) and 87.1%(27/31), respectively(p=0.113). 
Although there were no different between two groups in incidences of distal embolization(p=0.612), 
slow/no reﬂ ow phenomenon were more commonly observed in group II(22.6%, 7/31) compared 
to group I(0/31)(p=0.001). The incidence of MACE during hospitalization(0% vs 7.7%, p=0.237) 
and follow-up duration(6.9% vs 0%, p=0.500) (7.4±4.9 months) was not different between two 
groups. In 31 patients who were performed thrombosuction successfully, gross thrombi were 
obtained from 25 patients (80.6%) and, TIMI ﬂ ow was improved by just doing thrombosuction in 
19 patients(61.3%) without additional intervention. 
Conclusion: Thrombosuction using EAC provide simple, rapid and potentially effective method 
for removal of thrombi burden and restoration of coronary ﬂ ow before or during PCI in AMI. 
EAC(+) EAC(-) p-value
Angiographic success rate(%) 31/31(100%) 27/31(87.1%) 0.113
Distal embolization(%) 1/31(3.2%) 3/31(9.7%) 0.612
Slow/no reﬂ ow(%) 0/31 7/31(22.6%) < 0.001
MACE ihhospital(%) 0/31 2/31(6.5%) 0.237
MACE F/U(%) 2/31(6.5%) 0/31 0.500
9:30 a.m.
867-7 Angiomax Versus Heparin as an Antithrombotic 
Agent in Patients Undergoing Percutaneous Coronary 
Intervention With Distal Protection Device in Saphenous 
Vein Bypass Grafts
Seung-Woon Rha, Pramod K. Kuchulakanti, William W. Chu, Edouard Cheneau, 
Daniel A. Canos, Afework GebreEyesus, George Aggrey, Natalie Gevorkian, Rebecca 
Torguson, William Suddath, Kenneth Kent, Lowell Satler, Augusto Pichard, Ron 
Waksman, Washington Hospital Center, Washington, DC
Background: Distal protection during saphenous vein bypass graft (SVG) intervention has 
been shown to reduce atherothrombotic embolization and adverse periprocedural ischemic 
events. This study aimed to compare the efﬁ cacy and safety of bivalirudin (Angiomax®) with 
heparin in patients (pts) undergoing SVG intervention with distal protection device (DPD).
Methods: All pts were treated with either bivalirudin (0.75 mg/kg bolus and 1.75 mg/
kg/hr infusion) or heparin (40U/kg bolus) as a single antithrombotic agent during SVG 
intervention with either PercuSurge GuardWire or FilterWire EX system. Aspirin and 
Clopidogrel were administered with recommended continuation for at least 1 year.
Results: Overall, 61 pts (91 lesions) in the bivalirudin group and 60 pts (81 lesions) in the heparin 
group were included in the study. Baseline clinical characteristics were similar in both groups. 
There was a trend toward less no-reﬂ ow and repeat percutaneous coronary intervention (PCI) 
in the bivalirudin group. The incidence of overall bleeding and vascular complications were similar 
between the two groups, as well as the clinical outcomes at 30-day and 6-month follow-up.
Conclusion: Bivalirudin as a single antithrombotic agent in pts undergoing PCI with DPD 
in SVG is clinically safe and feasible compared to heparin. Its use is associated with 
trends toward less no-reﬂ ow and in-hospital repeat PCIs. The long-term clinical outcomes 
are comparable between the two treatment groups. 
Table. Clinical Outcomes
Variables (%) Bivalirudin (n = 61) Heparin (n = 60) p Value
In-hospital complications
Abrupt closure 0.0 1.8 0.329
No reﬂ ow 0.0 3.9 0.068
Repeat PCI 0.0 5.0 0.077
Q-wave MI 1.6 0 0.323
Non-Q-wave MI 9.8 18.3 0.179
Major bleeding 1.6 3.3 0.549
Vascular complications 1.6 5.0 0.301
Any hematoma 5.0 6.8 0.68
Transfusion 6.3 11.8 0.34
30-day outcomes
Death 2.1 2.3 1.0
Any MI 16.7 26.7 0.241
TVR-MACE 2.1 2.3 0.949
6-month outcomes
Death 6.1 2.6 0.59
Any MI 22.9 28.6 0.569
TVR-MACE 9.1 5.0 0.491
9:45 a.m.
867-8 The Next Generation of Embolic Protection: First 
Clinical Experience with the Rubicon Filter System in 45 
Patients
Eberhard Grube, Joachim Schofer, Karl-Eugen Hauptmann, Antonio Bartorelli, Horst 
Sievert, Heart Center Siegburg, Siegburg, Germany
Background: Embolization by atherothrombotic debris during native coronary or 
sapheous vein graft (SVG) intervention signiﬁ cantly increases morbidity and mortality. The 
Rubicon Filter (Rubicon Medical, Salt Lake City, Utah) is an embolic protection device that 
provides a low proﬁ le, simple method of capturing and retrieving plaque dislodged during 
percutaneous, catheter-based interventions. The 5mm Rubicon Filter consists of a 0.014 
inch guidewire with a 2.4 F crossing proﬁ le. The ﬁ lter material is a blend of polyurethanes 
with a 100-micron pore size. A long taper increases volume and exposes greater surface 
area to ﬂ ow. The ﬁ lter is deployed without a delivery catheter. Retrieval of the ﬁ lter is 
accomplished using a separate 6 F compatible capture catheter.
Methods and Results: The primary objective of the study was to demonstrate safety 
of deployment and retrieval of the Rubicon Filter System during treatment of coronary 
lesions with PTCA and stenting. At ﬁ ve study centers, 45 patients were included in this 
feasibility trial. Twenty out of these patients had a saphenous vein graft treated with this 
device. The Rubicon Filter System was successfully deployed and retrieved in forty-three 
(95%) of the forty-ﬁ ve cases. In two cases, the device did not cross the lesion due to a 
high-grade stenosis. However, none of the commercially available ﬁ lter devices were able 
to cross these lesions. Prior to ﬁ lter deployment, 82% of the patients had TIMI III ﬂ ow and 
9% of the patients had TIMI II ﬂ ow. After retrieval of the ﬁ lter and capture catheter, 89% of 
the patients had TIMI III ﬂ ow. MACE at 30 days occurred in 2% of the patients (n=1).
Conclusion: Safety of the Rubicon Filter embolic protection device was demonstrated 
in this 45-patient study. MACE at thirty days was considerably lower than reported MACE 
rates from similar clinical trials. A randomized US trial will be conducted in late 2004 to 
further evaluate the safety and efﬁ cacy of the Rubicon Filter System.
ORAL CONTRIBUTIONS
868FO  Featured Oral Session...Platelet 
Resistance: Importance, Detection, 
and Treatment
Wednesday, March 09, 2005, 8:30 a.m.-10:00 a.m.
Orange County Convention Center, Room 414A
8:45 a.m.
868-4 Aspirin and Clopidogrel Drug Response in Patients 
Undergoing Percutaneous Coronary Intervention: A 
Role for Dual Drug Resistance?
Eli I. Lev, Paul F. Bray, Rajnikant Patel, Tim Delao, Juan Granada, Neal S. Kleiman, 
Baylor College of Medicine, Houston, TX, The Methodist Hospital, Houston, TX
Background: High variability has been reported in the response to aspirin and clopidogrel. 
There is limited data on the simultaneous response to both drugs in the same patients 
(pts). We characterized the response to clopidogrel among aspirin resistant versus 
sensitive pts undergoing elective percutaneous coronary intervention (PCI).
Methods: Included were pts (n=80) treated with aspirin for ≥1 week but not clopidogrel. 
During PCI all pts received bivalirudin. Blood samples were drawn before PCI and 
clopidogrel loading, and 24 hours after a 300 mg load. Samples were evaluated by platelet 
aggregation (agg) in response to 5 and 20 µM ADP and 1.5 µM arachidonic acid (AA), 
Rapid Platelet Function Assay-ASA (RPFA) and ﬂ ow cytometric PAC-1 binding and P-
selectin expression. Aspirin resistance was deﬁ ned by at least 2 of 3 criteria: RPFA score 
≥550, 5 µM ADP agg ≥70% or AA agg ≥20%. Clopidogrel resistance was deﬁ ned as 
baseline minus post-treatment agg ≤10% in response to 5 and 20 µM ADP.
Results: Twelve pts (15%) were resistant to aspirin, 21 pts (26.3%) were resistant to 
clopidogrel; 6 pts (7.5%) were resistant to both drugs. Clopidogrel response, measured as 
change in platelet agg and activation markers between the 2 time points, among aspirin 
resistant and sensitive pts is presented.
Conclusions: Half of the aspirin resistant pts in our study were also resistant to 
clopidogrel. Furthermore, aspirin resistant pts as a group appear to have a lower inhibitory 
response to clopidogrel as compared to aspirin sensitive pts. 
Response to clopidogrel among aspirin resistent 
versus aspirin sensitive patients
Aspirin Resistant 
(n=12)
Aspirin Sensitive 
(n=68) P value
Number of clopidogrel resistant patients 6 (50%) 15 (22.1%) 0.07
Mean decrease in 20 µM ADP 
aggregation (%) 7.4±7.3 16.9±11.9 0.001
Mean decrease in PAC-1 (mean 
ﬂ uorescence intensity) 0.8±1 1.8±1.4 0.045
Mean decrease in P-selectin (mean 
ﬂ uorescence intensity) 4.0±2.8 5.9±4.1 0.1
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868-5 Superior Responder Rate for Inhibition of Platelet 
Aggregation With a 60 mg Loading Dose of Prasugrel 
(CS-747, LY640315) Compared With a 300 mg Loading 
Dose of Clopidogrel
John T. Brandt, Christopher D. Payne, Govinda Weerakkody, Bruce D. Behounek, Hideo 
Naganuma, Joseph A. Jakubowski, Stephen D. Wiviott, Kenneth J. Winters, Eli Lilly and 
Company, Indianapolis, IN, TIMI Study Group, Boston, MA
Background: Hypo-response to clopidogrel, as measured by inhibition of platelet 
aggregation (IPA), has been correlated with adverse outcomes after percutaneous 
coronary intervention (PCI). In preclinical studies, prasugrel (CS-747, LY640315), a novel 
thienopyridine P2Y12 receptor antagonist, demonstrated more potent IPA than clopidogrel. 
This clinical study compared the responder rate to loading doses (LD) of prasugrel and 
clopidogrel.
Methods: Healthy subjects (n = 68) were randomized to receive either a 60 mg LD of 
prasugrel or a 300 mg LD of clopidogrel. After a washout period they received the other 
treatment. Maximal platelet aggregation (MPA) and IPA to 20 µM ADP were determined 
by turbidometric aggregometry. A responder was pre-deﬁ ned by two methods: 1) >25% 
IPA at both 4 h and 24 h, or 2) >10% decrease in MPA at both 4 h and 24 h.
Results: There was a signiﬁ cantly higher responder rate with prasugrel vs. clopidogrel by 
either deﬁ nition. The mean IPA at 4 h (Table) and 24 h (not shown) was also signiﬁ cantly 
higher for prasugrel, even when the analysis was limited to clopidogrel responders (as 
deﬁ ned by method 1).
Conclusions: A 60 mg LD of prasugrel achieved a signiﬁ cantly higher responder rate 
and greater IPA compared to a 300 mg LD of clopidogrel. Future clinical studies will 
determine if the higher and more consistent IPA observed with the 60 mg LD of prasugrel 
is associated with a reduction in thrombotic complications in patients undergoing PCI.
9:15 a.m.
868-6 Clopidogrel Resistance, Asa Resistance And Coronary 
Stent Thrombosis: A Causal Relation?
Stefan Hoffmann, Robert Klamroth, Helmut Landgraf, Dietrich Andresen, Vivantes 
Klinikum im Friedrichshain, Berlin, Germany
Purpose:  Subacute stentthrombosis is a rare but potentially fatal complication after PCI. 
Clopidogrel in combination with ASA has been a major advance in supportive therapy in 
PCI. However, there is signiﬁ cant variability in patients response to these drugs and those 
who are poor respondors should be at higher risc for ischemic complications. Is there a 
lack of ASA and Clopidogrel efﬁ cacy in pat suffered from SAT?
Method: Between 2000 and 2003 we examined 12 pat with SAT between day 2 and 30 
post PCI.. All of this pat received a loading dose of 300 mg Clopidogrel followed by 75 mg/
day. in combination with ASA 100mg. Platelet inhibition was studied by light transmittance 
aggregometrie using platelet poor plasma as a reference. ASA resistance was deﬁ ned 
as platelet aggregation>30% after induction with 0,5 mg/ml arachidonic acid. Clopidogrel 
resistance was deﬁ ned as platelet aggregation>30% after induction with 20 mmol ADP. 
We compared these results with a matched group of 20 pat without SAT.
Results: In the SAT group 75% (9/12) had insufﬁ cient platelet inhibition despite the use of 
ASA and Clopidogrel. We observed ASA non respondors in 25% (3/12) and Clopidogrel 
non respondors in 66% (8/12). 2/12 pat did not show any antiplatelet effect despite the 
use of ASA and Clopidogrel. In the matched group without SAT we found 1 ASA (5%) and 
1 (5%) Clopidogrel non responder.
Conclusions: 1. Insufﬁ cient platelet inhibition is likely linked to stent thrombosis. 
2. Platelet function testing is able to detect insufﬁ cient platelet inhibition.  3. Early routine 
platelet function testing is a reasonable instrument to prevent coronary stent thrombosis
9:30 a.m.
868-7 Comparison Between Ticlopidine And Clopidogrel 
In Patients Undergoing Primary Stenting in Acute 
Myocardial Infarction. Results from the CADILLAC Trial.
Yosihiro Tsuchiya, Alexandra J. Lansky, Roxana Mehran, Ricardo A. Costa, Ecaterina 
Cristea, Moses Tarawali, Maria Corral, Cody Pietras, Yingbo Na, Robert Siegel, Cindy 
L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, John J. Grifﬁ n, Giulio 
Guagliumi, Thomas Stuckey, Mark Turco, John D. Carroll, Barry D. Rutherford, Gregg 
W. Stone, Columbia University Medical Center and the Cardiovascular Research 
Foundation, New York, NY
Background: Results from prior studies examining the relative efﬁ cacy of clopidogrel 
and ticlopidine after stent implantation have been conﬂ icting. A comparison of the two 
thienopyridines in patients undergoing primary stenting for AMI has not been examined.
Methods: In the multicenter, prospective CADILLAC trial, patients undergoing primary 
stenting were treated in-hospital at operator discretion with either ticlopidine (n=931) 
or clopidogrel (n=163). Results: Baseline clinical and angiographic characteristics 
were similar except for pre-procedure TIMI0/1 ﬂ ow (72.5% in clopidogrel vs. 63.9% in 
ticlopidine, p=0.04). Abciximab use and procedural ACT levels were similar in the two 
groups, though ﬁ nal TIMI-3 ﬂ ow tended to be more frequent with ticlopidine (97.2% vs. 
94.4%, p=0.08). The previously administered thienopyridine was given at discharge in 
95.1% of clopidogrel pts and 94.3% of ticlopidine pts. Clinical outcomes are in the Table. 
By multivariate analysis, clopidogrel use was an independent predictor of the composite 
of recurrent ischemia and ischemic TVR in-hospital (OR [95%CI] =2.83[1.36, 5.82], 
p=0.006) and at 30-days (2.03[1.21, 3.40], p=0.008), and moderate/severe bleeding 
in-hospital (3.48[1.61, 7.56], p=0.002) and at 30-days (3.05[1.57, 5.92], p=0.001). 
Conclusions: These data suggest that the relative safety and efﬁ cacy of clopidogrel 
and ticlopidine in patients undergoing primary stenting for AMI may not be the same. A 
prospective randomized trial is required. 
Adverse events In-hospital 30-days
Clopidogrel
(N = 163)
Ticlopidine
(N = 931) P
Clopidogrel
(N = 163)
Ticlopidine
(N = 931) P
Recurrent ischemia, % 6.1 2.4 0.02 10.5 5.8 0.02
Ischemic TVR, % 2.5 1.2 0.26 2.5 1.6 0.45
Subacute thrombosis, % 1.2 0.3 0.16 1.2 0.3 0.11
Stroke, % 2.5 0.2 0.006 3.1 0.7 0.004
Moderate/severe bleeding, % 6.1 1.9 0.005 7.4 2.7 0.002
MACE* 3.7 2.4 0.29 4.3 3.6 0.64
* Death, reinfarction, disabling stroke, or ischemic TVR
9:45 a.m.
868-8 A Comparison of Prasugrel (CS-747, LY640315) With 
Clopidogrel on Platelet Function in Healthy Male 
Volunteers
Fumitoshi Asai, Joseph A. Jakubowski, Kenneth J. Winters, Takashi Hirota, Nobuko 
Matsushima, Hideo Naganuma, Stephen Freestone, Eli Lilly and Company, Indianapolis, 
IN, Sankyo Co. Ltd, Tokyo, Japan
Background: Prasugrel, a novel thienopyridine P2Y12 receptor antagonist, achieves 
more potent inhibition of platelet aggregation (IPA) than clopidogrel in preclinical studies. 
This study assessed the safety, tolerability, and effect on platelet function of prasugrel 
compared with clopidogrel.
Methods: A double-blind, placebo-controlled, multiple oral dose study was conducted. 
Healthy male volunteers (n=30) were randomized into 5 groups: prasugrel (5, 10 and 20 
mg), clopidogrel (75 mg) and placebo. Study medications were each taken once daily for 
10 days and bleeding times and platelet aggregation (turbidometric) induced by ADP and 
collagen were measured.
Results: Multiple oral dosing of 5 to 20 mg prasugrel was safe and well tolerated. 
Prasugrel in a time and dose dependent manner inhibited ADP-induced platelet 
aggregation (Figure), reaching steady state IPA (60-70%) after 2 days of 10 and 20 mg. 
The 5 mg prasugrel and 75 mg clopidogrel doses reached steady state inhibition more 
slowly. After 10 days, the maximum level of IPA was greater for all prasugrel doses than 
for 75 mg clopidogrel (p<0.05).
Conclusions: Prasugrel was well tolerated by healthy subjects for 10 days and was 
substantially more potent at inhibiting platelet aggregation than clopidogrel. These data 
conﬁ rm preclinical observations and forms the basis for further clinical evaluation of 
prasugrel in patients with atherothrombotic disease. 
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876  Drug-Eluting Stents
Wednesday, March 09, 2005, 10:30 a.m.-Noon
Orange County Convention Center, Room 304A
10:30 a.m.
876-3 Sirolimus-Eluting Heparin-Coated Cobalt Chromium 
Stent in the Treatment of Patients with De Novo Native 
Coronary Artery Lesions in Small Vessels - Final 
Results of the EVOLUTION Study
J. Eduardo Sousa, Andrea S. Abizaid, Alexandre Abizaid, Frnz Neumann, D. Horstkotte, 
C. Nien Shen, S. Verheye, Ernesto Ban Hayashi, Roxana Mehran, Alexandra Lansky, 
Amanda Sousa, Fausto Feres, Marci Mogg, Roopan Sikand, Peter Fitzgerald, Martin 
Leon, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
Background: Small coronary arteries (< 2.5mm diameter) present important challenges 
with more difﬁ cult stent delivery, higher stent thrombosis and increased restenosis. To 
address these challenges, an optimized sirolimus-eluting, heparin-coated, thin strut 
cobalt chromium stent (SECS) was developed.
Methods: The EVOLUTION study was a prospective, multicenter, non-randomized ﬁ rst-
in-man trial to test the feasibility of this new SECS in small vessels (between 2.0mm and 
2.5mm). The primary end point was in-stent late-loss at 6 months. Secondary end points 
included angiographic restenosis at 6 months, target lesion revascularization (TLR), target 
vessel revascularization (TVR) and major adverse cardiac events (MACE) at 12 months.
Results: A total of 52 patients were enrolled at six centers. The mean age was 59.6 years, 
60% were male and 32.7% were diabetics. Procedure success was 100%. The mean 
reference vessel diameter was 2.15±0.22 mm and lesion length was 13.89±3.33mm. 
There was no in-hospital or late stent thrombosis. The 6-month angiographic and the 12-
month clinical results are shown in the table:
Conclusions: In this ﬁ rst-in-man assessment of an optimized drug-eluting small vessel 
stent: 1) the thin strut cobalt chromium open geometry was highly deliverable, 2) safety 
proﬁ le was excellent without stent thrombosis or death and only 1 non-Q MI and 3) 
despite 2.15 mm reference vessel diameter, in-lesion restenosis (12%) and TLR (9.6%) 
were favorable. 
6-mo Angiographic Results 12-mo clinical Results
In-stent late loss 0.30 ± 0.44 mm Death 0 %
In-lesion late loss 0.28 ± 0.45 mm MI: Q-waveNon-Q-wave
0 %
1 (1 %)
In-stent restenosis 5 (10 %) TVR 1 (1 %)
In-lesion restenosis 6 (12 %) TLR 5 (9.6%)
MACE 6 (11.5 %)
10:45 a.m.
876-4 Cypher Vs Taxus Implantation In Patients With Chronic 
Total Occlusions: Insights From The Recipe (Real-
World Eluting-Stent Comparative Italian Retrospective 
Evaluation) Study
Giuseppe Sangiorgi, Giuseppe Biondi-Zoccai, Corrado Tamburino, Massimo Margheri, 
Giancarlo Vitrella, Guido Vittori, Rossella Barbagallo, Elena Falchetti, Alaide Chieffo, 
Ioannis Iakavou, Antonio Colombo, EMO Centro Cuore Columbus, Milan, Italy
BACKGROUND: Preliminary evidence supports the role of Cypher™ drug-eluting stents 
(DES) for patients with chronic total occlusions (CTO). However, no data are yet available 
concerning the comparison of Cypher™ and Taxus™ in the treatment of CTO.
METHODS: Consecutive patients undergoing successful DES implantation for CTO lesions 
at 4 high-volume Italian centers were enrolled in the Real-world Eluting-stent Comparative 
Italian retrospective Evaluation (RECIPE) study. Major adverse cardiac and cerebrovascular 
events (MACCE) assessed at follow-up (FU) were death, myocardial infarction (MI), bypass 
surgery (CABG), target vessel revascularization (TVR) and stroke.
RESULTS: A total of 227 patients with CTO underwent DES implantation, 142 treated 
with Cypher™ vs 85 with Taxus™, for a total of 260 CTO lesions. High-risk characteristics 
were common in this cohort of consecutive patients, including concomitant multivessel 
disease in 71% and diabetes mellitus in 29%. High-risk lesion features were also 
prevalent, including small vessel disease in 26%, long lesions in 57%, ostial location in 
8% and bifucation in 15%, while CTO was due to in-stent restenosis in 17%. On average 
1.4±0.7 Cypher™ stents (average total length 41±19 mm) and 1.4±0.8 Taxus™ stents 
(average total length 38±25 mm) were implanted per lesion. Overall there was no in-
hospital MACCE with the exception of re-PTCA in 0.7% (n=1) of patients treated with 
Cypher™ vs 1.2% (n=1) with Taxus™ (p=1.0). One-month events did not signiﬁ cantly 
differ between patients treated with Cypher™ vs Taxus™. Speciﬁ cally, MACCE were 3.5% 
(n=5) vs 1.2% (n=1, p=0.41) respectively, death 0.7% (n=1) vs 0 (p=1.0), non-Q-wave 
MI 0.7% (n=1) vs 0 (p=1.0), TVR 2.1% (n=3) vs 1.2% (n=1, p=0.67), and CABG 0 vs 
1.2% (n=1, p=1.0). No stroke or subacute stent thrombosis was observed within 1 month. 
Continuous follow-up is in progress and will be extended to 6 months.
CONCLUSIONS: This stuy, reporting on the comparison of Cypher™ vs Taxus™ 
implantation in CTO, does not demonstrate differences in the early clinical and 
angiographic outcome between the two study stent groups. Long-term results might help 
physicians in device selection for CTO treatment.
11:00 a.m.
876-5 Percutaneous Coronary Intervention of De Novo 
Bifurcation Lesions: Therapy With Sirolimus-Eluting 
Stents is Associated With Fewer Major Adverse Cardiac 
Events and Target Lesion Revascularizations Compared 
With Paclitaxel-Eluting Stent Implantation
Angela Hoye, Carlos van Mieghem, Andrew TL Ong, Jiro Aoki, Gaston A. Rodriguez 
Granillo, Marco Valgimigli, Keiichi Tsuchida, Georgios Sianos, Eugene McFadden, 
Willem J. van der Giessen, Pim J. de Feyter, Ron T. van Domburg, Patrick W. Serruys, 
Thoraxcenter, Rotterdam, The Netherlands
Background: Both the sirolimus-(SES) and paclitaxel-eluting (PES) stents reduce 
restenosis rates. We evaluated a consecutive series of patients treated with drug-eluting 
stent (DES) implantation for de novo bifurcation lesions, and compared outcomes with 
respect to stenting strategy and stent type.
Methods: From April 2002 to September 2003, all patients at our institution were treated 
with DES. A consecutive series of 144 patients were treated for 167 de novo bifurcation 
lesions with SES, followed by 104 patients treated with PES for 113 lesions.
Results: Clinical follow-up at 6 months was obtained in 99% patients with survival-free of 
major adverse cardiac events (MACE) of 93.7% for SES versus 85.8% for PES, p=0.05. 
By multivariate analysis, factors predictive for MACE were age, diabetes mellitus, previous 
CABG, multivessel disease, treatment for acute myocardial infarction, and treatment with 
PES. The rate of survival-free of target lesion revascularization (TLR) was signiﬁ cantly 
higher for the SES compared with the PES (see ﬁ gure). The only independent predictor of 
TLR was stent type. Technique of stenting was not a predictor of either MACE or TLR.
Conclusions: MACE rates for both the SES and PES are low compared with historical 
data of bare metal stents. The most effective technique for bifurcation stenting remains 
undeﬁ ned. Our data suggests a higher need for TLR for the PES compared with the SES, 
however further randomized studies are needed. 
11:15 a.m.
876-6 Paclitaxel Increases the Length of Stent that is Free 
of Intimal Hyperplasia: An Intravascular Ultrasound 
Analysis from TAXUS-IV and TAXUS-VI
Esteban Escolar, Gary S. Mintz, Joerg Koglin, Peter Lam, Jeffrey J. Pompa, Mary 
Russell, Eberhard Grube, Keith Dawkins, Steve Ellis, Gregg W. Stone, Neil J. Weissman, 
Cardiovascular Research Institute, Washington, DC
Background. Paclitaxel eluting stents (TAXUS) inhibit neiontima hyperplasia (IH). 
However, it is not clear whether neointima suppression is uniform or whether signiﬁ cant 
lengths of the stent are left uncovered.
Methods. We analyzed the subset of 112 TAXUS IV-VI and 107 control stents with 
post-intervention and follow-up intravascular ultrasound (IVUS) and angiography. IH 
cross sectional area was measured in each mm through out the stent. % neointimal free 
length of stent (%NFLS) was deﬁ ned as the length of each stent free of IVUS-detectable 
neointima divided by the length of the stent.
Results. At 9 month follow-up, the %NFLS was longer in TAXUS than in controls (58.7± 
36% vs. 14.9±21%, p<0.0001). This difference corresponded to a greater suppression 
in conventional measures of in-stent restenosis: decrease in mean IH area (IH volume/
stent length) from 2.39±1.37mm2 to 0.84±1mm2 (p<0.0001), %IH from 29.73±13.67 % to 
11.08±11.96 % (p<0.0001), and angiographic late lumen loss (LLL) from 0.87±0.45mm 
to 0.42±0.62mm (p<0.0001). However, the correlation of IVUS %NFLS to conventional 
angiographic parameters was only moderate: LLL (r=0.49, p<0.0001) and diameter 
stenosis (r =-0.46 p<0.0001). The cumulative frequency distribution in %NFLS is shown 
in the ﬁ gure.
Conclusion: More than half the stent length is free of neointima at follow-up with 
paclitaxel-eluting stents. These ﬁ ndings correlate only moderately well with classical 
angiographic end point parameters.
2005_2_AngioInterCardio.indd   88 12/23/04   9:57:08 AM
JACC February 1, 2005 ABSTRACTS - Angiography & Interventional Cardiology  89A 
A
ngiography &
 Interventional C
ardiology
11:30 a.m.
876-7 ‘Hybrid Stenting’ vs ‘All DES’ for Multivessel 
Percutaneous Coronary Interventions
Ashok Seth, R. Salwan, P. Chandra, D. Singhania, P. Agarwal, A. Mathur, S. Bhandari, TS 
Kler, Escorts Heart Institute & Research Centre, New Delhi, India
Background: During Multivessel PCI at our centre, to contain costs, a number of pts 
undergo a combination of Drug Eluting Stent (DES) and Bare Metal Stent (BMS) - for this 
we have coined the term “HYBRID STENTING”. While another group of patients have 
“ALL DES”.
To evaluate the status of Hybrid Stenting in “Real World” we have compared safety and 
outcomes of these two groups of patients.
Methods: A retrospective analysis of clinical outcomes in 637 consecutive pts undergoing 
multivessel PCI at our centre between June 2002 and Feb. 2004 was done. In the Hybrid 
group DES were used for smaller vessels, longer lesions, proximal LAD, larger area of 
supply, collateral supplying vessels, while BMS were used for discrete lesions, large 
vessels, RCA, LCx Lesions, smaller area of supply. Clinical Follow-up was obtained in 
528 patients (83%).
Results (Table 1): There was no difference in baseline characteristics in both groups. 
40% pts had diabetes mellitus & 61% pts had recent MI/ACS. The mean no. of stent 
implanted per patient was 2.15 in DES group and 1.2 DES + 1.1 BMS in Hybrid group. In 
33% pts in the Hybrid group 3.5 / 4.0 mm stents were used while in DES group 2.25 mm 
stent was used in 10.9% pts. Event free survival at 1 yr was 95.9% in All DES vs 91.9% 
in Hybrid group (p=NS).
Conclusion: In patients with multivessel disease the strategy of “Hybrid Stenting” is 
associated with low MACE rates at 30 d, 6 m and 1 yr. This strategy contains costs without 
compromising patient outcome & has an important impact on practice of multivessel PCI 
in “Real World”.
Table 1 Results: 30 d, 6 m, 1 yr MACE
30 d 6 m 1 yr
DES
(n=272)
Hybrid
(n=256)
DES
(n=213)
Hybrid
(n=224)
DES
(n=195)
Hybrid
(n=172)
Death 1 (0.4%) 2 (0.8%) 1 (0.5%) 1 (0.4%) 1 (0.5%) 3 (1.7%)
Q wave MI 1 (0.4%) 1 (0.4%) - - - -
Repeat PCI 1 (0.4%) 1 (0.4%) - 4 (1.8%) 1 (0.5%) 3 (1.7%)
Recurrence of Angina - - 2 (0.9%) 8 (3.6%) 7 (3.6%) 11 (6.4%)
CABG - - - - - -
MACE 2 (0.8%) 3 (1.2%) 3 (1.4%) 9 (4.0%) 8 (4.1%) 14 (8.1%)
11:45 a.m.
876-8 Proximal Left Anterior Descending Coronary Artery 
Stenosis: Have Drug-Eluting Stents Made a Difference 
in Clinical Outcomes?
Wajeehuddin Mohammed, Haris Athar, Rachid A. Elkoustaf, Justin B. Lundbye, Gauhar R. 
Khan, Jeffrey F. Mather, Deborah Murphy, Francis J. Kiernan, William E. Boden, Raymond 
G. McKay, Hartford Hospital, Hartford, CT, Univesrity of Connecticut, Farmington, CT
Background: Percutaneous coronary intervention (PCI) of the proximal left anterior 
descending (LAD) artery has failed to match clinical outcomes after bypass surgery 
because of restenosis. Drug eluting stents (DES), by reducing restenosis, may decrease 
repeat intervention of this arterial segment.
Aim: To compare in-hospital and late clinical outcomes in patients with proximal LAD 
stenosis after DES therapy versus DES therapy of other native coronary segments.
Methods: Major adverse in-hospital and 9-month cardiac events in 132 patients with
proximal LAD stenoses treated with Sirolimus stents were compared to 547 patients 
treated with Sirolimus stenting of other native coronary segments. All patients presented 
with unstable angina (n=380) or non ST-segment elevation myocardial infarction (n=299). 
Patients with ST segment elevation myocardial infarction, cardiogenic shock and bypass 
graft PCI were excluded.
Results: There were no signiﬁ cant differences between the two groups in baseline 
demographics, cardiac risk factors, co-morbidities, extent of coronary atherosclerosis, left 
ventricular ejection fraction or the use of adjuvant pharmacotherapy. In-hospital and 9-
month clinical outcomes are listed below: 
In-Hospital Non proximal LAD Proximal LAD P value
Death 0.2 % 0.0% NS
Myocardial Infarction (CK-MB > 5x ULN) 3.5% 3.8% NS
Emergent CABG 0.0% 0.0% NS
Emergent Repeat PCI 0.2% 0.0% NS
9-month
Death 0.6% 0.0% NS
Myocardial Infarction 1.8% 0.0% NS
Angiography 12.6% 6.1% 0.03
Repeat Target Lesion Revascularization 9.5% 4.6% NS
Conclusion: DES therapy of the proximal LAD or other native coronary segment has similar in-
hospital and 9-month outcomes. In the era of drug-eluting stents, the proximal LAD is no longer a 
predictor of increased restenosis and the need for repeat target vessel revascularization.
ORAL CONTRIBUTIONS
878  Carotid Stenting: Contemporary 
Outcomes
Wednesday, March 09, 2005, 10:30 a.m.-Noon
Orange County Convention Center, Room 414A
10:30 a.m.
878-3 Pretreatment With Statins Reduces Ischemic 
Neurological Events in Patients Undergoing Carotid 
Stent Implantation
Stanislaw J. Skaluba, Robert J. Chilton, Steven R. Bailey, Devang N. Patel, Marc D. 
Feldman, Walter A. Tan, Amish J. Desai, Umesh K. Arora, Michael H. Wholey, The 
University of Texas Health Science Center at San Antonio, San Antonio, TX
BACKGROUND: Statins (ST) reduce the incidence of adverse cardiac outcome after 
coronary stenting. Whether pre-treatment with statins can improve immediate or long-
term outcome after carotid stenting (CS) is unknown.
METHODS: We performed a retrospective analysis of 433 patients (mean age=71.4 
years), who underwent CS between March 1995 and November 2001 and had available 
data on statin therapy before CS. In-hospital, 30-day and 1-year post-procedural ischemic 
stroke/neuro-related death (IS/NRD) events were analyzed in 337(77.8%) patients not 
taking ST and 96(22.2%) patients taking ST before CS. Mean follow-up was 21.5±15.7 
months.
RESULTS: There were no signiﬁ cant differences in serum total cholesterol, LDL and 
HDL levels [mg/dL] in the group with post-procedural IS/NRD and the group without 
neuro-events (206.7±15.8 vs. 204.0±2.7; 117.0±4.9 vs. 121.4±2.3; 44.0±3.8 vs. 47.6±0.9 
respectively; p=NS for all comparisons). In-hospital, 30-day and 1-year IS/NRD rates were 
lower in patients pre-treated with ST in contrast to those not taking ST prior to CS (1.0% 
vs. 4.5%, p=NS; 1.1% vs. 5.3%, p=0.049; 1.4% vs. 8.2%, p=0.036, respectively). Beneﬁ t 
of ST therapy was observed with and without the use of ﬁ lter wire.
CONCLUSIONS: 1.Pre-treatment with statins was associated with a signiﬁ cant reduction 
in the incidence of IS/NRD at 30 days and 1 year after carotid stenting. 2.A beneﬁ cial 
effect of statins was in addition to the use of distal embolic protection and independent 
of serum lipid levels. 
The incidence rates of ischemic strokes / neuro-events after carotid stenting.†
Follow-up Time Total # of patients No Statin Statin p value
In-hospital period 395 15/320 (4.7%) 0/75 (0.0%) 0.040
30 days 383 18/310 (5.8%) 0/73 (0.0%) 0.020
1 year 325 21/268 (7.8%) 0/57 (0.0%) 0.015
† Filter wire cases excluded
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878-4 Routine Cerebral Protection During Carotid Artery 
Stenting in Octogenarians Is Feasible and Safe: 
Results of a Multicenter Registry
Ioannis Iakovou, Bernhard Reimers, Giuseppe Sangiorgi, Jochen Schofer, Michael 
Schlueter, Nicola Corvaja, Flavio Airoldi, Iassen Michev, Matteo Montorfano, Mauro 
Carlino, Antonio Colombo, EMO Centro Cuore Columbus, Milan, Italy, San Raffaele 
Hospital, Milan, Italy
PURPOSE: Carotid artery stenting is being used as an alternative treatment to surgical 
endarterectomy. The availability of cerebral protection systems has expanded the area of 
application of this procedure. To evaluate the short-term outcome of patients ≥80 years 
who underwent carotid stenting with the routine use of cerebral protection devices.
METHODS: In 4 centers, 65 patient aged more than 80 years (72% men; mean [+/- SD] 
age, 83 +/- 3 years)were treated with carotid stent implantation on 69 arteries. Cerebral 
protection was used in all patients and involved ﬁ lter devices (n=56), occlusive distal 
balloons (n=11), or proximal balloon protection (n=2).
RESULTS: The protection device was positioned successfully in 98.5% of the 69 
attempted vessels. Neurologic complications occurred within 30 days after 4 procedures 
(5.8%), including 1 major stroke, 1 minor stroke, and 2 transient ischemic attacks. There 
was 1 death (following a major stroke). The post-hospital 30-day incidence of major stroke 
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and death was 1.4 %(1/69) vs. 1.8%(9/488) in patients <80 years (p=0.7). Two patients 
(2.9%) had non occlusive dissections related to usage of protection devices without 
neurologic complications.
CONCLUSION: Carotid stenting with routine cerebral protection in cotogenarians appears 
feasible and safe, with a low occurrence of major complications. The incidence of major 
neurologic complications in this study was lower than in previous reports of carotid artery 
stenting without cerebral protection.
11:00 a.m.
878-5 Reduction in the Risk of Peri-procedural Stroke during 
Carotid Stenting with the Use of an Emboli Protection 
Device - Meta-Analysis of European and U.S. Carotid 
Stenting Feasibility Studies.
Jay S. Yadav, Sidney A. Cohen, Hitinder S. Gurm, David B. Snead, Cordis European 
and U.S. Carotid Stenting Feasibility Study Investigators, Cleveland Clinic Foundation, 
Cleveland, OH
Objectives: Once emboli protection devices were developed, it was considered unethical 
to randomize carotid stenting patients to treatment with or without a protection device. 
To determine whether data supporting a beneﬁ t could be derived from non-randomized 
multi-center sub-studies, the rates of stroke from two feasibility studies where patients 
were treated with carotid stenting with or without AngioGuard distal emboli protection 
were evaluated.
Methods: Data from two carotid stenting feasibility studies using Cordis Nitinol stents 
with or without the Cordis AngioGuard distal emboli protection system were combined. 
The European CASCADE study was a non-randomized, multi-center study that enrolled 
121 patients with either symptomatic (> 70% stenosis) or asymptomatic (> 85% 
stenosis) carotid disease. The U.S. Carotid Feasibility study was a non-randomized, 
multi-center study that enrolled 261 patients with either symptomatic (> 60% stenosis) 
or asymptomatic ( > 80% stenosis) carotid disease. The primary endpoint for both studies 
was the incidence of death and any stroke at 30 days post-procedure, with follow-up to 
one year for CASCADE and annually to 3 years for the U.S. Carotid Feasibility. Both of 
these studies started before the AngioGuard became available and it was introduced 
during the studies with all patients receiving it after its introduction. The stents being used, 
the operators and the enrollment criteria all remained unchanged.
Results: Of the 382 patients who were enrolled into the CASCADE and Carotid 
Feasibility studies, 266 patients were stented without and 116 patients were stented with 
the use of AngioGuard distal emboli protection. The pooled thirty-day rate of all stroke for 
the group of patients stented without protection was 8.6%. The pooled thirty-day rate of 
all stroke for the group of patients stented with protection was 2.6%. The p-value for the 
difference was 0.02. 
Conclusions: Carotid stenting with distal emboli protection using AngioGuard reduces 
the risk of stroke compared to stenting without distal protection.
11:15 a.m.
878-6 Safety and Efﬁ cacy of Bilvalirudin for Adjunctive 
Anticoagulation During Carotid Artery Stenting
Ravish Sachar, Kiran Venkatesh, Tanya Smallwood, Kimberly Livingston, J. Tift Mann, III, 
WakeMed, Raleigh, NC
Background: Internal carotid artery stenting (CS) is becoming the procedure of choice 
for revascularization among patients with high-grade carotid stenosis who are at elevated 
surgical risk. Intraprocedural anticoagulation during CS has traditionally been achieved 
using unfractionated heparin (UFH). While the use of bivalirudin during coronary 
interventions has been well studied, its safety and efﬁ cacy for adjunctive anticoagulation 
during CS remains undeﬁ ned. 
Methods: We performed ﬁ fty-six CS procedures between October 2003 and July 2004. Of 
these, 50 patients had 52 procedures using bivalirudin for adjunctive anticoagulation. All 
patients were deemed to be high-risk for carotid endarterectomy (CEA) using previously 
validated criteria. Patients were followed for a composite thirty-day endpoint of death, 
stroke, or myocardial infarction (MI). 
Results: The mean patient age was 71 years and 66% were male. High-risk criteria for 
CEA included coronary artery disease requiring revascularization (n=44, 85%), chronic 
obstructive pulmonary disease (n=33, 63%), left ventricular dysfunction (n=20, 38%), 
restenosis after prior CEA (n=9, 17%), critical aortic stenosis (n=2, 4%), prior radical 
neck surgery (n=1, 2%), and prior neck radiation (n=1, 2%). Eighteen patients (35%) 
had a previous stroke, 26 (50%) had a previous transient ischemic attack, and 13 (25%) 
were symptomatic with an ipsilateral stroke or TIA within the 6 months preceding the 
intervention. The procedural success rate was 100%, and all procedures were performed 
using distal emboli protection. The mean activated clotting time was 360 seconds. All 
patients received aspirin and clopidogrel for a minimum of 30 days post-procedure. Two 
patients (4%) reached the composite endpoint at 30 days. One patient died of a non-
neurological and non-cardiac cause during the index hospitalization. One stroke was due 
to an air embolus in a patient in which a new type of stent was used. This stent has 
subsequently been taken off the market. There were no MI’s at 30 days.
Conclusion: Bivalirudin can be safely used for adjunctive anticoagulation during carotid 
stenting. A larger trial is needed to adequately compare its safety and efﬁ cacy to UFH.
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878-7 Renal Insufﬁ ciency is not a Predictor of Poor Outcome 
After Carotid Artery Stenting
Luis Gruberg, Majdi Halabi, Shirush Petchersky, Eﬁ m Kouperberg, Eugenia Nikolsky, 
Aaron Hoffman, Rafael Beyar, Rambam Medical Center, Haifa, Israel
Background: Renal function has shown to be an important independent predictor of poor 
outcome in patients who undergo percutaneous coronary intervention. The impact of 
renal function in patients who undergo carotid artery stenting is unknown.
Methods: We analyzed 99 consecutive patients who underwent carotid artery stenting 
and divided them into two groups based on the calculated creatinine clearance (CrCl): 
CrCl >60 ml/min (n= 55) and CrCl ≤60 ml/min, not on dialysis, (n=44).
Results: Patients with lower CrCl were older and more frequently female. Procedural 
success was >99% for all patients. In hospital outcomes were similar between the two 
groups, as shown in the Table. 
CrCl>60 ml/min
(n=55)
CrCl ≤60 ml/min
(n=44) p
Age (years) 66±8 75±5 <0.001
Female (%) 45.5 20.5 0.001
Diabetes (%) 30.9 40.9 NS
Hypertension (%) 83.6 81.8 NS
Ischemic heart disease (%) 54.6 50.0 NS
S/P CVA (%) 20.0 20.5 NS
S/P TIA (%) 20.0 18.2 NS
CrCl (ml/min) 84±21 46±10 <0.001
In hospital death (%) 1.8 0 NS
Major stroke (%) 0 0 NS
TIA (%) 1.8 4.6 NS
Retinal artery emboli (%) 1.8 0 NS
Bleeding complications (%) 1.8 2.3 NS
Conclusions: Despite signiﬁ cantly worse baseline clinical characteristics, patients with 
reduced renal function (CrCl <60 ml/min) who underwent carotid artery stenting had 
similar outcomes compared to patients with normal renal function.
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878-8 Stenting and Angioplasty with Protection in Patients at 
High Risk for Endarterectomy: The SAPPHIRE Study - 
Subset Analysis of Randomized Asymptomatic Patients
Gregory Mishkel, Gary Ansel, Sidney A. Cohen, St. John’s Hospital, Springﬁ eld, IL, 
Cordis Corporation, Warren, NJ
Background: The SAPPHIRE study is the ﬁ rst prospective, multi-center randomized 
controlled study comparing carotid stenting with distal protection (CAS-DP) versus carotid 
endarterectomy, in patients considered at increased risk for surgery (CEA). Analysis of 
the asymptomatic patient subset is presented.
Methods: This analysis focuses on asymptomatic patients with > 80% stenosis by 
ultrasound and a high risk criteria (CHF, severe COPD, previous CEA, severe CAD, radical 
neck surgery, or radiation therapy) who were randomized in the 29 US SAPPHIRE centers. 
Randomization to either CEA or stenting required consensus by a team composed of a 
neurologist, surgeon, and interventionalist. The primary endpoints were the incidence of 
Major Adverse Events (MAE), i.e., death, any stroke and/or MI at 30 days post-procedure, 
and a composite of MAE plus death and/or ipsilateral stroke between 31 days and 360 
days post-procedure, with follow-up annually to 3 years.
Results: Of the 334 patients randomized, 219 were asymptomatic (111 CAS-DP and 
108 CEA). Thirty day MAE rates were 5.4% for CAS-DP versus 10.2% for CEA (p=0.21). 
The 30-day rates for MI were 1.8% vs. 7.4% (p=0.06) and for major ipsilateral stroke were 
0.0% vs. 1.9% (p=0.24) in the CAS-DP patients vs. CEA patients.
One year Major Adverse Event (MAE) rate (Death/All Stroke and MI to 30 days, and All 
Death and Ipsilateral Stroke from 31-360 Days) was 9.9% for patients randomized to 
CAS-DP compared to 21.3% for patients randomized to treatment with CEA (p = 0.02). 
The data at one year demonstrated signiﬁ cantly more frequent MI (p = 0.02) and major 
ipsilateral stroke (p=0.03) in the CEA patients.
Conclusions: In the SAPPHIRE trial, approximately 66% of patients had asymptomatic 
carotid disease. These patients demonstrated a signiﬁ cantly lower risk of major adverse 
events at one year when treated with stenting and emboli protection when compared 
tostroke, MI and or death patients treated with carotid endarterectomy. Signiﬁ cant 
reductions in both MI and major ipsilateral stroke were observed in asymptomatic CAS-
DP treated patients compared to asymptomatic CEA treated patients.
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